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Abstract 
Kaposi’s sarcoma herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma 
(KS), the most common AIDS-associated malignancy.  KS lesions are comprised 
of poorly differentiated, spindle-shaped endothelial cells, the precursors of which 
are lymphatic endothelial cells (LEC).  KSHV infection of LEC induces 
transcriptional reprogramming towards a phenotype more analogous to blood 
vessel endothelial cells BEC. 
 
KSHV encodes 17 mature miRNAs (miRNA), 14 of which are co-expressed as a 
cluster. miRNAs are small non-coding RNA molecules that act post-
transcriptionally to negatively regulate gene expression.  It was the aim of this 
thesis to investigate the function of the KSHV miRNAs through identifying viral 
miRNA targets in LEC.  miRNAs silence their target genes by either blocking 
translation or inducing mRNA degradation. Gene expression microarray (GEM) 
analysis was used to quantify changes in mRNA abundance of LEC transcripts 
induced by the KSHV miRNA cluster. MAF, a leucine zipper transcription factor, 
was significantly down-regulated in the presence of the viral miRNAs. miRNA 
expression analysis of KS lesions identified those KSHV miRNAs which are 
expressed and therefore relevant to KS pathogenesis. 
 
In silico prediction analysis identified multiple KSHV miRNAs binding sites in the 
MAF 3’UTR, MAF silencing was mediated through specific interactions with these 
sites. In particular, KSHV miRNAs miR-K12-6 and miR-K12-11 were identified as 
individual miRNAs responsible for MAF down-regulation.  MAF was silenced 
specifically by these miRNAs during primary KSHV infection of LEC.  MAF has 
been previously characterised as a LEC-specific transcription factor, although its 
function and target genes were unknown.  GEM profiling of LEC in which MAF 
was silenced by siRNA revealed an increase in expression of BEC markers.  
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Therefore, in LEC, MAF acts a transcriptional repressor of BEC transcripts helping 
to maintain lymphatic identity. Gene set enrichment analysis of three GEM data 
sets revealed a significant concordant increase in BEC genes during primary 
KSHV infection, expression of the KSHV miRNA cluster and MAF silencing.  The 
miRNA cluster-induced up-regulation of BEC markers was shown to be by way of 
MAF silencing. 
 
In this study I have identified and validated MAF as a LEC-specific KSHV miRNA 
target and have shown MAF to have a role in maintaining LEC identity through 
repression of BEC markers. Consequently, down-regulation of MAF following 
KSHV miRNA expression contributes to the mechanism behind the transcription 
reprogramming of LEC observed upon KSHV infection.  
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Chapter 1. Introduction 
1.1 Kaposi sarcoma herpesvirus 
In 1872 the Hungarian dermatologist Moritz Kaposi reported five cases of 
‘idiopathic multiple pigmented sarcomas of the skin’ (Kaposi, 1872). This disease 
later became known as Kaposi sarcoma (KS). In 1981, increased incidences of an 
aggressive form of KS and Pneumocystis carinii pneumonia were reported 
amongst homosexual men in New York and California. These events marked the 
onset of HIV/AIDS epidemic and sparked a renewed interested in KS 
pathogenesis. The aetiological agent of KS was identified in 1994 when Yuan 
Chang and Patrick Moore (Chang et al., 1994) employed representational 
difference analysis to isolate unique DNA sequences from tumours of patients 
with AIDS-KS. This DNA was related to but distinct from other known 
herpesviruses, and represented a novel herpesvirus termed Kaposi sarcoma 
herpesvirus (KSHV, also called HHV-8).  
 
1.1.1 Kaposi sarcoma 
KS is a multifocal disease initially presenting as red lesions of the skin, particularly 
on the extremities (Fig. 1.1A). During disease progression lesions disseminate to 
the oral mucosa and visceral organs. KS tumours are highly vascularised and 
composed of proliferating spindle cells, lesions are typified by slit like vasculature 
and a strong inflammatory infiltrate (Fig. 1.1B) (Boshoff and Weiss, 2002). 
 
1.1.1.1 Clinico-epidemiologic forms 
There are four distinct clinico-epidemiologic forms of KS termed: classic, endemic, 
iatrogenic and AIDS-KS. 
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1.1.1.1.1 Classic KS 
This was the form of KS originally described by Moritz Kaposi, it is typically an 
indolent disease occurring predominantly in elderly men of Mediterranean, 
Eastern European or Jewish ancestry (Franceschi and Geddes, 1995).  
1.1.1.1.2 African or endemic KS 
In the 1950s a high incidence of KS was reported in the black population of 
equatorial African countries (OETTLE, 1962). This endemic form of KS 
predominantly occurs in men and is more aggressive than other forms of KS, 
often involving lymph nodes and visceral organs. In addition to adults, endemic 
KS also affects children (Olweny, 1984). 
 
1.1.1.1.3 Post-transplant or iatrogenic KS  
This form of KS occurs in patients receiving immunosuppressive therapy, such as 
those undergoing organ transplants (Harwood et al., 1979). It is estimated that the 
incidence of KS in this risk group is 150 times higher compared with the average 
Western population (Penn, 1997). In addition, there is an overrepresentation of 
patients from Mediterranean or Jewish origin who suffer from iatrogenic KS in 
North America (Franceschi and Geddes, 1995).  
 
1.1.1.1.4 Acquired Immunodeficiency Syndrome (AIDS)-KS 
AIDS-KS is the most common AIDS-associated malignancy (Beral et al., 1990), it 
is also the most aggressive form of the disease. If left untreated the disease can 
progress from lesions on the skin to visceral organs such as the lungs and gut 
(Boshoff and Weiss, 1998). AIDS-KS predominantly affects HIV-positive 
homosexual men over other HIV risk groups such as intravenous drug users 
(Beral et al., 1990; Rabkin et al., 1990). Widespread availability of antiretroviral 
therapy has led to a 90% decrease in AIDS-KS incidence in the US and Europe 
(Fig. 1.1C) (Gates and Kaplan, 2002; Portsmouth et al., 2003), however in Sub-
Saharan Africa, where such treatments are not readily available AIDS-KS remains 
a significant disease burden.
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Figure 1.1 KS lesions and incidence. A Pigmented KS lesions of the skin, the swelling under the 
eyes is characteristic of KS associated oedema. B Tumour cells of KS lesions displaying the 
characteristic spindle shape. Spindle cells stain positive for KSHV as evidenced by purple staining. 
Arrow heads indicate blood vessels which do not stain positive for the virus. C Male and female 
incidence of KS disease from 1975 to 2003. The sharp increase in male KS in 1981 signifies the 
onset of the HIV-AIDS epidemic. Incidence begins to decline around 1993 with the introduction of 
Herpesvirus-specific therapeutics, a further decline in incidence occurs in 1997 with the 
introduction of the first generation of anti-retroviral therapeutics. Graph taken from WHO 
http://www.who.int/en/.  
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1.1.1.2 Disease Progression 
If left untreated KS lesions will progress through three stages: patch, plaque and 
nodular. Early patch stage KS presents as flat red-brown lesions in the dermis, 
which are characterised by a high inflammatory infiltrate, including dendritic and 
mast cells, and an abundance of blood vessels. Lesion development is associated 
with neoangiogenesis and the appearance of spindle-shaped endothelial cells, 
which are considered to be the KS tumour cells (Ensoli et al., 2001; Gessain and 
Duprez, 2005). The spindle cells proliferate with disease progression to the 
plaque stage and neovascularisation continues along with extravasation of red 
blood cells which contributes to the deep red colour of the lesions (Regezi et al., 
1993). Nodular KS lesions are dominated by spindle cells, although immune cells 
are still present. These lesions are stratified by abnormal slit-like vasculature 
spaces (Regezi et al., 1993).  
 
1.1.1.3 Clonality  
Malignancy results from the clonal expansion of cells that have acquired 
mutations which confer a selective advantage (Yao and Rubin, 1993; Chow and 
Rubin, 1999a; Chow and Rubin, 1999b). The manifestation of KS lesions at 
multiple distinct sites in the body meant that the monoclonal or oligoclonal origin 
of the disease was unclear. Initial studies addressed this question by analysing 
the paternal origin of the inactivated X chromosome in females with KS lesions 
(Rabkin et al., 1997; Gill et al., 1998). Rabkin et al concluded that KS lesions were 
clonal, since all cells contained an inactivated X chromosome from the same 
parent (Rabkin et al., 1997). However, Gill et al found significant evidence for both 
paternal and maternal inactivated X chromosomes, therefore suggesting that the 
lesions arose from multiple cells (Gill et al., 1998). Subsequently, Duprez et al 
employed a PCR-based approach to quantify the length of viral terminal repeats 
present in KS lesions. Since KS has a male biased incidence this technique was 
superior in that it was not limited to only female samples (Duprez et al., 2007). 
82% of KS lesions showed heterogeneous terminal repeat lengths, indicating that 
multiple KSHV infected clones exist within a single lesion. Despite the majority of 
KS lesions being oligoclonal, clonal lesions were also detected within the same 
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patient (Duprez et al., 2007). Therefore, KS is a multifocal disease whereby 
disseminated lesions represent the expansion of distinct KSHV infected spindle 
cells. The mutliclonal nature of KS has led some to classify it as a reactive 
proliferation rather than a true malignancy (Judde et al., 2000).  
 
1.1.1.4 Histogenesis 
The spindle cells of KS lesions are the principle target of KSHV infection. In early 
lesions 10% of spindle cells are KSHV positive, this increases to 90% in 
advanced nodular lesions (Boshoff et al., 1995; Staskus et al., 1997; Dupin et al., 
1999). Advanced lesions are dominated by KSHV-infected spindle cells, therefore 
the spindle cell has been designated the tumour compartment of KS. Spindle cells 
are poorly differentiated but of endothelial origin as evidenced by the expression 
of the pan endothelial cell marker PECAM1 (Skobe et al., 1999). The origin of 
these cells from lymphatic or vascular endothelia has been strongly contested. 
 
In 1985 Beckstead et al performed immunohistochemistry on KS spindle cells 
testing a range of markers that distinguished between the two types of 
endothelium. This group was the first to show that spindle cells were 
phenotypically closer to lymphatic as opposed to vascular endothelial cells 
(Beckstead et al., 1985). Additional evidence supports a lymphatic origin for KS: 
the distribution of cutaneous KS lesions along the lengths of lymphatic vessels 
(Dorfman, 1988), the lack of KS in tissues devoid of lymphatics such as the 
central nervous system (Dorfman, 1988) and the paucity of KSHV staining in the 
vascular endothelium of KS lesions (Dupin et al., 1999). Immunohistochemical 
staining of KS lesions indicated the expression of the lymphangiogenic ligand, 
vascular endothelial growth factor-C (VEGF-C), within blood vessels and spindle 
cells stained positive for the associated receptors fms-related tyrosine kinase 4 
(FLT4) and kinase insert domain receptor (KDR) (Skobe et al., 1999; Marchio et 
al., 1999). Stimulation of FLT4 by VEGF-C initiates lymphangiogenesis and these 
molecules are required to maintain the lymphatic endothelium (Jeltsch et al., 
1997; Oh et al., 1997) In addition, KS spindle cells also stain positive for other 
markers of lymphatic endothelium, podoplanin (PDPN) and lymphatic vessel 
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endothelial hyaluronan receptor 1 (LYVE1). Furthermore, addition of VEGF-C to 
KS tumour cells in vitro stimulated proliferation (Skobe et al., 1999; Marchio et al., 
1999).  
 
More recently, gene expression microarray (GEM) profiling was performed on 
RNA from KS lesions, and compared to the characteristic gene expression profile 
associated with LEC and BEC (Wang et al., 2004). The resulting profile was 
closest to that of lymphatic endothelial cells (LEC) than blood vessel endothelial 
cells (BEC). However, KS spindle cells did not faithfully represent the LEC 
transcriptional profile but instead were poorly differentiated, expressing markers of 
both LEC and BEC endothelium (Wang et al., 2004). Wang et al also showed 
that, upon infection of either LEC or BEC, KSHV induces endothelial 
reprogramming, driving these cells away from their terminally differentiated state 
towards the opposing lineage (Wang et al., 2004). The resulting infected LEC or 
BEC are more similar to one another than their uninfected counterparts. These 
data were supported by findings from Hong and Carroll et al, whereby KSHV 
infection of BEC led to their lymphatic reprogramming, with up-regulation of the 
lymphatic master regulator PROX1 (Hong et al., 2004; Carroll et al., 2004). 
Crucially, the mechanism behind KSHV-induced reprogramming remains 
unknown.  
 
1.1.1.5 Epidemiology and Transmission 
There are three major patterns of KSHV seroprevalence throughout the world, 
high level endemic, intermediate level endemic and non-endemic. High level 
endemic seroprevalence is found in regions of sub-Saharan Africa, here 30-70% 
of adults in the general population are KSHV positive. This pattern of 
seroprevalence is strongly associated with HIV infection. In Mediterranean 
countries, which are classed as intermediate level endemic, there is a 10-25% 
seroprevalence. In non-endemic areas including North, Central and South 
America, Asia and Northern Europe there is <10% seroprevalence amongst the 
general adult population. However certain high risk groups in non-endemic areas 
exhibit increased seroprevalence akin to the high-endemic areas. These include 
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HIV positive and negative homosexual men. Currently, it is not known what 
factors, genetic or behavioural are responsible for this distribution of KSHV 
infection (See (Martin, 2007) and references therein). 
 
There is strong evidence for two main routes of KSHV transmission: Sexual 
transmission between homosexual men, particularly in non-endemic areas (Martin 
et al., 1998), and horizontal non-sexual transmission between children in high-
level endemic areas. In the latter cases sputum appears to be the main route of 
transmission. There is also evidence of transmission via infected organ 
transplants, sharing of infected needles amongst intravenous drug users and 
through transfusions of whole unprocessed blood in high-level endemic areas. 
However, the precise behavioural activities and mechanisms of transmission are 
not yet known. It is also unclear as to whether KSHV is transmitted from mother to 
child (Martin et al., 1998; Martin, 2007). Although there is no direct evidence for in 
utero, via placental transmission, children are more likley to test KSHV positive if 
their mothers are also positive, suggesting mother to child horizontal transmission 
(Whitby et al., 2000; Davidovici et al., 2001).  
  
1.1.1.6 Cytokines and the KS tumour microenvironment  
Angiogenesis, proliferating spindle cells and a prominent immune infiltrate are the 
characteristic hallmarks of KS lesions, each of these are an essential element of 
the tumour microenvironment (Fig. 1.2). The inflammatory cell infiltrate appears 
even before spindle cell formation highlighting the importance of this component 
to KS pathogenesis (Ensoli and Sturzl, 1998). In addition, KS has a propensity to 
occur at sites of local inflammation, a feature known as the Koebner phenomenon 
(Niedt and Prioleau, 1988). The immune infiltrate is largely comprised of CD8+ T 
cells and monocyte-macrophages. Dendritic cells, CD4+ T cells and B cells are 
also present, although not as abundant (Ensoli and Sturzl, 1998). Consequently, 
KS lesions are typified by high levels of inflammatory cytokines secreted by 
immune cells, including γIFN, TNF, IL-1, IL-6 and GMCSF. This cytokine profile 
influences endothelial cell activation and induces the production of angiogenic 
factors, leading to blood vessel formation and further recruitment of T cells and 
   
 
 
 
29 
monocytes. In addition to the cytokines produced by immune cells, KSHV infected 
spindle cells also secrete proangiogenic (ANG2, VEGFA and TGF-B) and 
proinflammatory factors (IL-1, IL-6 and GMCSF) (Di and Cesarman, 2004). This 
augments the cytokine profile and has a direct growth stimulatory effect on 
infected endothelial cells (Ensoli et al., 1989). The virus contributes directly to the 
proinflammatory and proangiogenic environment by encoding its own array of 
cytokines such as vIL-6 and the viral chemokines (v-CCL1-3) (Boshoff et al., 
1997).  
 
Due to the importance of the tumour microenvironment, KS development is often 
viewed as interplay between three essential components: proliferation of spindle 
cells, inflammation and angiogenesis. All three processes are continually active 
and necessary for KS progression (Fig. 1.2).  
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Figure 1.2 Characteristic hallmarks of KS lesions. KS development and progression is driven 
by the interplay of three essential components: proliferating spindle cells (Top, beige cell), 
inflammatory infiltrate (Right, blue cells) and angiogenesis (Left, red blood vessel endothelial 
cells).
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1.1.2 Lymphoproliferative disorders 
 
KSHV is also the aetiological agent of two lymphoproliferative disorders, 
multicentric Castleman’s disease (MCD) and primary effusion lymphoma (PEL) 
(Cesarman et al., 1995a). 
 
PEL is an aggressive non-Hodgkin’s B cell lymphoma which lacks a distinct 
tumour mass and manifests as malignant effusions in the pleural, pericardial or 
peritoneal cavities (Jenner and Boshoff, 2002). GEM profiling of PEL and a range 
of B cell tumours from different stages of B cell development characterised PEL 
as a post-germinal centre B cell lymphoma (Jenner et al., 2003). However, PEL 
cells frequently lack B-cell specific markers (Boshoff et al., 1998; Cesarman et al., 
1995b). Unlike KS, PEL is a clonal disease as evidenced by identical IgG 
rearrangements in all tumour cells. The majority of patients with PEL are HIV 
positive. In addition to being latently infected with KSHV, 80% of PEL cases are 
co-infected with EBV (Cesarman et al., 1995a; Jenner et al., 2003). Cell lines 
established from these lymphomas maintain the viral genome at high copy 
numbers and a result are widely used for experimental investigation into KSHV-
mediated oncogenesis. 
 
MCD is a polyclonal tumour with a heterogeneous pathogenesis. 50% of MCD 
cases in HIV-negative individuals are KSHV positive (Moore and Chang, 2003). 
Whereas nearly all cases of MCD in HIV positive individuals are KSHV positive 
(Soulier et al., 1995). It was the close association of MCD with KS in AIDS 
patients which prompted the discovery of the KSHV genome in these tumours 
(Soulier et al., 1995). The bulk of MCD tumour mass is comprised of uninfected B 
cells which are recruited to the site by cytokines expressed by a small population 
of KSHV infected cells. Human and viral interleukin 6 (IL6) are likely to play 
causative roles in the development of both PEL and MCD (Dupin et al., 2000). 
MCD plasmablasts originate from naïve B cells and unlike PEL co-infection with 
EBV does not occur (Du et al., 2001). 
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1.1.3 Related herpesviruses 
Herpesviridae are a large family of viruses which were initially classified on the 
basis of common biological properties. Herpes virions are spherical and 
composed of 4 major components. The core houses a single copy of the dsDNA 
genome varying in length from 125-245kbp. The genome is encapsulated by an 
icosahedron capsid surrounded by a viral protein-containing tegument. The final 
layer of lipid envelope is punctuated by viral membrane glycoproteins. Recently, 
the herpesvirus family has been more precisely sub-classified on the basis of 
genomic sequence information (McGeoch et al., 2000). Herpesviruses natural 
host range is typically restricted to a single species. This host-specific occurrence 
highlights that the co-evolution of herpesviruses with their hosts and, in the 
majority of incidences, infection does not result in severe disease (Davison, 
2002). 
 
There are three subfamilies of herpesviridae: alphaherpesvirinae, 
betaherpesvirinae and gammaherpesvirinae. The prototype member of each 
family is simplexvirus, cytomegalovirus and Epstein-Barr virus, respectively. Each 
subfamily displays distinct cellular tropisms: alphaherpesvirinae infect neurons, 
betaherpesvirinae are restricted to the monocyte lineage, whereas 
gammaherpesvirinae infect lymphocytes (Davison, 2007).    
 
The gammaherpesvirus subfamily is divided into two genera, lymphocryptoviridae 
and rhadinoviridae. KSHV is a rhadinovirus and was the eighth human 
herpesvirus to be discovered (Chang et al., 1994). KSHV is the only member of 
rhadinoviridae which infects humans. The most closely related human 
gammaherpesvirus to KSHV is the lymphocryptovirus EBV. In healthy individuals 
EBV establishes low level persistent infection of peripheral memory B-cells. 
However, especially in HIV-positive individuals EBV infection is associated with 
various lymphomas such as Burkitt’s lymphoma and Hodgkin’s disease (Boshoff 
and Weiss, 2002).  
 
   
 
 
 
33 
Related gammaherpesviruses that infect both Old- and New-world primates 
include the Rhesus monkey rhadinovirus, which is closely related to KSHV 
(Searles et al., 1999). These viruses provide important in vivo models with which 
to investigate gammaherpesvirus pathogenesis. Sequence analysis of the 
conserved herpesvirus DNA polymerase have shown that KSHV is most closely 
related to pan-rhadinoherpesvirus (pRHV1a) and gorilla-rhadinoherpesvirus 
(GorRHV1), which infect chimpanzees and gorillas, respectively (Lacoste et al., 
2000). Another rhadinovirus closely related to KSHV is the murine 
gammaherpesvirus 68 (MHV68). MHV68 latently infects B cells in culture and 
causes lymphoproliferative disease in mice (Sunil-Chandra et al., 1994). 
Consequently, MHV68 infection is used as a mouse model to study aspects of 
KSHV-pathogenesis.  
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1.1.4 KSHV genome 
Rhadinoviruses share a common genome structure. The term ‘rhadino’ derives 
from the ancient Greek word for fragile due to the propensity of the viral genome 
to dissociate into two fragments of differing density. The KSHV genome is linear 
dsDNA of around 160kbp, 140kb of which encode approximately 87 open reading 
frames (ORF) and has a low density. The coding DNA is flanked by ~800bp of 
multiple GC rich terminal repeats, which confer a higher density (Fig. 1.3) (Renne 
et al., 1996a; Russo et al., 1996). 
 
Herpesviruses share orthologous genes, these are found in comparable genomic 
locations and orientation (Longnecker and Neipel, 2007). These conserved 
proteins have roles in essential viral processes including cleavage and packaging 
of the viral genome, DNA replication and virion assembly (Russo et al., 1996). 
Sixty-seven of the KSHV ORFs have homologues in the γ2 prototype herpesvirus 
saimiri (HSV) and are numbered according to HSV nomenclature. The function of 
many KSHV genes has been assigned purely on the basis of sequence similarity 
with other viral proteins. Those viral genes lacking homology and which are 
unique to KSHV are prefixed with a K (Fig. 1.3). Strikingly, many of these genes 
share significant sequence similarity to cellular genes and are likely to have been 
pirated by KSHV from the host cell during viral evolution (Fig. 1.3) (Moore and 
Chang, 1998). These genes encode proteins involved in evasion of the host 
immune response, nucleotide metabolism and potential regulators of cell growth 
(Neipel et al., 1997a). The KSHV genome encodes viral homologues of Cyclin D2 
(vCyclin), vFLIP (Fas-associated death domain (FADD) interkeukin-1β-converting 
enzyme (FLICE) inhibitory protein), interferon regulator factors (IRFs), Bcl-2 and 
IL-8 receptor, IL6, CD200 and three chemokines (viral CC-class chemokine 
(vCCL) 1-3) (Fig. 1.3). Pirating of cellular genes is unique to KSHV and its related 
primate viruses; however other herpesviruses, particularly EBV, induce some of 
the same genes. For example EBV-encoded LMP-1 induces Cyclin D2 in B cells 
(Arvanitakis et al., 1995). 
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Figure 1.3 The KSHV episome. Numbers inside the episome identify the KSHV ORFs, unique 
ORFs are prefaced with a K.  Cellular homologues are in orange and the miRNAs in purple. Green 
arrows indicate latent genes, blue arrows indicate ORFs encoded in a 5’ to 3’ positive polarity, red 
arrows indicate ORFs encoded in a 3’ to 5’ negative polarity.  TR, terminal repeat; CBP, 
complement binding protein; ssDBP, single-stranded DNA binding protein; gB, glycoprotein B; 
DNA Pol, DNA polymerase; vIL6, viral interleukin-6; DHFR, dihydrofolate reductase; vMIR, viral 
modulators of immune responses; TS, thymidylate synthase; vMIP, viral macrophage inflammatory 
protein; vIAP, viral inhibitor-of-apoptosis protein; vBcl-2, viral Bcl-2; TK, thymidine kinase; gH, 
glycoprotein H; vPK, viral protein kinase; gM, glycoprotein M; UDG, uracil DNA glucosidase; gL, 
glycoprotein L; gp35-37, glycoprotein 35-37; vIRF, viral interferon regulatory factor; vFLIP, viral 
Fas-associated death domain interleukin-1b-converting enzyme inhibitory protein; vCyclin, viral 
Cyclin; LANA-1, latent nuclear antigen; vOX-2, viral OX-2; vGPCR, viral G-protein-coupled 
receptor; LAMP, latency-associated membrane protein. Adapted from Dr. R. Vart (Thesis).
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1.1.5 KSHV lifecycle  
 
1.1.5.1 Virus entry  
In vivo KSHV genomic DNA has been detected in a number of different cell types, 
including B cells, endothelial cells, CD45+/CD68+ monocytes, keratinocytes and 
epithelial cells (Ganem, 1998; Antman and Chang, 2000). Furthermore, KSHV 
has been shown to have a broad range of infectivity in vitro, infecting a wide 
range of both human and animal cells (Renne et al., 1998; Moses et al., 1999; 
Bechtel et al., 2003; Kaleeba and Berger, 2006a). Herpesvirus entry into host 
cells occurs after attachment to a host cell surface receptor and then via direct 
fusion between virion and target cell membrane (Spear and Longnecker, 2003). 
Virus attachment and entry is mediated by envelope-associated glycoproteins. 
KSHV encodes three conserved glycoproteins, gB, gH and gL, thought to be 
essential for entry of all herpesvirus, as well as additional envelope associated 
glycoproteins, gM, gN and gpK8.1A (Akula et al., 2001a; Naranatt et al., 2002; 
Spear and Longnecker, 2003). Herpesviruses are capable of engaging multiple 
cell surface receptors, some of which serve to concentrate the virus on the host 
cell and others are responsible for direct fusion entry. Like other herpesviruses, 
KSHV utilizes heparin sulphate for cell surface binding (Akula et al., 2001b). 
Whereas KSHV entry is facilitated by binding to the cell surface molecule xCT 
(Kaleeba and Berger, 2006b). KSHV fusion permissiveness correlates with xCT 
expression; furthermore xCT is expressed on a wide range of cell types which 
accounts for the broad range of KSHV infectivity in vitro. Akula et al showed that 
viral entry can also be mediated on B cells by glycoprotein gB binding to integrin 
α3β1 (Akula et al., 2001a). Interestingly, xCT is not expressed on CD19+ B cells 
(Kaleeba and Berger, 2006b) which are peripheral blood B cells thought to be the 
primary reservoir for persistent KSHV infection (Antman and Chang, 2000; 
Dourmishev et al., 2003).  The fact that inhibition of integrin α3β1 does not fully 
ablate KSHV entry to B cells indicates additional KSHV receptors are employed 
during viral penetration (Akula et al., 2002).  
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1.1.5.2 Latent infection  
Once the virus has entered the cell, KSHV modulates the host microtubule 
network through induction of Rho GTPases, this facilitates trafficking of the viral 
DNA to the nucleus (Naranatt et al., 2005). As with other Herpesviruses, once in 
the nucleus KSHV can undergo two modes of infection: lytic replication, 
culminating in the production of new virions, or latent infection resulting in 
persistent host cell infection. The majority of de novo KSHV infection results in the 
establishment of latency (Bechtel et al., 2003) and tumour cells of both KS and 
PEL are latently infected (Cesarman et al., 1995a; Zhong et al., 1996). As with 
EBV, latency is the default mode of KSHV infection and this ability to maintain 
long term infection in quiescent or proliferating cells is a defining feature of the 
herpesvirus family. Unlike lytic replication whereby the genes involved are 
conserved between herpesviruses, genes required for latency are unique to each 
virus.  
 
During latency the viral genome circularizes and is maintained as an extra-
chromosomal episome (Renne et al., 1996a). The episome is copied by the host 
cell machinery during replication and is tethered to host chromatin during mitosis, 
thus ensuring each daughter cell receives a copy of the viral genome. Only four 
viral proteins and a series of microRNAs (miRNAs) are expressed and have been 
detected in PEL and KS spindle cells (Li et al., 2002; Pearce et al., 2005; Cai and 
Cullen, 2006). The restricted number of latent gene products minimizes the 
number of antigens for presentation and recognition by the host immune 
response. The KSHV latent proteins are latent nuclear antigen 1 (LANA) 
(ORF73), vCyclin (ORF 72), vFLIP (ORF 71) and Kaposin (K12) (Zhong et al., 
1996; Dittmer, 2003). Since these are the primary proteins expressed in KSHV-
associated tumours they also play a crucial role in viral-induced pathogenesis. 
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1.1.5.3 Latent gene expression and function 
The major latency genes colocalise within 4.8kb of the viral genome referred to as 
the major latency locus. Within this region are genes expressing the three latent 
proteins (ORF71-73), followed by an array of miRNAs and then the final latent 
protein, Kaposin (Fig. 1.4). The latency gene products are transcribed from three 
differentially regulated promoters: LTc, LTi and LTd (Fig. 1.4) (Pearce et al., 2005; 
Sarid et al., 1999; Dittmer et al., 1998; Li et al., 2002). This creates a complex 
interwoven network of mono, bi and cistronic mRNAs. Transcription from LTc 
generates a 5.7kb transcript which encodes ORF71-73. Splicing of this long 
mRNA generates another shorter transcript encoding only ORF71 and ORF72 
(Dittmer et al., 1998). Regardless of mRNA splicing activities all three transcripts 
from LTc are coterminal. Transcription of ORF71-73 is also initiated from a 
promoter downstream of LTc and proximal to ORF73, designated LTi. This 
promoter is stimulated by transcription activator (RTA/ORF50) during lytic 
replication (Matsumura et al., 2005). The third promoter, LTd generates a 1.5kb 
product encoding ORF71 and ORF72, and a 2.5kb spliced mRNA which encodes 
all the kaposin isoforms (Sadler et al., 1999; Liu et al., 2002). The LTd promoter is 
active during latency and induced upon lytic replication. In addition to the 
kaposins, this 2.5kb mRNA may also give rise to the KSHV miRNAs (Fig. 1.4) 
(Pearce et al., 2005).  
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Figure 1.4 Organisation, promoters and transcripts of the KSHV latency region. Schematic 
representation of KSHV miRNA organization in the latency associated region of the viral genome. 
Viral miRNAs are indicated by horizontal blue lines with the genomic locations noted below. 
Individual KSHV miRNA hairpins are shown above. Protein coding open reading frames are 
shown in pink. The kaposin open reading frame is preceded by two sets of direct repeats (Blue 
rectangles, DR1 and DR2). The various promoters and transcripts encoding latency proteins and 
miRNAs are shown below. Black arrows correspond to promoters with purple arrows representing 
mRNA transcripts and black lines indicating excised RNA. The length of each transcript is noted. 
The miRNA cluster may be processed from a large intron spliced from the 2.5kb transcript 
initiated from LTd. Promoters: LTc, constitutively active latency promoter; LTi, inducible latency 
promoter; LTd, downstream latency promoter. ?, The promoter of this transcript identified by   
(Sadler et al., 1999) remains uncharacterized. 
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1.1.5.3.1 LANA 
LANA is a large protein with central region of acidic repeats separating the N- and 
C-terminal domains. The C-terminus is a sequence-specific DNA binding region 
which recognises the viral terminal repeats (Ballestas and Kaye, 2001), the N 
terminus interacts with host chromatin-associated histones (Cotter and 
Robertson, 1999; Barbera et al., 2006). Episome tethering to host chromatin is 
mediated by LANA through these domains and this protein has been shown to be 
the sufficient for long term episomal maintenance (Ballestas et al., 1999). During 
mitosis LANA is bound to the viral terminal repeats and interacts with histones H1, 
H2A and H2B present on host cell chromatin (Cotter and Robertson, 1999; 
Ballestas and Kaye, 2001; Barbera et al., 2006). In addition to tethering the viral 
episome, LANA has a number of additional functions which contribute more 
directly to KSHV-oncogenesis and has led to LANA being classified as an 
oncogene. 
 
LANA interacts with p53 repressing its transcriptional activity, the resulting 
attenuation of p53-mediated cell cycle arrest or apoptosis promotes cell survival 
(Friborg, Jr. et al., 1999). This correlates with the observation that expression of 
LANA in primary endothelial cells extends their lifespan in culture (Watanabe et 
al., 2003). However, PEL cells have been shown to respond to the 
chemotherapeutic agent doxorubicin with p53 activation and growth arrest, 
indicating that, at least in these cells, LANA does not completely abolish p53 
activity (Petre et al., 2007). LANA also binds to pRb which inhibits its association 
with E2F, leaving E2F free to activate genes controlling cell cycle progression 
(Radkov et al., 2000). However, as with p53, LANA inhibition of pRB is only partial 
(Platt et al., 2002).  Furthermore, LANA has been shown to bind to glycogen 
synthase kinase 3β (GSK-3β) relocating it to the nucleus (Fujimuro et al., 2003). 
This relocation prevents GSK-3β-dependent phosphorylation and subsequent 
proteosomal degradation of β-catenin. Consequently, β-catenin accumulates and 
activates transcription of c-myc, c-jun and Cyclin D. In this way LANA promotes 
entry to S-phase (Fujimuro et al., 2003). 
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1.1.5.3.2 vCyclin 
Viral Cyclin (vCyclin) is an orthologue of cellular Cyclin D (Chang et al., 1996). 
Cyclin D proteins activate kinases which phosphorylate key cell cycle check point 
proteins, promoting cell cycle progression. vCyclin, like its cellular counterpart, 
phosphorylates cdk6 leading to inhibition of pRB (Godden-Kent et al., 1997). 
However, vCyclin demonstrates additional properties that distinguish it from 
cellular Cyclin D. vCyclin has an expanded substrate specificity leading to 
phosphorylation of p27, H1 and cdc25a (Godden-Kent et al., 1997; Li et al., 1997; 
Mann et al., 1999). In addition, vCyclin displays decreased sensitivity to inhibition 
by Cyclin dependant kinases, such as p27 (Ellis et al., 1999; Mann et al., 1999). 
Indeed the acquired ability of vCyclin to phosphorylate its inhibitor p27 targets this 
protein for degradation releasing vCyclin from its control. Ectopic expression of 
vCyclin in primary cells causes growth arrest and sensitises cells to apoptosis, 
these effects are p53 dependant (Verschuren et al., 2002). Therefore, only in the 
absence of p53 can vCyclin confer a growth advantage to cells (Verschuren et al., 
2002). 
 
1.1.5.3.3 vFLIP 
vFLIP is a small protein composed of two tandem death effector domains. vFLIP 
is so called due to its homology to cellular FLICE-inhibitory proteins (FLIPs) 
(Thome et al., 1997). These proteins inhibit apoptosis by blocking recruitment of 
caspase 8 to the death receptor signalling complexes. Exogenous vFLIP 
expression in B cells has also been shown to inhibit apoptosis in this manner 
(Djerbi et al., 1999). In addition, vFLIP inhibits apoptosis by activating NFκB. 
vFLIP binds to the γ subunit of IKB kinase (IKK) which induces phosphorylation of 
this protein and eventual proteolysis (Liu et al., 2002; Field et al., 2003; Bagneris 
et al., 2008). Degradation of IKK releases NFκB subunit which moves to the 
nucleus and stimulates gene expression. NFκB activation results in the up-
regulation of cytokines including chemokines. Therefore, the expression of vFLIP 
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in latently infected KS spindle cells explains in part the mechanism behind the 
proinflammatory microenvironment which is characteristic of KS (Xu and Ganem, 
2007; Punj et al., 2009; Sakakibara et al., 2009). Through activating NFκB, vFLIP 
induces cytoskeletal rearrangements which produce the typical spindle shape of 
KSHV infected endothelial cells (Grossmann et al., 2006). PEL cells are 
dependant on vFLIP for their survival. Consequently, silencing of vFLIP by siRNA 
or inhibition of NFκB in vitro (Keller et al., 2000; Guasparri et al., 2004) and in vivo 
(Godfrey et al., 2005) led to B cell death. vFLIP expression in B cells led to 
tumour development in mice, due to inhibition of apoptosis (Djerbi et al., 1999). 
Therefore, vFLIP is likely to play a pivotal role in KSHV-mediated oncogenesis.  
 
1.1.5.3.4 Kaposins 
The kaposins are a set of three proteins latently expressed in PEL and KS 
(Staskus et al., 1997; Sturzl et al., 1997). The kaposins are transcribed on a 
distinct transcriptional unit from other latency proteins (Sadler et al., 1999). 
Transcription from the kaposin promoter encodes a small open reading frame, 
which is preceded by two direct repeats of GC rich sequences (DR1 and DR2). 
Translation of the ORF generates Kaposin A, whereas translation of the two DR 
gives rise to kaposin B. Translation of the DRs in frame with the ORF generates 
the final kaposin, kaposin C (Sadler et al., 1999).  
 
Kaposin A is a transmembrane protein whose over-expression transformed 
immortalised rodent fibroblasts, clones of which generated tumours in nude mice 
(Muralidhar et al., 1998). The mechanism and relevance of this finding remains 
obscure, since spindle cells from KS tumours do not form colonies in soft agar, 
neither do they induce colonies in mice. Kaposin A binds the guanine exchange 
factor cytohesin-1, which is a regulator of integrin mediated cell adhesion. 
Potentially, this interaction may explain Kaposin A’s transforming abilities. 
Alternatively, Kaposin A has also been shown to interact and inhibit septin A, 
which is a proapoptotic caspase 3 activator. This function may also contribute to 
kaposin A mediated transformation (Lin et al., 2007). Kaposin B is a small 
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polypeptide with no known catalytic motifs, it therefore elicits its function through 
interacting with other proteins (McCormick and Ganem, 2005). One such protein 
is mitogen-activated protein kinase-associated protein kinase 2 (MK2), binding of 
MK2 by kaposin B leads to MK2 activation via p38 phosphorylation (McCormick 
and Ganem, 2005). Activated MK2 is then free to phosphorylate its downstream 
targets, one of which is tristeraprolin (TTP). TTP stabilises mRNAs which contain 
AU-rich elements (ARE) including cytokine and growth factors (Sandler and 
Stoecklin, 2008). Therefore, along with vFLIP, kaposin B expression contributes 
to the cytokine rich tumour microenvironment of KS. To date there are no studies 
investigating the function of kaposin C and as a result its role in latency or 
pathogenesis remains obscure. 
 
1.1.5.3.5 KSHV-encoded microRNAs (miRNAs) 
In addition to the latent proteins, KSHV encodes an array of miRNAs, which are 
expressed primarily during latency (Pfeffer et al., 2005; Samols et al., 2005; Cai et 
al., 2005). miRNAs are small non-coding RNA molecules which negatively 
regulate gene expression (Bartel, 2004). KSHV encodes 12 pre miRNAs, 10 of 
which are located in a 3.6kbp intragenic gap between the Kaposin open reading 
frame and vFLIP; this is the longest sequence devoid of open reading frames in 
the unique region of the KSHV genome (Cai et al., 2005; Samols et al., 2005). 
The other two pre miRNAs are located upstream, one is situated within the K12 
ORF and the other just proximal to the K12 coding sequence (Grundhoff et al., 
2006). These 12 pre-miRNAs give rise to 17 mature effector miRNAs which are 
capable of regulating both host and viral gene expression. There is very little 
sequence variation in viral miRNAs between KSHV isolates (Marshall et al., 
2007), however these miRNAs are not conserved between different herpesviruses 
(Schafer et al., 2007).  
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The role of the KSHV miRNAs in establishing infection and KS pathogenesis is 
still poorly understood. Thrombospondin-1 (THBS1) was the first cellular target of 
the KSHV miRNAs to be identified (Samols et al., 2007). THBS1 is a 
multifunctional protein; it is a known agonist of angiogenesis and its expression 
up-regulates cell adhesion molecules and promotes recruitment of monocytes to 
endothelial cells (Narizhneva et al., 2005). Therefore, THBS1 down-regulation by 
the KSHV miRNAs may contribute to the angiogenic phenotype of KS lesions and 
aid immune evasion of infected cells (Samols et al., 2007). Another validated 
miRNA target is BCLAF1, down-regulation of this protein in latently infected PEL 
cells led to decreased virus production following lytic induction (Ziegelbauer et al., 
2009). This finding suggests the viral miRNAs may act to promote latency. Similar 
to protein coding viral genes, KSHV miRNA miR-K12-11 displays significant 
sequence similarity to the cellular miRNA miR-155 (Skalsky et al., 2007; Gottwein 
et al., 2007). These two miRNAs share the same seed region, which dictates 
miRNA target-specificity, consequently they regulate an overlapping set of genes 
(Skalsky et al., 2007; Gottwein et al., 2007). miR-155 is a lymphoid specific 
miRNA with a role in B and T cell differentiation (Thai et al., 2007; Turner and 
Vigorito, 2008) and T cell regulation (Lu et al., 2009). Furthermore, this miRNA is 
also implicated in B cell transformation and is frequently up-regulated in certain 
lymphomas (Eis et al., 2005; Costinean et al., 2006). Since miR155 is not 
expressed in PEL cells, it is tempting to speculate that miR-K12-11 mimics its 
function, playing an important role in PEL development (Skalsky et al., 2007). 
However, the role of miR-K12-11 is KS pathogenesis has not been investigated.  
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An investigation by Murphy et al into whether herpesvirus-encoded miRNAs 
regulate viral gene expression, revealed that although lacking sequence 
conservation miRNAs from all three herpesvirus families, including KSHV, were 
predicted to suppress immediate early proteins (Murphy et al., 2008). 
Suppression of the IE gene, IE1, was experimentally confirmed in the context of 
HCMV infection, and this silencing suppressed lytic reactivation (Murphy et al., 
2008). These findings suggest a role for viral miRNAs in maintaining latency. The 
KSHV miRNAs were predicted to target the KSHV early lytic protein, RTA which is 
the major inducer of lytic replication (Murphy et al., 2008). Recent studies have 
experimentally confirmed KSHV miRNA auto-regulation of RTA, in this manner 
the KSHV miRNAs favour latency by down-regulating levels of the lytic 
transactivator (Bellare and Ganem, 2009; Lei et al., 2010; Lu et al., 2010).  
 
1.1.5.4 Lytic infection  
Latently infected cells provide a reservoir of viral genomes from which KSHV can 
be produced, resulting in dissemination within or between hosts. In order to do so 
the virus must be reactivated from latency through a programme of active gene 
expression and DNA replication, culminating in the synthesis of new virions and 
host cell death. In KS lesions 1-5% of spindle cells at any one time are 
undergoing lytic replication (Staskus et al., 1997; Direkze and Laman, 2004). 
KSHV reactivation precedes the development of KS, with viral replication 
increasing during disease progression (Campbell et al., 2000; Boneschi et al., 
2001). Furthermore, an increase in KSHV DNA correlates with the appearance of 
new KS lesions (Cannon et al., 2003) and lytic gene products contribute to KS 
pathogenesis through paracrine effects (Direkze and Laman, 2004). These data 
highlight the pathogenic effect of lytic reactivation in KSHV-induced disease. 
 
Through the in vitro study of lytic reactivation from latent PEL cells, a number of 
factors have been shown to trigger the switch from latent to lytic infection. The 
most potent and widely used chemical inducer is phorbol ester tetradecanoyl 
phorbol acetate (TPA) (Renne et al., 1996b). Other stimuli include interferon γ 
(IFNγ) and additional cytokines (Mercader et al., 2000), NFkB inhibitors 
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(Grossmann and Ganem, 2008) and expression of the transcription factor XBP-1 
(Wilson et al., 2007). The mechanisms of action of these stimuli highlight multiple 
mechanisms by which lytic infection can be induced. Despite extensive in vitro 
characterisation, the physiological ligands which reactivate KSHV in vivo remain 
unknown. The principle site of lytic reactivation in vivo is the B cells of the tonsil or 
other lymphoid tissue in the oropharynx (Duus et al., 2004). A single viral gene 
known as replication and transcription activator or RTA is both necessary (Lukac 
et al., 1999) and sufficient (Gradoville et al., 2000) to bring about lytic replication. 
RTA is a sequence specific DNA binding protein (Lukac et al., 1998) that triggers 
the lytic cycle by activating transcription from key lytic promoters, as well as 
initiating viral DNA replication (Song et al., 2003). RTA also activates its own 
promoter, augmenting lytic protein expression and DNA replication (Gradoville et 
al., 2000). In those lytic promoters which lack an RTA binding motif, RTA activates 
transcription through protein-protein interactions with cellular transcription factors 
including CSL-1(Liang et al., 2002; Liang and Ganem, 2003) and CRB binding 
protein (CBP) (Gwack et al., 2001). In latently infected PEL cells the RTA 
promoter is silenced by methylation (Chen et al., 2001). In addition, LANA has 
been shown to negatively regulate RTA both directly (Lan et al., 2004) and 
indirectly through sequestering of RTA cellular cofactors (Lan et al., 2005). 
Therefore, KSHV employs a number of mechanisms to minimize RTA expression 
in order to maintain latency.  
 
Lytic reactivation initiated by RTA is characterised by a tightly regulated temporal 
cascade of gene expression that culminates in the production of new viral 
particles. The first wave of gene expression is termed immediate early (IE), these 
genes are regulators of lytic gene expression. The IE genes switch on the delayed 
early (DE) genes which mediate viral DNA replication, immune evasion and host 
gene expression shutoff. Following DNA replication the late (L) genes are 
activated, these form the structural components of the virion. Once newly 
synthesized capsids exit the nucleus they acquire an envelope by budding 
through the cellular membrane.  
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1.1.5.5 Lytic proteins 
Multiple lytic proteins have been shown, via paracrine effects, to contribute to the 
proangiogenic and proinflammatory environment of KS.  
 
1.1.5.5.1 Viral interleukin 6 (vIL6) 
vIL6 is homologous to hIL6, sharing 25% amino acid identity (Molden et al., 1997; 
Neipel et al., 1997b). vIL6 is expressed in approximately 5% of KS spindle and 
PEL cells, which corresponds to the proportion of lytic cells present in these 
tumours (Parravicini et al., 2000; Brousset et al., 2001). vIL6 is a functional 
cytokine which stimulates the proliferation of cells in vitro (Burger et al., 1998; 
Moore and Chang, 1998) and activates signalling pathways through stimulation of 
Jankus activated kinases (JAK)/signal transducers and activators of transcript 
(STAT) and the mitogen activated protein kinases (MAPK). In addition to these 
effects, vIL6 up-regulates proangiogenic molecules vascular endothelial growth 
factor (VEGF) A (Aoki et al., 1999) and angiopoietin-2 (Vart et al., 2007). hIL6 
signals by binding to the IL6 receptor which consists of the gp80 binding subunit 
and the signal transducing subunit, gp130. hIL6 signalling is regulated by the 
limited distribution of gp80. However, vIL6 signals solely through gp130 and 
therefore has wider ranging effects (Molden et al., 1997). KS tumours are rich in 
hIL6 (Miles et al., 1990) with vIL6 augmenting the expression of its cellular 
counterpart (Mori et al., 2000), highlighting the importance of IL6 as an 
inflammatory molecule in KS development.  
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1.1.5.5.2 Viral CC-class chemokines (vCCLs) 
KSHV encodes three chemokine homologues, known as vCCL1 (K6) vCCL2 (K4) 
and vCCL3 (K4.1), (also referred to as viral macrophage inhibitory proteins, 
vMIP1-3) (Moore et al., 1996; Nicholas et al., 1997) all of which are expressed 
during lytic replication. These chemokines interact with the chemokine (C-C motif) 
receptors (CCR) 3, 4 and 8, each showing distinct receptor specificity (Boshoff et 
al., 1997; Sozzani et al., 1998; Stine et al., 2000). The vCCLs attract inflammatory 
cells to the site of KS lesions including eosinophils and TH2 cells (Nicholas, 
2005), thereby contributing to the proinflammatory environment of KS lesions. 
Interestingly, unlike their cellular homologues the vCCLs are angiogenic in the 
chick chorioallantoic (CAM) assay (Boshoff et al., 1997; Stine et al., 2000).  
 
1.1.5.5.3 Viral G-protein coupled receptor (vGPCR) 
Another one of KSHVs pirated cellular genes is viral G protein-coupled receptor 
(vGPCR), a constitutively active transmembrane signalling molecule (Cesarman 
et al., 1996; Arvanitakis et al., 1997). vGPCR is related to the cellular IL8 
receptors CXCR1 and CXCR2 (Cesarman et al., 1996). vGPCR induces the 
angiogenic molecules VEGFA (Bais et al., 1998), angiogenin  (Sadagopan et al., 
2009) and angiopoietin-2 (Vart et al., 2007), as well as proinflammatory factors 
IL6, IL4 and IL8 (Shepard et al., 2001). vGPCR also activates a number of 
signalling pathways including the mitogenic p38 MAPK, MEK and JNK pathways 
(Smit et al., 2002), the antiapoptotic AKT pathway (Montaner et al., 2001) and NF-
κB (Shepard et al., 2001). Transgenic mice expressing vGPCR form vascular 
tumours which are morphogenically similar to KS lesions (Guo et al., 2003) and its 
expression transforms mouse NIH3T3 cells (Bais et al., 1998). Therefore, despite 
the fact that only 5% of KS spindle cells express vGPCR, its upregulation of 
angiogenic and inflammatory cytokines could be pivotal in the development of KS. 
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1.1.5.5.4 Viral Interferon regulatory factors (vIRFs)  
KSHV encodes four genes with sequence similarity to human interferon regulatory 
factors (IRFs): vIRF1, vIRF2, vIRF3 (also known as LANA-2) and K10.5/10.7. 
Phylogenetic analysis revealed vIRF1 is likely derived from a host IRF and 
subsequent gene duplication gave rise to the other three vIRFs (Jenner and 
Boshoff, 2002). The cellular IRFs are a family of transcription factors which in 
response to interferon signalling, mediate the host antiviral and antibacterial 
immune response (Paun and Pitha, 2007). The programme of vIRF gene 
expression is not as well defined as other KSHV genes. vIRF is latently expressed 
in PEL cell lines and in KS, however it is also induced upon lytic replication 
(Dittmer, 2003; Pozharskaya et al., 2004). vIRF3 shows latent expression in both 
PEL and MCD, although is not detected in KS (Rivas et al., 2001). Therefore, the 
vIRFs may be relevant to both lytic and latent lifecycles with their expression 
varying between KSHV-associated malignancies.  
 
vIRF1 is the most extensively characterised, it plays an important role in 
regulating the host immune response to KSHV by inhibiting IFN signalling within 
infected cells. vIRF1 has been shown to inhibit both INFα and INFβ stimulated 
transcription (Zimring et al., 1998; Li et al., 1998; Lin et al., 2001). vIRF1 can bind 
directly to DNA through its DNA binding domain (Park et al., 2007), thereby 
inhibiting expression of genes involved in the immune response. However, vIRF1 
also binds to and sequesters transcriptional coactivators CREB and CBP, thus 
preventing them from activating transcription of antiviral cytokines (Li et al., 1998; 
Seo et al., 2000; Lin et al., 2001). Binding of vIRF1 to p300 represses this 
protein’s histone acetylase activity, further inhibiting gene activation (Li et al., 
2000). vIRF2 acts in a similar manner to vIRF1, inhibiting the interferon response 
by binding to cellular IRFs and p300. In this way vIRF2 inhibits IRF1 and IRF3 
mediated transcriptional activation of the IFNα promoter (Burysek et al., 1999). 
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1.2 Lymphatic Endothelium   
The primary function of the lymphatic vasculature is to collect and drain protein 
rich fluid (lymph) from extracellular spaces within most organs, and return this 
interstitial fluid to the cardiovascular system to maintain normal tissue fluid 
balance and interstitial pressure (Oliver and Alitalo, 2005; Karpanen and Makinen, 
2006; Cueni and Detmar, 2008). The lymphatic system developed in higher 
organisms in response to an additional need to clear tissues of substances not 
absorbed by the blood vasculature (Yoeffry and Courtice, 1970). First described 
as “milky veins” in 1627 by Gasparo Asellius (Asellius, 1627) the lymphatic 
vasculature has gone largely un-investigated until recent years when molecular 
biology techniques facilitated the identification and characterisation of lymphatic-
specific molecules and the role they play in lymphangiogenesis (growth of new 
lymphatic vessels from pre-existing lymphatic vessels) (Alitalo and Carmeliet, 
2002).  
 
1.2.1 Organisation of the lymphatic system 
Unlike the blood vasculature which is circulatory, the lymphatic system is 
unidirectional. Lymph fluid is collected from tissues by lymph capillaries and 
returned to the venous arteries through a series of larger collecting lymphatic 
vessels (Fig. 1.5) (Witte et al., 2001). Lymphatic capillaries responsible for 
absorbing lymph fluid are distinct from blood capillaries, in that they are blind 
ended structures which lack a continual basal lamina (Oliver and Alitalo, 2005) . 
Lymph capillaries are composed of a single layer of endothelial cells which, unlike 
blood vessels, lack intercellular continuous VE-cadherin linked tight junctions. 
Instead, lymphatic endothelial cells (LEC) form discontinuous button-like 
intercellular junctions generating small inter-endothelial pores (Leak, 1976; 
Dejana, 2004; Baluk et al., 2007). LEC are anchored by filaments to this 
discontinuous basement membrane (Gerli et al., 2000). These features render 
lymphatic capillaries highly permeable to lymph fluid as well as pathogens and 
migrating cells, free movement of which are required for lymphatic functioning 
(Dejana, 2004; Oliver and Alitalo, 2005). Lymphatic capillaries also lack 
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supporting pericytes which in blood vessel capillaries act to reduce leakage and 
prevent haemorrhaging (Oliver and Alitalo, 2005; Baluk et al., 2007). Small 
lymphatic capillaries feed into larger lymphatic vessels, which are lined with 
smooth muscle cells to facilitate fluid transport and contain flap-like valves to 
prevent lymph backflow (Fig. 1.5). The lymphatic vessels collect at the thoracic 
duct and right lymphatic duct where lymph fluid is returned to the blood circulatory 
system via large veins at the base of the neck (Fig. 1.5) (Oliver and Alitalo, 2005). 
The lymphatic system lacks a central pump such as the heart. Instead, fluid is 
moved by the combined actions of skeletal muscle, respiratory movement and 
peristaltic contractions of the smooth muscle cells lining the lymphatic vessels 
(Cueni and Detmar, 2008). 
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Figure 1.5 Lymphatic vasculature organisation. Lymph fluid is collected from tissues by 
permeating blunt-ended lymphatic capillaries. These capillaries are tethered to the extra cellular 
matrix by anchoring filaments. The lymphatic capillaries drain into the pre-collector lymphatic 
vessels, which in turn empty into larger collecting lymphatic vessels. Large lymphatic vessels are 
lined with smooth muscle cells to facilitate fluid transport and flap-like valves which aid directional 
flow and prevent lymph back flow. The lymphatic vessels converge at the thoracic duct and return 
lymph to the blood circulatory system via the subclavian vein. Picture taken from Maby-EL and 
Petrova (Maby-El and Petrova, 2008).  
   
 
 
 
53 
In addition to lymphatic vessels, the lymphatic system includes the lymphoid 
organs; these are the lymph nodes, tonsils, peyers patches, spleen and the 
thymus, all of which are involved in the immune response. Lymphatic vessels are 
not found in the brain and retina, as well as avascular tissues such as the 
epidermis, hair, nails, cartilage and cornea.  
 
1.2.2 Lymphatic function in health and disease 
In addition to collecting and redistributing tissue fluid, the lymph system has an 
important role in immune surveillance. Upon antigen recognition, stimulated 
dendritic cells exit tissues and enter the lymphatic vasculature, from here they 
migrate to lymph nodes and other lymphoid organs where immune responses are 
mounted (Johnson and Jackson, 2008). In the intestine the lymphatic system also 
plays a role in fat absorption, here specialised lymph vessels called lacteals 
absorb dietary fat and transport it via the lymphatic vasculature back to the 
circulatory system (Cueni and Detmar, 2006). Acquired or congenital defects in 
the lymphatic system lead to lymphoedema, an accumulation of lymph fluid in the 
tissues, which results in swelling of the extremities and can often involve 
inflammatory reactions and fibrosis (Witte et al., 2001; Cueni and Detmar, 2008). 
During oncogenesis the lymphatic vasculature provides migrating tumour cells an 
access route to secondary sites within the body, thereby facilitating metastasis 
(Skobe et al., 2001). The loosely connected lymphatic endothelium and 
discontinuous basement membrane facilitates tumour cell egress and 
dissemination to regional lymph nodes (Alitalo and Carmeliet, 2002). In breast 
cancer the degree of tumour-associated lymphangiogenesis correlates with 
secondary metastasis to the lymph nodes and lung (Skobe et al., 2001). 
Importantly, tumour cell metastasis to lymph nodes is used as a prognostic 
indicator in the assessment of cancer patients and can influence the adopted 
therapeutic regime. An additional role for the lymphatic system in cancer was 
highlighted by studies suggesting the lymphatic origin of KS tumour cells (Jussila 
et al., 1998; Skobe et al., 1999; Hong et al., 2004; Wang et al., 2004).  
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1.2.3 Lymphangiogenesis  
In mice the lymphatic vasculature develops at embryonic day 5 (E5), after the 
formation of a functional blood vasculature (Oliver and Detmar, 2002) . Through 
ink injection experiments in developing pigs, Florence Sabin observed that 
primitive lymph sacs in the jugular region originated from endothelial cells budding 
off from pre-existing veins (Sabin, 1902). This observation led Sabin to propose 
the centrifugal theory of lymphatic development, stating that lymphatic endothelial 
cells were derived from venous endothelium (Sabin, 1902). The primitive lymph 
sacs formed after endothelial budding are present one month after the 
development of the first blood vessels in six week old mice (van der Putte, 1975). 
After the establishment of lymph sacs, cells sprout towards the periphery where 
they form capillaries which permeate tissues and organs (Sabin, 1902; van der 
Putte, 1975). The recent discovery of lymphatic-specific markers has furthered 
research into the process of lymphangiogenesis and the molecules which regulate 
it. Observing the sequential acquisition of LEC markers during embryogenesis, 
Oliver and Harvey formulated a step wise model of lymphatic development (Oliver 
and Harvey, 2002). The four main steps are LEC competence, LEC bias and LEC 
specification culminating in lymphatic vessel differentiation and maturation (Oliver 
and Harvey, 2002; Oliver, 2004)  
 
1.2.3.1 Initiation of lymphatic endothelial phenotype  
Lymphatic vasculature development begins with a subset of venous endothelial 
cells in the anterior cardinal vein responding to lymphangiogenic signals. Although 
these inducing signals are not yet known, the expression of lymphatic endothelial 
hyaluronan receptor-1 (LYVE1) at E9 in developing mice is the first indication of 
lymphatic commitment (Banerji et al., 1999; Prevo et al., 2001). Expression of 
LYVE1 indicates that venous endothelial cells are primed for lymphatic 
development and ready to receive additional inductive signals for LEC 
specification (Wigle et al., 2002). However, the absence of lymphatic vasculature 
defects in LYVE-1 knock-out mice suggests the existence of additional molecules 
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and pathways involved in initiating lymphatic development (Gale et al., 2007). 
LYVE1 is a hyaluronan transporter which aids leukocyte migration across the 
lymph vessel wall (Jackson, 2004). In adults, LYVE1 expression is down-
regulated in collecting lymph vessels but up-regulated in lymphatic capillaries 
(Makinen et al., 2005).  
 
A few hours after LYVE1 expression at E9.5, PROX1 (prospero homeobox 1) is 
detected in developing mice (Wigle and Oliver, 1999). In contrast to LYVE1 
expression which is uniform, PROX1 is expressed in a small sub-population of 
endothelial cells located at one side of the cardinal vein (Wigle and Oliver, 1999). 
Polarized expression of PROX1 gives rise to the entirety of the lymphatic system, 
with cells budding and migrating in a directional manner from the site of PROX1 
expression, eventually giving rise to the primary lymph sacs (Maby-El and 
Petrova, 2008). The venous origin of the lymphatic system was conclusively 
proven by lineage tracing experiments, whereby LEC were shown to sprout from 
venous derived lymph sacs which then proliferated and migrated to give rise to 
the lymphatic vasculature (Srinivasan et al., 2007). PROX1 is an evolutionary 
conserved homeobox-containing transcription factor, it is the most specific marker 
of lymphatic endothelium, identified so far. PROX1 knock-out mice are embryonic 
lethal and completely lack a lymphatic vasculature which is attributed to failure in 
LEC specification. In contrast, the blood vasculature develops as normal in these 
mice (Wigle and Oliver, 1999; Wigle et al., 2002). Several lines of evidence have 
led to the classification of PROX1 as the master regulator of lymphatic 
differentiation: In the absence of PROX1 venous endothelial cells fail to begin 
lymphatic specification, those cells which bud from the cardinal vein lack LEC 
marker expression, instead they continue to express blood vessel endothelial cell 
(BEC) markers; ectopic expression of PROX1 in cultured BEC suppresses BEC 
identity and induces expression of LEC specific genes (Hong et al., 2002; Petrova 
et al., 2002; Wigle et al., 2002). Therefore, PROX1 is both required and sufficient 
to confer the LEC phenotype. These findings led Wigle et al to propose that the 
default ground state of LEC was that of venous endothelium and only after 
expression of PROX1 will these cells enter the path of lymphatic differentiation 
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(Wigle et al., 2002; Oliver and Detmar, 2002). PROX1 is expressed in a range of 
other tissues, such as the retina, brain and kidney where it also plays a role in 
tissue specification and development, however it is not expressed in blood 
vessels endothelial cells (Wigle and Oliver, 1999; Wigle et al., 2002). PROX1 can 
function both as an enhancer or repressor of transcription. 
 
Despite the well characterised role for PROX1 in lymphatic development, the 
signals which trigger its own expression and the expression of downstream target 
genes are poorly understood (Maby-El and Petrova, 2008). Interleukin 3 and 7 
have both been shown to induce PROX1 expression in cultured BEC, however 
validation of these as PROX1 initiating signals in vivo has yet to be been 
confirmed (Al-Rawi et al., 2005; Groger et al., 2004). Groger et al showed that 
LEC, but not BEC, constitutively expressed IL3 which regulated expression of 
PROX1 and podoplanin (PDPN), another LEC distinguishing protein (Groger et 
al., 2004). Furthermore, when IL3 was inhibited in LEC, this abolished PROX1 
and PDPN expression. Therefore, in vitro at least, IL3 is required to maintain LEC 
differentiation status (Groger et al., 2004). In cultured LEC, PROX1 was shown to 
initiate expression of key regulators of lymphatic development, including VEGRF3 
(Petrova et al., 2002; Saharinen and Petrova, 2004; Wigle et al., 2002) and 
integrin α9 (Mishima et al., 2007).  
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1.2.3.2 Plasticity of the LEC phenotype 
Cellular differentiation occurs at specific points during development and is 
coordinated by cascades in gene expression initiated by master regulator 
transcription factors, which are themselves regulated by signals from the local 
tissue environment. The classical viewpoint of differentiation is that of a 
unidirectional, terminal and irreversible process (Weissman, 2000). The 
specialisation of blood and lymphatic vessels in this manner is reflected by distinct 
gene expression profiles and signalling pathways in the corresponding endothelial 
cells (Seo et al., 2006; Adams and Alitalo, 2007). For example, arterial endothelial 
cells express a distinguishing array of genes which are absent from venous or 
lymphatic endothelial cells (Adams and Alitalo, 2007).  
 
However, there is mounting evidence in support of developmental plasticity, 
whereby transcription factors can re-programme fully differentiated cells. 
Takahashi et al induced pluripotent stems cells from somatic cells by transduction 
of four specific transcription factors (Takahashi and Yamanaka, 2006). Plasticity 
of lymphocytes was demonstrated when mature B cells were reprogrammed into 
functional T cells through inhibition of PAX5 (Cobaleda et al., 2007; Cobaleda and 
Busslinger, 2008). Disruption or forced expression of notch signalling 
reprogrammed arterio-venous identity, demonstrating the plasticity of blood vessel 
endothelial cells (You et al., 2005; Roca and Adams, 2007).  
 
In LEC, PROX1 is expressed in post-natal LEC and lymphatic vessels throughout 
adult life. Down-regulation of PROX1 was observed in defective lymphatics of 
mutant mouse models (Wilting et al., 2002; Odaka et al., 2006; Backhed et al., 
2007; Baluk and McDonald, 2008). LEC identity is acquired upon expression of 
PROX1 in BEC and siRNA knock down of PROX1 in LEC leads to upregulation of 
BEC markers and down-regulation of LEC specific genes (Petrova et al., 2002; 
Hong et al., 2002). These findings argue against terminal differentiation, instead 
they provide evidence for LEC plasticity. The majority of PROX1 heterozygous 
knockout mice die shortly after birth, those which survive have mis-patterned and 
leaky lymphatic vasculature suggesting lymphatic functioning is sensitive to 
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PROX1 dosage (Harvey et al., 2005). Johnson et al elegantly proved the plasticity 
of LEC identity through the use of time specific conditional PROX1 knockout mice 
(Johnson et al., 2008). When PROX1 was silenced in either the embryonic, post-
natal or adult mouse, severe defects in the lymphatic vasculature were observed 
(Johnson et al., 2008). Therefore, PROX1 is required not only for the initiation of 
LEC identify but also the maintenance of LEC phenotype throughout adult life. 
Interestingly, adult PROX1 mutant lymphatic vessels became morphologically 
akin to blood vessels: supporting pericytes were identified, LEC specific button 
junctions were lost and connections to the blood circulation initiated with red blood 
cells appearing in the lumen of mutant vessels. COUPTFII (Chicken ovalbumin 
upstream promoter transcription factor II) is expressed exclusively in venous 
endothelial cells and genetic loss of this transcriptional co-regulator results in a 
switch from venous to arterial identity (You et al., 2005). Recently, COUPTFII was 
identified as a coactivator of PROX1(Lee et al., 2009). COUPTFII physically 
interacts with PROX1 (Lee et al., 2009; Yamazaki et al., 2009) GEM profiling of 
LEC lacking either or both proteins confirmed that COUPTFII augments PROX1 
activation of certain LEC specific genes (Lee et al., 2009). These data suggest 
COUPTFII may be an important cofactor in establishment of LEC fate (Lee et al., 
2009). There were a number of LEC specific genes differentially regulated by the 
two factors, suggesting there are other important regulators of LEC fate yet to be 
identified. 
 
1.2.3.3 Lymphatic sprouting and proliferation: VEGFR3 and VEGFC 
Following specification in the cardinal vein, LEC undergo directional proliferation 
and sprouting resulting in the formation of primary lymph sacs at a defined 
location. This polarized migration is regulated through expression of a lymphatic-
specific receptor signalling system (Oliver, 2004). VEGF receptor 3 (VEGFR3) 
was identified as one of the first markers associated with lymphatic development 
(Kaipainen et al., 1995). Missense mutations in VEGFR3 in patients with 
hereditary lymphoedema highlight the importance of this gene in lymphatic 
development (Karkkainen et al., 2004). VEGFR3 is expressed early during mouse 
embryonic development and is widely expressed in both the lymphatic and blood 
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vasculature, including the anterior cardinal vein (Kaipainen et al., 1995; Dumont et 
al., 1998). VEGFR3 is expressed in all endothelial cells and plays an important 
role in blood vasculature remodelling during embryogenesis (Kaipainen et al., 
1995; Dumont et al., 1998). Consequently, VEGFR3 null mice are embryonic 
lethal, dying at E9.5 due to defective remodelling of the primary vascular plexus, 
and prior to the onset of lymphangiogenesis (Dumont et al., 1998). Later in 
development and into adulthood VEGFR3 expression is subsequently down-
regulated in the blood vasculature and restricted to lymphatic endothelial cells 
(Kaipainen et al., 1995; Wigle et al., 2002). 
 
Vascular endothelial growth factor C (VEGFC) is the main ligand for VEGFR3 and 
the primary lymphangiogenic growth factor (Joukov et al., 1996; Kukk et al., 
1996). VEGFC is expressed by mesenchymal cells surrounding the cardinal vein, 
where signalling in PROX1-expressing LEC is essential for sprouting and 
migration as well as promoting LEC proliferation and survival (Oh et al., 1997; 
Saaristo et al., 2002; Karkkainen et al., 2004). VEGFC null mice are embryonic 
lethal highlighting the importance of VEGFC in lymphatic development. LEC 
specification occurs as normal in these mutant mice, however they fail to form 
primary lymph sacs and completely lack a lymphatic vasculature as LEC do not 
migrate from the cardinal vein (Karkkainen et al., 2004). Blood vessels are 
unaffected in VEGFC knock-out mice. Post-embryonic development, VEGFC is 
down-regulated in the majority of tissues, but its expression remains high in LEC 
and lymph nodes (Lymboussaki et al., 1999). In addition to VEGFC, VEGFD also 
signals via VEGFR3, thereby stimulating lymphangiogenesis (Byzova et al., 2002; 
Rissanen et al., 2003). However, VEGFD is dispensable for lymphatic 
development as null mice display only mild hyperplasia of the pulmonary 
vasculature (Baldwin et al., 2005). Although VEGFC is the primary 
lymphangiogenic growth factor, exogenous VEGFD expression is capable of 
rescuing defective vessel sprouting in VEGFC null mice (Karkkainen et al., 2004; 
Baldwin et al., 2005). Both growth factors are produced as precursor proteins 
which are activated by proteolytic cleavage, certain processed forms can also 
interact with VEGFR2 (Joukov et al., 1996; Tammela et al., 2005). 
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1.2.3.4 Regulators of lymphatic vasculature development  
Major progress has been made during the last few years to characterise the key 
molecular pathways governing lymphangiogenesis (Tammela and Alitalo, 2010). 
In addition to the proteins discussed above, Table 1.1 details proteins which play 
important role in lymphatic endothelial biology. Despite these recent advances, 
there is still a lot to be deciphered regarding lymphangiogenesis. The initiating 
signal that governs lymphatic endothelial cell fate choice is unknown, as is the 
role of circulating lymphangioblasts as a potential source of lymphatic progenitors 
(Oliver and Alitalo, 2005; Ny et al., 2005; Wilting et al., 2006). 
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Gene 
 
Protein 
 
Function 
 
Expression 
 
Reference 
 
LYVE1 
Type I integral 
membrane 
glycoprotein 
Receptor for hyaluronon in LEC, 
mediates cell migration during 
embryogenesis. Specific marker of 
lymphatic endothelium 
Mouse anterior 
cardinal vein at 
E9.5,   cell surface 
receptor 
 
(Knudson and 
Knudson, 
1993; Banerji 
et al., 1999; 
Prevo et al., 
2001) 
 
PDPN 
 
Type I integral 
membrane 
glycoprotein 
 
Precise function unknown, may 
contribute to LEC adhesion and 
migration. Distinguishing marker of 
lymphatic endothelial cells 
 
 
Mouse E11, 
expressed in 
budding embryonic 
and adult LEC 
(Oliver, 2004; 
Breiteneder-
Geleff et al., 
1999) 
 
ANGPT2 
 
Ligand for Tie2 
receptor tyrosine 
kinase 
 
Required for normal LEC 
development and patterning. Null 
mice display disorganised and leaky 
lymphatic vasculature 
 
 
Restricted to sites of 
vascular 
remodelling 
 
(Veikkola and 
Alitalo, 2002; 
Maisonpierre et 
al., 1997; Gale 
et al., 2002) 
 
NRP2 
 
Non-receptor 
tyrosine kinase 
 
Selective role in the development of 
small lymphatic vessels. Binds 
VEGFC 
 
Anterior cardinal 
vein and budding 
LEC 
(Yuan et al., 
2002; Oliver, 
2004) 
 
FOXC2 
 
Forkhead 
transcription factor 
 
Essential for morphogenesis of lymph 
valves. Cooperates with VEGRF3 
during lymphatic vasculature 
patterning 
 
Cardinal veins, 
jugular lymph sacs, 
lymph capillaries 
(Dagenais et 
al., 2004; 
Petrova et al., 
2004) 
 
EFNB2 
 
Transmembrane 
ligand for Eph 
tyrosine kinase 
 
 
Essential regulator of lymphatic 
development. Required for 
remodelling of primary lymphatic 
plexus 
 
Collecting lymph 
vessels 
 
(Makinen et al., 
2005) 
 
SYK/ 
LCP2 
 
spleen tyrosine 
kinase /lymphocyte 
cytosolic protein 2 
 
Both proteins mediate the separation 
of blood and lymphatic vasculature. 
Precise mechanism unknown 
 
 
Circulating 
haematopoietic cells 
(Abtahian et 
al., 2003) 
 
Table 1.1 Proteins involved in lymphangiogenesis and lymphatic vasculature development. 
Gene name, protein function and expression during lymphatic development are shown. 
Information was obtained from the listed references. 
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1.3 MAF 
1.3.1 Maf family identification and classification 
In 1910 Peyton Rous first described the existence of a transmissible avian tumour 
virus, this discovery led to the identification and classification of transforming 
proteins known as oncogenes (ROUS, 1910). Since this seminal discovery, 
numerous cellular oncogenes have been identified, many through the prior 
identification of a viral homologue. One such example is vMAF (viral-Musculo-
Aponeurotic-Fibrosarcoma), isolated from the oncogenic avian retrovirus AVS05, 
which induces musculo-aponeurotic-fibrosarcoma in chickens (Nishizawa et al., 
1989; Kawai et al., 1992). Using a probe containing vMAF sequences, the cellular 
counterpart, MAF (v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian), also referred to as c-maf) was cloned in a number of vertebrate genomes 
(Nishizawa et al., 1989). MAF is the archetypal transcription factor of the Maf 
family, which are basic leucine zipper (bZIP) transcription factors belonging to the 
AP1 superfamily (Fig. 1.6). According to nomenclature, the family of proteins is 
referred to as Maf and in humans the individual proteins are represented by 
capitals e.g. MAF or MAFB (Eychene et al., 2008). This API superfamily also 
includes the FOS, Jun, CREB and ATP families (Fig. 1.6) (Eychene et al., 2008). 
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Figure 1.6 MAF classification.  An unrooted phylogenic tree of the AP1 family of proteins. MAF 
Is a member of the API super family of bZIP transcription factors. The Maf family is sub-divided 
into large Mafs, of which MAF is a member, and the small Mafs. The two sub-groups are classified 
on the basis of structure and function. Proteins written in blue text represent Maf orthologues in D. 
melanogaster, those in pink correspond to C. elegans orthologues. Picture adapted from (Eychene 
et al., 2008).  
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Jun is the paradigm for transforming bZIP transcription factors and was identified 
in viral oncogenic form during the same period as vMAF (Maki et al., 1987). All 
AP1 transcription factors possess a bZIP domain: a region rich in basic residues 
followed by heptad repeats of hydrophobic residues forming the leucine zipper 
(Blank and Andrews, 1997). There are 53 genes in the human genome 
possessing a bZIP domain (Vinson et al., 2002). The leucine zipper domain 
facilitates the formation of homo or heterodimers between other bZIP possessing 
proteins, a feature characteristic of this class of transcription factors and a 
prerequisite for DNA binding (Yang and Cvekl, 2007). DNA binding is mediated 
directly by the adjacent basic region (Yang and Cvekl, 2007) that, as a 
homodimer, recognises palendromic sequences in the promoters of target genes 
(Eychene et al., 2008). The AP1 superfamily recognises a common DNA motif 
with either a TRE (TPA-responsive element) or CRE (cAMP responsive element) 
at its core (Shaulian and Karin, 2002; Eferl and Wagner, 2003).  
 
There are seven Maf family members, classified by the presence of an extended 
homology region (EHR) (Blank and Andrews, 1997), located adjacent to the basic 
DNA binding region. Maf proteins are highly conserved throughout evolution with 
orthologues in mammals, birds, frogs and fish, as well as invertebrates including 
drosophila (Coolen et al., 2005). The Maf family is subdivided into four large 
(MAFA, MAFB, MAF and NRL) and three small Mafs (MAFF, MAFK and MAFG), 
classified based on structure and function (Fig. 1.6) (Blank and Andrews, 1997). 
Once MAF had been discovered additional family members (MAFB, MAFF, MAFK 
and MAFG) were identified using a MAF probe and low stringency hybridisation 
conditions (Fujiwara et al., 1993; Kataoka et al., 1994b; Kataoka et al., 1994a; 
Kataoka et al., 1995) MAFA was later discovered in quail retina (Benkhelifa et al., 
1998) and chicken lens (Ogino and Yasuda, 1998) libraries. Small mafs lack a 
transactivation domain at their amino terminus, consequently these proteins were 
presumed to act as transcriptional repressors due to their inability to recruit 
transcriptional cooactivators (Blank and Andrews, 1997; Kusunoki et al., 2002). 
However, when small Mafs heterodimerise with Cap’n’coller or Bach family bZIP 
transcription factors they have been shown to both repress and activate 
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transcription (Motohashi et al., 2002). This finding highlights the importance of the 
dimerization partner in determining transcription factor activity. Conversely, large 
Mafs activate transcription via their transactivation domain by recruiting co-
activators including p300, CBP (Chen et al., 2002), P/CFF (Rocques et al., 2007) 
and TBP (Friedman et al., 2004). Phylogenetic analysis of 38 large Maf genomic 
sequences revealed a single origin of a large Maf precursor which, via gene 
duplication gave rise to additional family members (Coolen et al., 2005). 
 
1.3.2 MAF DNA binding and dimerization  
The EHR region of Maf proteins distinguishes the family from other API members, 
the EHR cooperates with the adjacent basic region to mediate DNA binding (Fig. 
1.5A) (Yang and Cvekl, 2007). Consequently, Maf proteins recognise longer 
sequences, termed Maf recognition elements (MARE), than other API 
transcription factors (Fig. 1.7A) (Dlakic et al., 2001; Kerppola and Curran, 1994; 
Kusunoki et al., 2002). At the core of a MARE is the common TRE/CRE element 
which is flanked by unique TGCs contacted by the EHR. While the core element 
is important for DNA binding it is also more degenerate, the flanking GCs however 
are indispensible for MAF function (Eychene et al., 2008). MAREs with TRE core 
are referred to as T-MAREs, where as C-MARE denotes those with a CRE core 
(Fig. 1.7B) (Kerppola and Curran, 1994; Kataoka et al., 1994b). In addition to 
these consensus sites, MAF can also bind to a 10bp antioxidant response 
element (ARE), which contains half a MARE site at the 5’ end (Fig. 1.7B). 
Sequence analysis of validated MAF target genes including crystallin and 
rhodopsin revealed that MAF target sequences can be comprised of only half a 
palindromic site, referred to as a half MARE (Yoshida et al., 2005). This is 
suggestive of heterodimer regulation; however, MAF homodimers were also 
shown to regulate these sites. Furthermore, MAF binding sites lacking an internal 
TRE/CRE site have also been identified (Kerppola and Curran, 1994). In binding 
numerous different sites MAF is unique among the bZIP transcription factors, this 
complexity makes it difficult to predict MAF target genes. Consequently, genome-
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wide identification of MAF target genes in vivo has thus far proved unsuccessful 
(Kataoka, 2007). 
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Figure 1.7 MAF structure and DNA recognition sequences. A Diagrammatic representation of 
MAF protein domains. His and gly, represent histidine and glycine rich regions, respectively. HER: 
extended homology region. B Palindromic MAF DNA recognition elements are shown. Purple 
residues indicate bases contacted by the extended homology region, arrows highlight sequence 
bound by a MAF monomer. TRE: TPA responsive element, CRE: cAMP responsive element, 
MARE: MAF recognition element, ARE: antioxidant response element. 
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Like all bZIP transcription factors MAF can from homo or heterodimers, 
dimerization occurs by way of the leucine coiled-coil domain (Kerppola and 
Curran, 1994; Motohashi et al., 2002). Large Mafs have been shown to dimerise 
with each other, but never to small Mafs (Yang and Cvekl, 2007). Vinson et al 
analysed the binding properties of all 53 human bZIP-containing proteins. Four 
critical amino acids were identified, the properties of the amino acids located at 
these key positions influenced dimer partner selectivity (Vinson et al., 2002). 
Analysis of MAF amino acid sequence classified MAF as a transcription factor 
prone to forming heterodimers (Vinson et al., 2002). Experimental analysis has 
confirmed these predictions, in vitro assays demonstrated MAF 
heterodimerisation with cFOS and cJUN (Kerppola and Curran, 1994). In addition, 
large scale analysis of 492 pairings of the coiled coil strands from human bZIP 
proteins characterised the binding partners and relative strength of bZIP 
heterodimer interactions (Newman and Keating, 2003). This analysis confirmed 
and identified novel, potential dimerization partners for MAF, including the large 
MAFs, MAFB and NRL; Fos transcription factors FOS, FOSB, FRA2; ATF4 and 
the cap’n’collar transcription factor BACH1 (Newman and Keating, 2003). 
However, it must be noted that in vivo confirmation of these interactions is still 
lacking. 
 
MAF mRNA undergoes RNA processing to generate two isoforms: a long species 
which encodes a short single exon-encoded protein (MAF-S) or a shorter isoform 
which is alternatively spliced to give a longer, double-exon protein (MAF-L) (Chesi 
et al., 1998). MAF-S is an intronless 4.4kb long mRNA which is translated into 
373 amino acids with 86% amino homology to the avian and 95% identity to the 
mouse MAF homologue (Chesi et al., 1998). MAF-L is identical to MAF-S from the 
5’UTR to amino acid 373, where there is an alternative splice site; splicing 
removes a ~4kb intron which corresponds to the MAF-S ‘3UTR. The resulting 
spliced mRNA has an additional exon of 220bp, encoding 30 amino acids, 
generating a longer protein of 403 amino acids (Chesi et al., 1998). Both isoforms 
were detected via Northern blotting in a range of different tissues, although MAF-
S was more abundant than MAF-L (Chesi et al., 1998). The additional amino 
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acids of MAF-L may affect sub-cellular localisation and Valanciute et al reported a 
significant increase in MAF-S, but not MAF-L, during relapse of the kidney 
disorder minimal change nephritic syndrome (MCNS), However, the functional  
difference between these two isoforms was not investigated (Valanciute et al., 
2004). Sequence analysis identified no known structural motifs or functional 
domains in the extra exon, therefore its function remains unclear (Chesi et al., 
1998).  
 
1.3.3 MAF expression 
Unlike the API transcription factors FOS and JUN, MAF transcription is not 
stimulated by extracellular growth signals, instead expression of the Maf family is 
tightly regulated in a spatio-temporal manner (Eychene et al., 2008). Expression 
studies in developing Xenopus tropicialis (Coolen et al., 2005) and the chick 
embryo (Lecoin et al., 2004) revealed distinct expression patterns at specific 
developmental stages for each large Maf protein. This is exemplified in the 
developing lens, where there is a cascade of large Maf gene expression during 
development (Reza and Yasuda, 2004). Here there is spatial confinement, with 
MAF expressed in the lens fibre and MAFB in the lens epithelia (Kawauchi et al., 
1999). MAF is capable of self-regulation through the presence of a MARE in its 
promoter, Sakai et al reported marked activation of the rat MAF gene through this 
element (Sakai et al., 2001). Further to the reported auto-regulation, there may be 
a degree of co-operation in the regulation of gene expression by different large 
Maf proteins (Sakai et al., 2001). MAF is highly expressed in the developing lens, 
with MAF mRNA detectable at E9 in the mouse lens placode (Kawauchi et al., 
1999). MAF expression is then sustained in the lens vesicle and further up-
regulated in the primary lens fibre cells (Ring et al., 2000). 
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MAF expression has also been observed in a wide range of other tissues. Saki et 
al confirmed expression of rat MAF in adult muscle, spleen, lung and kidney 
(Sakai et al., 1997); Lecoin et al demonstrated expression in the chick embryonic 
neuroretina, notochord and endothelium of extra-embryonic blood vessels (Lecoin 
et al., 2004). 
 
1.3.4 MAF function 
1.3.4.1 MAF regulates cellular differentiation 
Although initially characterised as a transforming oncogene, MAF plays a role in 
tissue specification and terminal differentiation. This is contrary to the function of 
most oncogenes which tend to mediate proliferation or apoptosis (Eychene et al., 
2008). Due to the difficulty in predicting MAF binding sites, the number of 
validated MAF target genes is relatively few. However, experimentally defined 
targets from a range of cell types indicate that MAF target genes are highly cell 
type specific (Table 1.2).  
 
Homozygous MAF knockout mice die shortly after birth, the major reported 
phenotype of these mice is inhibited lens development (Kim et al., 1999; 
Kawauchi et al., 1999; Ring et al., 2000). A significant lack of α, β and γ crystallins 
in the mutant mouse lens induces microphthalmia (Ring et al., 2000). Promoter 
studies have confrimed that MAF is responsible for the activation of αA, αB, αB2 
and γF crystallins in the lens (Chauhan et al., 2004; Yang et al., 2004). A naturally 
occuring MAF point mutation in the basic domain generates mild pulverulent 
cataracts in humans (Jamieson et al., 2003) and mutations in the mouse MAF 
gene lead to the disorder opaque flecks in lens (OFL) (Lyon et al., 2003). In MAF 
knock-out mice, the expression of lens lineage-specifiying factors such as PAX6 
and the SOX proteins was unaffected (Yang and Cvekl, 2007). Therefore, despite 
its pivitol role in lens development, MAF is not a master regulator of cell fate in 
this tissue. Outside of the lens MAF has also been shown to play a role in T 
helper cell differentation. MAF activates IL4 expression, thus promoting the 
development of the Th2 lineage (Ho et al., 1996; Ho et al., 1998). Reavaluation of 
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MAF homozygous knockout mice revealed endochondral bone abnormalities, 
identifying a role for MAF in chondrocyte differentiation (MacLean et al., 2003; 
Huang et al., 2002). MAF is also reported to influence myeloid differenitation 
(Table 1.2) (Hegde et al., 1999). 
 
Although more commonly an activator, MAF can also function as a transcriptional 
repressor. Interestingly, MAF activation or repression is often mediated through 
cooperation with an additional transcription factor (Table 1.2) (Kataoka, 2007). 
This synergism is exemplified in the lens where MAF and the master regulator 
PAX6 cooperate to activate crystallin gene expression. Similarly, MAF and SOX9 
synergise to active the COL2A1 gene during chondrocyte differentiation 
(MacLean et al., 2003). Binding sites of MAF and the cooperating transcription 
factor are often found in close proximity to each other within the enhancer region 
of the promoter (Kataoka, 2007). However, the exact mechanism underlying 
synergy has not been elucidated. A point mutation in the EHR domain which led 
to cataracts in mice was shown not to affect DNA binding, but instead impaired 
synergy between SOX and MAF, thus highlighting the importance of synergy in 
MAF gene regulation (Rajaram and Kerppola, 2004).  
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Table 1.2 Experimentally validated MAF target genes. Cell type, mode of regulation, function 
and cooperating transcription factors for MAF target genes are listed. Information was obtained 
from listed references. 
Target 
Gene Cell type 
Activator/ 
repressor Function 
Cooperating 
factor Reference 
PCP2 Purkinjie activator Unclear NRL (Kurschner and Morgan, 1995) 
IL4 T helper 2 activator 
 
Promotes Th2 
differentiation, 
skewing immune 
response 
towards a Th2 
pathway 
 
NF-ATp (Ho et al., 1996; Ho et al., 1998) 
ANPEP 
(CD13) HUVEC activator 
 
Endothelial 
invasion on 
tumour 
vasculature 
 
Unknown (Mahoney et al., 2007) 
ANPEP 
(CD13) 
Myeoblastic 
cells repressor 
 
Influence 
myeloid 
differentiation 
 
c-MYB (Hegde et al., 1999) 
p53 NIH3T3 activator 
 
Potentially 
induce p53-
mediated cell 
death 
 
cFOS, cJUN (Hale et al., 2000) 
Col2a1 chondrocytes activator 
 
Chondrocyte 
terminal 
differentiation 
 
SOX9 
 
(Huang et al., 
2002; MacLean 
et al., 2003) 
NADPH 
NQO1 
GSTYa 
Human 
Hepatoblasto
ma (Hep-G2) 
repressor 
 
Detoxifying 
enzyme 
expression and 
induction in 
response to anti-
oxidants 
 
Unknown 
(Dhakshinamoort
hy and Jaiswal, 
2002) 
CRYAB 
CRYA2 
CRYA4 
lens fibre activator Lens fibre cell differentiation PAX6 
(Kawauchi et al., 
1999; Ring et al., 
2000; Chauhan 
et al., 2004; Yang 
et al., 2004) 
Crygf 
αTN4 lens 
epithelial 
cells 
activator Lens development Sox1-3 
 
(Kim et al., 1999; 
Rajaram and 
Kerppola, 2004) 
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1.3.4.2 MAF as an oncogene 
Similar to vMAF which induces tumours in chickens (Nishizawa et al., 1989), MAF 
is implicated in the development of human tumours. MAF is over-expressed in 
50% of multiple myeloma cases (Hurt et al., 2004) and 60% of 
angioimmunoblastic T cell lymphomas (Murakami et al., 2007; Morito et al., 2006). 
Likewise, over-expression of MAF in the lymphoid compartment of mice induced T 
cell lymphoma (Morito et al., 2006). However, MAFs transforming abilities are not 
universal, but depend on cell context. MAF over-expression transformed primary 
chicken embryo fibroblasts, but in neuroretinal cells where MAF is known to play a 
role in differentiation, increased MAF protein had no effect on transformation 
(Pouponnot et al., 2006). On the contrary, in this cell type MAF expression was 
anti-tumourigenic, counteracting transformation induced by the 
RAS/RAF/MEK/ERK pathway. These findings suggest a dual role for MAF in 
oncogenesis (Pouponnot et al., 2006), whereby in certain cellular contexts MAF 
acts as an oncogene and in others a tumour suppressor.  
 
Interestingly, no activating mutations have been found within MAF in human 
cancers, instead MAF-mediated transformation appears to be dependent on its 
elevated expression (Eychene et al., 2008). Accordingly, only those mice with 
high MAF copy number develop T cell lymphoma (Morito et al., 2006). In 5% of 
multiple myeloma cases, MAF over-expression is induced by a chromosomal 
translocation that juxtaposes MAF with the IgG enhancer locus. This translocation 
was shown to be the oncogenic event driving multiple myeloma development 
(Chesi et al., 1998). Although MAF over-expression is detected in almost half of 
multiple myeloma cases, the exact proportion of cases where this is the causal 
event has yet to be experimentally determined (Eychene et al., 2008). MAFs 
transforming capacity is dependent on its role as a transcription factor due to 
increased expression of target genes as a consequence of elevated MAF protein 
(Zhan et al., 2006). However, transformation is not mediated through up-
regulation of the target genes listed in Table 1.2 as none of these genes are de-
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regulated in MAF transformed cells (Eychene et al., 2008). Instead, additional 
cancer-associated MAF targets including Cyclin D2, integrin β7 and ARK5 have 
been identified (Zhan et al., 2006; Hurt et al., 2004; Suzuki et al., 2005). Through 
activating Cyclin D2 MAF promoted cell cycle progression; upregulation of integrin 
β7 increased stromal interaction thereby enhancing adhesion and proliferation. 
Morito et al observed differences in MAF tumour promotion, whereby MAF 
activation in the thymus led to peripheral T-cell cancers, as opposed to T-cell 
acute lymphoblastic leukaemia which is observed after activation of most proto-
oncogenes (Morito et al., 2006). The authors hypothesised that this may be due to 
relatively weak oncogenic activity of MAF and that over-expression may not be 
sufficient for transformation (Morito et al., 2006). Therefore, in addition to 
increased expression, MAF-mediated transformation may also be dependent on 
the myriad of other bZIP transcription factors and accessory transcription factors 
present in a particular cell type or on post-translational modifications acquired at 
specific times. These findings would help to explain MAFs cell context dependant 
behaviour during oncogenesis. 
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1.4 microRNAs  
miRNAs are short, 21-23nt, non-coding RNA molecules which act post-
transcriptionally to negatively regulate gene expression (Bartel, 2004). Ubiquitous 
throughout nature, miRNAs have been identified in all metazoan eukaryotes. To 
date over 700 human miRNAs have been identified (Griffiths-Jones et al., 2006), 
which are predicted to regulate up to 30% of the genome (Farh et al., 2005). 
 
1.4.1 miRNA discovery and classification 
miRNAs were first described in C. elgans by Lee and colleagues in 1993 (Lee et 
al., 1993). Characterisation of loss of function mutations which caused 
developmental timing defects, led to the identification of lin-4.  The authors 
showed that, rather than encoding for a protein, the lin-4 gene gave rise to a 22 
nucleotide RNA molecule (Lee et al., 1993). Antisense sites complimentary for lin-
4 were identified in the 3’UTR of the protein coding gene lin-14 (Lee et al., 1993; 
Wightman et al., 1993). Wightman et al demonstrated that lin-4 acted via these 
sites to reduce protein output without any effect on mRNA levels (Wightman et al., 
1993). Together these findings provided the first model of endogenous small RNA 
regulation leading to decreased protein output of the target mRNA. Consequently, 
lin-4 is regarded as the founding member of the class of small RNAs, known as 
miRNAs (Bartel, 2004). The discovery of a second miRNA, let-7, which also 
controlled developmental timing of C. elegans (Reinhart et al., 2000; Slack et al., 
2000) and identification of homologous RNAs in drosophila and a wide range of 
animal species (Pasquinelli et al., 2000) indicated that miRNAs were not specific 
to C. elegans, but a widely distributed class of regulatory molecules. Small RNA 
cloning by several laboratories expanded the number of known miRNAs, 
identifying 60 additional C. elegans miRNAs and 20 miRNAs in drosophila, (Lee 
and Ambros, 2001; Lau et al., 2001), as well characterising the first human 
miRNAs (Lagos-Quintana et al., 2001). Since these discoveries, miRNAs have 
been found throughout the animal kingdom as well as in plants, green algae and 
viruses (Griffiths-Jones et al., 2008). The registry miRBase was established to 
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record all newly identified miRNAs, at its latest release there were 10883 entries 
(mirbase.org/) (Griffiths-Jones, 2004).  
 
miRNAs have been implicated in regulation of almost every cellular process 
investigated so far, including differentiation, immunity, and metabolism, as well as 
pathological conditions such as cancer (Chen et al., 2004; Lu et al., 2005; Croce, 
2009). Large-scale investigations into the effects of miRNAs on their target 
proteins show they act as rheostats rather than an on-off switch (Baek et al., 
2008; Selbach et al., 2008) miRNA expression serves to fine-tune protein output, 
maintaining a delicate balance of target proteins. Despite their modest effects on 
protein output, miRNAs can be indispensible for cellular functions, especially in 
lineage specification (Xiao et al., 2007; Thum et al., 2007).  
 
1.4.2 miRNA biogenesis 
miRNAs are located within the introns of protein coding genes or at sites distant 
from annotated genes; the majority are solitary and expressed under the control 
of their own promoter (Ambros, 2004). However, miRNA coding regions can also 
be arranged in clusters, the individual miRNAs of which are transcriptionally co-
regulated (Lagos-Quintana et al., 2001; Ambros, 2004). Those miRNAs located in 
protein coding introns in the same orientation as the mRNA, are processed from 
the intron rather than transcribed from their own promoters (Bartel, 2004). 
 
miRNA biogenesis begins with RNA polymerase II-mediated transcription of a 
primary transcript ranging from hundreds to thousands of nucleotides in length 
(Fig. 1.8) (Lee et al., 2004). This transcript, termed the primary miRNA (pri-
miRNA), is capped at the 5’ end and polyadenylated at the 3’ end. Pri-miRNAs 
contain an imperfect ~60nt hairpin structure which is excised in the nucleus by 
Drosha, a nuclease RNase III enzyme (Lee et al., 2003). Drosha mediates 
cleavage with the aid of DGCR8, together these proteins form the essential 
components of the microprocessor complex. DGCR8 acts as a molecular anchor 
facilitating microprocessor recognition of the pri-miRNA (Du and Zamore, 2005). 
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After Drocha cleavage the resulting hairpin structure, known as the precursor-
miRNA (pre-miRNA), is exported to the cytoplasm by Exportin-5 for further 
processing (Lund et al., 2004; Yi et al., 2003). Once in the cytoplasm Dicer, 
another RNase III enzyme, cleaves the hairpin releasing a 22nt long, double 
stranded molecule known as the mature miRNA (Bernstein et al., 2001). One 
strand of this imperfectly paired duplex, referred to as the guide strand, is 
incorporated into a large ribonucleoprotein complex, known as the RNA induced 
silencing complex (RISC) (Fig. 1.8). The other passenger strand of the mature 
miRNA is not involved in silencing and therefore gets degraded. The decision 
between which strand is the guide and which the passenger, is governed by 5’ 
end stability. The strand with the lowest base-paring stability is preferentially 
selected for RISC incorporation (Schwarz et al., 2003). At the core of the RISC, 
are the highly conserved Argonaute proteins (Hammond et al., 2000; Elbashir et 
al., 2001; Martinez et al., 2002). Argonaute binds to the guide strand which directs 
the RISC complex to homologous sequences located in the 3’UTR. In addition to 
the Argonaute proteins, the RISC complex includes proteins which function as 
assembly and regulatory factors, as well as those which mediate silencing 
(Filipowicz et al., 2008).   
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Figure 1.8 miRNA biogenesis.  Schematic representation of the canonical miRNA biogenesis 
pathway. The first step is RNA POL II mediated transcription of the primary miRNA transcript 
(pri-miRNA), the hairpin containing precursor miRNA (pre-miRNA) is then excised by the 
microprocessor complex Drosha–DGCR8. The pre-miRNA is then exported to the cytoplasm by 
Exportin5. In the cytoplasm, Dicer in complex with the double stranded RNA-binding protein 
TRBP, excises the double stranded mature miRNA duplex. The guide strand (red) is then 
loaded into the RNA induced silencing complex (RISC) which contains the central component 
Argonaute (Ago2). The passenger strand (black) of the mature miRNA is degraded. The guide 
strand then directs the RISC complex to target sites located in 3’UTR. Picture from (Winter et 
al., 2009). 
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1.4.3 miRNA target recognition 
In plants, miRNAs bind to their targets with near perfect sequence 
complementation, this triggers mRNA degradation through endonucleolytic 
cleavage initiated at the centre of the miRNA-mRNA duplex (Filipowicz et al., 
2008). This method of silencing can also occur in vertebrates and from viral 
encoded miRNAs, however it is relatively rare (Bartel, 2009). Instead, the major 
mechanism of silencing in vertebrates is via translation inhibition with minimal 
effect on mRNA levels. At least 1000 miRNAs are predicted in humans, and 
identifying the target genes of these regulatory RNAs has been facilitated by a set 
of experimentally and bioinformatically defined rules (Doench and Sharp, 2004; 
Brennecke et al., 2005; Lewis et al., 2005; Grimson et al., 2007; Nilsen, 2007). 
Various combinations of these rules have been incorporated into a number of 
miRNA target prediction algorithms, which are reviewed along with a detailed 
analysis of miRNA-target recognition by Bartel (Bartel, 2009).  
 
Instrumental to miRNA target recognition is conserved Watson and Crick base 
pairing across nucleotides 2-7 of the miRNA, which is referred to as the seed 
region (Krek et al., 2005; Brennecke et al., 2005; Lewis et al., 2005). Base pairing 
across this region greatly increases prediction reliability; accordingly it is this 5’ 
region of the miRNA which is most conserved across metazoan miRNAs (Lewis et 
al., 2005; Lim et al., 2005). G:U base pairings or mismatches across the seed 
region can significantly impair target repression (Filipowicz et al., 2008). In 
addition, an adenosine residue at position one and an adenosine or uracil at 
position nine have been shown to improve site efficiency, but do not necessarily 
have to be paired with the miRNA. Complementarity outside the seed region is 
not essential for target recognition, as a result mismatches and bulges are 
common. However, base pairing especially at nucleotides 13-16 can improve 
miRNA recognition, particularly if complementation is sub-optimal across the seed 
(Brennecke et al., 2005). Other factors known to improve site efficacy are high 
A/U density surrounding the target site and location of site within the UTR, with 
the extremes being favoured over the middle region (Grimson et al., 2007; Nilsen, 
2007). In addition, accessibility of the RISC complex to the target site has been 
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shown to influence silencing (Kertesz et al., 2007). Whereby target sites 
embedded in secondary RNA structures are less favoured over those in relative 
accessible regions of the UTR (Kertesz et al., 2007). Since many miRNAs are 
conserved throughout evolution, identifying a potential miRNA target site in 
multiple genomes of different species through alignment of orthologous 3’UTRs, 
greatly improves predictability (Karolchik et al., 2008). The number of false 
positives in prediction analysis can be reduced by stipulating a perfect 8bp seed 
match as well as multiple miRNA binding sites within a single target. However, 
experimentally validated targets often only possess one 7nt binding site. Although 
useful there are many deviations to the aforementioned target prediction rules 
found in bone fide miRNA targets (Bartel, 2009).  
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1.4.4 Mechanism of miRNA silencing 
The mature miRNA sequence directs RISC to homologous sequences primarily 
located within the 3’UTR of the mRNA to be silenced (Schwarz et al., 2003). The 
ensuing method of protein inhibition is governed by the degree of sequence 
complementation between the miRNA seed and target site. Perfect 
complementation promotes mRNA degradation, most likely by Argonaute RNase-
H induced cleavage (Yekta et al., 2004; Davis et al., 2005) this method of 
silencing is termed slicing. Argonaute 2 is the only human Argonaute to possess 
nuclease activity. Central mismatches in the seed region lead to bulges in the 
RNA duplex which can hinder Argonaute accessibility, thereby preventing 
nuclease activity. In the case of poorly matched targets, silencing is instead 
mediated via translation inhibition with no effect on mRNA abundance (Fig. 1.9) 
(Wu and Belasco, 2008). However, there are exceptions to the above rules 
whereby targets with perfect complementation are inhibited at the translational 
level (Umbach et al., 2008). Therefore, it is incorrect to assume mRNA 
degradation will always ensue upon perfect sequence complementation 
(Filipowicz et al., 2008). Likewise, mRNA degradation has also been observed in 
targets which have imperfect base pairing (Eulalio et al., 2008). miRNA binding 
sites found in close proximity (less than 40bp apart) to one another have been 
shown to cooperatively silence their targets (Doench and Sharp, 2004; Grimson et 
al., 2007). Similarly silencing complexes have been shown to function 
cooperatively, whereby increased number of RISC complexes per transcript 
correlates with increased repression (Doench et al., 2003; Doench and Sharp, 
2004).  
 
   
 
 
 
82 
miRNAs have been shown to repress protein synthesis in four main ways (Fig. 
1.9) (Eulalio et al., 2008; Filipowicz et al., 2008). Firstly, miRNAs can block 
translation initiation, here silencing occurs at the early stages of translation prior 
to elongation of the polypeptide (Pillai et al., 2005; Humphreys et al., 2005). 
Translation initiation can be blocked by Argonaute proteins competing directly 
with the translation initiation factor eIF4E for cap binding (Kiriakidou et al., 2007) 
or by interacting with eIF6, thereby preventing the association of the large and 
small ribosomal subunits (Chendrimada et al., 2007). Alternatively, miRNAs can 
interfere after initiation, during the peptide elongation phase; this is mediated 
either by premature ribosome drop off or slowed elongation (Maroney et al., 2006; 
Petersen et al., 2006; Nottrott et al., 2006). Evidence showing repressed mRNAs 
associated with actively translating polyribosomes supports the model whereby 
miRNAs act post translation initiation (Maroney et al., 2006; Petersen et al., 2006; 
Nottrott et al., 2006); equally there is a lot of evidence of inhibition of translation 
initiation. This is a highly controversial field with many questions still to be 
answered. Another cotranslational method of miRNA inhibition is continual 
degradation of the nascent polypeptide as it is being synthesised (Nottrott et al., 
2006). The final mechanism is miRNA-mediated mRNA decay which is initiated by 
deadenylation and decapping, followed by mRNA degradation (Wu et al., 2006; 
Behm-Ansmant et al., 2006; Giraldez et al., 2006). The latter can be an 
independent mechanism of silencing or as a consequence of translational 
inhibition (Eulalio et al., 2008). It is still not known whether there is a predominant 
mechanism of translation inhibition or whether multiple models operate in 
succession at various stages during translation (Filipowicz et al., 2008). Overall it 
seems that the main mechanism involves mRNA destabilisation in some form, 
such as deadenylation, rather than a form of pure translational repression such as 
ribosome drop-off.   
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i)
ii)
iii)
iiii)
 
 
Figure 1.9 Mechanisms of miRNA-mediated silencing. miRNA bound RISC is represented 
by the beige circle and red line corresponds to the mature miRNA. The mRNA target is 
depicted in green, with the 5’ cap as a blue circle and the polyA tail as a sequence of blue As. 
Silencing is mediated by one of a number of mechanisms, i) mRNA decay which is initiated by 
deadenylation and decapping. Inhibiting translation initiation by ii) Argonaute competing with 
eiF4E (purple semi-circle) for cap binding or iii) Argonaute binding eIF6 (purple ellipse) 
thereby preventing association of the small and large ribsomal subunits (teal circles). iiii) 
Cotranslational inhibition by either premature ribosome (light blue circles) drop of, slowed 
elongation or continual digestion of the nascent polypeptide (red dots).  
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1.4.5 Different classes of small RNA molecules 
Small RNA silencing pathways, with the exception of budding yeast, are 
conserved throughout eukaryotes, indicating an ancient evolutionary origin 
(Moazed, 2009). In addition to miRNAs, there are other abundant small regulatory 
RNA molecules, including short interfering RNAs (siRNAs) and piwi interacting 
RNAs (piRNAs) (Moazed, 2009). The Argonaute family of proteins is key to all 
known RNA silencing pathways. There are two main phylogenetic branches of 
Argonaute proteins, the AGO and PIWI clades which associate with miRNA and 
siRNA or piRNA, respectively (Carmell et al., 2002). siRNAs are the most widely 
conserved small RNA family, in addition to animals they are also found in plants, 
fungi and ciliates. piRNAs are restricted to animals, whereas miRNAs are found in 
both animals and plants (Moazed, 2009).  
 
In 1998 RNAi was first described in C. elegans by Fire et al as the silencing of 
homologous sequences by exogenously induced dsRNA molecules (Fire et al., 
1998). It is now known that miRNAs and siRNA are generated by core biogenesis 
machinery and are identical both in chemical composition and in mechanism of 
action (Ambros et al., 2003). Both duplexes are generated by Drosha cleavage of 
long precursor molecules and processed by Dicer before being loaded onto RISC 
complexes to silence homologous sequences in the genome (Bartel, 2004). 
However, differences in the origin, evolutionary conservation, and types of genes 
regulated permit distinction and classification of siRNA and miRNA. These 
distinguishing features are detailed in Table 1.3 (Bartel and Bartel, 2003; Bartel, 
2004). 
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siRNA 
 
miRNA 
 
Source 
 
 
mRNA, transposons, 
heterchromatin, viruses 
 
Intergenic regions, introns, viruses 
 
 
Evolutionary 
conservation 
 
 
Endogenous siRNAs are rarely 
conserved 
 
High degree of sequence conservation 
between distantly related organisms 
 
Precursor 
 
 
Long dsRNA with near perfect 
complementarity 
 
Imperfectly paired dsRNA containing a 
hairpin 
 
No. of effectors 
from a single 
precursor 
 
 
Multiple siRNA duplexes 
synthesised continually from a 
single precursor 
 
One miRNA duplex per pre-miRNA 
 
Effector strand 
selection 
 
 
Both strands of siRNA duplex 
utilised 
 
Typically one strand favoured as the 
guide strand 
 
Target gene 
 
 
 
Same loci, auto-silencing 
 
Distinct loci, hetero-silencing 
 
Mechanism 
 
mRNA degradation 
 
Primarily translation inhibition, to a 
lesser extent mRNA degradation 
 
 
Table 1.3 Differences between siRNA and miRNA. Information taken from (Bartel and Bartel, 
2003; Bartel, 2004). 
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piRNAs are the most recently discovered class of regulatory RNA molecules (Lau 
et al., 2006). They are generated from a diversity of sequences, in particular 
repetitive elements and transposons. The mechanisms of piRNA biogenesis are 
not yet fully understood, but it is thought to be distinct from the miRNA/siRNA 
pathway. piRNA-mediated silencing utilises the nuclease activity of the PIWI 
proteins, in a similar fashion to the RNase-H like piwi domain of Argonaute-2 
(Choudhuri, 2009). piRNAs have been classed as the ‘guardian of the germline 
genome’ due to their silencing of endogenous genetic elements such as 
retrotransposons and repetitive sequences in germline cells particularly those of 
the testes. Consequently, they are most abundant in germline cells with piwi 
mutant animals displaying defects in germ cell development (Aravin et al., 2007). 
For an extensive review of recent data on piRNAs see Thomson and Lin 
(Thomson and Lin, 2009).  
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1.4.6 miRNAs in cancer 
miRNAs regulate a diverse range of cellular processes including cell cycle 
progression and apoptosis, and are predicted to target ~30% of human genes 
(Bartel, 2004). Unsurprisingly then, miRNAs are strongly implicated in 
oncogenesis both as promoting and inhibitory agents (Garzon et al., 2009). 
Accordingly, miRNA-encoding regions of the genome are both amplified and 
deleted in multiple different human tumours, depending on whether the miRNA 
functions as an oncogene or a tumour suppressor (Calin et al., 2002).  
 
1.4.6.1 miRNAs as tumour suppressors  
miRNAs acting as tumour suppressors are lost during tumourogenesis by 
deletions, mutations, epigenetic silencing or processing mutations (Calin et al., 
2002). Calin et al cloned two miRNAs miR-15a and miR-16-1 to a region on 
chromosome 13 which was deleted in 50% of cases of chronic lymphocytic 
leukaemia, previously attempts to identify protein coding tumour suppressor 
genes in this region had failed (Calin et al., 2002). These miRNAs target Bcl-2 
and wt-1 to promote apoptosis, consequently reduced expression of these 
miRNAs was shown to increase tumourogenicity (Cimmino et al., 2005; Linsley et 
al., 2007). Calin et al extended their study on chromosome 13 and found a 
common pattern whereby miRNA genes are frequently located at fragile sites as 
well as sites of minimal amplification (Calin et al., 2004), these data are 
supportive of a tumour suppressor function for miRNAs. Another set of miRNAs 
commonly down regulated in human tumours and located at fragile genomic 
locations is the let-7 family (Yanaihara et al., 2006; Iorio et al., 2005). These 
miRNAs function as tumour suppressors by silencing multiple oncogenes 
including RAS, HMGA2 and c-MYC (Johnson et al., 2005; Lee and Dutta, 2007; 
Sampson et al., 2007). Recently, p53 was shown to mediate some of its 
antiapoptotic tumour suppressor functions through the miRNA family miR-34 
(Raver-Shapira et al., 2007; Chang et al., 2007). p53 expression correlated with 
that of the miRNAs and chromatin immunoprecipitation assays confirmed p53 
presence on the miR-34 promoter.  
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There is correlative evidence that many other miRNAs can function as tumour 
suppressors, however this needs further experimental validation (Garzon et al., 
2009).   
 
1.4.6.2 miRNAs as oncogenes  
miR-155 was one of the first miRNAs to be describe as an oncogene (Metzler et 
al., 2004; Kluiver et al., 2005). miR-155 is essential for normal B cell development 
and differentiation. miR-155 is up-regulated in many lymphomas including 
Burkitt’s lymphoma, Hodgkin’s disease as well as in acute myeloid leukaemia 
where it has been shown to play a role in early leukaemogenesis (Metzler et al., 
2004; Garzon et al., 2008). Transgenic mice with targeted B cell miR-155 over-
expression developed aggressive B cell malignancies, confirming a causal role for 
this miRNA in oncogenesis (Costinean et al., 2006). However, the mechanism of 
miR-155 regulation and over-expression is human cancer is still poorly 
understood (Garzon et al., 2009). miR-155 mediates some of its oncogenic effects 
through cooperation with c-Myc; a screen for additional miRNAs which synergise 
with onocogenes during transformation identified miR-372 and miR-373 as 
potential oncomirs (Voorhoeve et al., 2006). miR-372 and miR-373 cooperated 
with RAS to neutralise p53, thereby increasing proliferation and tumourogenesis 
(Voorhoeve et al., 2006). The miR-17-92 cluster encodes 6 miRNAs and is 
located at 13q31.3, a chromosomal region frequently amplified in follicular 
lymphoma and diffuse large B cell lymphoma. The cluster is essential for B cell 
proliferation; over expression of these miRNAs in mouse B cells is sufficient to 
induce lymphoproliferative disorders (Ventura et al., 2008; Xiao et al., 2008). 
Increased expression of miR-17-92 is observed in a range of solid tumours as 
well as haematological malignancies (Mendell, 2008). These miRNAs drive 
tumourogenesis by promoting proliferation through regulation of E2F (O'Donnell et 
al., 2005), inhibiting apoptosis via silencing pro-apoptotic proteins BIM, PTEN and 
p21 (Ventura et al., 2008; Xiao et al., 2008), as well as inducing tumour 
angiogenesis (Mendell, 2008).  
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1.4.6.3 miRNAs as therapeutic targets  
In conjunction with their role as both tumour suppressors and oncogenes, miRNA 
expression profiling has been used to predict patient survival and miRNAs are 
currently being investigated as potential anticancer therapeutic targets (Garzon et 
al., 2009). Expression of a sub-group of six miRNAs was used to distinguish long-
term survivors of pancreatic cancer from those who died within 24 months 
(Bloomston et al., 2007). Increased miR-21 expression correlated with short 
overall survival of colon cancer patients (Schetter et al., 2008). Further studies will 
determine whether miRNAs could be employed to stratify patients for cancer 
treatment (Garzon et al., 2009). miRNAs represent attractive therapeutic targets 
for several reasons. A single miRNA regulates multiple targets many of which 
could be involved in different oncogenic pathways, therefore targeting one miRNA 
may have multiple anticancer effects (Croce, 2009). A small group of miRNAs are 
consistently de-regulated in a large number of diverse malignancies. Therefore, 
silencing of oncomirs or re-introducing tumour suppressor miRNAs could affect 
multiple different groups of cancer patients. Re-introduction of tumour suppressor 
miRNAs miR-221 and miR-222 suppressed growth of erythroleukemic cells in 
which these miRNAs had been down-regulated (Felli et al., 2005). Furthermore, 
exogenous expression of miR-29 suppressed the tumourogenicity of lung cancer 
cells (Fabbri et al., 2007). miRNAs which act as oncogenes are silenced using 
complimentary RNA molecules known as antagomirs (Krutzfeldt et al., 2005). In a 
proof of principle experiment, Elmen et al delivered locked nucleic acid (LNA) 
modified antagomirs against miR-122, a liver specific miRNA, to primates. This 
led to effective miRNA depletion without any evidence of toxicity (Elmen et al., 
2008). 
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1.4.7 Viral miRNAs 
Viral miRNAs were first reported in EBV in 2004 after small RNA profiling of 
infected cells (Pfeffer et al., 2004). Since this discovery miRNAs have been 
identified in all herpesviruses examined to date (Cullen, 2009). Including 
herpesviruses which infect species other than humans such as mouse, chicken 
and monkey (Cullen, 2009). Viral miRNAs are largely confined, although not 
exclusive to herpesviruses. In addition to herpesviruses, miRNAs have been 
identified in human adenovirus and several members of the polyomavirus family, 
including SV40 (Sullivan et al., 2005; Xu et al., 2007). miRNAs provide an 
excellent means of regulating both host and viral gene expression thereby 
creating a permissive cellular environment in which to establish infection. Viral 
miRNAs are transcribed and processed using the cellular miRNA machinery 
(Cullen, 2009). Notably miRNAs are only found in nuclear DNA viruses which 
favour long term, persistent infection. Viruses which replicate exclusively in the 
cytoplasm, including RNA viruses, will not have access to core miRNA biogenesis 
machinery which is localised to the nucleus. Furthermore, miRNA regulation is not 
an instantaneous process; the existing pool of proteins must decay before a 
miRNA induced phenotype is observed. Therefore, for viruses with short lifecycles 
requiring quick entry and exit from the cell, miRNAs do not present a useful 
means of regulation. These factors explain why miRNAs are consistently found in 
herpesviruses, which establish persistent latent infection, but in only a few other 
virus families. miRNAs are an attractive means of gene regulation for several 
reasons. They are encoded by a relatively small amount of DNA (<200bp) which 
is advantageous due to the tight space constraints of viral genomes. miRNAs are 
non-immunogenic and therefore go undetected by immune surveillance (Pfeffer et 
al., 2004). Finally, one miRNA can regulate multiple target genes; in this manner a 
single molecule has the power to modulate many distinct cellular pathways which 
may affect the outcome of infection (Umbach and Cullen, 2009). Deep 
sequencing of KSHV infected PEL cell lines showed that viral miRNAs constituted 
92% of the total miRNA content (Umbach and Cullen, 2010). These data suggest 
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that viral miRNAs dominate cellular miRNAs and in some way are preferentially 
processed by the miRNA biogenesis machinery (Umbach and Cullen, 2010). 
 
Despite being identified six years ago the function of viral miRNAs is largely 
unknown and only a small number of targets have been identified. Experimentally 
validated targets are detailed in Table 1.4. The array of validated targets shows 
that viral miRNAs can perform autoregulation, whereby they silence expression of 
viral-encoded proteins. In this manner viral miRNAs have been shown to down-
regulate immediate early proteins thus helping to ensure the correct temporal 
mode of gene expression. Targeting immediate early genes causes a reduction in 
viral immunogenic proteins and can facilitate the transition between lytic and 
latent infection (Umbach et al., 2008; Murphy et al., 2008; Grey et al., 2007; 
Bellare and Ganem, 2009). Autoregulating miRNAs can be transcribed antisense 
to their target mRNA as is the case with SV40 miR-S1 and EBV miR-BART2 
(Sullivan et al., 2005) or they can target miRNAs at a distinct locus  (Samols et al., 
2007). Viral miRNA targets are in theory easier to identity than their cellular 
counterparts, due to the perfect sequence complementation of autoregulating 
targets and the small size of the viral genome in which to search for targets.  
 
There are a number of validated cellular viral miRNA targets (Table 1.4), these 
tend to fall into three categories: apoptosis regulators, immunomodulators and 
latency regulation (Umbach and Cullen, 2009). In this manner viral miRNA 
regulation prolongs survival of the infected cell, maximising replication potential 
and sustaining infection. Two examples of apoptosis regulators include the EBV 
encoded miRNA BART5 which down-regulates the proapoptotic protein PUMA 
(Choy et al., 2008) and a subset of KSHV miRNAs which silence BCLAF1 
(Ziegelbauer et al., 2009). miRNA silencing of cellular antiviral targets represents 
a novel mechanism of immune evasion. This is highlighted in HCMV, where miR-
UL112-1 was shown to silence the natural killer cell ligand MICB (Stern-Ginossar 
et al., 2007). Down-regulation of MICB may protect infected cells from natural 
killer cells, which is one of the first lines of antiviral immune defence. In addition to 
regulating MICB, miR-UL112-1 performs autoregulation (Stern-Ginossar et al., 
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2007). This is the first example of a viral miRNA targeting both viral and host 
transcripts. EBV encoded miRNAs have also been shown to modulate the host 
immune response, whereby BHRF1 down-regulates the potent T cell 
chemoattractant CXCL11 (Xia et al., 2008). Recently a number of studies have 
shown that in addition to targeting lytic proteins, viral miRNAs also control the 
lytic-latency balance through silencing cellular proteins (Lei et al., 2010; Lu et al., 
2010). Deletion of the KSHV miRNA Cluster from the viral genome led to 
increased lytic gene expression and viral replication (Lei et al., 2010; Lu et al., 
2010). Through silencing the NFκB inhibitor, IκBα, miR-K12-1 expression 
activated the NFκB pathway thereby inhibiting viral replication and favouring latent 
infection (Lei et al., 2010). Lu et al reported marked loss of both viral and cellular 
DNA methylation, due to miR-K12-4-5p induced silencing of the DNA 
methylatransferase inhibitor RBL2; it was proposed that his global epigenetic 
reprogramming helped to maintain the latent state of the KSHV genome (Lu et al., 
2010). 
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Virus 
 
miRNA 
 
Target 
 
Protein 
 
Outcome of miRNA Regulation 
 
Reference 
 
SV40 
 
miR-S1 T antigen 
 
Reduce detection of immediate early gene, SV40 
antigen by cytotoxic T cells 
 
(Sullivan et 
al., 2005) 
 
KSHV 
 
 
miR9* RTA 
Prevent inappropriate entry to lytic cycle through 
fine-tuning expression of lytic reactivator 
 
(Bellare and 
Ganem, 
2009) 
 
miR-BART2 BALF5 
Down-regulation of DNA polymerase is proposed to 
inhibit the transition from latent to lytic replication 
 
(Barth et 
al., 2008) 
 
EBV 
 
 
miR-BART1-
5p; BART16; 
BART17-5p 
LMP-1 
Modulating expression levels of oncogenic signalling 
molecule to balance the contradictory growth 
promoting and inhibitory functions of LMP1 
 
(Lo et al., 
2007) 
 
HCMV 
 
miR-UL112-1 IE1 
Removal of immediate early transcription factor at 
later stages of viral life cycle. 
 
(Murphy et 
al., 2008; 
Grey et al., 
2007) 
 
miR-H2-3p 
 
ICP0  
HSV-1 
 
miR-H6 
 
IC4 
 
Silencing immediate early protein facilitates the 
establishment and maintenance of latency 
 
 
(Umbach et 
al., 2008) 
HSV-2 miR-H3 
miR-H4 ICP34.5 
Reducing levels of this pathogenicity factor may 
protect neurons from neurovirulent effects during 
virus reactivation 
 
(Tang et al., 
2008; Tang 
et al., 2009) 
HvAV miR-1 
 
Viral 
 
ORF1 
Silencing DNA polymerase may inhibit lytic 
replication and promote latency 
 
(Xu et al., 
2007) 
miR-BART5 PUMA 
Protect infected cells from apoptosis by down-
regulating pro-apoptotic factor 
 
(Choy et al., 
2008) 
EBV 
miR-BHRF1-3 CXCL11 
Down-regulating of T cell chemoattractant may 
protect infected cells from immune detection 
 
(Xia et al., 
2008) 
 
HCMV miR-UL112-1 MICB 
Silencing may offer protection from NK immune 
surveillance 
(Stern-
Ginossar et 
al., 2007) 
 
miR-K12-1; 
K12-3; 
K12-6-3p; 
K12-11 
 
 
THBSD1 
Silencing may promote survival, angiogenesis and 
inhibit detection by immune surveillance 
 
(Samols et 
al., 2007) 
 
miR-K12-11 
 
BACH1 
Silencing the transcriptional repressor BACH1 up-
regulates xCT on macrophages and endothelial 
cells. This increases permissiveness to KSHV 
infection and protects against oxidative stress 
(Skalsky et 
al., 2007; 
Gottwein et 
al., 2007; 
Qin et al., 
2010) 
miR-K12-5; 
K12-9;   K12-
10 
 
BCLAF1 
Reduction of BCLAF1 may stabilise latency through 
an as yet unknown mechanism 
(Ziegelbaue
r et al., 
2009) 
miR-K12-4-5p RBL2 
Silencing of RBL2, a repressor of DNA methylation, 
reduces viral and cellular DNA mutilation levels 
helping to maintain latency 
(Lu et al., 
2010) 
 
KSHV 
miR-K12-1 
 
Cellular 
IκBα 
Viral replication is inhibited, favouring latency, 
through silencing the NFκB inhibitor and activating 
the NFκB pathway 
(Lei et al., 
2010) 
 
 
Table 1.4 Experimentally validated viral miRNA targets. Both viral and cellular miRNA targets 
are shown. miRNA, target and consequence of silencing is shown, information was obtained from 
listed references.  
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1.6 Thesis Aims 
The aim of this thesis was to investigate the role of the KSHV-encoded miRNAs in 
infected lymphatic endothelial cells. Specifically, the KSHV miRNA Cluster was 
expressed in isolation in lymphatic endothelial cells to identify cellular targets de-
regulated at the mRNA level. Regulation by the KSHV miRNAs of the transcription 
factor MAF was studied along with an investigation into the biological significance 
of MAF silencing during KSHV infection of LEC.  
 
 
 
  
 
 
95 
Chapter 2. Materials and Methods 
2.1 Cell culture 
All cells were cultured at 37oC, 5% CO2 in a humid environment.  
 
2.1.1 Lymphatic endothelial cells 
Lymphatic endothelial cells (LEC) were purchased from TCS Cellworks 
(Buckingham, U.K). The LEC identity of these cells was confirmed by qRT-PCR 
analysis and staining for lymphatic-specific markers including PDPN, LYVE1 and 
PROX1.  Prior to culturing flasks or wells were coated with 1-5 µg/cm2 of 
fibronectin diluted in phosphate buffered saline (PBS) for 30 min at 37oC, after 
which fibronectin was removed and the plasticware rinsed with PBS.  LEC were 
cultured in endothelial-cell growth medium MV (PromoCell) supplemented with 10 
ng/mL VEGF-C (R&D Systems), media was changed every 24-48 hrs. LEC were 
purchased at passage 0, expanded and used for experiments at passage 2-8. 
 
Sub-confluent LEC (70-80%) were split 1:3. Cells were washed with PBS and 
then incubated for 5 min at 37oC with trypsin-EDTA (Invitrogen) diluted 1:5 in 
PBS. After the majority of cells had detached the trypsin-EDTA was quenched 
with an equal volume of LEC media, cells were collected and pelleted by spinning 
for 5 min at 1200rpm. LEC were re-suspended in LEC media, cells were then 
seeded at a density of ~5x105 per T75 flask.  
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2.1.2 Blood vessel endothelial cells 
Microvascular myometrium endothelial cells were isolated by Dr. L. Nikitenko (CR-
UK Viral Oncology group, UCL) as previously described (Nikitenko et al., 2006).  
The blood vessel endothelial (BEC) identity of these cells was confirmed by qRT-
PCR analysis and staining for blood vessel specific markers including EDGN, 
CD34 and VEGRF1.  Prior to seeding flasks were coated for 30 min at room 
temperature with attachment factor (TCS Cellworks). Cells were seeded at a 
density of 5×105 cells/cm2. BEC were cultured in endothelial-cell growth medium 
MV2 (PromoCell), media was changed every 24-48hrs. Cells were passaged at 
1:3 when 80% confluent. Media was removed and BEC were washed with PBS, 
cells were then incubated for 5 min at 37oC in trypsin for endothelial cell cultures 
(Sigma). After the majority of cells had detached, cells were collected and pelleted 
by spinning for 5 min at 1200rpm. 
 
2.1.3 Transformed cell lines 
293T and HeLa cells were cultured in Dulbecco modified Eagle medium (DMEM) 
(Gibco, Invitrogen), supplemented with 10% FCS (Sigma) and 10% 100units/ml 
penicillin G and 100µg/ml streptomycin (Gibco, Invitrogen). 293 cell lines stably 
transfected with the KSHV miRNA Cluster or empty pcDNA vector (Samols et al., 
2007) were cultured as above but with 100µg/ml Geneticin (Gibco, Invitrogen) 
selection. Cells were split 1:10 every 3 days at a density of ~1x106 per T75 flask. 
 
BCLB-1 cells latently infected with recombinant GFP-KSHV (Vieira et al., 2001) 
were grown in suspension in RPMI 1640 (Invitrogen) supplemented with 10% 
FCS and 400ng/ml Geneticin (Invitrogen). Cells were grown at a density of ~4-
6x105 cells/ml.  Cells were split 1:10 every 3 days by transferring 10% of the 
culture to a new flask of media.  
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2.1.4 Thawing cells 
Frozen cells were stored in 1:10 DMSO-FBS in cryovials in liquid nitrogen tanks. 
Cells were thawed by heating in 37oC water bath. The thawed suspension was 
added to 3mls of the appropriate media and spun at 1200rpm for 5 min to pellet 
the cells and remove DMSO.  The cell pellet was resuspended in 1ml of media 
and added to a flask or dish containing 9mls of pre-heated media.   
 
2.2 Transfection, virus production and infection 
2.2.1 DNA transfections of 293T and HeLa cells 
Cells were seeded the day before, density of seeding varied according to the 
experiment, as specificed in text. Transfection of 293T and HeLa cells was 
performed using FuGENE (Roche) according to manufacturer’s instructions. 
FuGENE is a non-liposomal, lipid-based transfection reagent, which facilitates 
DNA uptake by eukaryotic cells. Prior to transfection, media from all wells or 
plates to be transfected was removed and cells were washed with pre-warmed 1x 
PBS, serum free OPTI-MEM (Invitrogen) was then added. 1ml or 8ml of OPTI-
MEM was added to a 6-well, 12-well or a 10cm plate, respectively. Standard 
transfection procedure was adopted regardless of the number of cells being 
transfected: 3x the volume of FuGENE was added to the concentration of DNA in 
µg. DNA to be transfected was suspended in double distilled water (ddH20), and 
made up to 50µl with OPTI-MEM in a 1.5ml Eppendorf tube. In a separate 1.5ml 
Eppendorf tube, FuGENE was added to OPTI-MEM giving a final volume of 50µl. 
Both tubes were incubated at room temperature (RT) for 5 min. The FuGENE-
OPTI-MEM mix was then added to the DNA mix giving a final volume of 100µl, the 
DNA-FuGENE mix was incubated for 15-30 min at RT. 100µl was then added 
dropwise to the 6, 12-well or 10cm plate; 5 or 16hours (overnight) after DNA 
addition the transfection media was removed and fresh media added. Cells were 
harvested 24, 48 or 72hrs post-transfection.  Master mixes of DNA or FuGENE 
were prepared when more than one well or plate was to be transfected. 
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2.2.2 KSHV production and infection of LEC 
KSHV was produced from BCLB-1 cells latently infected with recombinant GFP-
expressing KSHV (Vieira et al., 2001). For KSHV production BCLB-1 cultures 
were expanded to ~2.5L which yielded one batch of ~11ml of concentrated virus, 
during expansion Geneticin selection was removed. Lytic replication was induced 
in BCLB-1 cultures at a density of ~1.2x105 cells/ml by the addition of 
tetradecanoyl phorbol acetate (TPA) (Sigma) at 20 ng/mL final concentration. 3-4 
days post induction, virus was harvested and concentrated through a two step 
centrifugation using a Beckman JLA-10.500 rotor. The first spin at 400 x g for 15 
min pelleted the majority of cellular debris. The supernatant was then transferred 
to fresh clean tubes and the virus concentrated by spinning at 12500 x g for 3hrs. 
The supernatant was poured off and discarded, the virus-containing pellet was re-
suspended in 12mls of endothelial-cell growth medium MV. Re-suspended virus 
was filtered through a 45µm filter to remove all traces of cellular debris, virus was 
then aliquoted and stored at -80oC. 
 
To test the infectivity of viral preparations, 500µl of virus was added to 1x105 293T 
cells seeded in 6 well plates at a total volume of 2ml per well whilst cells were still 
in suspension. 72hrs post infection, cells were detached from the plate and re-
suspended in 1ml of PBS and subjected to flow cytometry using a FACSCaliber 
flow cytometer (BD Biosciences). Provided more than 20% of 293T cells were 
GFP positive, KSHV preparations were then used to infect LEC.     
 
1x105 LEC were seeded in 1ml of LEC media in a 6 well the day prior to infection. 
Once the cells had adhered, 1ml of KSHV preparation was added per well and the 
cells spun at 2500rpm in an Eppendorf desktop centrifuge at room temperature 
for 30 min. Cells were incubated with the virus overnight, the media was then 
changed. Infections were scaled up or down according to the number of cells 
being infected. Infection typically resulted in 15-40% of LEC expressing GFP 
72hrs post-infection (p.i.), this was assessed both visually using an Axiovert 100 
fluorescent microscope (Carl Zeiss) and by flow cytometry using a FACSCaliber 
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flow cytometer. The number of viral genomes per cell was also assessed by 
quantitative PCR (see Section 2.3.10), infection typically resulted in 100-150 viral 
copies/cell. In situations where 100% KSHV positive cells were desired, cells 
were detached from the well and passed through the cell sorter MoFlow (DAKO), 
only GFP positive cells were retained for further experiments.  
 
2.2.3 Lentivirus production and infection of LEC 
Lentivirus was produced as previously described (Vart et al., 2007). Vesicular 
stomatitis virus-G (VSV-G) envelope-pseudotyped lentivirus virions were 
produced by co-transfecting 1.5µg of VSV-G plasmid with 2µg of lentiviral 
construct containing the gene of interest (pSIN-MCS), and 1.5µg of the packaging 
plasmid p8.91. 5µg of plasmid DNA was transfected into a 70% confluent 10cm 
plate of 293T cells using the FuGENE protocol.  Five hours post transfection, the 
OPTI-MEM media was removed and fresh DMEM added. Virus containing 
supernatants were harvested 48hrs post transfection, filtered through a 45µM filter 
and then stored at -80°C. For those lentiviral prep arations with low infectivity, the 
virus containing supernatant was concentrated 10x by spinning for 5hrs at 48000g 
using a JA-25.50 rotor. After centrifugation the supernatant was poured off and 
the virus containing pellet was re-suspended in LEC media at a ratio of 1ml of 
LEC media to one 10cm plate of 293T cells, supernatant was then stored at -
80oC.  
 
Lentiviral infections were performed by incubating the desired amount of virus 
with LEC in culture, typically 2ml of concentrated lentivirus was added to 5x104 
cells. The virus was removed either 5 or 16hrs post infection and fresh LEC media 
added. Infected LEC were typically harvested 72hrs post infection. Infectivity of 
lentiviral preparations was assessed by performing qPCR 72hrs post transfection 
quantifying the levels of lentiviral packaging signal. Expression of the lentiviral 
constructs was determined by quantitative reverse transcriptase-PCR (qRT-PCR) 
for the gene of interest cloned into the lentiviral backbone. 
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2.3 Molecular biology techniques  
2.3.1 Bacterial transformation   
Plasmid DNA was amplified through chemical transformation and expansion of 
bacterial cultures. One vial of 50µl One Shot TOP10 chemically competent E.coli 
(Invitrogen) was transformed with 1-5µl of ligation reaction or plasmid DNA 
(~100ng).  Bacteria were incubated on ice for a minimum of 5 mins and then heat 
shocked at 42oC for 30 seconds, after which they were placed on ice. 250µl of 
room temperature SOC media (Invitrogen) was added to each vial of bacteria and 
incubated at 37oC for 1 hour with shaking. If bacteria were transformed with 
ligation mixture, after shaking 200µl was streaked on ampicilin containing LB agar 
plates [LB agar (Sigma) with 100 µg/ml ampicilin (Sigma)]. Plates were incubated 
overnight at 37oC, successfully transformed bacteria contained an ampicilin 
resistant cassette, and therefore survived ampicilin selection growing to form 
visible colonies, which were then picked for subsequent expansion. Alternatively, 
if bacteria were transformed with a pure solution of plasmid DNA, SOC media was 
expanded directly to 5mls with LBamp. This feeder culture was grown for 3-4hours 
at 37oC with shaking, and then expanded to 100mls with LBamp, which was  grown 
overnight.  
 
2.3.2 Plasmid purification 
Plasmid DNA was extracted from transformed bacterial cultures using Qiagen 
miniprep or maxiprep kits according to manufacturer’s instructions. Minipreps 
were performed on 5ml of bacterial cultures typically transformed with ligation 
reactions during the cloning process in order to test for the presence of a DNA 
insert. Minipreps yielded approximately 20µg of plasmid DNA.  
 
For minipreps, a single bacterial colony was picked and placed into 5mls of LBamp, 
which was grown overnight at 37oC with shaking. Bacteria were pelleted by 
spinning at 3000rpm for 15min in an Eppendorf desktop centrifuge. The bacterial 
pellet was re-suspended, lysed and neutralized through an alkaline lysis method 
according to manufacturer’s instructions (Qiagen). Cellular debris and genomic 
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DNA were pelted by spinning at 13000 rpm in a desktop centrifuge. The resulting 
clear solution containing the plasmid DNA was passed through a mini-prep 
column by spinning at 13000rpm in a desktop centrifuge for 1 min. Wash steps 
were performed according to manufacturers protocol and clean plasmid DNA 
solution was eluted in 50µl of ddH20. 
 
Maxipreps were performed on 100ml of bacterial culture from which bacteria were 
pelleted through spinning at 3500rpm for 15 min at 4oC. The pellet was re-
suspended, lysed and neutralised according to manufacturer’s instructions. 
Genomic DNA was pelleted through centrifuging the solution at 3500rpm for 30 
min at 4oC. Subsequent wash steps and elution were performed according to 
manufacturer’s instructions. Eluted DNA was precipitated with isopropanol and 
washed with 70% ethanol. Precipitated DNA was them resuspended in 500µl of 
ddH20. Maxipreps typically yielded ~1µg/µl of plasmid DNA.  
 
Plasmid DNA concentration and purity was quantified by measuring the 
absorbance at 260nm/230nm and the absorbance at 260nm/280nm respectively 
using a NanoDrop UV spectrophotometer. 
 
2.3.3 Restriction enzyme digest 
Restriction enzyme digestion was performed either on plasmid DNA to confirm the 
presence of a cloned insert or on PCR amplified products which were to be 
subsequently ligated into plasmid DNA. All restriction enzyme digests were 
performed for 1-2hrs at 37oC with 5-10 units of each enzyme in a total volume of 
15-25µl. Included in the restriction enzyme mix was 10x restriction enzyme buffer 
and ~1µg of DNA. The appropriate buffer was selected by consulting Promega’s 
enzyme buffer compatibility chart and determining in which buffer the two 
enzymes had maximum activity. After restriction enzyme digestion, 6x DNA 
loading buffer (Fermentas) was added and the product resolved by 
electrophoresis on an agarose gel, the product was then excised and cleaned up 
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using QIAquick Gel Extraction Kit (Qiagen). Alternatively, digested PCR products 
were purified directly using the QIAquick Gel Extraction Kit.  
 
2.3.4 Agarose gel electrophoresis  
Gel electrophoresis was performed to visualise DNA and or for gel purification. 
Typically 1% weight/volume (w/v) agarose (Sigma) in TAE buffer (Tris-acetate 
0.4M, ethylene diamino tetraacetic acid (EDTA) 0.01M) gels were used to resolve 
DNA fragments > 200bp. For resolution of DNA <200bp 2-4% agarose gels were 
used. DNA was visualised through the addition of 0.04mg/ml of ethidium bromide 
(Sigma). Agarose gels were electrophoresed in TAE buffer at a voltage of 100V. 
DNA bands in the gel were visualised using the G:Box gel documentation system 
(Syngene). DNA ladders (Fermentas) of the appropriate size range were 
separated alongside experimental samples to estimate the size of DNA 
molecules.  
 
2.3.5 Agarose gel extraction 
Agarose gel extraction was performed on PCR products or digested plasmids to 
be used for subsequent ligation or sequencing. Gel extraction was performed 
using the QIAquick Gel Extraction Kit (Qiagen).  Excised DNA-containing gel 
pieces were weighed and three times the volume of QG buffer added. Gel was 
dissolved in QG buffer by incubating at 50oC until all gel was in solution. Then one 
volume of isopropanol was added and samples loaded onto the QIAquick spin 
column and processed according to manufacturer’s protocol. DNA was eluted 
from the column in 30µl of ddH20. The QIAquick kit was also used to clean up 
PCR products which had been restriction digested, these products were not run 
on a gel as digesting the product had little effect on size and therefore 
electrophoresis was unnecessary. After restriction digest, 300µl of QG buffer was 
added to the DNA, followed by 100µl of isopropanol. The sample was then loaded 
onto the column and processed according to the manufacturer’s instructions. DNA 
was eluted in 30µl of ddH20.  
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2.3.6 Ligation 
Ligation reactions were performed in a total volume of 20µl using 20 units (1µl) of 
T4 DNA ligase and 2µl of 10x T4 DNA ligase buffer (New England Biolabs). 
Varying ratios of insert to plasmid DNA were used in ligation reactions, always 
keeping the insert at higher concentration to the plasmid DNA to encourage 
ligation and prevent vector re-ligation. Two different restriction enzymes were 
used in the cloning process, this aided cloning of the fragment in the correct 
orientation and minimised vector re-ligation. In addition, prior to ligation 200-
1000ng of gel purified restriction digested vector was incubated with 2µl (2 units) 
of shrimp alkaline phosphatase (Promega) as well as 10x enzyme buffer 
(Promega). The enzyme-DNA mixture was incubated at 37oC for 15 min after 
which the alkaline phosphatase was inactivated by heating to 65oC for 15 min.  
Alkaline phosphatase treatment is another measure designed to minimise vector 
re-ligation, promoting the uptake of cloned insert.  Typically, the highest ratio of 
insert to vector was used depending on the DNA concentration of the insert. 
Ligation reactions were carried out at 16oC overnight.  
 
2.3.7 PCR cloning strategy 
The MAF ORF and 3’UTR fragment were cloned using a PCR cloning strategy. 
The first step was to design 5’ and 3’ PCR primers containing different restriction 
enzymes. There were two criteria used to select restriction enzymes for cloning. 
Firstly, there had to be no restriction sites present within the region to be cloned.  
The DNA sequence to be cloned was obtained from the NCBI GenBank 
depository of sequenced DNA, this was then entered into pDRAW32 
(acaclone.com). This program identified all user specified restriction enzyme sites 
present within the sequence; enzymes which did not cut the DNA could then be 
selected. The second criterion in selecting restriction enzymes was the presence 
of the restriction site within the multiple cloning site (MCS) of the vector. These 
were restriction enzyme sites included into a defined region of the vector during 
vector design to facilitate the cloning process.  
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Primers complimentary to the beginning and end of the sequence to be cloned 
were designed using Primer3 v0.4.0 software (frodo.wi.mit.edu/primer3/). The 
DNA sequence to be cloned was entered into the program; variables including 
primer length, C/G composition, product length and primer melting temperature 
were then specified. Once complimentary primers had been designed and the 
appropriate restriction enzymes selected, a random sequence of junk DNA was 
added to the ends of both primers, this facilitated restriction enzymes digestion.   
 
PCR was performed with 2µl of 10µM forward and reverse primers, 1µl of 10mM 
dNTPs (Invitrogen), 5µl PfuTurbo 10x reaction buffer (Stratagene) or 10µl of 
HotStart HiFidelity 5x PCR Buffer (Qiagen), 1µl of PfuTurbo DNA polymerase (2.5 
units) (Stratagene) or 1µl of HotStart HiFidelity DNA polymerase (2.5 units) 
(Qiagen) and 100-1000ng of template DNA made up to a final volume of 50µl with 
ddH20. PCR conditions were as specified by the manufacturer’s instructions, 
typically the polymerase was activated and DNA denatured by incubating at 95oC 
for 2-5min.  Followed by 20-40 cycles of 95oC for 1 min, 55oC for 1 min, 72oC for 1 
min; during which double stranded DNA is denatured, primers anneal and 
polymerase mediated elongation of PCR produced occurs.  The final step was 1 
hold of 7 min at 72oC, this ensured any remaining single stranded DNA was fully 
extended. Variables in the PCR program were cycle number, extension time and 
primer annealing temperature. Extension time was dictated by the length of the 
product, with 1min/1kb of DNA, primer annealing temperature was governed by 
the base composition and length of primers.  The melting temperature of primers 
was calculated using the formula 2(A/T) + 4(G/C). However, to experimentally 
determine the optimum primer annealing temperature, a temperature gradient 
PCR was performed. In this program the annealing temperature increases in 
defined increments across the PCR block, the products were then run on a gel 
and the temperature yielding the maximum PCR product was used for 
subsequent cloning. 
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Non-template controls, whereby all reactions minus template DNA were run to 
confirm reagents were uncontaminated. Amplification of the PCR product of the 
correct size was confirmed by resolving the product on an agarose gel, the correct 
sequence was then confirmed through sequencing.  
 
The KSHV miRNAs cloned into the pcDNA vector were supplied by Dr. R. Renne 
(University of Florida) (Samols et al., 2007). Therefore, the miRNAs did not need 
to be PCR amplified, instead they were subcloned from this vector into the 
lentivirual vector (pSIN-MCS). First of all the miRNAs were digested out of the 
pcDNA vector using restriction sites flanking the inserts, then they were ligated 
into digested pSIN-MCS vector. The presence of the inserts was confirmed by 
agarose gel electrophoresis and sequencing. The sequence of all PCR primers 
and conditions used are detailed in Table 2.1, additional plasmid used throughout 
experiments are detailed in Table 2.2. 
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Target 
 
Vector 
 
Plasmid 
name 
 
Restriction 
enzymes 
 
Template 
 
 
Forward 
primer 
 
Reverse 
primer 
PCR 
conditions 
MAF pSIN-MCS 
pSIN-
MAF 
BamH1/ 
Nde1 
LEC 
cDNA 
cgcggatc
cgcagga
gaatggca
tcag 
ggaattcc
atatgtatc
agggtggc
tagctgga 
 
30 cycles 
of 
95oC for 1’ 
54oC for  1’ 
72oC for 
1.5’ 
 
MAF 
3’UTR 
psi-
check2 
psi-MAF-
UTR 
XhoI/ 
NotI 
LEC 
cDNA 
ccgctcga
gtgccaatc
tgaaattct
cca 
ataagaat
gcggccgc 
tccactgga
gaaaagg
atgc 
 
40 cycles 
of 
95oC for 1’ 
64oC for  1’ 
72oC for 
2.25’ 
 
 
Table 2.1 PCR cloning details. The pSIN-MCS vector was supplied by Dr. R. Vart (CR-UK Viral 
Oncology group, UCL), psi-Check2 was purchased from Promega. Red: junk DNA, blue: 
restriction enzyme site used for cloning, black: sequence complimentary to DNA. 
 
 
 
Vector 
 
Insert 
 
Plasmid name 
 
pSIN-MCS 
 
KSHV miRNA Cluster  pSIN-K-Cluster 
 
pSIN-MCS 
 
Individual KSHV miRNAs  pSIN-K-miR-X 
pGL3 Control 
 
2 synthetic KSHV miRNA 
target sites 
 
pGL3-T-miR-X 
 
 
Table 2.2 Plasmids used in luciferase assays. The cloning vector, insert and resulting plasmid 
name are indicated.  
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miRNA 
 
Forward primer 
 
Reverse primer 
 
KSHV-miR-
K12-1 
 
 
cagttgtattgtggtgcagaactggatttt
agttaacttaaaaaaaaatccacagttt
taaagg 
 
cctttaaaactgtggatttttttttaagttaactaaaatcc
agttctgcaccacaatacaactg 
 
 
KSHV-miR-
K12-6-3p 
 
 
caccctcactccttctcaaccagcctctt
ccgagatgaaagaaaa 
 
ttttctttcatctcggaagaggctggttgagaaggagt
gagggtg 
 
KSHV-miR-
K12-11 
cactgactgtattgaaaaccagcgtatt
aggaggggaaacgcccctg 
gtgactgacataacttttggtcgcataatcctccccttt
gcggggac 
 
Table 2.3 Primers used for mutagenesis of KSHV miRNA binding sites. Red: mutated bases 
to be incorporated into the psi-MAF-UTR vector. 
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2.3.8 Site directed mutagenesis 
Site directed mutagenesis was performed using the QuikChange XL Site-Directed 
mutagenesis kit (Stratagene) to mutate KSHV miRNA binding sites identified in 
the MAF 3’UTR. Mutagenic primers were designed according to protocol 
guidelines and are detailed in Table 2.3. The primers are complementary to 
opposite strands of the UTR, located in the centre are the altered bases to be 
incorporated (red bases in Table 2.3). The first step was to incorporate the altered 
bases through PCR with the mutagenic primers. PfuTubro enzyme was used 
according to manufacturer’s instructions; this is a non-strand displacing DNA 
polymerase and therefore generates single strand nicks in the plasmid DNA. PCR 
was performed with 125ng of forward and reverse primers and 50ng of psi-MAF-
UTR vector, containing the first 2kb of the MAF UTR. PCR conditions were as 
follows:  one hold of 95oC for 1 min, 18 cycles of 95oC for 50 seconds, 60oC for 50 
seconds, 68oC for 2.5 min and concluded with one hold at 68oC for 7 min. A 
distinct mutated UTR was made for miR-K12-6-3p, miR-K12-11 and miR-K12-1. 
 
Parental psi-MAF-UTR plasmid containing wild type miRNA binding sites was 
isolated from E. coli which dam methylates all DNA. Therefore, all un-mutated 
parental DNA was removed by treatment with DpnI endonuclease which is 
specific for methylated DNA. 1µl DpnI (10 units) was incubated with the PCR 
mixture for 1 hour at 37oC. After DpnI digestion, 5µl of the reaction was used to 
chemically transform XL10-Gold*** Ultracompetent Cells (Stragene) according to 
manufacturer’s instructions. The next day bacterial colonies were picked and 
minipreps performed to isolate plasmid DNA which was sent for sequencing to 
confirm the presence of mutated sites.   
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2.3.9 Genomic DNA extraction 
Genomic DNA was extracted from cultured cells using the QIAmp DNA Mini Kit 
(Qiagen). Cells were detached with trypsin and pelleted by spinning at 13000rpm 
in a table top centrifuge. Cells were then lysed and genomic DNA released by 
treatment with 20µl of Protease K, 200µl of buffer AK was added to the cells and 
mixed by pulse-vortexing. Samples were incubated at 56oC for 10 min, after which 
200µl of 100% ethanol was added and mixed by pulse-vortexing. Samples were 
passed through a QIAmp spin column by spinning at 13000rpm in a table top 
centrifuge for 1 min. Columns were then washed according to manufacturers 
protocol and cleaned genomic DNA was eluted in 50µl of ddH20. The 
concentration and purity of the DNA was determined by measuring absorbance at 
260nm (A260) and 280nm (A280) with a NanoDrop spectrophotometer. An 
A260/A280 ratio of 1.8-2.0, indicating DNA free of contaminants, was obtained for 
all samples. DNA was stored at -20oC until use. 
 
2.3.10 Quantitative polymerase chain reaction (qPCR) 
In order to determine the number of lentiviral copies per infected cell (c/c) qPCR 
was performed for glyceraldehydes 3-phosphate dehydrogenase (GAPDH) and 
the lentiviral packaging signal. Genomic DNA was extracted 72hrs post lentiviral 
infection as described in Section 2.3.9. GAPDH primers and probes used for 
qPCR were as previously described (Bourboulia et al., 2004). Primers were used 
at a concentration of 0.7µM and probes at 0.15µM. GAPDH forward primer: 5’- 
GGAGTCAACGGATTTGGTCGTA-3’ and reverse primer: 5’-
GGCAACAATATCCACTTTACCAGAGT-3’; GAPDH TaqMan probe: 5’-FAM-
GGCAACAATATCCACTTTACCAGAGT-3’TAMRA. Primers and probe for the 
lentiviral packaging signal were used as previously described (Vart et al., 2007). 
Lentiviral forward primer: 5’-GCACGGCAAGAGGCGA-3’, reverse primer: 5’-
CGCACCCATCTCTCTCCTTCTA-3’ and TaqMan probe: 5’-FAM-
CGGCGACTCTCTCCTTCTA-3’. Reactions were performed in a total volume of 
50µl using the Absolute QPCR ROX and dUTP mix (ABgene) and 0.01 units/µl 
AmpErase (Applied Biosystems). 10µl of genomic DNA at a concentration of 50-
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100 ng/µl was added to the reactions. The q-PCR conditions used were as 
follows: 50°C for 2 min followed by 95°C for 15 min  and 40 cycles of 95°C for 15 
sec and 60°C for 1 min. Reactions were run in Optic al 96-Well Thermal Cycling 
Plates (Applied Biosystems) on an Eppendorf PCR machine. DNA mixtures 
containing linearized pSIN-MCS plasmid (Vart et al., 2007) and pcDNA3.1/V5-His-
TOPO-GAPDH plasmid (Bourboulia et al., 2004) at known copy numbers were 
used as standards. The number of c/c was determined by adjusting the number of 
lentiviral constructs present to the number of cells analyzed, using GAPDH. For 
each sample a neat and 1/10 dilution of genomic DNA was run, a negative control 
of ddH20 was performed for all PCRs. 
 
2.3.11 RNA extraction  
Prior to working with RNA all surfaces and pipettes were cleaned with RNaseZAP 
(Ambion) to remove any traces of RNase enzymes which could contaminate 
samples and lead to RNA degradation.  In addition, a dedicated set of pipette tips 
were used for RNA extraction.  The amount and purity of the RNA was 
determined by measuring absorbance at 260nm (A260) and 280nm (A280) with a 
NanoDrop spectrophotometer. An A260/A280 ratio of 1.8-2.0, indicating RNA free 
of contaminants, was obtained for all samples. RNA was stored at -80oC until use. 
 
2.3.11.1 RNeasy Mini Kit (Qiagen) 
Total RNA was extracted from cultured cells using the RNeasy mini kit according 
to manufacturer’s protocol. Cells in culture were washed with PBS and then lysed 
directly in the well by addition of 350µl of buffer RLT, 350µl of ethanol was added 
and the mixture passed through an RNeasy mini-column to isolate RNA. The 
sample was then washed according to manufacturer’s instructions. To remove 
any traces of genomic DNA contamination, DNase I digestion was performed by 
adding 4µl of 10x DNase I reaction buffer and 2µl of DNase I (2 units) to the 
column and incubating at room temperature for 15 min.  RNA was then eluted 
from the column in 30µl of ddH20.  
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2.3.11.2 miRNeasy Mini Kit (Qiagen) 
The RNeasy kit extracts total RNA longer than 200bp, anything smaller is 
removed during extraction.  Therefore, in order to extract total RNA including the 
small RNA fraction which contains amongst other species miRNAs, the miRNeasy 
kit was used. This protocol was used both on cultured cells and human tissue. 
Cultured cells were washed with PBS, then 700µl of QIAzol added to lyse and 
homogenize the sample, this mixture was transferred to a 1.5 ml Eppendorf tube 
and incubated at room temperature for 5 min to promote the dissociation of 
nucleoprotein complexes. 140µl of chloroform was added to the homogenate, 
after incubating at room temperature for 2-3 min the sample was spun at 13000 
rpm for 15 min at 4oC. Addition of chloroform promotes the separation of the 
sample into three distinct phases: RNA molecules longer than 18 nucleotides are 
located in the upper clear aqueous phase, whereas DNA separates to the 
interphase and proteins to the lower, organic phase. The upper, RNA containing 
layer was transferred to a 1.5ml Eppendorf tube, after which 1.5 volume (typically 
525µl) of ethanol was added. This mixture was then passed through an RNeasy 
Mini spin column to isolate total RNA. Phenol and other contaminants were 
washed off according to manufacturer’s protocol. On-column DNase digestion 
was performed to remove any contaminating DNA. RNA was eluted in 30µl of 
sterile RNase free ddH20.  A similar protocol was adopted for total RNA extraction 
from human tissue. Tissue was removed from storage in liquid nitrogen, samples 
were weighed and no more than 50mg of tissue was processed at one time. Prior 
to thawing 700µl of QIAzol was added and tissue shredded using a scalpel. This 
mixture was homogenized using a Tissue-Tearor (Biospec Products). The 
homogenate was then processed as above. 
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2.3.11.3 TRIzol (Invitrogen) 
TRIzol extraction and subsequent purification using the RNeasy mini column 
(Qiagen) was performed when RNA was to be used for gene expression 
microarray analysis. Cultured cells were washed once with PBS and then lysed 
directly in the well by addition of 1ml of TRIzol reagent, lysed cells were removed 
from the well by scraping with a cell scraper. This mixture was transferred to a 
1.5ml Eppendorf tube, RNA was then extracted according to manufacturer’s 
instructions. Briefly, chloroform was added to the sample, which was then mixed 
and centrifuged. After centrifugation the sample had separated into three phases, 
the upper, aqueous RNA-containing phase was transferred to a 1.5ml Eppendorf 
and precipitated by addition of isopropanol. The sample was centrifuged, pelleted 
RNA washed with 75% ethanol and re-suspended in 34µl of sterile RNase free 
ddH20 (Ambion). RNA clean up was then performed using the RNeasy mini 
column clean up protocol. RNA was brought up to 100µl total volume with RNase 
free ddH20, to which 350µl of buffer RLT was added.  After addition of 350µl of 
ethanol the sample was passed through RNeasy spin column to isolate RNA. 
RNA was then washed according to manufacturer’s instructions to remove all 
traces of phenol and other contaminants. RNA was eluted in 30µl of sterile RNase 
free ddH20. 
 
2.3.12 cDNA synthesis 
Between 100-5000ng of RNA isolated by one of the above methods was used for 
complimentary DNA (cDNA) synthesis. cDNA was synthesized using SuperScript 
II reverse transcriptase (Invitrogen). Firstly, RNA was incubated at 70oC for 6 min 
with 1µl of 5µM oligo(dT) and  1µl of 10µM dNTP mix at a total volume of 12µl 
made up with ddH20. After incubation the mix was cooled on ice, the following 
mixture was then added: 4µl of 5x first-Strand buffer (Invitrogen), 2µl of 0.1 M DTT 
(Invitrogen), 1µl of RNaseOUT (200units, Invitrogen) and 1µl of Superscript II 
reverse transcriptase (200 units, Invitrogen). Samples were incubated for 1 hr at 
40oC and then heated to 70oC to inactivate SuperScript II. cDNA was stored at -
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20oC until required, it was then either used neat or diluted 1/100 depending on 
abundance of the transcript. 
 
cDNA synthesis for qRT-PCR quantification of miRNAs was performed using the 
TaqMan® miRNA Reverse Transcription Kit (Applied Biosystems), according to 
manufacturer’s instructions. RNA was extracted from cells or tissue using the 
miRNeasy total RNA extraction kit (Qiagen). 5ng of total RNA at 1ng/µl was used 
per 15µl reaction. Reverse transcription was performed using 3µl of custom 
designed miRNA specific primers from TaqMan® miRNA Assays (Applied 
biosystems). A reverse transcription master mix of the following was prepared: 1µl 
MultiScribe™ reverse transcriptase (50units/µl), 0.15µl of 100mM dNTPs, 1.5µl 
l0x reverse transcription buffer, 0.19µl of RNase Inhibitor (20units/µL), 4.16µl 
nuclease-free water. The reaction conditions were as follows: 16oC for 30 min, 
42oC for 30 min, 85oC for 5 min, samples were then cooled to 4oC. 
 
2.3.13 Quantitative real time reverse transcriptase polymerase 
chain reaction (qRT-PCR) 
Real-time qRT-PCR was performed using Sybr Green (Applied Biosystems) for a 
range of genes, the primers of which are detailed in Table 2.4, primers were 
designed using Primer Express software (Applied Biosystems). GAPDH primers 
were designed as previously described (Bourboulia et al., 2004). All primers were 
used at a concentration of 0.3µM. qRT-PCRs were performed in a total volume of 
25µl using Sybr Green PCR master mix (Applied Biosystems), 1µl of neat or 
diluted cDNA, and 0.75µl of forward and reverse primers. qRT-PCRs were 
performed in Optical 96-Well Thermal Cycling (Applied Biosystems), sealed with 
optical adhesion film (Applied Biosystems) and run on an Eppendorf Mastercycler 
ep Realplex PCR machine.  Reaction conditions were as follows: 50oC for 2 min, 
95oC for 10 min to activate the DNA polymerase, followed by 40 cycles of 95oC for 
15 sec and 60oC for 1 min. Relative expression of the gene of interest was 
quantified using the comparative CT method with GAPDH used as a housekeeping 
gene.  
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Real-time qRT-PCR was performed using TaqMan Gene Expression Assays 
(Applied Biosystems) according to the manufacturer’s instructions, genes are 
detailed in Table 2.4. Reactions were performed in a total volume of 25µl using 
the TaqMan universal PCR master mix and 20x TaqMan probe and primer mix, to 
this 1µl of neat or diluted cDNA was added. Reactions were performed and 
analysed as described above. 
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Gene 
Symbol Assay Forward primer Reverse primer 
 
 
GAPDH 
 
GGAGTCAACGGATTTGGTCG
TA 
GGCAACAATATCCACTTTACCAG
AGT 
 
HDAC9 
 
CAGCAACGAAAGACACTCCA
ACTA CCGTGTACCAGAGCTTGGGAT 
 
FLT1 
 
CTTCTCCTTAGGTGGGTCTC
CATAC 
GTACTCAGGAGCTCTCATCCTCA
TG 
 
FLT4 
 
ACGGCCTGGTGAGTGGC CGTTTGACTCCTCCGTGATG 
 
LYVE1 
 
CCCTGTCTGGATCCTATCCT
CC 
GGATATTATTAGGACATAGCCAG
GCTAG 
 
PDPN 
 
AGCCTCCTGAGTAGCTGGGA
CT 
AAACCCCATCTCTACTAAAAATA
CAAAAATT 
 
CXCR4 
 
GCATGACGGACAAGTACAG
GC CAGAAGGGAAGCGTGATGACA 
 
CXCL12 
 
CATGCCGATTCTTCGAAAGC CAGTTTGGAGTGTTGAGAATTTTGAG 
ITGB3 
 
GTTTACCACTGATGCCAAGA
CTCATA 
CCGTCATTAGGCTGGACAATG 
MAF-S 
 
TTTACTTTTAGAGCTTGCTGT
GTTGC 
CTCGGAAGAGATGGGTGGAGAA 
MAF-L 
Sybr 
Green 
 
 
CCTCTCCCGAGTTTTTCATAA
CTG 
CGTCCTCTCCCGAGTTTTTCA 
 
MAF 
 
N/A N/A 
 
NRCAM 
 
N/A N/A 
 
TFEC 
 
N/A N/A 
 
SLC1A1 
 
N/A N/A 
 
GULP1 
 
Taq 
Man 
N/A N/A 
Table 2.4 Real-time qRT-PCR assay and primers. N/A: not applicable, TaqMan Gene 
Expression assays purchased contained primers and probe.  
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Quantification of KSHV miRNA expression and the human small nucleolar RNA, 
RNU66 (small nucleolar RNA, H/ACA box 66) was performed using TaqMan® 
miRNA Assays (Applied Biosystems, Warrington, U.K). Custom designed assays 
were used for the KSHV miRNAs, these were designed against the mature 
miRNA sequences which were obtained from version 11.0 of miRBase 
(http://microrna.sanger.ac.U.K/sequences/). RNU66 was quantified using an 
inventoried product from Applied Biosystems. Real-time qRT-PCR reactions were 
composed of the following: 1µl of 20x TaqMan MicroRNA Assay, 1.33µl of miRNA 
specific cDNA, 10µ of 2x TaqMan Universal PCR Master Mix, no AmpErase UNG, 
7.67µl of Nuclease-free water, at a final volume of 20µl. Reactions were run in 
Optical 96-Well Thermal Cycling Plates (Applied Biosytems) on an Eppendorf 
Mastercycler ep Realplex PCR machine. PCR conditions were as follows: 10 min 
hold at 95oC, followed by 40 cycles of 95oC for 15 sec and 60oC for 1 min. 
 
miRNA qRT-PCR expression data was expressed as delta Ct values, whereby the 
difference in threshold detection cycle between viral miRNA and loading control 
RNU66 is plotted. Low expression levels correspond to a high delta Ct, whereas 
highly expressed miRNAs have low delta Cts.  In some cases where miRNA 
expression is extremely high, such as the viral miRNAs, these were detected 
before the loading control and therefore have negative delta Ct values. 
 
2.4 Gene expression microarray analysis   
The transcriptional profile of samples was determined using the Human Genome 
U133 Plus 2.0 Array (Affymetrix), this platform quantified the relative mRNA 
abundance of over 47,000 transcripts covering the entire human genome. The 
high density arrays contain 1,300,000 oligonucleotide features which 
corresponded to 11 probe pairs per transcript. Multiple independent 
measurements per transcript, as well as inbuilt controls provide robust mRNA 
quantification. Each chip contains sequences controlling for hybridization 
efficiency, a set of probes for normalization and housekeeping control genes. 
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Sequences for probe design were obtained from GenBank, dbEST and RefSeq, 
probes correspond to the 600 bases proximal to the 3’ end of each transcript. 
 
2.4.1 Sample preparation 
The GEM profile of LEC expressing the KSHV miRNA Cluster was compared with 
that of cells infected with empty lentiviral vector. Three distinct infections per 
condition were profiled. Passage four LEC were removed from liquid nitrogen 
storage and grown until confluent, cells were then plated at a density of 105 cells 
per well on 6 well plates. The day after plating LEC were transduced with KSHV 
miRNA Cluster or empty lentiviral vector at a copy number of ~12.7 c/c as 
confirmed by q-PCR. 72hrs post-infection media was removed, cells washed with 
PBS and 1ml of TRIzol added to one well. Cells were removed by scrapping and 
the TRIzol-Cell mix transferred to the next well, in this manner all 6 wells of one 
plate were pulled together. RNA was then extracted and cleaned up and 
quantified as described in Section 2.3.11.3. 
 
The GEM profile of LEC transfected with MAF siRNA (siMAF) or a non-targeting 
control (siCON) was obtained. 5x104 cells were plated per 6-well, cells were 
transfected with 100nM siMAF or siCON and harvested 48hrs post transfection as 
described above. Three samples per condition were profiled. 
 
All RNA samples had an absorption 260/230nm ratio of ~2 which indicated RNA 
was devoid of salt and other organic contamination and a ratio of ~2 for 
absorption at 260nm/280nm indicating samples were free of protein 
contamination. The RNA was therefore of suitable quality for further processing.  
 
Total RNA was then subjected to RiboMinus™ (Invitrogen) treatment to remove 
18s and 28s ribosomal RNA (rRNA), thereby enriching the sample for mRNA 
molecules prior to GEM analysis. According to manufacturer’s instructions 2-10µg 
of RNA in a volume less than 20µl was hybridized to biotin labeled locked nucleic 
acid (LNA) probes specific to rRNA. 8µl of 100 pmol/µl RiboMinus Probe and 
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300µl of hybridization buffer were added to total RNA. Samples were heated to 
70oC for 5 min to denature the RNA and then cooled over a period of 30 min to 
37oC. The RiboMinus™ magnetic beads (Invitrogen) were prepared and re-
suspended in hybridization buffer according to manufacturer’s instructions. rRNA 
was removed by incubating the sample with RiboMinus magnetic beads at 37°C 
for 15 min and allowing the rRNA to bind to the LNA probes. Samples were left to 
stand on a magnetic stand which collected the rRNA-bound beads, supernatant 
containing the RiboMinus RNA fraction was then transferred to a 1.5ml Eppendorf 
tube. 528µl of supernatant was cleaned and concentrated by ethanol precipitation 
according to manufacturer’s instructions. RNA was re-suspended in 10µl of 
RNase free water (Ambion). 
 
2µg of RNA per chip of LEC-Cluster or LEC-pSIN, 1µg of LEC-siMAF or LEC-
siCON was subject to one-cycle target labeling assay according to manufacturer’s 
protocol (Affymetrix). Briefly, first strand cDNA synthesis was primed by T7-
Oligo(dT) and performed with Superscript II. Second strand reactions were then 
prepared with:  91 µL of RNase-free Water, 30 µL of 5X 2nd Strand Reaction Mix, 
3 µL of 10mM dNTP, 1µl of E. coli DNA ligase, 1.4µl of E. coli DNA Polymerase 
and 1µl of RNase H. This master mix was added to cDNA and incubated at 160C 
for 2hrs. Double stranded cDNA was subsequently cleaned with the GeneChip 
Sample Cleanup Module (Affymetrix) according to manufacturer’s instructions. 
The purified cDNA served as a template for in vitro transcription (IVT) reaction. 
IVT was performed overnight at 16oC by T7 RNA polymerase in the presence of 
biotinylated nucleotide analog/RNA mix generating biotin labeled complimentary 
RNA (cRNA). Amplification of cRNA at this stage generates sufficient RNA for 
chip hybridization. The biotinylated cRNA targets were purified using the Sample 
Cleanup Module, 20µg of clean cRNA was then fragmented using fragmentation 
buffer (Affymetrix) according to manufacturer’s instructions. 
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2.4.2 Chip hybridization and scanning 
Fragmented, labeled cRNA was supplied to the Cancer Institute Scientific Support 
Services Facility (http://www.ucl.ac.uk/cancer/core-facilities/index.htm) who 
carried out target hybridization, washing, staining and array scanning.  
 
2.4.3 GEM data analysis 
The raw GEM data in the format of Affymetrix CEL files was provided after array 
processing by the Cancer Institute Scientific Support Services. Bioinformatician 
Dr. S. Henderson (CR-UK Viral Oncology group, UCL) performed the initial 
processing of raw microarray data as previously described (Lagos et al., 2007), 
generating the microarray log expression values, as well as the statistical p and q 
values. In summary, the Bioconductor (http://www.bioconductor.org/) ‘affy’ 
package written in the R statistical programming language (http://www.r-
project.org/) was used to normalize the raw array data and determine the 
microarray log expression values (Gautier et al., 2004). All analysis was 
performed at the probe level, internal chip controls including the mismatch probes 
were used to determine whether the experimental procedure was successful. To 
assess the significance of difference between two experimental conditions a 
moderated t-statistic was applied to microarray log expression values (Smyth, 
2004). p values were corrected for multiple comparisons and false discovery rate 
(FDR) to obtain q-values (Storey and Tibshirani, 2003). Statistical selection of 
differentially expressed transcripts was performed using the ‘limma’ package 
(Smyth, 2004). Values are standardized Z-scores indicating how many standard 
deviations a particular probe is from the mean of log2 expression values across 
all samples.  
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The raw and background corrected data for GEM data used within this thesis can 
be accessed using the following links (Table 2.5). 
 
 
 
Data 
set 
 
Geo 
accession 
number 
 
 
URL 
 
LEC 
Cluster 
vs 
pSIN-
MCS 
 
GSE16355 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16355 
 
LEC 
siMAF 
vs 
siCON 
 
GSE16356 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16356 
 
miRNA 
profile 
KLEC 
vs 
LEC 
 
GSE17016 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17016 
 
miRNA 
profile 
KS 
lesions 
and 
skin 
 
GSE16353 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE16353 
 
Table 2.5.  GEM and miRNA profiling data sets. Raw and background 
corrected microarray data are deposited in the Gene Expression Omnibus (GEO) 
site http://www.ncbi.nlm.nih.gov/geo/.  GEO accession numbers and links for 
individual data sets are listed.
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2.4.4 Using LEC versus KLEC GEM data sets to analyze Maf 
family mRNA changes upon KHSV infection 
 
GEM data from six LEC and KLEC (72hrs post infection at a minimum of 50% 
GFP positivity) hybridized to Affymetrix Human Genome U133 plus 2 GeneChips 
were obtained from Dr. D. Lagos (CR-UK Viral Oncology group, UCL) (Lagos et 
al., 2007).  GEM data for the seven Maf family transcription factors was extracted 
from all GEM data of LEC vs KLEC. Those probes with expression levels above 
4.5 and a q-value of <0.05 (FDR threshold of 0.5%) were selected and expression 
data represented in the heatmap shown in Figure 4.6A.  
 
2.4.5 Using LEC versus BEC GEM data to compile a list of BEC 
and LEC specific genes 
Previously in the laboratory Dr. D. Lagos (CR-UK Viral Oncology group, UCL) 
performed GEM profiling using the Affymetrix Human Genome U133 plus 2 
GeneChips of six cultured BEC (Unpublished data). Using the ‘affy’ statistical 
analysis package the gene expression profile of these BEC were compared with 
LEC. A List of differentially expressed genes distinguishing the two endothelial 
cell types was generated, a heatmap of which is shown in Figure 5.5. 
 
2.4.6 Gene expression heatmaps 
Heatmaps representing differentially expressed probes were generated using R 
software with the help of Dr. S. Henderson (CR-UK Viral Oncology group, UCL). 
Values used in heatmaps were standardized Z-scores, expression of each probe 
set in units of standard deviation across all samples is shown. The scale located 
at the bottom of each heatmap represents the relationship between colour and its 
intensity and the microarray probe log expression value’s amount of standard 
deviation from the mean.  
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2.5 miRNA microarray profiling 
miRNA profiling of KS biopsies and normal skin samples was performed using the 
Human miRNA microarray V2 (Agilent). This microarray quantifies 723 human 
miRNAs and 76 human viral miRNAs by ~15,000 probes. miRNA probe 
sequences were sourced from miRBase (http://www.mirbase.org/).  Each miRNA 
is quantified by 20 randomly distributed probes; 5 sequence variations per miRNA 
are repeated 4 times at different locations across the chip.  Probes were designed 
to distinguish miRNAs from the same family which differ by no more than one 
nucleotide. 
 
2.5.1 Tissue profiled 
Two nodular KS lesions and three normal skin biopsies were obtained from Dr. M. 
Bower (Chelsea and Westminster Hospital, Imperial College London). Normal skin 
sections were from the same individuals as the KS biopsies, but taken from sites 
devoid of KS lesions. Absence of KSHV from these samples was confirmed by 
qRT-PCR for multiple viral-encoded genes. Three additional nodular KS biopsies 
were provided by the ACIR, NIH.  All participants were male, with AIDS-KS and 
were undergoing anti-retroviral therapy at the time of sectioning.  Participants 
were from a range of ethnic backgrounds and aged 25-57.  All biopsies were 
harvested and fresh frozen in liquid nitrogen until use.   
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2.5.2 Sample preparation 
Tissue was disrupted and homogenised using the Tissue-Tearor (Biospec 
Products).  RNA was extracted using the miRNeasy mini kit as described in 
Section 2.3.11.2.  Prior to further processing for microarray analysis, the 
abundance and quality of small RNA fraction was assessed using the Agilent 
small RNA Kit, according to manufacturer’s instructions. 1-20ng of total RNA was 
loaded in 1µl onto the small RNA chip, nucleic acid fragments were separated 
electrophorectically according to size. 11 samples were analysed per chip, a small 
RNA ladder was run alongside to determine the size of each fraction. Samples 
plus the small RNA ladder were denatured before use by heating to 70oC for 2 
min, then stored on ice. The electrophoretic gel and sample dye were prepared 
and loaded onto the chip according to manufacturer’s instructions. RNA between 
6 and 150nts was visualised using the Agilent 2100 Bioanalyzer (Agilent).  The 
miRNA fraction was assessed by the size of the peak at 10-40nt on the 
electrophoregram, only those samples with a sufficient miRNA content were used 
for miRNA microarray analysis.  
 
100ng of total RNA was incubated with 0.7µl Calf Intestine Alkaline phosphatise 
(25 unit/µl, TaKaRa) at 37oC for 30 min to dephosphorylate the sample according 
to manufacturer’s instructions.  Dephosphorylated RNA was then denatured by 
treatment with 5µL of 100% DMSO and heating to 100oC for 7.5 min, samples 
were then placed on ice. Fluorescent miRNA was generated by labelling the RNA 
with Cyanine 3-pCp at the 3’end according to manufacturer’s instructions. Briefly, 
ligation master mix was prepared with the following: 2µl 10x T4 RNA ligase buffer 
(New England Biolabs), 2µ RNAse-Free Water, 3µ pCp-Cy3 (Agilent), 1µl NEB T4 
RNA ligase (20units/µl, New England Biolabs) giving a total volume of 8µ per 
sample. The ligation mixture was added to the sample and incubated at 16oC for 
2hrs. Labelled RNA was made up to a total volume of 50µl with ddH20, then 
purified by passing the sample through Micro Bio-spin 6 columns (BioRad), 
according to manufacturer’s instructions. These columns contain Bio-Gel P which 
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desalts samples and removes unincorporated dye, smaller RNA fragments are 
retained while larger molecules are excluded.   
 
2.5.3 miRNA microarray hybridization and scanning 
Clean, labelled miRNA samples were then prepared for hybridisation following 
manufacturer’s protocol. Briefly, 10x blocking agent (GE Healthcare) was 
reconstituted with 125µL of nuclease-free water. Labelled samples were dried 
using a speed-vac, spinning at 45oC for 1 hour. RNA was re-suspended in 18µl of 
DNase/RNase-free water and 4.5µL of the 10X GE Blocking Agent added to each 
sample. 22.5µL of 2x Hi-RPM Hybridization buffer was added and samples 
incubated for 5 min at 100oC.  Labelled miRNA was then hybridized to miRNA 
microarrays and scanned following manufacturer’s protocol with the assistance of 
Dr. E. Coulter (Division of Infection Immunity, UCL). The hybridisation mixture was 
added to a clean gasket slide and loaded into the Agilent SureHyb chamber base. 
Samples were rotated and hybridized at 55°C for a m inimum of 20hrs. After 
which, chips were washed with Gene Expression wash buffer (Agilent) containing 
Triton X-102 according to manufacturer’s protocol.  Washed chips were scanned 
using the Agilent microarray scanner and data extracted with the Agilent Feature 
Extraction Software.  
 
2.5.4 miRNA microarray data analysis 
A quality control (QC) report was generated and assessed after scanning to 
confirm that the experimental procedure was successful. Agilent miRNA arrays 
were analyzed by Dr. S. Henderson (CR-UK Viral Oncology group, UCL) using 
the 'limma' package for the R programming language and additional custom 
methods. Background subtraction was undertaken for all probes, negative values 
were given a small positive value. Sets of probes for each gene were converted to 
log2 and a summary calculated from the median. Differential expression between 
summary probe set values was then calculated using the 'limma' methodology.   
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2.6 Protein analysis  
2.6.1 Western blotting 
Protein was extracted from cells using radioimmunoprecipitation assay (RIPA) 
buffer plus protease inhibitor and phosphatase inhibitor cocktails (Sigma). The 
composition of lysis buffer is detailed below: 
 
Lysis buffer: 
150 mM NaCl 
50 mM Tris-HCL pH 7.5 
1% [volume/volume (v/v)] NP40 
0.5% (w/v) Deoxycholic acid 
0.1% (w/v) Sodium dodecyl sulphate (SDS) 
1/100 Protease inhibitor cocktail  
1/100 Phosphatase inhibitor cocktail I 
1/100 Phosphatase inhibitor cocktail II 
 
20-100µl lysis buffer was added either to cell pellets (1x105 - 1x106 cells) in 1.5ml 
Eppendorf tubes and mixed by pipetting or directly to a well or 10cm dish of 
confluent cells. If added directly to cells, media was removed and cells washed 
with PBS, cells were then placed on ice to prevent evaporation and lysis buffer 
added. Cells were retrieved with a cell scrapper and collected in a 1.5ml 
Eppendorf tube. Lysates were then incubated on ice for 30 min and the 
centrifuged at 13000 rpm for a minimum of 20 min at 4oC to pellet cellular debris. 
Supernatant was removed and protein stored at -20oC until required.  
 
Protein concentration was measured using the Bradford assay (Bio-Rad). 2µl of 
protein lysate was diluted to 500µl with distilled water (dH20) to which 500µl of 
Bradford assay reagent was added. 200µl of each sample was added in duplicate 
to a 96-well and the absorption at 595nm was measured with the FluroSkan 
Ascent (Thermo Fisher). To obtain the protein concentration of lysates, absorption 
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of samples were compared with those of a standard curve, which was produced 
with dilutions of bovine serum albumin (BSA) solution (10mg/ml) (Promega). 
 
5-30µg of protein was mixed with 4x SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) sample loading buffer, the composition of which is listed below. All 
samples were made to the same volume with PBS. In addition, 10µl per sample of 
Rainbow colour protein molecular weight ladder (Bio-Rad) was mixed with 4x 
SDS-PAGE buffer and made up to equal volume with PBS. Prior to loading, 
protein was denatured by heating to 100oC for 5 min and allowed to cool. 
 
4x SDS-PAGE sample loading buffer 
250nM Tris-HCL pH 6.8  
8% (w/v) SDS 
10% (v/v) Glycerol 
5% (v/v) β-mecaptoethanol 
0.05% (w/v) Bromophenol blue 
 
Denatured protein lysates were run on 12% polyacrylamide gels which were 
composed of a 1.5mm thick stacking gel and a 12% resolving gel. The 
composition of each gel is listed: 
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Stacking gel 
1.4ml dH20 
0.33ml 30% (w/v) acrylamide 
0.25ml 1.0M Tris pH 6.8 
0.02ml 10% (w/v) SDS 
0.02ml 10% (w/v) ammonium persulfate 
0.002ml TEMED 
 
12% Resolving gel 
4ml dH20 
3.3ml 30% (w/v) acrylamide 
2.5ml 1.5M Tris pH 6.8 
0.1ml 10% (w/v) SDS 
0.1ml 10% (w/v) ammonium persulfate 
0.004ml TEMED 
 
Lysates and ladder were loaded on polyacrylamide gels, to empty lanes equal 
volume of PBS-4x-SDS-PAGE loading buffer was added. Proteins were 
fractionated by electrophoresis at 100V in SDS-PAGE running buffer (National 
Diagnostics) until the bromophenol blue marker ran off the gel. Protein was 
transferred onto immobilon P membranes (Millipore) at 20 V for 1 hour using 
semi-dry transfer apparatus (Bio-Rad) and transfer buffer (National Diagnostics). 
Prior to transfer the membrane was activated by soaking in methanol for 5 min 
and equilibrated in transfer buffer. Membranes were then blocked in blocking 
solution [5% (w/v) milk, 0.05% (v/v) Tween20 (sigma) in PBS] for 1 hour at room 
temperature. After blocking membranes were incubated with primary antibody 
diluted in blocking solution, overnight at 4oC with rotation. Primary antibodies used 
are listed in Table 2.6. After primary antibody incubation membranes were 
washed three times for 15 min with rocking in PBS -Tween [5% (w/v) milk, 0.05% 
(v/v) Tween20 (sigma) in PBS] at room temperature and then incubated for one 
hour at room temperature with the appropriate horse-radish peroxidase (HRP) 
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conjugated secondary antibody, also diluted in blocking solution. After incubation 
unbound antibody was washed off with 3 x 15 min washes in PBS-Tween at room 
temperature with rocking. Bound antibody was then visualized using ECL (GE 
Healthcare) according to manufacturer’s instructions. The resulting chemi-
luminescence signal was detected with Hyperfilm (GE Healthcare). After 
development membranes were washed three times with PBS and incubated with 
Restore Western blot stripping buffer (Themo Scientific) for 10 min at 37oC with 
shaking, stripping agent was then removed by washing 2x with PBS. Membranes 
were wrapped in foil and stored at -20oC.  
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Antibody 
 
Supplier 
 
Protein 
 
Dilution/Amount 
 
Technique 
 
N15 
 
Santa Cruz MAF 1/100 
 
IMG-
6076 
 
Imgenex MAF 1/200 
 
RGM2 
 
Advanced 
ImmunoChemical GAPDH 1/10000 
 
CP01-
1EA 
 
Calbiochem ACTB 1/10000 
 
SC-126 
 
Santa Cruz P53 1/5000 
Western Blotting 
 
IMG-
6076 
 
Imgenex MAF 1/200 
 
SC-2027 
 
Santa Cruz rabbit IgG 1/200 
Immunofluorescence 
 
M153 
 
Santa Cruz MAF 0.28µg 
 
SC-2027 
 
Santa Cruz rabbit IgG 2µg 
Immunoprecipitation  
 
M153 
 
Santa Cruz MAF 20µg 
 
SC-900 
 
Santa Cruz RNA POL II 10µg 
 
SC-2027 
 
Santa Cruz rabbit IgG 10µg 
 
Chromatin 
Immunoprecipitation 
 
 
Table 2.6. Primary antibodies used for protein detection and quantification. Antibody, 
supplier, technique and dilution factor or total amount is listed. 
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2.6.2 Nuclear and cytoplasmic fractionation 
The nuclear and cytoplasmic protein fractions were extracted from LEC and 293T 
cells using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Peirce, Thermo 
Scientific) according to manufacturer’s instructions. This method of protein 
extraction was used to enrich for nuclear proteins such as the MAF transcription 
factor for use in downstream immunoprecipitation assays.  Briefly, the packed cell 
volume of pelleted cells was estimated and 10x the volume of ice cold CERI 
buffer was added. Samples were vortexed and 55% of the packed cell volume of 
CER II was added, after vortexing and centrifugation the cytoplasmic fraction was 
transferred to a new 1.5ml Eppendorf. The remaining nuclei were then lysed by 
the addition of 5x the packed cell volume of NER, after 40 min incubation on ice 
with repeated vortexing, debris was pelleted by centrifugation and the nuclear 
extract transferred to a new 1.5ml Eppendorf tube. Protein concentration was 
quantified using the Bradford assay (Bio-Rad); successful fractionation was 
confirmed by the absence of nuclear or cytoplasmic proteins in the cytoplasmic or 
nuclear fraction, respectively.  
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2.6.3 Immunofluorescence assay 
Cells to be analyzed by Immunofluorescence assay (IFA) were grown on 
fibronectin-coated chamber slides (Lab-Tek, Nunc), 7.5x103 cells were plated per 
well. Cells were either grown for 48hrs, infected with KSHV, MAF or pSIN-MCS 
lentivirus and processed for IFA 72hrs p.i. Media was removed and cells washed 
with 500µl of cold PBS, never letting the cells dry out. Cells were then fixed by 
incubation at room temperature for 7 min with 400ul of 4% paraformaldehyde 
(Sigma). After fixation cells were washed 2x with PBS, then permeabilized and 
blocked with 300µl of blocking solution (10% serum-PBS-0.01% TritonX-100) 
incubating at room temperature for a minimum of 30 min.  After blocking cells 
were washed 2x with PBS and incubated at 4oC overnight with either 200µl of 
control or primary antibody re-suspended in PBS with 2% serum and Triton-X100 
to reduce background signal. After primary antibody incubation samples were 
washed 3 x for 5 min with PBS/0.001% Triton-X100 and then incubated for 1 hour 
at room temperature with the appropriate FITC-conjugated secondary antibody re-
suspended in PBS with 2% serum. Secondary antibody incubation was performed 
in the dark to protect the flurochrome from bleaching. Prior to mounting, cells 
were washed 3x with PBS/0.001% Triton-X100, after all liquid was removed the 
chambers were detached and one drop of VECTASHIELD mounting medium with 
4’,6-diamidino-2-phenylindole (DAPI) (Vector) was added to each well, one cover-
slip was used per slide. Visualization was performed using the Zeiss AxioImager 
A1 fluorescent microscope. The serum used in washes matched the species of 
origin (Goat, horse or rabbit) of the secondary antibody. 
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2.6.4 MAF protein immunoprecipitation 
500µg of total protein or nuclear extract from 293T or LEC was 
immunuoprecipitated for MAF using 2µl of M153 antibody (200µg/ml) (Santa 
Cruz), as a control samples were also precipitated with 10µl of rabbit IgG 
(200µg/ml) (Vector). These antibody concentrations had previously been 
experimentally defined to give equal concentration of IgG’s. Protein lysates were 
made up to 1ml in RIPA+PI, 50µl of which was aliquoted and stored at -20oC for 
subsequent Western blot analysis. Samples were pre-cleared with species and 
isotype matched IgG; 1µg of IgG per 500µg lysate and 20µl of protein A/G 
agarose beads (Invitrogen) were incubated at 4oC with rotation for 30 min. A/G 
agarose beads were pelleted by spinning in a table top centrifuge at 2500rpm at 
4oC for 5 min, pre-cleared lysate was then transferred to a new 1.5ml Eppendorf 
tube, 20-50µl of which was aliquoted and stored at -20oC. Pre-cleared lysate at a 
total volume of 1ml was incubated with either M153 or IgG antibody for a 
minimum of 1 hour at 4oC with rotation, 20µl of protein A/G agarose beads were 
then added and incubated at 4oC overnight with rotation. After precipitation, 
samples beads were pelleted by spinning in a table top centrifuge at 2500rpm at 
4oC for 5 min, the depleted supernatant was then removed and stored at -20oC. 
Protein-bound beads were washed 4x in 1ml of RIPA buffer, spinning and 
pelleting the beads between each wash. Finally, beads were resuspended in 40µl 
of RIPA+PI, 10-25µl of which was resolved by Western blotting along with the 
other previously collected fractions which had been stored at -20oC during the 
immunoprecipitation protocol. 
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2.7 Luciferase reporter assays 
Luciferase assays were performed to assess miRNA activity from pSIN-K-Cluster 
in 293T cells and to quantify miRNA repression of the MAF 3’UTR in HeLa. 
Plasmids used in luciferase assays are detailed in Table 2.7. 
 
For the miRNA activity 105 293T cells were seeded per 6-well, 24hours later 
increasing concentrations of pSIN-K-Cluster or empty pSIN-MCS vector were co-
transfected using FuGENE (Roche) along with the 100ng of individual miRNA 
sensor vectors (pGL3-K-miR). miRNA sensor vectors were provided by Dr. R. 
Renne (University of Florida) (Samols et al., 2007), they contained two synthetic 
miRNA target sites inserted in tandem downstream of the firefly luciferase gene. 
For 3’UTR repression assays, the first 2.3kb of the MAF 3’UTR was cloned into 
the psiCheck-2 renilla reporter. 100ng of reporter plasmid (either wild type or 
mutated psi-MAF UTR) was co-transfected with 500ng of the KSHV miRNAs or 
empty lentiviral vector in 2.5x104 HeLa cells.  
 
DNA concentration was kept constant in all wells using the non-coding pGL3 
basic vector (Promega). Cells were harvested 48hrs post transfection, luciferase 
activity was measured using the Dual-Luciferase Reporter Assay System 
(Promega) based on manufacturer’s protocol. Cells were washed with PBS and 
lysed in 500µl or 250µl Passive Lysis Buffer per well of a 6-well or 12-well plate 
respectively, cells were incubated with shaking for 15 min at room temperature. 
10µl of each sample was assayed in duplicate on a 96-well white non-transparent 
plate (Thermo Fisher Scientific). Plates were read using a Fluoroskan Ascent FL 
luminometer (Thermo Fisher Scientific), following the addition of 50µl firefly 
luciferase substrate after a 10 second lag. Subsequently, 50µl of Renilla 
luciferase substrate was dispensed into each well and luminescence measured. 
Luminescence was recorded as relative light units (RLU). 
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For the miRNA reporter assays luminescence was normalized to total protein as 
determined by Bradford assay based on manufacturer’s protocol. This method of 
normalisation has been previously performed (Cannon et al., 2003). Firefly 
luciferase was normalized to total protein to account for any difference between 
samples due to differences in cell number or pipetting error. In the case of psi-
MAF-UTR experiments, the psi-Check2 plasmid contained an internal firefly 
luciferase gene which was used to normalise renilla values, controlling for 
variations in transfection efficiencies as well as pipetting errors.  
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Plasmid 
 
Reporter 
 
Promoter 
 
Supplier 
 
pSIN-K-Cluster 
 
n/a SFFV promoter n/a 
 
pSIN-K-miR-X 
 
n/a SFFV promoter n/a 
 
pSIN-MCS 
 
n/a SFFV promoter n/a 
 
pGL3-T-miR-X 
 
Firefly luciferase SV40 promoter n/a 
 
psi-MAF-UTR 
 
Firefly & renilla 
luciferase 
Firefly – HSV-TK promoter 
Renilla – T7 promoter Promega 
 
pGL3 control 
 
Firefly luciferase SV40 promoter Promega 
 
pGL3-basic 
 
Firefly luciferase No promoter Promega 
 
Table 2.7 Plasmids used in luciferase assays. Promoters identified drive expression of either 
luciferase reporter or gene of interest. HSV-TK, herpes simplex virus-thymidine kinase. n/a not 
applicable. 
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2.8 siRNA transfections 
LEC were seeded at a density of 5x104 per 6-well 16hrs prior to transfection. 
100nM of either MAF On-Target Plus SMARTpool or the On-Target plus Non-
targeting Pool (Thermo Fisher Scientific) siRNA per well was transfected in 1ml of 
OPTI-MEM (Invitrogen) using Oligofectamine™ (Invitrogen), according to 
manufacturer’s instructions.  Four hours post transfection 1.5ml of LEC media was 
added per well, the media was then changed 24hrs post transfection. Cells were 
harvested 48, 72 or 96hrs post transfection and MAF mRNA levels assessed by 
qRT-PCR.   
 
2.9 KSHV miRNA inhibition 
KSHV miRNAs were inhibited using miRIDIAN microRNA Hairpin Inhibitor 
(Dharmacon) or LNA™ modified oligonucleotides (Exiqon).  
 
10^5 293T cells were transfected in OPTI-MEM using oligofectamine™ with 0.4nM 
or 0.8nM miRIDIAN microRNA Hairpin Inhibitors designed against the mature 
miRNA sequence of miR-K12-11 or miR-K12-6-5p. Control cells were mock 
transfected with an equal volume of oligofectamine™ only. The day after 
transfection 50ng of luciferase sensor vector pGL3-T-miR11 and 500ng of 
lentiviral plasmid pSIN-K-miR11 or pSIN-MCS were cotransfected using 
oligofectamine™. Samples were harvested and luciferase activity quantified 48hrs 
post inhibitor transfection.  
 
A similar protocol was adopted for the LNA-modified miRNA inhibitors, whereby 
10^5 293T cells were transfected in OPTI-MEM using oligofectamine™ with 10nM 
or 50nM of three different inhibitor designs against miR-K12-11. Control cells 
were mock transfected with oligofectamine™ only. The cells were then treated as 
described above. 
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2x104 LEC were infected with 1.5ml pSIN-MCS, pSIN-K-miR-6 or pSIN-K-miR-11, 
then 24hrs later transfected in OPTI-MEM using oligofectamine™ with 400nM  
miRIDIAN microRNA Hairpin Inhibitors designed against the mature miRNA 
sequence of miR-K12-6-5p and miR-K12-11 or a non-targeting control. Cells were 
incubated for 5hrs in the transfection mixture, 1ml of LEC media was then added 
per well. Alternatively, LEC were transfected with the inhibitors 24hrs prior to 
KSHV infection of LEC. All samples were harvested 48hrs post inhibitor 
transfection.  
  
For the LNA inhibitors, 2x104 LEC were transfected in OPTI-MEM using 
oligofectamine™, with 50nM of inhibitors designed against the mature miRNA 
sequence of miR-K12-6-3p, miR-K12-6-5p, miR-K12-8, miR-K12-11 or a non-
targeting control. Three different inhibitor designs were tested per KSHV miRNA.  
Cells were incubated for 5hrs in the transfection mixture, 1ml of LEC media was 
then added per well. 24hrs post transfection, cells were washed and media 
changed. 48hrs post transfection LEC were infected with 1ml of KSHV, 24hrs post 
infection cells were harvested and MAF mRNA levels assessed by qRT-PCR. 
  
2.10 Chromatin immunoprecipitation-PCR 
ChIP was performed as previously described (Boyer et al., 2005), with the 
assistance of Dr. R. Jenner (Division of Infection and Immunity, UCL). 6.7x107 
293T cells per ChIP were chemically crosslinked in 1ml of fresh 11% 
formaldehyde solution, per 10cm plate, for 15 min at room temperature. Cells 
were rinsed twice with PBS, harvested with a cell scraper and flash frozen in 
liquid nitrogen where they were stored until use.  The fixed cell pellets were 
resuspended and lysed in lysis buffer plus protease inhibitor. DNA was then 
sonnicated to solubilise and shear crosslinked DNA. All pellets were processed 
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together in a single tube using the Misonix Sonicator 3000. Samples were 
sonnicated for a total of 5min at 24 Watts, for 30sec pulses with intermittent 
breaks of 1min at 4°C, samples were immersed in an ice bath during 
sonnnication. 100µl of cell lysate from each sample was aliquoted as input whole 
cell extract (WCE) and stored at -20oC.  
 
The remaining whole cell extract was incubated overnight at 4°C with 100 µl of 
Dynal protein G magnetic beads per ChIP. The beads had been pre-incubated for 
6-8hrs at 4oC with 10µg of Rabbit IgG or RNA POL II or 20µg of M153 antibody.  
Antibody-bound beads were isolated out of solution using a magnet, washing 
three times with PBS/BSA in between bead isolation. The beads were then added 
to sonicated cell lysate and immunoprecipitated on a disc rotator overnight 4°C.  
Bound complexes were isolated using a magnet, the beads were then washed 
and complexes eluted from the beads by heating at 65°C for one hour, vortexing 
every 10min. The beads were spun down and the supernatant transferred into a 
new tube, and incubated at 65oC for 6-7hrs to reverse the DNA-protein 
crosslinking, whole-cell extract DNA was also treated for crosslink reversal.  
 
Samples were then treated with RNaseA and proteinase K to destroy any RNA 
and protein and purify DNA. The DNA was then ethanol-precipitated overnight at  
-20oC. DNA pellets were washed and air dried before being resuspended in 
10mM Tris (pH8). The DNA concentration was determined using a NanoDrop UV 
spectrophotometer, WCE samples were normalised to 100ng/µl with 10mM Tris 
(pH8). Approximately 5ng/µl of DNA per ChIP was obtained and ~250ng/µl of 
WCE DNA. 
 
Five fold serial dilutions of WCE DNA from 100ng/µl to 0.16ng/µl were qPCR 
amplified with each primer pair (Table 2.8), generating a linear standard curve 
whereby the threshold detection cycle directly corresponded to the amount of 
DNA in ng/µl. PCR primers were also used to amplify DNA precipitated in each of 
the three ChIPs. Using the threshold detection cycle, ng/µl of precipitated DNA 
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was extrapolated from the standard curve generated by the WCE. Fold 
enrichment was calculated by comparing ng/µl of precipitated DNA from the test 
antibody (RNA POL II or MAF) with that precipitated by the control Rabbit IgG 
antibody.  
 
 
Target 
 
Forward primer 
 
Reverse primer 
 
HDAC9 
upstream 
 
CACCCTCACAACCTTCCTGT AGCAGGAGCGTTAGGTTTCA 
 
HDAC9 
928 
 
TGTTCTATTTCTGTGCCTGTGG CTAAAGCGAGTGATAATCCATTTG 
 
HDAC9 
1476 
 
GAGCAGTGATGAATGTTTCATG CCACCCCATCTGAGGAAA 
 
HDAC9 
1546 
 
CGAGAGTGACTCCTGTTTTTCC TGAGCTGATCATACTGTGCATTC 
 
CD13 
 
CTGTTGGAGCCCTGGTTAAT CGGGCTTATATCCCCAAAG 
 
Cyclin D2 
 
GGGAGAGGCGAGACCAGTTT CAGAAGGGAGAT 
 
Table 2.8 PCR primers used to amplify chromatin immunoprecipitated DNA. Primers were 
designed against experimentally defined MAREs in CD13 (Mahoney et al., 2007) and Cyclin D2 
(Hurt et al., 2004) or putative MAREs identified in the HDAC9 3’UTR. As a negative control 
primers were also designed against a region of HDAC9 lacking a putative MARE (HDAC9 
upstream). 
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2.11 miRNA target prediction 
miRNA target prediction was performed using PITA software (Kertesz et al., 2007) 
with the help of Dr. S. Henderson (CR-UK Viral Oncology group, UCL). The PITA 
algorithm was used to calculate both a single miRNA to target interaction score 
(ddG) and a cumulative score for multiple miRNA to target interactions. All 3’ UTR 
sequences of genes which were expressed in LEC, as determined by previous 
GEM data (Lagos et al., 2007) were obtained from Biomart 
(http://www.ensembl.org/Multi/martview). The positions of potential KSHV 
miRNAs interactions were identified using the PITA algorithm according to the 
authors recommended formula: 
 
http://genie.weizmann.ac.il/pubs/mir07/mir07_notes.html: 
 
ddGsum = -log (Σ(e-ddG)) 
 
The strength of the interaction (ddGsum) was calculated, only those with an 
energetically favourable interaction, i.e. a negative ddG value were considered as 
potential KSHV miRNA targets. In order to minimise the number of false positives, 
only those potential interactions of 8mer target sites with either one G:U wobble or 
one mismatch but not both, were considered. The cumulative interaction scores 
for genes down-regulated in the presence of the KSHV miRNA Cluster were 
calculated for only those KSHV miRNAs that were found to be significantly 
expressed in AIDS-KS relative to skin.  
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2.12 Gene set enrichment analysis (GSEA) 
GSEA (Subramanian et al., 2005) was used to assess the enrichment of a gene 
set within a GEM experiment and was performed by Dr. S. Henderson (CR-UK, 
Viral Oncology group, UCL) on three GEM data sets generated by myself (LEC-
Cluster and LEC-siMAF) or previously by Dr. D. Lagos (KLEC) (CR-UK Viral 
Oncology group, UCL)  (Lagos et al., 2007). Briefly, the GSEA method compares 
an experimental dataset to a set or sets of genes of interest (Mootha et al., 2003; 
Subramanian et al., 2005). In this case, the experimental datasets were GEM 
profiles and the gene set of interest were BEC or LEC specific genes as 
determined by comparing LEC and BEC expression profiles. Lists of 50-250 
genes, increasing in 50 gene increments, were analysed. This method firstly 
determines whether the order of the set of interest is random within the sorted 
experimental dataset, that is whether the set of interest is significantly correlated 
within the experimental dataset assigning a false discovery rate (FDR) q-value 
based on a permutation test. The resulting Enrichment Score (ES) is a metric of 
the skew of a gene set within the rank of genes sorted by their GEM expression 
difference. Secondly, if the gene set is significantly correlated it finds a 'leading 
edge' or subset of the genes that form a 'core' of the most significantly changed 
genes. Leading edge genes are the subset that contributes most to the ES. 
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2.13 Statistical analysis 
Standard deviation (SD) was used to calculate the error bars for in vitro 
experiments. SD is the square root of the variance (σ2), it is a measure of the 
spread of a particular distribution and indicates how much variability there is about 
the mean. It is used to measure the variation between sample values:  
 
σσ =
  ∑ −= 2)(2 µσ x  
 
(Where X is a sample value and µ is the mean of the sample values) 
 
To determine whether the difference between two experimental conditions was 
significant (except in GEM analysis, where the FDR was used) p values were 
calculated using a two-tailed Student’s t test. The difference was considered 
significant if p <0.05. 
 
2 
N 
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Chapter 3. Identification of KSHV miRNA targets 
3.1 Introduction and aims 
The aim of this chapter was to establish an experimental system in which to 
identify the cellular targets of the KSHV-encoded miRNAs. Specifically, to 
discover target genes deregulated in LEC, the closest cell type to the KS spindle 
cell (Wang et al., 2004). To achieve this aim a combination of experimental and in 
silico analysis techniques were employed. The viral miRNA expression profile in 
KS lesions was determined in order to refine analysis to miRNAs relevant to KS 
biology. 
 
Previously, a subset of cellular KSHV miRNA targets were identified in latently 
infected B cells and 293 cell lines (Samols et al., 2007; Ziegelbauer et al., 2009; 
Gottwein et al., 2007; Skalsky et al., 2007). To date there has been no 
investigation into KSHV miRNA targets in LEC. Since miRNA targets are likely to 
be highly cell context dependant, identification of mRNAs deregulated in LEC 
through the action of KSHV-encoded miRNAs may generate more relevant insight 
into the functional roles of the KSHV miRNAs during primary infection and KS 
pathogenesis.  
 
  
 
 
 
 
 
 
144 
miRNAs act to subtly suppress expression of their target mRNAs and, 
subsequently, modulate the proteome of the cell in which they are expressed 
(Baek et al., 2008; Selbach et al., 2008).  miRNAs exert their effect by inducing 
small fold-changes in the steady state levels of multiple mRNAs, such changes in 
mRNA abundance can be quantified by GEM analysis (Lim et al., 2005; Krutzfeldt 
et al., 2005).  To identify changes in mRNA abundance attributed solely to the 
KSHV miRNAs it was necessary to work with the viral DNA encoding the miRNAs 
in isolation. Previously in our laboratory, an HIV-based lentiviral vector system 
was established to study the function of individual KSHV genes in LEC (Vart et 
al., 2007). Employing this system, the KSHV miRNA Cluster was cloned into the 
lentiviral vector to permit LEC target identification. This lentiviral system has 
proven efficacious in expressing exogenous genes in LEC (Naldini et al., 1996; 
Lagos et al., 2007; Vart et al., 2007), as lentiviruses can infect both dividing and 
non-dividing cells, an advantage when working with slowly dividing primary cells 
(Naldini et al., 1996). Transduction of LEC with lentiviral vectors permits delivery 
of exogenous DNA to primary cells that are sensitive to transfection reagents 
such as Oligofectamine and FuGENE. In addition, following infection, lentiviral-
encoded RNA is reverse transcribed into DNA which inserts into the host genome, 
allowing stable expression. The resultant expression levels are also more 
physiologically relevant than those obtained after plasmid transfection.  
 
The KSHV miRNA expression profile has been extensively characterised in 
latently infected tumour cells (Cai et al., 2005; Samols et al., 2005; Pfeffer et al., 
2005); at the onset of this work expression of the KSHV viral miRNAs had not 
been confirmed in KS lesions. miRNA microarray profiling was performed to 
confirm and characterise viral miRNA expression in KS lesions, identifying 
miRNAs which were of relevance to KS pathogenesis. To identify cellular targets 
not picked up by the array, in silico miRNA target prediction analysis was 
performed using the publically available prediction algorithm PITA (Probability of 
Interaction by Target Accessibility) (Kertesz et al., 2007). PITA identifies putative 
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miRNA targets according to a defined set of criteria that are primarily miRNA-
target seed sequence complementation and thermodynamic feasibility of binding. 
Target prediction analysis was only applied to those miRNAs expressed in KS 
lesions, restricting analysis those miRNAs relevant to the disease.  
 
3.2 KSHV miRNA expression in Kaposi sarcoma 
The KSHV miRNA profile of five AIDS-KS lesions was characterized using Agilent 
miRNA microarray profiling. The aim was to determine the expression profile of 
the KSHV miRNAs, therefore three KSHV-negative skin biopsies were used as 
controls, allowing a baseline to be set for viral miRNA detection in samples 
lacking the viral genome. KS biopsies are largely comprised of spindle cells, 
whereas skin biopsies contain additional cell types as well as LEC. For this 
reason skin is not an optimal comparison for profiling experiments analysing 
global gene expression; however, in the context of this experiment, the essential 
criterion was the absence of KSHV infection in control tissue so that viral miRNA 
expression could be compared, therefore skin was deemed an acceptable control 
tissue. Normal skin was harvested from three participants with AIDS-KS at sites 
distal from any obvious KS lesions and qRT-PCR for viral gene expression 
confirmed KSHV infection of the KS biopsies (Fig. 3.1A). LANA was detected in 
all KS biopsies, whereas the key lytic reactivator ORF50 was detected at a lower 
level in four out of five biopsies (Fig. 3.1A). This difference in viral gene 
expression reflects increased proportion of KS spindle cells that are latently 
infected with KSHV, with only 5% undergoing lytic replication (Staskus et al., 
1997). No viral gene expression was detected in the skin biopsies, confirming 
their KSHV negative status (Fig. 3.1A).  Since the miRNA fraction is often lost or 
degraded during sample preparation it was important to confirm the quality and 
quantity of RNA prior to profiling. The miRNA content of RNA extracted from all 
KS and skin biopsies was assessed using the Agilent small RNA kit (Fig. 3.1B 
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and C).  The Bioanalyzer (Agilent, California) identified samples with sufficient 
miRNA content and only this RNA was included in further processing for miRNA 
profiling (Fig. 3.1C).  
  
 
 
 
 
 
 
147 
A
15
20
25
30
35
40
Skin P1 Skin P2 Skin P3 KS 330 KS P2 KS 248 KS 606 KS 602
Th
re
sh
o
ld
 
Cy
cl
e
GAPDH
LANA
ORF50
marker
20nt
40nt
150nt
B
marker
miRNA 
fraction
C
 
 
 
Figure 3.1. Skin and KS biopsies used for miRNA profiling. A Viral gene expression was 
detectable in Kaposi sarcoma, but not in uninfected skin biopsies. qRT-PCR detection of KSHV-
encoded genes LANA and ORF 50, and cellular housekeeping gene GAPDH. The threshold cycle 
of detection is shown. Expressed transcripts have a threshold cycle of less than 35. Values for all 
skin and KS biopsies profiled are shown. B An electropherogram of the small RNA ladder used to 
quantify the miRNA fraction of total RNA to be profiled. The size of the RNA molecule is 
proportional to the time taken for fractionation [S]. Peaks corresponding to 20nt, 40nt and 150nt 
are indicated. C Representative electropherogram of total RNA extracted from tissue. Mature 
miRNAs are ~22nt long, and fractionated between 45-50s. Peak height corresponds to proportion 
of RNAs within total RNA.  
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Expression levels of individual KSHV miRNAs from all KS biopsies and normal 
skin are shown in the boxplots describing the log2 expression levels (Fig. 3.2A 
and 3.3A). Each participant had a different viral load and therefore participants 
express varying levels of KSHV miRNAs. This is reflected in the spread of the 
data and by the presence of sample outliers.  Those miRNAs with significant 
differential expression between skin and KS are shown in figure 3.2A. Ten out of 
the 17 mature viral miRNAs had significantly higher expression in KS lesions than 
in uninfected skin and were therefore classed as expressed (Fig. 3.2A). miR-K12-
4, miR-K12-1, miR-K12-11 and miR-K12-6-5p show the most significant 
differential expression (Fig. 3.2A).  
 
To confirm the viral miRNA microarray data, qRT-PCR quantification of the 
mature form of KSHV miRNAs was performed (Fig. 3.2B). The difference in 
threshold detection cycle (delta Ct) between each KSHV miRNA and RNU66 is 
shown in both KS lesions and skin. RNU66 is a small nucleolar RNA whose 
expression does not vary between KSHV infected and uninfected tissue. 
Therefore, in a similar manner to the cellular housekeeping gene GAPDH, RNU66 
is used as a loading control for normalisation. Viral miRNAs with a delta Ct of 
greater than zero are detected at earlier PCR cycles and are therefore more 
abundant than RNU66. miRNAs expressed in KS lesions were largely 
undetectable after 40 cycles of amplification in normal skin samples, generating a 
delta Ct of -8 (Fig. 3.2B). miR-K12-10a was amplified in KSHV negative tissue 
generating a higher delta Ct than other viral miRNAs (Fig. 3.2B). However, there 
was a significant difference in the delta Ct of miR-K12-10a between skin and KS. 
Detection of miR-K12-10a above background levels detected in skin, suggests 
this miRNA is expressed in KS lesions. 
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Figure 3.2. Differential expression of KSHV miRNAs in KS lesions A miRNA microarray log2 
expression values of significantly expressed miRNAs in KS biopsies (relative to KSHV-negative 
skin, p<0.05). Boxplots show the median, interquartile boxes, 95th percentile range, and outliers 
as points. Five AIDS-KS biopsies and three KSHV-negative reference skin samples were 
profiled. B qRT-PCR confirmation of the miRNA profiling data. All miRNAs assayed were 
expressed at higher levels in KS lesions compared to normal skin. Values were normalised to 
RNU66. The delta Ct represents the difference in threshold detection cycle between RNU66 and 
viral miRNA. Viral miRNAs were undetectable in skin biopsies. Error bars correspond to 
standard deviation, n: 5 KS biopsies; 3 normal skin. 
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Agilent miRNA profiling failed to detect significant differential expression of the 
remaining seven mature KSHV miRNAs between KS and skin samples (Fig. 
3.3A). Five viral miRNAs (miR-K12-3*, miR-K12-5, miR-K12-9, miR-K12-9* and 
miRK12-12) were undetectable in KS lesions and were therefore classed as 
unexpressed (Fig. 3.3A). miR-K12-3 and miR-K12-7 cross-reacted in both KSHV 
positive and negative samples, making it difficult to confirm their expression (Fig. 
3.3A). qRT-PCR for miR-K12-3, miR-K12-9 and miR-K12-9* failed to detect these 
miRNAs in KS tissues, confirming the miRNA microarray data (Fig. 3.3B). 
However, miR-K12-5 and miRK-12-12 were detected in KS lesions by qRT-PCR 
(Fig. 3.3B). This discrepancy may be due to a higher detection threshold of the 
qRT-PCR assay or as a consequence of miRNA microarray probe design. A 
naturally occurring polymorphism exists in the precursor stem-loop of miR-K12-5 
which inhibits Drosha processing and leads to diminished levels of the mature 
miRNA (Gottwein et al., 2006). It is possible that KS biopsies were infected with a 
viral strain possessing this polymorphism and that miR-K12-5 is present at low 
levels. Similar to the miRNA microarray data, miR-K12-7 amplified in both KS and 
KSHV negative skin samples; therefore it was not possible to confirm expression 
of this miRNA in KS lesions (Fig. 3.3B). However, significant differential 
expression of miR-K12-3 was detected in KS above the background levels 
detected skin, suggesting this miRNA may be expressed (Fig. 3.3B).  
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Figure 3.3. KSHV miRNAs not expressed in KS lesions. The microarray log2 expression 
value of KSHV miRNAs whose expression is not significantly differ between KS and KSHV 
negative skin (p>0.05). miR-K12-3 and miR-K12-7 both show high background levels in 
uninfected skin samples. The remaining miRNAs are undetectable in KS lesions. Boxplots show 
the median, interquartile boxes, 95th percentile range, and outliers as points. Five AIDS-KS 
biopsies and three KSHV-negative reference skin samples were profiled. B qRT-PCR 
quantification of the KSHV miRNAs whose expression did not significantly differ between KS 
and skin biopsies. Contrary to the miRNA microarray data miR-K12-3, miR-K12-5 and miR-K12-
12 were detectable in KS lesions, but not in KSHV negative skin. Similar to the miRNA profiling 
data, miR-K12-7 was detected in both KS and skin. The remaining miRNAs were undetected in 
KS lesions. Values were normalised to RNU66. The delta Ct represents the difference in 
threshold detection cycle between viral miRNA and RNU66. Error bars correspond to standard 
deviation, n: 5 KS biopsies; 3 normal skin. 
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3.3 Sub-cloning the KSHV miRNAs 
 
KSHV encodes 17 mature miRNAs which are generated from 12 pre-miRNAs 
(Fig. 3.4A). Ten of these pre-miRNAs, generating 14 mature miRNAs, are 
organised as a Cluster located in the latency-associated region of the genome, in 
an intergenic region between vFLIP and Kaposin (Fig. 3.4A). The other two pre-
miRNAs are located further upstream. miR-K12-10 is unusual due to its location 
within the Kaposin ORF, processing of miR-K12-10 generates two isoforms 
referred to as miR-K12-10a and b. miR-K12-12 is located upstream of the 
Kaposin ORF (Fig. 3.4A). 
 
Previously, nucleotides 119,365 to 122,481 from the KSHV genome had been 
cloned into the pcDNA3.1/V5/HisA vector (Samols et al., 2007). This construct, 
along with a subset of individual KSHV pre-miRNAs, also in the context of 
pcDNA3.1/V5/HisA, were provided by Dr. R. Renne (University of Florida). The 
individual pre-miRNA vectors consisted of 200 nucleotides surrounding the pre-
miRNA (Samols et al., 2007).  To allow expression in the lentiviral system, the 
KSHV miRNA Cluster and individual miRNAs were excised from the pcDNA 
plasmid by restriction digest with BamHI and NotI; the digested DNA fragments 
were ligated into the similarly cut pSIN-MCS vector. Subsequent restriction 
enzyme digestion confirmed the presence of inserts of the correct size in pSIN-K 
miR vectors (Fig. 3.4B). The sequence of the miRNA insert was confirmed by 
DNA sequencing, only plasmid DNA with miRNA inserts lacking mutations were 
used. 
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Figure 3.4. Restriction enzyme digestion of pSIN-MCS constructs. A Schematic showing the 
genomic organisation of KSHV miRNAs in the latency-associated region of the viral genome. The 
KSHV miRNAs are indicated by horizontal blue lines with the genomic locations noted below. 
Individual KSHV miRNA hairpins are shown above. Promoters are represented by dark purple 
arrows, protein coding open reading frames are shown in pink. The Kaposin open reading frame is 
preceded by two sets of direct repeats (Blue rectangles, DR1 and DR2). B ~1µg of pSIN-MCS 
constructs were digested with BamHI and NotI to excise the cloned KSHV miRNA from pSIN-
MCS. The top band is empty linearised pSIN-MCS and bands running at ~200bp are the excised 
pre-miRNAs. Uncut pSIN-MCS was run with K12-1 and K12-8, this plasmid DNA is supercoiled 
and therefore runs faster than linearised vector.  
A 
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3.4 KSHV miRNA activity from pSIN-K-Cluster 
It was necessary to confirm the cloned miRNAs were expressed from the lentiviral 
vectors and capable of silencing.  miRNA activity was assessed using reporter 
vectors containing two inverse copies of individual miRNA target sites located 
downstream of the luciferase firefly coding sequence in the 3’UTR (Luciferase 
plasmids provided by Dr. R. Renne, [Samols et al., 2007]). miRNA-mediated 
silencing reduces levels of the firefly luciferase enzyme, the magnitude of 
silencing is quantified by the reduction in light emitted after addition of luciferase 
enzyme substrate. The resistance of LEC to transfection necessitated these 
assays being performed in 293T cells where the reporter constructs could be 
expressed.  
 
Increasing concentrations of pGL3 control plasmid, that lacks KSHV miRNA target 
sites, were transfected into 293T cells to determine the range of sensitivity and 
concentration of sensor vectors to be used when testing KSHV miRNA expression 
(Fig 3.5). The standard curve of luminescence is linear from 6µg to 78.14ng of 
pGL3 control plasmid, therefore low concentrations of plasmid can be transfected 
and accurately quantified (Fig 3.5). 100ng was selected as the optimal 
concentration of miRNA sensor vector. To determine the concentration of miRNA-
expressing lentivirus at which miRNA silencing is detected, increasing 
concentrations of pSIN-K-miR11 with 100ng of pGL3-T-miR-11 were titrated (Fig. 
3.6A). A reduction in luminescence was detected with 50ng of pSIN-K12-11 when 
compared to control pGL3 plasmid. Increasing concentrations of miRNA-
expressing plasmid induced a corresponding decrease in luminescence, 
confirming cloned miR-K12-11 was expressed and capable of silencing target 
sites (Fig. 3.6A). 500ng of pSIN-K-miR11 caused a 97% reduction in luciferase 
activity compared to pGL3 control (Fig. 3.6A); this concentration of miRNA-
lentiviral vector was used in all subsequent experiments. 
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A time-course experiment was performed to determine the time at which maximal 
miRNA silencing occurred. 500ng of pSIN-K-miR11 and 100ng of sensor vector 
pGL3-T-miR-11 were co-transfected into 293T cells and luciferase activity 
measured 24, 48 and 72hrs post-transfection (Fig. 3.6B). Maximal repression was 
detected 24hrs post-transfection, silencing persisted until 72hrs (Fig. 3.6B). Forty-
eight hours post-transfection, pSIN-K-miR11 induced an 87% reduction in 
luciferase activity compared to empty lentiviral vector (Fig. 3.6B). In some 
instances the miRNA expression vector had to be transfected and then on the 
following day the sensor vector was transfected. Therefore, although maximal 
repression was observed 24hrs post transfection, to ensure consistency, all 
luciferase assays were harvested 48hrs post-transfection. 
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Figure 3.5. Luciferase activity standard curve. Increasing concentrations of pGL3 control 
plasmid were transfected into 293T cells. The standard curve is linear from 6µg to 78.14ng of 
transfected plasmid DNA, therefore plasmids can be transfected within these concentrations and 
accurately quantified. RLU: relative light units. Error bars correspond to standard deviation, n = 3.
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Figure 3.6 KSHV miRNA-mediated reporter silencing. A Increasing concentrations of pSIN-K-
miR11 silenced synthetic luciferase reporter vector pGL3-T-miR11. 293T cells were co-transfected 
with 0ng, 250ng or 500ng of pSIN-K-miR11 plasmid and KSHV miRNA sensor vectors. Relative 
light units (RLU) were normalised to total protein content and the ratio shown. B  Maximal 
silencing occurs 24hrs post pSIN-K-miR11 transfection. 293T cells were co-transfected with pSIN-
K-miR11 and pGL3-T-miR11 and harvested 24, 48 or 72hrs post transfection. Relative light units 
(RLU) were normalised to total protein content and the ratio relative to pSIN-MCS is shown. Error 
bars correspond to standard deviation, n = 3. 
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Sensor vectors for nine out of 17 mature KSHV miRNAs were provided by Dr. R. 
Renne (University of Florida). For those mature miRNAs that generated two 
effector miRNAs, one sensor was constructed. miR-K12-2 was the only miRNA 
not to have a sensor vector for either branch of the mature miRNA. To test KSHV 
miRNA activity from pSIN-K-Cluster, increasing plasmid concentrations were 
transfected in the presence of 100ng of individual miRNA sensor vector (Fig 3.7); 
this induced a corresponding decrease in luciferase activity for all sensor vectors 
tested (Fig. 3.7). These data confirm KSHV miRNA expression and activity from 
the pSIN-K-Cluster lentiviral vector. 
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Figure 3.7. KSHV miRNAs expressed from pSIN-K-Cluster silence reporter constructs. 293T 
cells were co-transfected with 0ng, 250ng or 500ng of pSIN-K-Cluster plasmid and KSHV miRNA 
sensor vectors. Luminescence (RLU) was normalised to total protein content and the ratio is 
shown. Increasing concentration of pSIN-K-Cluster corresponds to decreased RLU:Protein ratio. P 
values (Student’s T-test) relative to 0ng pSIN-K-Cluster: *<0.05 **<0.005. Error bars correspond to 
standard deviation, n = 3. 
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3.5 KSHV miRNA expression from pSIN-K-miR 
miRNA Cluster-encoding lentivirus was produced in 293T cells after transfection 
of pSIN-K-Cluster vector and the two packaging plasmids, p8.91 and pMD.G. The 
infectivity of lentiviral preparations was determined by qPCR for the lentiviral 
packaging signal. LEC were initially infected with 1ml of un-concentrated 
lentivirus, which yielded 0.81 lentiviral copies per cell (c/c) (Fig. 3.8A). This 
confirmed the Cluster lentivirus was infective and capable of integrating into the 
host cell genome. There are approximately ten viral genomes per latently infected 
KS spindle cell (Asahi-Ozaki et al., 2006), thus a lentiviral titre of approximately 
ten c/c was used to achieve expression levels comparable to KS spindle cells. 
Various optimisation steps were performed to increase the lentiviral copy number 
(Fig. 3.8A). Viral preparations were concentrated 10-fold, leading to increased 
viral titre; all subsequent experiments were performed with concentrated 
lentivirus. Lentivirus-containing supernatant was harvested from 293T cells 
between 48-72hrs post-transfection. To determine whether harvesting at a later 
time point would yield more concentrated viral preparations, virus was harvested 
at both 48 and 72hrs post-transfection and c/c compared. Harvesting virus 72hrs 
post-transfection led to an increase in titre (Fig. 3.8A). However, infecting cells 
with 0.5ml of virus from both time points did not result in increased infection (Fig. 
3.8A). Based on these optimisation steps, harvesting at 72hrs post-transfection 
and infecting LEC with 1.5ml of Cluster-expressing lentivirus achieved the highest 
titre (Fig. 3.8A).  
 
To confirm KSHV miRNA expression in LEC transduced with pSIN-K-Cluster, 
miRNA expression was quantified by qRT-PCR for the mature form of the miRNA. 
This method is preferable to assaying early precursor miRNA forms as the mature 
miRNA is directly responsible for silencing, and in general in higher abundance 
than the precursor. Furthermore, due to differences in processing or stability, 
levels of pre or pri-miRNA are not always synonymous with levels of mature 
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miRNA.  At the time of this work there existed no commercially available qRT-
PCR assays for the KSHV miRNAs. Therefore, the sequence of all KSHV mature 
miRNAs was taken from miRBase (www.mirbase.org/) and provided to Applied 
Biosystems™ (California, USA) who designed and synthesized custom TaqMan 
assays.   
 
Using optimized experimental conditions, KSHV miRNA expression was 
assessed.  The difference in threshold detection cycle (delta Ct) between each 
KSHV miRNA and RNU66 is shown (Fig. 3.8B). Viral miRNAs with a delta Ct of 
greater than zero are detected at earlier PCR cycles and are therefore more 
abundant than RNU66 (Fig. 3.8B). The majority of mature viral miRNAs were 
expressed from the lentiviral vector. qRT-PCR of two miRNAs, miR-K12-10a and 
miR-K12-12, not present in the Cluster generated a delta Ct of less than -4.8. 
Typically one strand of the mature miRNA is preferentially loaded into the RISC 
complex and consistently used as the guide strand, the other passenger strand is 
degraded; miRNA cloning strategies may sometimes identify two guide miRNAs 
from the same mature miRNA (Bartel, 2009). Relative abundance of the cloned 
miRNAs indicate the predominately expressed miRNA, in this case the less 
abundant form is denoted with a *. This has been reported for miR-K12-3* and 
miR-K12-9* (Pfeffer et al., 2005). However, the qRT-PCR data presented here 
(Fig. 3.2 and 3.3) indicated that these miRNAs had delta Ct values of less than -
4.8, which is comparable with miRNAs not present in the Cluster and suggests 
that these miRNAs were not expressed. When cloning data identify equal 
abundances for both arms of the mature miRNA, these miRNAs are denoted by 
“3p” or “5p” to indicate from which arm of the mature miRNA they originated. This 
was observed for KSHV miR-K12-6 and miR-K12-4 (Pfeffer et al., 2005). 
Concurring with the nomenclature, both isoforms of miR-K12-6 and miR-K12-4 
were detected in Cluster expressing LEC. 
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Figure 3.8. LEC transduced with the KSHV miRNA Cluster. A Optimisation of Cluster lentivirus 
infection. Lentiviral copies per cell in LEC transduced with Cluster lentivirus as determined by q-
PCR for lentivirus packaging signal and GAPDH. The time of lentivirus harvesting (hr) and the 
volume of virus (ml) added to 10^5 LEC is shown. Harvesting 72hr post transfection and infecting 
LEC with 1.5ml of virus yielded the highest lentivirus c/c. 48>72hr 1.5ml: 0.5ml of virus harvested 
at 48hrs was added, plus 1ml of virus harvested at 72hrs post transfection. B qRT-PCR 
quantification of mature KSHV miRNAs in LEC transduced with KSHV miRNA Cluster. Delta Ct 
represents the difference in threshold detection cycle between viral miRNA and RNU66. Higher 
delta Cts correspond to more abundant transcripts. miR-K12-10a and miR-K12-12 are not present 
in the Cluster, KSHV miRNAs K12-3* and K12-9* which have delta Ct of less than -4 are therefore 
classed as unexpressed (grey diamonds). Error bars correspond to standard deviation, n = 3. 
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3.6 KSHV miRNAs induce changes in LEC gene 
expression 
miRNAs regulate their targets by inducing mRNA degradation, such changes in 
mRNA steady-state levels are quantifiable by GEM profiling (Lim et al., 2005; 
Ziegelbauer et al., 2009). To detect targets of the KSHV miRNAs whose 
expression was regulated by mRNA degradation, the GEM profile of LEC 
transduced with KSHV miRNA Cluster was compared to LEC expressing empty 
lentiviral vector (Fig. 3.9). An average viral titre of approximately 12 c/c was 
achieved, as confirmed by qPCR (Fig. 3.9). Although this approach included the 
majority of KSHV miRNAs, it will not detect those genes deregulated by the three 
mature miRNAs encoded outside the Cluster. 
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Figure 3.9. Experimental overview of KSHV miRNA Cluster GEM profiling. Schematic 
representation of KSHV miRNA organization in the latency-associated region of the viral genome. 
Nucleotides 119,326-121,991 were cloned into pSIN-MCS lentiviral vector. Cluster and empty 
vector lentivirus were produced and used to infect LEC. Three independent infections per 
condition at a lentiviral titre of ~12 copies per cell were profiled using Affymetrix Human Genome 
U133 Plus 2.0 Arrays. Error bars correspond to standard deviation, n = 3. 
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GEM analysis was performed on RNA from three independent infections per 
condition using Human Genome U133 Plus 2.0 Affymetrix arrays. Probes 
significantly deregulated (q<0.13) across all samples are shown in Figure 3.10A.  
Down-regulated probes represent candidate KSHV miRNA target genes. As 
observed in other studies of this kind, numerous small fold-changes in gene 
expression were detected, ranging from 25-50% down-regulation, this is in 
accordance with the fine tuning nature of viral miRNA silencing (Appendix 1) 
(Ziegelbauer et al., 2009). In addition to decreases in gene expression, a number 
of probes were up-regulated in the presence of the KSHV miRNA Cluster (Fig. 
3.10A). These changes may be a secondary effect induced by miRNA silencing of 
an upstream repressor. Alternatively, contrary to the dogma of miRNAs as 
negative regulators of gene expression there have been contentious reports of 
miRNA-induced up-regulation (Vasudevan et al., 2007; Ghosh et al., 2008; Place 
et al., 2008). Therefore, it can not be excluded that the up-regulated probes are 
also direct KSHV miRNA targets. Over-expression of the KSHV miRNAs may 
saturate the silencing machinery, this would alleviate silencing of endogenous 
miRNA targets. Therefore, the up-regulated genes may be targets of endogenous 
miRNAs highly expressed in LEC. Previously this effect was shown to be a 
consequence of over-expressing miRNAs (Khan et al., 2009). Further work will be 
needed to determine the mechanism behind these observed increases in mRNA 
abundance.  
 
The top three down-regulated probes were H19 (imprinted maternally expressed 
transcript), MAF (v-maf musculoaponeurotic fibrosarcoma oncogene homologue) 
and HES1 (hairy and enhancer of split) (Fig. 3.10A). Cluster-induced down-
regulation of these three genes was confirmed at the mRNA level in three 
independent infections by qRT-PCR (Fig. 3.10B).  
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Figure 3.10. KSHV miRNA Cluster induces changes in LEC gene expression. A Heatmap of 
deregulated probes after transduction of LEC with either the KSHV miRNA Cluster or empty vector 
(pSIN-MCS) 72hrs post infection. This set of most significantly different genes has a false 
discovery rate (q value) of 0.13. The Z-score scale shows mean scaled and zero centered log2 
GEM expression values for each row. For all down-regulated genes (shown in red), a cumulative 
interaction score (ddGsum) with the expressed KSHV miRNAs is shown. B Down-regulation of the 
top three cellular genes in LEC transduced with the miRNA Cluster confirmed by qRT-PCR. 
Expression is relative to empty vector, pSIN-MCS. Values were normalised to GAPDH. p values 
relative to LEC transduced with pSIN-MCS: *<0.05 **<0.005. Error bars correspond to standard 
deviation, n = 3. 
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3.7 KSHV miRNA target prediction 
A single miRNA can regulate multiple mRNAs, with over a third of the human 
genome predicted to be under miRNA regulation (Stark et al., 2005; Farh et al., 
2005). In response to this widespread regulation, in silico miRNA target prediction 
algorithms have been developed to facilitate global target identification (Bartel, 
2009). Target prediction algorithms provide a complimentary approach to 
experimental target identification and are able to identify targets regulated by both 
mRNA degradation and translation inhibition, whereas GEM analysis only 
identifies the former. To further investigate KSHV miRNA function, target 
prediction analysis was performed for all the KSHV miRNAs expressed in KS 
lesions. The GEM data were used to validate the prediction algorithm, and to test 
whether such algorithms provided further support for favourable targeting of 
experimentally identified targets. 
 
3.7.1 Prediction strategy  
The main determinant for miRNA-target recognition is the sequence 
complementation of 6-8 nucleotides comprising the miRNA seed region. However, 
prediction algorithms working on this principle alone would produce an excessive 
number of false positive results. Additional parameters based on empirical and 
theoretical principles are incorporated to improve prediction sensitivity. The target 
prediction algorithm PITA (Probability of Interaction by Target Accessibility) 
(Kertesz et al., 2007) was used to identify KSHV miRNA targets. 
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This programme incorporates the degree of target-seed sequence 
complementation, as well as the role of target-site accessibility in determining 
miRNA-target pairing and subsequent silencing. Complex mRNA secondary 
structure embedding a target site will restrict RISC access to the target and 
thereby impair silencing, even if the site has high sequence complementation, as 
secondary structure and any intramolecular base pairing would have to be 
unwound to permit RISC access (Kertesz et al., 2007). There is an energetic cost 
to facilitating miRNA accessibility under these circumstances, which may render 
the miRNA-target interaction unviable. 
 
To ensure the viability of predicted targets, PITA takes these factors into 
consideration when analysing 3’UTRs for miRNA target sites (Illustrated in Fig. 
3.11). The free energy generated upon miRNA-target duplex formation is 
calculated (∆duplex), followed by calculation of the energetic cost of unwinding any 
secondary miRNA structure and unpairing intramolecular bases as well as 
additional bases flanking the seed (∆open). RNA secondary structures are modeled 
using built-in structure prediction algorithms and the final score represents the 
difference between these two factors and is expressed as ∆∆G (Kertesz et al., 
2007). Gibbs free energy (G) refers to the amount of energy capable of doing 
work in a reaction. Favourable, exergonic reactions generate products with a 
lower free energy than the reactants; this is expressed as a negative ∆G value. 
Conversely, unfavourable endergonic reactions require an input of energy 
generating a positive ∆G value. Such reactions are physically impossible. 
Therefore, the more negative the ∆∆G score calculated by PITA the higher the 
likelihood of a miRNA regulating a specific target site (Kertesz et al., 2007).  
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Figure 3.11. Schematic describing PITA scores based on thermodynamic modelling. i) 
miRNA target sites located within mRNA secondary structures must be unwound before miRNA-
target binding can occur. There is an energetic cost to freeing mRNA secondary structure 
(∆Gopen). ii) Free energy is gained from miRNA-target duplex formation (∆GDuplex). iii) The 
resulting ∆∆G score is the combination of energy invested and energy gained. Energetically 
feasible reactions have negative ∆∆G scores. Schema taken from (Hofacker, 2007). 
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The accuracy of miRNA target prediction algorithms is greatly improved by 
considering species conservation, whereby a site is only considered if it is also 
present in a number of orthologous 3’UTRs (Lewis et al., 2005). Although this 
approach improves detection it also excludes a large number of species-specific 
miRNA targets (Bentwich et al., 2005). As KSHV is a human-specific herpesvirus, 
which has co-evolved with its host, filtering results on the basis of species 
conservation would provide no additional benefit. This choice is supported by the 
lack of sequence conservation between the KSHV miRNAs and their counterparts 
in murine and primate herpesviruses, suggesting that viral miRNAs have evolved 
to target host-specific mRNAs. Other than thermodynamic modelling, PITA 
enforces no additional filters. 
 
To create a more sophisticated search, a number of additional filters and 
parameters were incorporated into PITA (with the help of Dr. S. Henderson, CR-
UK, Viral Oncology group, UCL). An overview of target prediction with additional 
parameters is shown in Figure 3.12. The primary interest was in LEC-specific 
targets, only the 3’UTRs of genes expressed in LEC where used as input for 
miRNA target prediction. To improve prediction sensitivity only those target sites 
with an 8bp seed, which contained either a G:U wobble or a mismatch, but not 
both, were considered. A number of additional determinants beyond seed pairing 
have been characterized (Grimson et al., 2007). These findings highlighted the 
impact of target site context on miRNA regulation, in terms of sequence 
composition and target site location. Once PITA analysis had generated ∆∆G 
scores for all predicted targets, the results were filtered according to additional 
context parameters defined by Grimson et al (Grimson et al., 2007). miRNA sites 
located within 40bp of one another have been shown to function cooperatively, 
therefore a boost of -2 was added to closely positioned sites (Fig. 3.12).  
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Figure 3.12. Overview of PITA KSHV miRNA target prediction analysis. 3’UTRs from all genes 
expressed in LEC were used as input for target prediction. Shown in pink are the PITA defined 
parameters used to generate ∆∆G scores. In purple are additional filters added based on 
parameters defined in Grimson et al. The equation generating the final PITA score is shown.  
LEC GEM data ranked according to expression. Probes with 
log2 expression values of <5 are classed unexpressed and 
excluded from future analysis 
Minimum seed of 8bp 
One mismatch OR 
G:U wobble permited 
Exclude miRNAs not 
expressed in KS 
Run PITA to obtain 
∆∆G scores 
Filter results further 
by ‘contexts’ which 
are not captured by 
∆∆G 
Exclude sites within 
15nt of stop codon  
Additional Watson-
Crick Pairing at 
Nucleotides 12–17 
Exclude sites located 
in the centre of 3’UTR  
Boost the ∆∆G score of cooperative 
targets which are located within 40bp 
of one another by -2 
Final PITA score =  
- log (Σ(e-∆∆Gboost)) 
Query Biomart with Affymetrix probe IDs to obtain 3’UTRs for 
expressed LEC transcripts. Multiple transcripts per gene 
permitted. 
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3.7.2 Prediction results  
A ∆∆G threshold of -15 was set and only those miRNAs within the KSHV miRNA 
Cluster and expressed in KS lesions were considered. These conditions 
generated 205 predicted targets (Appendix A2). None of the down-regulated 
genes identified in the GEM target identification were present in this list, neither 
were any of the up-regulated genes (Table 3.1 and Fig. 3.10A).  Likewise, none of 
the top 20 PITA predicted targets were significantly de-regulated in the GEM 
experiment, at a significance threshold of q<0.13.  miRNAs are known to induce 
small fold changes in steady state mRNA levels when targets are silenced by both 
mRNA degradation and translation inhibition (Baek et al., 2008; Selbach et al., 
2008).  Predicted targets may show decreased expression in the presence of the 
Cluster which fell below the significance threshold of q<0.13.  Table 3.1 shows the 
log2 fold change in expression of the top 20 PITA targets in the Cluster GEM 
experiment. Although none of these genes had significant q values (q<0.13), a 
quarter were down-regulated by <10% at the mRNA level in the presence of the 
Cluster (Table 3.1). Abundance of the remaining 15 genes either stayed constant 
or increased slightly in Cluster expressing LEC (Table 3.1). Therefore, there is 
minimal overlap between those genes identified in the Cluster-GEM experiment 
and the PITA prediction analysis.  
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Gene 
 
 
microRNA 
 
 
Seed 
 
Sum for 
Gene 
 
 
Average LFC 
 
Ratio 
Cluster:pSIN 
HS3ST3B1  
miR-K12-6-3p 08:00:00 -19.15 -0.393 0.761 
RAB31  
miR-K12-4-3p 08:01:00 -21.86 -0.359 0.780 
SENP7  
miR-K12-4-3p 08:00:00 -22.62 -0.208 0.866 
ERMP1  
miR-K12-6-3p 08:00:01 -35.3 -0.188 0.878 
IRF2BP2  
miR-K12-6-5p 08:00:00 -20.03 -0.145 0.904 
FOXP1  
miR-K12-1 08:01:00 -40.4 -0.058 0.961 
C1orf151  
miR-K12-1 08:00:00 -21.2 -0.056 0.962 
KPNA6  
miR-K12-6-3p 08:00:01 -33.2 -0.039 0.973 
KIF1B  
miR-K12-6-3p 08:00:01 -33.96 -0.024 0.983 
MTMR9  
miR-K12-4-3p 08:00:00 -21.4 -0.023 0.984 
MTRF1L  
miR-K12-1 08:01:00 -21.68 -0.009 0.994 
CYP2U1  
miR-K12-6-5p 08:01:00 -22.07 -0.008 0.995 
SLC25A29  
miR-K12-4-3p 08:00:01 -19.19 0.015 1.011 
PIN4  
miR-K12-6-3p 08:00:00 -36.02 0.023 1.016 
C2orf18  
miR-K12-11 08:00:00 -20.09 0.049 1.034 
DCTN4  
miR-K12-1 08:00:01 -35.51 0.068 1.049 
RAD21  
miR-K12-1 08:00:00 -21.31 0.080 1.057 
C2orf60  
miR-K12-6-5p 08:00:00 -20.44 0.090 1.064 
RABEPK  
miR-K12-6-3p 08:01:00 -20.26 0.174 1.128 
EXO1  
miR-K12-2 08:01:00 -33.95 0.247 1.187 
Table 3.1 mRNA abundance of top PITA predicted targets in the presence of the 
KSHV miRNA cluster. The top PITA predicted KSHV miRNA targets and targeting miRNA 
are shown, along with the average log fold change (LFC) in expression in presence of the 
KSHV miRNA Cluster compared with empty vector (pSIN). 
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Target prediction algorithms are known to generate a high number of false 
positive results. To test the modified algorithm, PITA prediction analysis was 
performed for three validated miRNA targets selected from the literature (Table 
3.2).  PITA was able to predict experimentally identified miRNA target sites in all 
three instances (Table 3.2, blue text). However, in the 3’UTRs of MAF and PTEN, 
PITA also predicted energetically feasible sites for other non-related miRNAs, 
which were included as negative controls. The experimentally validated sites in 
HOXD10 had a ∆∆G score of -11.22, which is below the threshold of -15 ∆∆G set 
in KSHV miRNA target prediction. In the case of MAF and PTEN the 
experimentally validated sites were not the sites with the most favourable ∆∆G 
score, and were both significantly lower than -15∆∆G. This analysis reveals the 
high signal to noise ratio of PITA and highlights the difficulty in identifying bone 
fide miRNA targets from the noise of false positive results. 
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Gene 
 
microRNA 
 
Start 
 
End 
 
Seed 
 
PTIA 
score 
HOXD10 hsa-miR-10b 282 274 08:00:01 -11.22 
MAF hsa-miR-10b 706 698 08:01:01 -1.57 
MAF hsa-miR-10b 2439 2431 08:01:01 -4.55 
MAF hsa-miR-10b 3078 3070 08:01:01 -3.49 
MAF hsa-miR-10b 3877 3869 08:01:00 -5.28 
MAF hsa-miR-155 863 855 08:01:01 -1.74 
MAF hsa-miR-155 891 885 06:00:00 -4.41 
MAF hsa-miR-155 1071 1063 08:01:01 1.24 
MAF hsa-miR-155 1076 1068 08:01:01 -2.83 
MAF hsa-miR-155 1756 1748 08:01:01 -5.42 
MAF hsa-miR-155 2484 2476 08:01:00 -12.99 
MAF hsa-miR-155 4368 4360 08:01:01 -7.17 
MAF hsa-miR-155 4371 4363 08:01:01 -7.18 
MAF hsa-miR-214 540 532 08:00:01 -11.68 
MAF hsa-miR-214 903 895 08:01:01 -7.55 
MAF hsa-miR-214 993 985 08:01:00 -6.67 
MAF hsa-miR-214 2219 2211 08:01:01 -4.15 
MAF hsa-miR-214 2608 2600 08:01:01 -2.77 
MAF hsa-miR-214 3967 3959 08:01:01 -8.08 
PTEN hsa-miR-10b 167 159 08:01:00 -4.89 
PTEN hsa-miR-10b 1473 1465 08:01:01 -1.63 
PTEN hsa-miR-10b 3195 3187 08:01:00 -3.67 
PTEN hsa-miR-155 86 78 08:01:01 -4.47 
PTEN hsa-miR-155 263 255 08:01:00 -6.91 
PTEN hsa-miR-155 2243 2235 08:01:01 1.69 
PTEN hsa-miR-155 2385 2377 08:00:01 -2.8 
PTEN hsa-miR-155 2521 2513 08:01:01 -1.9 
PTEN hsa-miR-155 2741 2733 08:01:00 -1.05 
PTEN hsa-miR-214 1021 1013 08:01:00 -8.57 
Table 3.2 Testing the ability of PITA to identify experimentally validated miRNA 
target sites. All three genes are validated miRNA targets, MAF  is targeted by miR-155 
(Rodriguez et al., 2007), HOXD10 by miR-10a (Ma et al., 2007) and PTEN by miR-214 
(Yang et al., 2008). PITA identifies the experimentally confirmed site in each target (blue 
text), other high scoring false positive sites are also detected for both the targeting and 
non-targeting miRNAs. 
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The 3’UTRs of all genes with decreased mRNA abundance in the presence of the 
Cluster were scanned for potential KSHV miRNA binding sites (Fig 3.10A). For 
each down-regulated transcript the cumulative PITA score for all expressed viral 
miRNAs (Fig. 3.2) was calculated (Fig. 3.10).  Although these down-regulated 
genes were not amongst the top PITA predicted targets, nine out of thirteen 
genes had negative ∆∆G values, which is indicative of miRNA regulation.  Given 
that experimentally validated targets sites also generated relatively low ∆∆G 
scores (Table 3.2) these genes could be considered as putative KSHV miRNA 
targets. Employing multiple prediction algorithms and focusing on the overlap 
between programmes, is one method of increasing confidence in target 
prediction. However, this approach was not suitable for the KSHV miRNAs as 
PITA is one of the few prediction programmes which does not require species 
conservation as a prediction parameter, therefore there was no suitable additional 
programme with which to compare prediction results.   
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3.8 Discussion  
The data presented here have confirmed expression of the KSHV miRNAs in KS 
lesions. Since only a limited number of gene products are expressed in latently 
infected KS spindle cells, it is likely that the viral miRNAs contribute to KSHV-
mediated oncogenesis.  Expression of ten out of 17 mature miRNAs was 
confirmed by both miRNA microarray and qRT-PCR; three miRNAs were detected 
by qRT-PCR only, this may reflect differences in detection thresholds of the two 
techniques adopted. Another three miRNAs were undetectable by either qRT-
PCR or miRNA microarray. Probes for the miRNA, miR-K12-7, cross-reacted in 
both skin and KS samples and this miRNA cannot be classified as either 
expressed or unexpressed in KS. 
 
The miRNA profiling data reported here differs from the KSHV miRNA expression 
data from PEL cell lines, a larger repertoire of KSHV viral miRNAs were detected 
in PEL  compared to KS lesions (Cai et al., 2005; Pfeffer et al., 2005; Samols et 
al., 2005). PEL cells have approximately 65 KSHV episomes per cell (Lallemand 
et al., 2000), whereas KS spindle cells typically have approximately 10. This 
discrepancy in viral titre may explain why less abundant KSHV miRNAs were not 
detected in KS lesions. Furthermore, the different cellular origin of PEL and KS 
may favour expression of a distinct repertoire of miRNAs which have evolved to 
silence cell-type specific genes, thus explaining the differing KSHV miRNA 
expression profiles.  
 
While this work was being completed a report describing the expression of a 
subset of KSHV pre-miRNAs in KS lesions was published (O'Hara et al., 2009). 
The methods employed to identify these miRNAs differ from those presented 
here. O’Hara et al used primer pairs for nine out of 12 pre-miRNAs and confirmed 
expression of five of these in AIDS-KS biopsies and provide preliminary evidence 
of viral miRNAs expression in KS, which is corroborated and expanded upon in 
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this thesis. The quantification of the mature miRNA by microarray or qRT-PCR 
used here is more informative than assaying the pre-miRNA alone, as differences 
in processing or stability of miRNA intermediates mean pre and pri-miRNA levels 
are not always synonymous with the mature, effector miRNA.  
 
qRT-PCR of mature KSHV miRNAs confirmed a similar expression profile in KS 
lesions and Cluster-expressing LEC. miR-K12-3*, miR-K12-9 and miR-K12-9* 
were undetectable in both samples. The other miRNAs showed comparable 
expression levels in KS and Cluster-expressing LEC. This suggests similar 
processing and expression from the cloned miRNA Cluster with that present in 
KSHV infected spindle cells. Therefore the lentiviral system is a good model with 
which to study KSHV miRNA function and perform miRNA target identification in 
LEC. 
 
GEM profiling of LEC transduced with the KSHV miRNA Cluster identified a 
cohort of putative viral miRNA targets. Down-regulation of the top three genes 
was confirmed by qRT-PCR in independent infections. Two of these genes, MAF 
and HES1, are transcription factors. Viral-induced silencing of a single 
transcription factor could potentially modulate the expression of a much larger set 
of downstream genes from multiple pathways, thereby increasing the functional 
outcome of miRNA-directed silencing. H19 is a non-coding RNA molecule which 
is maternally imprinted.  This RNA was shown to encode a mature miRNA miR-
675, which is expressed during vertebrate embryonic development, although the 
targets of this miRNA are yet to be characterised (Cai and Cullen, 2007). This 
may represent a novel function for viral miRNAs, whereby they directly regulate 
host cellular miRNAs through silencing pre-miRNA transcripts. Importantly, GEM 
analysis will only identify those targets silenced by mRNA degradation. A 
proteomics approach such as stable isotope labeling by amino acids in cell culture 
(SILAC) is required to identify KSHV miRNA targets in LEC silenced by translation 
inhibition (Vinther et al., 2006). 
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A number of additional putative KSHV miRNA targets were identified using the 
target prediction algorithm PITA (Kertesz et al., 2007).  PITA was selected on the 
basis of its dynamic user interface and extensive thermodynamic modelling to 
predict miRNA targets.  The stringency of search parameters was increased in an 
attempt to improve the typically high signal to noise ratio of prediction 
programmes. However, experimentally validated miRNA targets can deviate from 
these rules, some having seed matches of only 6 base pairs and containing 
mismatches and G:U wobbles (Bartel, 2009). Through computational and 
experimental analysis Grimson et al identified five additional factors beyond seed 
complementation which influenced miRNA-mediated repression (Grimson et al., 
2007). Two of these site-context features, preferential location of sites in an A/U 
rich regions and flanking A’s surrounding the target site, were already captured by 
PITA analysis. The other three factors were incorporated into PITA analysis by 
filtering results or boosting PITA prediction scores.  
 
A comparison of experimental and in silco target identification revealed a quarter 
of genes were both predicted targets and down-regulated in the GEM target 
identification experiment. This minimal degree of overlap may be due to the high 
rate of false positives of PITA obscuring identification of bone fide miRNA targets. 
Importantly, the mRNA secondary structure prediction algorithm (modified RNA 
fold algorithm) employed by PITA to model the structure of the 3’UTR does not 
take into account the affect of RNA binding proteins on mRNA structure.  RNA 
binding proteins are important regulators of miRNA silencing, these proteins have 
the potential to alter the mRNA secondary structure either facilitating or blocking 
miRNA silencing (Kedde et al., 2007). Unknown RNA binding proteins may 
mediate silencing, as these factors are not considered by PITA this may explain 
the relatively low ∆∆G scores of experimentally validated miRNA targets and 
suggests the target genes down-regulated by the KSHV miRNA Cluster with poor 
∆∆G scores may still be genuine KSHV miRNA targets. Experimental validation of 
these putative targets and identification of RNA binding proteins regulating KSHV 
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miRNA-mediated silencing will provide greater insight and facilitate miRNA target 
identification. Furthermore, specific rules pertaining to viral miRNA targeting may 
be discovered in the future which influence target prediction.  
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Chapter 4. MAF is a KSHV miRNA target 
4.1 Introduction and aims 
Amongst the multiple putative KSHV miRNA targets described in Chapter 3, the 
transcription factor MAF was one of the most significantly down-regulated genes. 
The aim of this chapter was to experimentally validate MAF as a KSHV miRNA 
target.  
 
MAF represented an interesting KSHV miRNA target as transcription factor 
silencing has potentially wide-reaching secondary effects, dependant on the 
repertoire of target genes. In this manner, miRNA repression of a single gene 
following viral infection could present an elegant means of controlling the 
expression of multiple proteins.  Previous gene expression studies have classified 
LEC and BEC on the basis of their differing transcriptional profiles (Petrova et al., 
2002; Hong et al., 2004). In this analysis MAF was classified as a LEC-specific 
transcript due to its higher level of expression in LEC compared to BEC (Petrova 
et al., 2002; Hong et al., 2004).  Despite this classification, the function of MAF 
and its target genes in LEC are unknown. LEC are the most similar primary cells 
to KS tumour cells, and are subject to KSHV-directed transcriptional 
reprogramming (Wang et al., 2004; Hong et al., 2004). I hypothesised that KSHV 
miRNA-mediated regulation of a LEC-specific transcription factor could have an 
important role in viral-mediated oncogenesis.    
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4.2 MAF is down-regulated by the KSHV miRNA Cluster 
qRT-PCR analysis of LEC expressing the KSHV miRNA Cluster confirmed a 25-
50% repression of MAF mRNA levels compared to empty lentiviral vector (pSIN-
MCS, Fig. 4.1A).  This magnitude of repression is comparable to other validated 
KSHV miRNA targets and is in keeping with the fine-tuning nature of miRNA 
regulation (Samols et al., 2007; Ziegelbauer et al., 2009). In addition, MAF mRNA 
was reduced in 293T cells transduced with the Cluster and in a 293 cell line stably 
expressing the miRNA Cluster (Fig. 4.1A). Increasing copy number of Cluster-
lentivirus per cell induced a corresponding decrease in MAF mRNA levels, 
suggesting MAF silencing is a function of the KSHV miRNAs (Fig. 4.1B). MAF 
mRNA was down-regulated by 13% 24hrs post infection with lentivirus encoding 
the miRNA Cluster (Fig. 4.1C). Silencing increased with time, maximal MAF 
repression occurred at 72hrs post infection when MAF mRNA levels were reduced 
by -40% compared to empty vector control (Fig. 4.1C). These data confirm MAF 
down-regulation at the mRNA level in the presence of the KSHV miRNA Cluster 
and validate the GEM data (Fig. 3.10A). MAF mRNA reduction was also evident 
at the protein level, whereby MAF protein was reduced by approximately 40% in 
LEC expressing the Cluster compared to empty lentiviral vector (Fig. 4.1D).  
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Figure 4.1. KSHV miRNA Cluster induces MAF down-regulation. A MAF mRNA down-
regulation in LEC and 293T cells transduced with the miRNA Cluster (72hr post infection) and in 
293 cell line stably expressing the Cluster. p values relative to empty vector in the respective cell 
type:  *<0.05; **<0.005.  B MAF mRNA levels in LEC transduced with Cluster lentivirus. Magnitude 
of silencing increases with viral titre c/c: copies per cell. p values relative to pSIN-MCS at the 
equivalent viral titre: *<0.05 C Cluster-lentivirus time course infection of LEC. MAF mRNA was 
maximally repressed at 72hrs post infection. D Western blot analysis of MAF and loading control 
actin in LEC transduced with either miRNA Cluster or pSIN-MCS 48hrs post infection. 
Quantification of relative intensity was performed by Scion Image software. Error bars correspond 
to standard deviation, n = 3. 
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4.3 MAF is down-regulated by miR-K12-11 and miR-K12-6 
To identify individual KSHV miRNAs capable of silencing MAF a lentiviral screen 
was performed. Ten KSHV pre-miRNAs were individually expressed in LEC, 
which were then assayed for MAF repression (Fig. 4.2A). miR-K12-6 and miR-
K12-11 induced a small but significant decrease in MAF mRNA compared to 
empty lentiviral vector in all three screens (Fig. 4.2A). miR-K12-11 is a viral 
orthologue of cellular miR-155 (Skalsky et al., 2007; Gottwein et al., 2007) and 
previous work has characterised MAF as a miR-155 target in Th2 cells (Rodriguez 
et al., 2007). In this study, a number of mouse miR-155 target sites were identified 
in the Maf 3’UTR and mRNA levels were elevated or suppressed in mice lacking 
or over-expressing miR-155, respectively (Rodriguez et al., 2007). miR-155 
regulation of Maf in murine T helper cells led to decreased expression of the Maf 
target gene IL4 and a shift in the balance between a Th1 and Th2 immune 
response in favour of Th2 cells (Rodriguez et al., 2007). In the context of these 
data from Rodriguez et al, the identification of miR-K-12-11 as a MAF repressor, 
confirms previous work showing that viral and cellular homologues regulate an 
over-lapping set of target genes (Skalsky et al., 2007; Gottwein et al., 2007). 
 
miR-K12-10 lentivirus, which encodes for two of the three miRNAs located outside 
the Cluster failed to reproducibly silence MAF (Fig. 4.2A). This suggests that the 
Cluster is primarily responsible for MAF silencing and that further experiments 
performed with this Cluster-expressing lentivirus would capture the majority of 
MAF silencing and any down-stream effects. 
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qRT-PCR for miR-K12-6-5p and miR-K12-11 confirmed KSHV miRNA expression 
in LEC transduced with lentivirus expressing individual pre-miRNAs (Fig. 4.2B).  
This analysis revealed differences in the relative abundances of Cluster-encoded 
miRNAs. miR-K12-11 was more abundant than miR-K12-6-5p in LEC transduced 
with the whole Cluster and at equivalent titres of individual miRNA-expressing 
lentivirus (Fig. 4.2B). This may be due to differences in miRNA processing since 
two mature miRNAs are expressed in LEC transduced with miR-K12-6 compared 
to just one from the miR-K12-11 lentivirus. MAF mRNA levels decreased with 
increasing titre of both miR-K12-6 and miR-K12-11 lentivirus (Fig. 4.2C). These 
data identify two miRNAs from the KSHV Cluster capable of silencing MAF at the 
mRNA level. This concurs with other validated cellular miRNA targets which are 
regulated by multiple KSHV miRNAs (Samols et al., 2007; Ziegelbauer et al., 
2009; Qin et al., 2010).  
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Figure 4.2. miR-K12-6 and miR-K-12-11 induce MAF silencing. A Screen for MAF repression in 
LEC transduced with ten individual KSHV miRNAs. miR-K-12-6 and miR-K12-11 are the only two 
miRNAs to induce a significant, reproducible reduction in MAF mRNA. Values are relative to 
GAPDH and normalised to LEC transduced with empty lentiviral vector (pSIN-MCS). p values 
relative to pSIN-MCS: *<0.05. B miR-K12-6-5p and miR-K12-11 are expressed in LEC transduced 
with lentivirus encoding the entire Cluster and individual miRNAs, expressed miRNAs have a 
positive delta Ct value. Values are relative to RNU66. p values relative to pSIN-MCS: *<0.05; 
**<0.005. C MAF mRNA levels in LEC transduced with increasing titre of individual miRNA 
expressing lentivirus. MAF silencing decreased with increasing viral titre, c/c: copies per cell. Error 
bars correspond to standard deviation, n = 3. 
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4.4 KSHV miRNAs are predicted to target the MAF 3’UTR  
miRNAs predominantly regulate their targets through binding sites located in the 
3’UTR (Bartel, 2009). The MAF 3’ UTR was scanned for potential KSHV miRNA 
binding sites using the PITA prediction algorithm (Kertesz et al., 2007). The 
number of identified sites was refined by considering only those viral miRNAs 
expressed in KS lesions and including sites with either a perfect match, one GU 
wobble or mismatch, but not both, in an 8bp seed. This analysis identified 11 
putative KSHV miRNA binding sites located throughout the 4.45kb MAF 3’UTR 
(Fig. 4.3). The alignment of mature KSHV miRNAs with their predicted binding 
sites is shown (Fig. 4.3B). To avoid missing any potential KSHV miRNA binding 
sites, all sites with a negative ∆∆G score were considered. miR-K12-6-5p had the 
strongest predicted site (approximately -10 ∆∆G) (Fig. 4.3A). With four predicted 
targets, miR-K12-6-3p had the highest number of sites and is the only miRNA with 
a target site showing perfect sequence complementation across the entire 8bp 
seed region (Fig. 4.3A and B). The degree of sequence complementation 
between miRNA seed and 3’UTR has been shown to correlate with increased 
prediction ability and silencing via mRNA degradation (Bartel, 2009). miR-K12-11 
was the only other miRNA to have more than one predicted target site. Despite 
relatively weak ∆∆G scores, the PITA prediction analysis is supportive of a role 
for KSHV miRNA regulation of MAF. In particular, miR-K12-6 and miR-K12-11 
have multiple PITA-predicted target sites throughout the MAF 3’UTR and were the 
two miRNAs identified as suppressors of MAF mRNA in the lentiviral screen.  
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Figure 4.3. Predicted KSHV miRNA bindings sites in the MAF 3’UTR. A The positions of 
energetically favorable predicted seed site interactions of expressed KSHV miRNAs are shown for 
the MAF 3’UTR. On the Y axis (∆∆G), the length of each line corresponds to the predicted 
strength of individual interactions. The more negative the value, the more energetically favorable 
the interaction. B  Sequence alignment of the mature KSHV miRNAs and their predicted binding 
sites in the MAF 3’UTR. Predicted sites for all KSHV miRNAs expressed in KS are shown. 
Complementary bases are indicated by vertical lines. Seed regions of 8 bases were considered, 
one mismatch or G:U wobble (indicated by :) but not both was permitted across the seed. 
Predictions were made using the PITA algorithm (Kertesz et al., 2007). miR-K12-6-3p site at 
3723bp highlighted in blue bold is the only predicted site with full sequence complementation 
across the entire 8bp seed.  
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4.5 MAF silencing via KSHV miRNA binding sites in the 
3’UTR 
To confirm the KSHV miRNAs were regulating MAF mRNA through interaction 
with the 3’UTR at the PITA-predicted sites, luciferase-reporter assays were 
performed (Fig. 4.4). These assays permit quantification of the magnitude of 
target silencing by miRNAs. The 3’UTR associated with the target mRNA is 
cloned downstream of the renilla ORF into a dual-luciferase reporter vector (psi-
check2) and binding of the miRNA to a target site located in the cloned 3’UTR, 
reduces expression of the renilla luciferase protein (Fig. 4.4A). The reduction in 
renilla protein levels corresponds to a reduction in enzymatic activity, which is 
represented as a reduction in light emitted after the addition of substrate. This 
vector also encodes the firefly luciferase ORF, which is resistant to miRNA-
mediated silencing. Firefly luciferase expression and activity is therefore used to 
control for transfection efficiency and normalise loading between samples, without 
requiring co-transfection of an additional plasmid.  
 
The repetitive and G/C-rich nature of the 3’UTR sequence increases its 
propensity to generate hairpins and complex secondary structure. These 
structural elements can impede polymerase processing and impair efficient PCR 
amplification, making cloning problematic. The MAF 3’UTR is 4.3kb long, which in 
addition to the G/C rich sequence, further impeded PCR cloning. Only accurate 
amplification of the initial 2.3kb of the MAF 3’UTR closest to the STOP codon was 
achieved and subject to further study. This region was inserted downstream of the 
renilla ORF into a dual-luciferase reporter vector (Fig. 4.4A and B). This fragment 
of the MAF 3’UTR contained four predicted KSHV miRNA target sites, including 
one site for each of the two candidate MAF repressors miR-K12-6 and miR-K12-
11, as well as a site for miR-K12-1 and miR-K12-4-3p (Fig. 4.3A). However, there 
are limitations to using a fragment of the 3’UTR compared with the full length 
sequence in assessing miRNA-mediated silencing.  The 3’UTR is not linear but 
instead forms a complex secondary structure. This structure has an important role 
in miRNA mediated silencing, by  regulating access to miRNA target sites and 
providing structural features which are recognised by RISC-associated and 
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regulatory RNA binding proteins. Reducing the length of the 3’UTR, as in the case 
of MAF, creates a different secondary structure which could inhibit or promote 
miRNA-mediated silencing. Furthermore, the location of miRNA target sites has 
been shown to play a role in the probability of silencing (Grimson et al., 2007). 
Halving the 3’UTR moves sites located in the middle of the full length sequence to 
the end, which is a more favourable location for silencing (Grimson et al., 2007). 
Therefore, the MAF 3’UTR reporter assay can only inform on whether a KSHV 
miRNA regulates a specific site within the context of this experiment. 
 
The 293T cells used previously for luciferase assays (Chapter 3) express high 
levels of MAF mRNA, as evidenced by low a delta Ct value (Fig. 4.4C). miRNA 
binding sites in the endogenous MAF 3’UTR may sequester viral miRNAs away 
from the luciferase reporter vector. To limit this effect, 3’UTR experiments were 
performed in cells expressing low levels of endogenous MAF. Four cell lines were 
tested for MAF mRNA and HeLa cells were found to express MAF at the lowest 
levels. These cells were used for 3’ UTR KSHV miRNA repression studies (Fig. 
4.4C). 
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. Figure 4.4. A Schematic of the psi-MAF-UTR plasmid. A The first 2.3kb of the MAF 
3’UTR was inserted into the multiple cloning site (MCS) down-stream of the renilla luciferase 
ORF (yellow box) into the psi-Check2 vector. This vector also encodes the firefly luciferase 
enzyme (green box) which is used to normalise for transfection efficiency and sample 
loading. B ~1µg of psi-MAF-UTR was digested with XhoI and NotI to excise the MAF 3’UTR. 
The top band is empty, linearised psi-Check2 plasmid, bands running at ~2.3kb are the 
excised MAF 3’UTR. C MAF mRNA levels in four cell lines.  The difference in threshold 
detection cycle (Ct) between GAPDH and MAF is shown (delta Ct). HeLa cells gave the 
highest delta Ct and therefore express the lowest levels of MAF mRNA. MSC+T: 
mesenchymal stem cells plus tert, HF: human fibroblasts. 
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MAF 3’UTR luciferase assays were performed using the experimental conditions 
optimised for the miRNA sensor luciferase assays (Section 3.3). Expression of the 
KSHV miRNA Cluster induced a significant reduction in renilla activity compared 
to empty vector control (Fig. 4.5B). Similarly, co-transfection of pSIN-K-miR-6 and 
pSIN-K-miR-11 also led to a significant reduction in renilla activity (Fig. 4.5B). 
pSIN-K-miR-6 induced a 50% reduction compared with 23% induced by the pSIN-
K-Cluster (Fig. 4.5B).  Eleven mature miRNAs are expressed and processed from 
pSIN-K-Cluster, four of which have predicted binding sites in the fragment of the 
MAF 3’UTR tested. Conversely, only two mature miRNAs are encoded by pSIN-K-
miR-6, with half of the expressed miRNAs having a target site in the MAF 3’UTR. 
This relative difference in the proportion of expressed MAF-targeting miRNAs may 
explain why pSIN-K-miR-6 induced greater repression than the entire Cluster (Fig. 
4.5B). pSIN-K-miR-6 was a more potent MAF silencer compared to pSIN-K-miR-
11, which reduced renilla activity by 21%. This may be due to differences in levels 
of mature miRNA.  Alternatively, in the context of the shortened MAF 3’UTR the 
target site for miR-K12-6-3p may be more accessible than that for miR-K12-11, 
explaining the increased silencing by miR-K12-6-3p (Fig. 4.5). miR-K12-1 failed to 
induce MAF down-regulation when LEC were transduced with a lentivirus 
encoding for this miRNA (Fig. 4.2A). However, when transfected into HeLa cells 
miR-K12-1 significantly reduced MAF 3’UTR luciferase reporter activity by 
approximately 43% (Fig. 4.5B). This discrepancy may be due to higher miRNA 
expression levels in 293T cells transfected with the miR-K12-1 plasmid, or as a 
result of increased accessibility in shortened 3’UTR compared to endogenous, full 
length sequence. Absence of miR-K12-1 induced MAF mRNA down-regulation 
(Fig. 4.2A) suggests that miR-K12-1 does not significantly contribute to KSHV 
miRNA MAF regulation. Expression of two viral miRNAs (miR-K12-7 and miR-
K12-8) with no predicted binding sites in the MAF 3’UTR failed to induce silencing 
(Fig. 4.5B). These data strongly suggest MAF regulation is mediated through 
miRNA interactions with the 3’UTR.  
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To confirm KSHV miRNA regulation was specifically via the PITA predicted sites, 
site directed mutagenesis was performed, disrupting the seed region so that the 
mature miRNA was no longer complimentary to its predicted target (Fig. 4.5C). 
Three bases in the seed were changed to a non-specific sequence, one mutant 
UTR was made for each predicted site. Seeds were disrupted for miR-K12-1, 
K12-6-3p and K12-11 (Fig. 4.5C).  Site directed mutagenesis of these predicted 
targets ablated KSHV miRNA silencing induced by all three miRNAs, restoring 
renilla levels to that comparable to empty vector (Fig. 4.5B). These data support 
MAF down-regulation by way of KSHV miRNA binding to target sites located in 
the 3’UTR and identify potential sites of KSHV miRNA interaction. These data 
also show miR-K12-1 is capable of targeting the shortened MAF 3’UTR, although 
it is not clear this miRNA also silences the full length 3’UTR.  
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Figure 4.5. miR-K12-6, miR-K12-1 and miR-K-12-11 target the MAF 3’UTR. A Rug plot analysis 
of the section of MAF 3’UTR cloned into psiCheck2. This portion contains four predicted KSHV 
miRNA binding sites. B KSHV miRNA-induced repression of MAF 3’UTR. Individual KSHV 
miRNAs were co-transfected with the MAF 3’UTR luciferase reporter plasmid. Either wild type or 
mutated MAF 3’UTR was transfected. Mutated UTRs had the seed region of the corresponding 
miRNA disrupted by site directed mutagenesis. The ratio of renilla to firefly luciferase relative light 
units was normalized to empty vector (pSIN-MCS) and the relative change is shown. p values 
relative to pSIN co-transfected with WT MAF 3’UTR: *<0.05; **<0.005. C Sequence alignment of 
the KSHV miRNAs and their predicted seed regions in the MAF 3’UTR. The black line identifies 
bases disrupted by site directed mutagenesis, altered bases are shown above in red. Error bars 
correspond to standard deviation, n = 3. 
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4.6 MAF is down-regulated during primary KSHV 
infection  
To study the relevance of MAF silencing by KSHV miRNAs, regulation of MAF 
expression during primary KSHV infection of LEC was investigated. MAF belongs 
to the AP1 super-family of basic leucine zippers and is the founding member of 
the Maf family of transcription factors (Nishizawa et al., 1989). To determine 
whether expression of MAF, or any other family members, was deregulated 
during primary KSHV infection the gene expression profiles of infected and 
uninfected LEC were compared. MAF was the only transcription factor from this 
family that decreased upon primary infection (Fig. 4.6A). The Maf family is 
classified into two groups: large and small Mafs. In addition to MAF down-
regulation, there was a significant up-regulation of two other small Maf 
transcription factors: MAFF and MAFK at the mRNA level (Fig. 4.6A).  
 
To determine whether MAF down-regulation occurred early during infection, MAF 
mRNA levels were quantified during a time-course infection of LEC. MAF mRNA 
was down-regulated early at 6hrs post KSHV infection, this down-regulation was 
significant and persisted until 72hrs post infection (Fig. 4.6B). MAF down-
regulation was also observed at the protein level by approximately 50% 48hrs 
post KSHV infection of LEC (Fig. 4.6C). Although MAF mRNA was down-
regulated at 6hrs post infection, a decrease in protein levels was not observed 
until 48hrs. This lag in protein down-regulation reflects the time required for a 
decrease in mRNA levels to yield a corresponding decrease in protein. MAF 
down-regulation occurs in the context of KSHV miRNA Cluster but is also 
detected during whole virus infection of LEC. These data highlight MAF as a 
relevant KSHV miRNA target for further investigation in the context of KSHV 
infected LEC.   
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Figure 4.6. MAF is down-regulated during primary KSHV LEC infection. A MAF mRNA was 
down-regulated in LEC 72hrs post KSHV infection (KLEC). The heatmap shows the z-score of the 
GEM data in which each normalized expression value is divided by the mean and centred around 
zero (n=6). Down-regulated probes are shown in red, up-regulated probes in yellow. B MAF 
mRNA down-regulation at 6 and 72hrs post KSHV infection of LEC, as quantified by qRT-PCR. p 
values relative to uninfected LEC at the equivalent time point: *<0.05; **<0.001. C Western blot 
analysis of MAF and loading control actin in uninfected and KSHV infected LEC (KLEC, 48hrs post 
infection). Quantification of relative intensity was performed by Scion Image software. Error bars 
correspond to standard deviation, n = 3. 
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4.7 KSHV miRNA expression during primary LEC 
infection 
Agilent miRNA microarray profiling of KSHV-infected LEC 72hrs post infection 
was performed by Dr. D. Lagos (Lagos et al., 2010). Analysis of these data 
confirmed expression of the KSHV miRNAs during primary infection (Fig. 4.7).  
Figure 4.7 shows the log2 expression values for those miRNAs significantly 
differentially expressed between infected and uninfected LEC. Eleven out of 17 
mature miRNAs are expressed during primary infection. The viral miRNA profile of 
KLEC is comparable to that of KS lesions (Fig. 4.7, Fig. 3.2A and 3.3A), with the 
exception of miR-K12-9*, which was not significantly differentially expressed 
between KS and normal skin (Fig. 3.3A).  
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Figure 4.7. KSHV miRNA expression during primary LEC infection. miRNA microarray log2 
expression values of significantly expressed miRNAs in KSHV infected LEC 72hrs post infection 
(relative to uninfected LEC, p<0.05). Boxplots show the median, interquartile boxes, 95th 
percentile range, and outliers as points. Error bars correspond to standard deviation, n = 3. 
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KSHV miRNA expression in primary infected LEC was confirmed by qRT-PCR for 
miR-K12-6-5p and miR-K12-11 at 6 and 72hrs post infection (Fig. 4.8). Both 
miRNAs were detectable at 6hrs, which is the same time point at which MAF 
mRNA levels begin to decrease (Fig. 4.8). The viral latent protein LANA was also 
detectable 6hrs post infection (Fig. 4.8). miRNA expression increased between 6 
and 72hrs, as evidenced by an increase in the difference between relative miRNA 
levels between uninfected and infected cells (Fig. 4.8). As LANA and KSHV 
miRNA expression increased with time, MAF mRNA levels decreased (Figure 
4.8).  
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Figure 4.8. KSHV miR-12-6-5p and miR-K12-11 expression during primary infection. The 
graph shows the relative change in expression of each gene before (LEC) and after KSHV 
infection of LEC (KLEC) at 6 and 72hrs post infection. KSHV viral gene expression was confirmed 
by qRT-PCR for LANA, expression is relative to GAPDH. KSHV miRNA expression is relative to 
RNU66. The bars show the average (n=3) difference in relative expression between LEC and 
KLEC (DDCt = DCt LEC-DCt KLEC). p values: *<0.001; **<0.005. Error bars correspond to 
standard deviation, n = 3. 
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4.8 KSHV miRNA inhibition  
4.8.1 miRIDIAN hairpin KSHV miRNA inhibitors 
To confirm that MAF down-regulation in KLEC occurred by way of KSHV miRNA-
mediated silencing, in particular miR-K12-6 and miR-K12-11, these miRNAs were 
inhibited during primary KSHV infection. miRNA inhibitors are synthetic 
oligonucleotides complementary to the mature miRNA of interest. Successful 
miRNA inhibition impairs silencing, resulting in an increase in mRNA and protein 
of bone fide targets. The first generation of miRNA inhibitors consisted of 2’-O- 
methyl modified oligoribonucleotides complementary to the mature miRNA; these 
inhibitors interacted with the miRNA–RISC nucleoprotein complex successfully 
blocking target mRNA degradation (Meister et al., 2004; Hutvagner et al., 2004). 
The 2’O-methyl modification protects oligoribonucleotides from degradation and 
promotes rapid and stable hybridisation to ssRNA (Meister et al., 2004; Hutvagner 
et al., 2004).  This type of inhibitor was previously used to successfully inhibit 
KSHV-miRNA RISC-containing complexes in a 293 cell line stably expressing the 
miRNA Cluster (Samols et al., 2007). The second generation of miRNA inhibitors, 
referred to as antagomirs, had additional structural and chemical features 
designed to improve miRNA inhibition. At the time of this work there were no 
commercially available antagomirs against the KSHV miRNAs. Therefore, custom 
miRIDIAN miRNA hairpin inhibitors against miR-K12-6-5p and miR-K12-11, the 
viral miRNAs shown to silence MAF, were purchased from Dharmacon (Thermo-
Fisher, Colarado). miRIDIAN miRNA inhibitors contain secondary structural 
elements flanking the mature miRNA sequence, these hairpins increase inhibitor 
function and permit multi-miRNA inhibition (Vermeulen et al., 2007). It was 
proposed that miRIDIAN miRNA inhibitors would allow miRNA inhibition at sub-
nanomolar concentrations due to the incorporation of a flanking hairpin; this is 
necessary when transfecting oligonucleotides into primary LEC which are very 
sensitive to cytotoxic effects of transfection reagents. 
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4.8.1.1 KSHV miRNA inhibition of luciferase reporter silencing 
miR-K12-11 inhibitor was optimised by confirming the inhibition of silencing of a 
synthetic luciferase reporter. These initial experiments were performed in 293T 
cells with miR-K12-11 inhibitor only, as a reporter vector was available for this 
miRNA. 293T cells were sequentially transfected, first with inhibitors against miR-
K12-11, then with luciferase sensor vector (pGL3-T-miR11) and lentiviral plasmid 
pSIN-K-miR11.  Two inhibitor concentrations were tested, and inhibitor miR-K12-
6-5p was transfected to control for non-specific effects on silencing (Fig. 4.9A). As 
expected, miR-K12-11 silenced expression of pGL3-T-miR11, however, the 
inhibitor specific for miR-K12-11 failed to abolish silencing of the luciferase 
reporter (Fig. 4.9A). Titrating increasing amounts of this inhibitor slightly 
augmented silencing, although this was not statistically significant (Fig. 4.9A).  
Inhibitor miR-K12-6-5p had no significant effects on miR-K-11-mediated silencing. 
These data suggested the inhibitors may have a non-specific negative effect on 
luciferase activity. To test this, luciferase activity of pGL3-T-miR11 was measured 
in the presence of both inhibitors and a non-targeting control (Fig. 4.9B). The 
inhibitor against miR-K12-11 induced a significant reduction in pGL3-T-miR11 
compared to the non-targeting control; the inhibitor against miR-K12-6-5p also 
induced a reduction in luminescence, although this was not statistically significant 
(Fig. 4.9B). Therefore, in this experimental system the inhibitor against miR-K12-
11 induced significant non-specific affects on reporter luciferase activity. 
 204 
 
0
200000
400000
600000
800000
1000000
1200000
1400000
pSIN-
MCS
i11            
0.4nM
i6 
0.4nM
Lu
m
in
e
sc
e
n
ce
 
(R
LU
)
pGL3-T-miR-11
i11            
0.8nM
i6 
0.8nM
pSIN-K-miR11
i11            
0nM
B
A
0
2000000
4000000
6000000
8000000
10000000
12000000
14000000
Lu
m
in
e
sc
e
n
ce
 
(R
LU
)
i11 
0.4nM
I6-5p 
0.4nM
pGL3-T-miR-11
NTC 
0.4nM
*
*
 
 
 
Figure 4.9. KSHV miRNA inhibitor optimisation in 239T cells. A pGL3-T-miR11 luciferase 
activity in 293T cells transfected with inhibitors against miR-K12-11 and as a negative control miR-
12-6-5p. In the absence of inhibitors miR-K12-11 induced a significant reduction in luminescence 
compared to pSIN-MCS. Transfecting increasing concentrations of miR-K12-11 inhibitor failed to 
ablate silencing, luminescence levels did not vary significantly between 0nM, 0.4nM or 0.8nM i11. 
Inhibitors against miR-K12-6-5p had no significant effect on pGL3-T-miR11 activity. p values 
relative to pSIN-MCS: *<0.05. B Inhibitor miR-K12-11 has a significant negative effect on pGL3-T-
miR11 luciferase activity. Luminescence was significantly reduced in cells transfected with 0.4nM 
of i11 compared with NTC. Luminescence was also reduced in the presence of i6-5p, although this 
was not statistically significant. i11: miRNA inhibitor specific for miR-K12-11; i6-5p: miRNA 
inhibitor specific for miR-k12-6-5p. Error bars correspond to standard deviation, n = 3. 
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4.8.1.2 KSHV miRNA inhibition in LEC with miRIDIAN inhibitors  
To avoid the non-specific effects on luciferase activity observed in the context of 
these inhibitors, the experimental system was modified and miRNA-mediated 
MAF silencing was challenged in LEC expressing individual KSHV miRNAs. 
Previous work in our laboratory using the fluorescent labelled inhibitor analogue 
siGLO (Dharmacon) confirmed inhibitor delivery to LEC nuclei using the 
Oligofectamine transfection reagent. A time course monitoring fluorescence post 
inhibitor-transfection showed maximal fluorescence 24hrs post-transfection, signal 
remained high until 48hrs, and then significantly decreased by 72hrs post-
transfection. Based on these data inhibitors were transfected for 48hrs to allow 
strong expression and permit time for inhibitor activity. Maximal siGLO 
fluorescence corresponds to optimal oligonucleotide uptake; however there is no 
means of directly confirming inhibition of miRNA-mediated silencing. qRT-PCR 
quantification of the mature miRNA before and after inhibition, would inform on 
total miRNA levels, but gives no indication of activity. Furthermore, miRNA 
inhibitors have been shown to comprise the accuracy of miRNA qRT-PCR 
quantification by directly interfering with the PCR reaction (unpublished 
observations). Therefore, assessing mRNA levels of a miRNA target is currently 
the optimal readout of miRNA-inhibitor activity.  
 
Maximal MAF mRNA reduction had previously been observed 72hrs following 
lentiviral expression of the KSHV miRNAs. To create an optimal environment 
whereby KSHV miRNAs were expressed during maximal inhibitor uptake, LEC 
were first infected with the appropriate lentivirus and transfected with inhibitors 
24hrs later. miR-K12-11 induced a small but significant reduction in MAF mRNA 
compared to pSIN-MCS (Fig. 4.10). MAF mRNA levels were similar in cells 
transfected with miR-K12-11 inhibitors or a non-targeting control, suggesting that 
the miR-K12-11-specific inhibitor had no effect of MAF silencing (Fig. 4.10). miR-
K12-6 caused a significant reduction in MAF mRNA, which was ablated in the 
presence of miR-K12-6-5p inhibitor (Fig. 4.10). The non-specific effects seen in 
the luciferase assay were not as significant in this system.  In the context of 
lentivirus expressing empty vector, the inhibitor specific for miR-K12-11 caused a 
small increase in MAF mRNA compared to NTC, whereas inhibitor against miR-
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K12-6-5p induced a decrease in MAF mRNA (Fig. 4.10). However, neither of 
these effects was statistically significant.  These data support MAF silencing by 
way of miR-K12-6-5p, but are inconclusive for miR-K12-11. Increasing 
concentration of inhibitors were transfected into LEC in an attempt to titrate miR-
K12-6-5p-mediated MAF silencing and to test whether increased inhibitor 
concentration reversed miR-K12-11 silencing.  However, increasing the amount of 
DNA transfected into LEC requires a reciprocal increase in the volume of 
transfection reagent Oligofectamine, which LEC are highly sensitive to.  Attempts 
to transfect more than 0.4nM of inhibitors resulted in widespread cell death due to 
Oligofectamine-induced cytotoxicity, making it impossible to quantify silencing in 
the presence of higher inhibitor concentration.  
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Figure 4.10. KSHV miRNA miRIDIAN inhibitor optimisation in LEC.  MAF mRNA levels in LEC 
transduced with lentivirus expressing individual KSHV miRNAs and transfected with the 
corresponding miRNA inhibitor or non-targeting control (NTC). pSIN-K-miR11 and pSIN-K-6 
induce a small but significant reduction in MAF mRNA compared with pSIN-MCS. The presence of 
an inhibitor against miR-K12-11 had no effect on MAF silencing, where as miR-k12-6-5p inhibitor 
led to increased in MAF mRNA. p values relative to pSIN-MCS NTC: *< 0.05.  Error bars 
correspond to standard deviation, n = 3. 
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Inhibition of viral miRNA function was also performed using the miRIDIAN 
inhibitors in the context of KSHV infection. In this system, MAF down-regulation 
occurs 24hrs post infection. To ensure maximal inhibitor uptake, LEC were first 
transfected with miRNA inhibitors and then infected 24hrs later. Samples were 
harvested 48hrs post inhibitor transfection, and 24hrs post KSHV infection.  MAF 
mRNA was down-regulated in KSHV-infected cells and in the presence of a non-
targeting control (Fig. 4.11A). Inhibitors specific for miR-K12-11 and miR-K12-6-
5p had no effect on silencing, MAF mRNA levels were comparable between all 
KSHV-infected samples regardless of the inhibitor present (Fig.  4.11A).  
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Figure 4.11. KSHV miRNA miRDIAN inhibitor optimisation in KLEC.  Viral miRNA inhibitors 
had no effect on MAF mRNA during KSHV infection. In KSHV infected LEC MAF mRNA is 
unchanged in the presence of inhibitors specific for miR-K12-11 or miR-k12-6-5p compared with a 
non-targeting control (NTC). p values relative to LEC NTC: *<0.05. 4.8.2 LNA-modified KSHV 
miRNA inhibitors. Error bars correspond to standard deviation, n = 3. 
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4.8.2 LNA-modified KSHV miRNA inhibitors 
Due to the inconclusive data obtained with the miRIDIAN hairpin inhibitors, an 
alternative inhibitor designed was tested to determine whether miRNA inhibition 
successfully reversed MAF silencing.  Locked nucleic acid (LNA) is a three 
dimensional analogue of RNA. The conformation of the ribose sugar in LNA is 
'locked' in the RNA shape by virtue of its rigid bicyclic structure (Petersen et al., 
2000). LNA-modified nucleotides undergo conventional Watson-Crick base 
pairing and, when incorporated into oligonucleotides, the LNA modification 
conveys dramatically enhanced binding affinity to complementary RNA 
sequences and greatly increases the stability and specificity of duplexes (Vester 
and Wengel, 2004). For these reasons LNA-modified oligonucleotides are widely 
used as miRNA inhibitors. Exiqon (Vedbaek, Denmark) specialise in LNA-
modified oligonucleotides and at the time of this work the company was trialling 
different miRNA inhibitor designs. In collaboration with Exiqon, three independent 
designs of viral miRNA inhibitors were tested for their ability to reverse MAF 
silencing. The inhibitors were designed to inhibit exogenous miRNAs and to be 
active at low concentrations, which would circumvent the need to use toxic 
concentrations of transfection reagents. Since these reagents were not 
commercially available, other than the LNA modifications, the specifics of the 
different versions were not disclosed. LNA inhibitors were provided for MAF-
targeting miRNAs, miR-K12-11 and both isoforms of miR-K12-6, as well as a non-
targeting KSHV miRNA miR-K12-8. Three versions of each inhibitor were 
provided.  
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4.8.2.1 LNA miRNA inhibition of synthetic luciferase targets 
As a proof of principle the three LNA miRNA inhibitor designs against miR-K12-11 
were tested for the ability to inhibit miRNA-induced silencing of target luciferase 
constructs in 293T cells.  The experiment was complicated by the need to 
transfect three different reagents into the cell: the miRNA expression vector, the 
miRNA sensor vector and the miRNA inhibitors. Since optimal oligonucleotide 
uptake occurs at 48hrs post-transfection, and miR-K12-11 silencing is detected 
24hrs post-transfection (Fig. 3.6), 293T cells were first transfected with inhibitors 
then 24hrs later co-transfected with pSIN-K-miR11 and the corresponding sensor, 
pGL3-T-miR-11. Cells were harvested 48hrs post inhibitor transfection. These 
inhibitors were designed to be active a low concentrations, therefore cells were 
transfected with 10 and 50nM of each of the three inhibitor designs (Fig. 4.12).  
 
miR-K12-11 induced a reduction in sensor luciferase activity, compared to empty 
vector control.  Inhibitor version one caused a slight decrease luminescence at 
10nm, but at the higher concentration of 50nM luminescence increased by 
approximately 20% compared to mock transfected cells (Fig. 4.12A). Inhibitor 
Version 2 was active at the lower concentration of 10nM, with luminescence 
increasing slightly with increased inhibitor concentration (Fig. 4.12B). Similar to 
version one, 50nM of inhibitor version two increased luminescence by 
approximately 20% compared to mock transfected cells (Fig. 4.12B). At 10nM 
inhibitor version three increased luminescence by approximately 15%, however 
this effect did not titrate with increasing inhibitor concentration (Fig. 4.12C). These 
data suggest the LNA miRNA inhibitors were successfully reversing KSHV miRNA 
silencing. The luciferase assays revealed a difference in inhibitor efficacy and 
potency between the three different designs. Based on these preliminary findings 
with inhibitor 11, all inhibitors were then tested in a more physiologically relevant 
system.   
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Figure 4.12. KSHV LNA miRNA inhibitor optimisation in 293T cells. The miR-K12-11 
expression vector (pSIN-K-miR11) and miRNA sensor (pGL3T-miR-11) were co-transfected into 
293T cells which had previously been mock transfected (0nM) or transfected with 10 or 50nM of 
inhibitor specific for miR-K12-11. Three different inhibitor designs (A-C) were tested for the ability 
to inhibit miR-K-12-11 induced silencing of the luciferase sensor vector.  Luciferase activity is 
relative to 293T cells transfected with pGL3-T-miR-11 only. pSIN-K-miR11 induces a reduction in 
luciferase activity; all three inhibitor designs reverse silencing to varying degrees at either 10 or 
50nM. 
A B C 
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4.8.2.2 LNA miRNA inhibition of KSHV induced MAF silencing  
 
The inhibitors were then tested for the ability to reverse KSHV induced MAF-
silencing. This system was selected over LEC expressing lentiviral-encoded 
KSHV-miRNAs, as the KSHV miRNA expression, and MAF silencing, occurs 
earliest in KLEC, meaning samples could be harvested at 48hrs post inhibitor 
transfection, when oligonucleotide uptake is optimal. The inhibitors were tested at 
the higher concentration of 50nM, which was within the recommended range for 
the product. LEC were transfected with all three versions of inhibitors specific for 
the MAF targeting miRNAs: miR-K12-11, miR-K12-6-3p and miR-K12-6-5p, as 
well as a non-targeting miRNA, miR-K12-8. Twenty four hours post inhibitor 
transfection, LEC were infected with KSHV and harvested after a further 24hrs.  
 
KSHV infection induced a significant reduction in MAF mRNA, compared to LEC 
transfected with NTC (Fig. 4.13). KSHV LNA-inhibitors specific for miR-K12-11 
and both isoforms of miR-K12-6 successfully reversed MAF silencing, as 
evidenced by an increase in MAF mRNA levels, relative to KLEC transfected with 
a non-targeting control (Fig. 4.13). However, similar to the luciferase inhibitor 
data, there were differences in inhibitor efficacy between the three designs (Fig. 
4.13). Design two was the most consistent, reversing silencing mediated by all 
three MAF-targeting miRNAs (Fig. 4.13). Whereas design one failed to 
reproducibly reverse silencing induced by any of the three viral miRNAs (Fig. 
4.13). Design three was variable, in that it reversed miR-K12-6-3p and miR-K12-
6-5p silencing; however the inhibitor specific for miR-K12-11 had no significant 
effect on MAF mRNA levels, compared with a non-targeting control. In contrast, 
all three inhibitor designs against miR-K12-8, a miRNA not predicted to target 
MAF, had no effect on the suppression of MAF mRNA by KSHV (Fig. 4.13). 
These data confirm that MAF silencing in KSHV infected LEC is mediated 
specifically by miR-K12-6 and miR-K12-11. Inhibition of both mature isoforms of 
miR-12-6 led to an increase in MAF mRNA, suggesting both branches of the 
stem-loop contribute to MAF down-regulation, concurring with the in silico target 
prediction analysis (Fig. 4.3A).  
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Figure 4.13. Inhibition of miR-K12-6, miR-K12-11 and miR-K12-1 attenuates MAF silencing.  
LEC were infected with KSHV in the presence of LNA inhibitors against miRK12-11, miR-K12-6-
3p, miR-K12-6-5p, miR-K12-8 or a non-targeting control (NTC). Three versions of each inhibitor 
were tested, denoted by v1-v3. In KSHV infected LEC MAF mRNA was significantly reduced in the 
presence of a NTC compared to uninfected cells (black bars). Stars indicate samples with 
significantly different MAF mRNA levels compared to KLEC NTC. Inhibitor version 2 of all targeting 
miRNAs abolishes silencing. None of the inhibitor designs specific for miR-K12-8, a non-targeting 
KSHV miRNA had any effect on MAF mRNA levels. Error bars correspond to standard deviation, n 
= 3. 
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4.9 Does hsa-miR-155 contribute to MAF silencing? 
KSHV miR-K12-11 is a known orthoglogue of cellular miR-155 (Skalsky et al., 
2007; Gottwein et al., 2007) (Fig. 4.14A). Since MAF is a validated target of 
mouse miR-155 in T lymphocytes, it was possible that miR-155 was contributing 
to MAF silencing observed in KSHV-infected LEC. miRNA profiling data of miR-
155 expression in KS and KSHV-infected LEC is shown in Figure 4.14B (LEC and 
KLEC data provided by D. Lagos (Lagos et al., 2010)). Burkitt's lymphoma (miR-
155 positive (Eis et al., 2005))  and PEL cells (miR-155 negative (Gottwein et al., 
2007; Skalsky et al., 2007)) were included as controls. miR-155 is expressed in 
LEC and was found to be induced upon KSHV infection (Fig. 4.14B). However, 
miR-155 was undetectable in both skin and KS lesions (Fig. 4.14B). The total log2 
expression values for miR-K12-11 and miR-155, 6 and 72 hour post KSHV 
infection of LEC are shown (Fig. 4.14C). Both miRNAs are expressed at similar 
total levels in KSHV-infected cells (Fig. 4.14C). Six hours post KSHV infection 
miR-155 is induced by approximately 2 fold; this induction is maintained 72hrs 
post infection (Fig. 4.14D). KSHV-encoded miR-K12-11 is detected 6hrs post 
KSHV infection (Fig. 4.14D) and its expression increases by approximately 30 fold 
by 72hrs (Fig. 4.14D). Since miR-155 is only marginally induced upon infection, 
MAF silencing observed in KSHV infected LEC is likely to primarily be as a 
consequence of the substantial induction of KSHV-encoded miR-K12-11. 
Furthermore, since miR-155 was undetectable in KS lesions, its role in MAF-
regulation during KSHV infection was not investigated any further. 
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Figure 4.14. KSHV regulation of miR-155. A Sequence alignment of mature miR-155 and miR-
K12-11. These orthologous miRNAs share the same seed sequence. Lines indicate matching 
bases. B Heatmap showing miRNA profiling data for miR-155. Expressed probes are in red, 
unexpressed in blue. Red arrow: positive control, Burkitt’s lymphoma. Blue arrow: negative control, 
PEL cell line. miR-155 is not expressed in skin or KS. KSHV infection of LEC induced miR-155 
expression. C Total microarray log2 expression levels for miR-155 (white) and miR-K12-11 (gray) 
in LEC and KLEC at 6 and 72hrs. KSHV-encoded miR-K12-11 is undetectable in uninfected cells, 
generating negative log2 expression levels. miR-K12-11 is detected 6hrs post KSHV infection, 
expression increases with time.   miR-155 is expressed in LEC and induced upon KSHV infection. 
D Fold change in miR-155 and miR-K12-11 expression levels upon KSHV infection, at 6 and 72hr 
time points. miR-155 is induced by 2 fold post infection. There is a ~30 fold induction in miR-K12-
11 between 6 and 72hr post KSHV infection. Error bars correspond to standard deviation, n = 3. 
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4.10 MAF regulation in PEL 
miR-155 is essential for normal B cell development (Rodriguez et al., 2007; Thai 
et al., 2007; Vigorito et al., 2007).  miR-155 was one of the first miRNAs to be 
classified as an oncomir due to it’s ability to induce pre-B cell lymphomas in mice 
(Costinean et al., 2006); miR-155 is up-regulated in a range of B cell lymphomas 
including diffuse large B cell lymphoma, chronic leukaemia, Burkitt's lymphoma, 
Hodgkin’s Lymphoma and primary mediastinal B cell lymphoma (PMBL) (Eis et 
al., 2005). Strikingly, miR-155 is not expressed in PEL, instead the viral 
homologue miR-K12-11 is expressed (Skalsky et al., 2007; Gottwein et al., 2007). 
Deep sequencing of  PEL cells revealed that over 90% of the miRNA content is 
comprised of viral-encoded miRNAs (Umbach and Cullen, 2010), suggesting an 
important role for viral miRNAs in the development and maintenance of  PEL.  
 
Since both viral and cellular miRNAs are known to target MAF in other cell types 
(Rodriguez et al., 2007) (and work presented within this thesis), it is plausible that 
MAF is also under miRNA regulation in KSHV-associated B cell lymphomas. 
Relative MAF mRNA levels were assessed in a range of transformed B cell lines 
spanning different stages of B cell development (Fig. 4.15); every cell line tested 
expressed either miR-155 or miR-K12-11 (Eis et al., 2005; Gottwein et al., 2007; 
Skalsky et al., 2007). MAF mRNA was undetectable in a range of PEL cell lines, 
nor was it detectable in B cell lines representing plasma cell leukaemia, diffuse B 
cell lymphoma or Burkitt’s lymphoma, as evidenced by high delta Ct values (Fig. 
4.15). The only cell lines expressing MAF were those derived from multiple 
myeloma; these samples had low delta Ct values of <8 (Fig. 4.15). MAF over-
expression in these cells is due to a chromosomal translocation juxtaposing MAF 
next to the IgG heavy chain promoter (Chesi et al., 1998). Correspondingly, MAF 
was detected in multiple myeloma cell lines with this mutation but not in a cell line 
lacking the translocation (see KMS in Fig. 4.15).  These data suggest rather than 
being under miRNA regulation, MAF is not expressed in transformed B cells. The 
exception to this is a sub-set of multiple myeloma cells lines, where a 
chromosomal translocation switches on MAF expression. 
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Figure 4.15. MAF expression in B cell lymphoma cell lines. qRT-PCR quantification of MAF 
mRNA in a range of lymphoma derived B cell lines. The difference in threshold detection cycle (Ct) 
between MAF and GAPDH is shown. Unexpressed transcripts have a Ct of >35, generating a 
delta Ct of >17. MAF mRNA was undetectable in the majority of cell lines. MAF mRNA was 
detected in three multiple myeloma cell lines, OPM-2, H929 and RPMI 8226, as evidenced by low 
delta Ct values. These three cell lines contain a MAF activating translocation, whereas multiple 
myeloma cell line KMS does not possess this mutation.  
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4.11 Discussion 
This work shows that multiple KSHV-encoded miRNAs, in particular miR-K12-11 
and miR-K12-6, function in concert to target the bZIP transcription factor MAF. 
Importantly, MAF is the first KSHV miRNA target to be indentified in LEC, the 
closest primary cells to KS tumour cells (Hong et al., 2004; Wang et al., 2004).  
 
MAF mRNA was down-regulated by approximately 40% in LEC transduced with 
the viral miRNA Cluster and 60% in KSHV-infected cells; this led to a similar 
reduction in MAF protein levels. This level of repression is in keeping with other 
validated miRNA targets. A reduction of this magnitude for a transcription factor 
could have significant impact, leading to down-stream effects whereby target 
genes regulated by MAF are no longer activated or repressed. For this reason 
MAF represented an interesting KSHV miRNA target for further investigation.  
 
Seven out of ten of the expressed KSHV miRNAs have predicted binding sites in 
the MAF 3’UTR. In particular, expression of miR-K-12-11 and miR-K12-6 induced 
a significant reduction in MAF mRNA. miR-155 is orthologous to miR-K12-11 and 
a validated MAF-targeting miRNA (Gottwein et al., 2007; Skalsky et al., 2007; 
Rodriguez et al., 2007).  Since the orthologues share a seed region they are 
expected to regulate an overlapping set of target genes (Gottwein et al., 2007; 
Skalsky et al., 2007). In a lentiviral screen testing all the KSHV miRNAs for their 
ability to silence MAF, the viral homologue of miR-155 was identified as a MAF-
repressing miRNA. These data provide evidence of functional homology between 
viral and cellular miRNAs. miR-155 and MAF are co-expressed in LEC, upon 
KSHV infection there is a significant induction of viral miRNA expression and only 
a marginal increase in miR-155. Therefore, it is probable that MAF silencing 
observed upon KSHV infection is by way of the KSHV miRNAs, including miR-
K12-11, and not a consequence of miR-155 expression.  
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Similar to MAF, the transcriptional repressor BACH1 has also been validated as 
both a miR-155 and miR-K12-11 target (Qin et al., 2010). Previously, BACH1 was 
shown to heterodimerise with both MAFK and MAF (Newman and Keating, 2003). 
However, BACH1 mRNA increases upon KSHV infection of LEC (Lagos et al., 
2007). Therefore, either BACH1 is not under KSHV miRNA regulation in LEC or 
other signalling events are counteracting viral miRNA silencing.   
 
All experimentally validated cellular KSHV miRNA targets, including MAF, are 
regulated by more than one miRNA (Samols et al., 2007; Ziegelbauer et al., 2009; 
Qin et al., 2010). Similarly, endogenous cellular miRNA targets are often 
regulated by multiple members of clustered miRNAs which share the same seed, 
such as the Let7 family (Lee and Dutta, 2007). Redundancy of targeting by 
multiple miRNAs may represent a safety mechanism whereby the virus ensures 
target mRNAs will be down-regulated.  
 
Site directed mutagenesis disrupting PITA predicted KSHV miRNA target sites 
abolished miRNA silencing of a fragment of the MAF 3’UTR in a luciferase 
reporter vector. These data confirm KSHV miRNA silencing is via binding sites in 
the MAF 3’UTR and validate miRNA target prediction analysis. The site directed 
mutagenesis showed that PITA sites with a seemingly insignificant ∆∆G score (-3 
∆∆G for miR-K12-11), which would fall below stringent threshold cut-offs, can be 
bone fide miRNA target sites. Interestingly, the magnitude of silencing observed 
when the Cluster or individual miRNAs were co-transfected with the MAF 3’UTR 
was consistently less than when they were co-transfected with the synthetic 
miRNA sensor vectors (Fig. 3.7 and 4.5B). This difference may be due to 
variations in target site efficiency, or as a consequence of the shortened MAF 
3’UTR fragment in the reporter vector. Perfect seed matches were inserted, in 
tandem, into the sensor vectors; according to miRNA targeting rules regulation of 
these sites is expected to initiate a high level of silencing. Perfect miRNA target 
sites are not particularly common in endogenous miRNA targets (Grimson et al., 
2007; Bartel, 2009), indeed none of the predicted sites in the cloned region of 
MAF 3’UTR were fully complementary. Instead all sites contained wobbles or 
mismatches, which are known to negatively affect silencing. miRNA target sites 
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located within 40bp of each have been shown to act cooperatively during 
silencing; whereas sites further apart act independently (Grimson et al., 2007; 
Baek et al., 2008). Since none of the KSHV miRNA target sites are closely 
situated, MAF silencing by multiple viral miRNAs is likely to be additive.  The 
magnitude of MAF 3’UTR silencing was greatest in the presence of miR-K12-6 
compared to the entire Cluster. This may be due to differences in relative 
expression levels of MAF-targeting miRNA, and is suggestive of cooperative 
rather than synergistic regulation by the Cluster. However, maximal MAF mRNA 
repression was observed both in Cluster expressing and KSHV-infected LEC 
compared to LEC expressing individual miRNAs. Clearly further experimental 
work is needed to fully understand the mode of regulation by multiple KSHV 
miRNAs.  
 
Agilent miRNA profiling of KSHV-infected LEC confirmed viral miRNA expression 
during primary infection (Lagos et al., 2010).  Expression of KSHV miRNAs had 
previously been confirmed in KSHV-infected human umbilical endothelial cells 
(O'Hara et al., 2009). However, these are the first data confirming viral miRNA 
expression in KLEC, the experimental model of primary infection most closely 
related to KSHV infected spindle cells (Hong et al., 2004; Wang et al., 2004).  
Importantly, the viral miRNA profile of KS lesions and KSHV-infected LEC were 
identical, with the exception of miR-K12-9* which was only detected in KLEC.  
This similarity in miRNA expression profile supports the choice to exclude those 
miRNAs not expressed in KS lesions in prediction analysis as these miRNAs not 
only appear to be irrelevant to KS biology, but also during primary infection. It is 
possible that viral miRNAs not expressed in KS or KLEC target specific transcripts 
only relevant KSHV infection of B cells.  
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MAF was down-regulated at both the RNA and protein level in KSHV-infected 
LEC. MAF repression during whole virus infection, and not only in the presence of 
the KSHV miRNA Cluster, makes it a physiologically relevant target. GEM 
analysis of the entire Maf family of transcription factors revealed MAF to be the 
only member down-regulated upon KSHV infection. There was also significant up-
regulation of two small Maf transcription factors, MAFF and MAFK. Small Maf 
transcription factors lack a transactivation domain, therefore as homodimers these 
proteins act as repressors (Motohashi et al., 2002; Blank and Andrews, 1997). 
However, small Mafs can also activate transcription when in complex with other 
leucine zipper proteins (Motohashi et al., 2002). There is limited functional 
redundancy between the different family members, especially between the small 
and large Mafs (Blank and Andrews, 1997; Eychene et al., 2008). MAFF regulates 
expression of the oxytocin receptor (OTR) during pregnancy (Kimura et al., 1999). 
All small Mafs heterodimerise with the NF-E2 transcription factor, this 
transcriptional complex is crucial for the regulation of erythroid gene expression 
and platelet formation (Toki et al., 1997). Therefore, due to the difference in both 
dimer partner and target genes it is unlikely that the small Maf upregulation 
observed upon KSHV infection serves to functionally compensate for MAF 
silencing. 
 
Failure to detect inhibition of the synthetic luciferase miRNA targets and lack of a 
positive control meant it was not possible to determine whether the Dharmacon 
miRIDIAN inhibitors were functional. This made it difficult to draw conclusions on 
the lack of MAF silencing seen in the presence of the miRIDIAN inhibitors. When 
inhibiting exogenous miRNAs, both inhibitor and miRNA must be added 
separately to the cell. The timing and order of events may be important factors in 
determining whether silencing occurs and whether it can be quantified. In 
addition, LEC are toxic to high levels of the transfection reagent, oligofectamine 
making it difficult to determine whether increasing inhibitor concentration would 
have successfully inhibited MAF silencing. 
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In contrast, KSHV miRNA-mediated silencing of a luciferase reporter and MAF 
mRNA, was successfully inhibited by LNA-modified inhibitors. Three different LNA 
inhibitor designs were tested for their ability to reverse viral miRNA silencing. 
Since these were pilot experiments for the purpose of product optimisation, the 
differences in inhibitor design were not disclosed. Preliminary experiments with 
miR-K12-11 inhibitor, revealed increased luminescence from the reporter vector in 
the presence of all three inhibitor designs, suggesting the LNA modified 
oligonucleotides were inhibiting KSHV miRNA activity. Different levels of inhibition 
were observed between the three designs. The inhibitors were then tested in a 
more physiologically relevant system for the ability to reverse KSHV-induced MAF 
down-regulation in LEC. Inhibitor design two successfully inhibited miR-K12-11 
silencing of a luciferase reporter vector, and reversed MAF silencing mediated by 
all three MAF-targeting miRNAs. Importantly, design two specific for miR-K12-8, a 
non MAF-targeting miRNA, had no affect on MAF mRNA levels in KLEC. Inhibitor 
design one reversed miR-K12-11 mediated luciferase silencing at 50nM, however 
at the same concentration this design had no significant affect on MAF mRNA 
levels for any of the MAF-targeting KSHV miRNAs.  Inhibitor design three 
reversed MAF silencing induced by two out of three targeting miRNAs. These 
findings supported experimental optimisation performed by Exiqon and the 
second version of inhibitor design is now commercially available.  
 
Inhibition of all three individual MAF-targeting miRNAs with inhibitor design two 
restored MAF mRNA levels back to that comparable with LEC. This was 
surprising since inhibiting a single viral miRNA in KLEC would only affect a 
fraction of targeting miRNAs. It was therefore expected that MAF would continue 
to be silenced, albeit to a lesser degree, by the other non-inhibited miRNAs.   
However, since the window of down-regulation is relatively small (approximately 
40%) it may be beyond the sensitivity of the assay to dissect the individual 
contributions of multiple KSHV miRNAs in this experiment.  
 
 224 
Due to MAF miRNA regulation by either miR-155 or miR-K12-11 in T cells and 
LEC respectively, I hypothesised that MAF may also be under miRNA regulation 
in transformed B cells. MAF mRNA was undetectable in KSHV positive PEL cell 
lines and a range of cells spanning different stages of B cell development. It is 
unlikely that miRNA regulation of a target gene would lead to complete absence 
of the mRNA as miRNAs do not function as on/off switches. MAF is not expressed 
in primary B cells isolated from bone marrow (Vigorito et al., 2007) and GEM 
analysis of miR-155 deficient mouse B cells compared to normal B cells did not 
reveal up-regulation of Maf, at the RNA level (Vigorito et al., 2007). Therefore, 
these data suggest that MAF is not under miR-155 or miR-K12-11 regulation in B 
cells, and MAF is unlikely to be relevant to B cell biology or transformation. With 
exception of a subset of multiple myeloma cases in which MAF over-expression 
promotes transformation (Chesi et al., 1998). 
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Chapter 5. KSHV miRNA regulation of MAF 
induces endothelial reprogramming  
5.1 Introduction and aims 
The aim of this chapter was to investigate the functional significance of miRNA-
mediated MAF down-regulation during KSHV infection of LEC.  
 
MAF is involved in tissue specification and terminal differentiation of the lens, T-
lymphocytes and endochondral bone (Kim et al., 1999b; Ring et al., 2000; 
Kawauchi et al., 1999; MacLean et al., 2003; Kim et al., 1999a) and regulates a 
distinct repertoire of target genes specific to each cell type (Eychene et al., 2008). 
Genome-wide identification of MAF targets has been problematic due to the 
degeneracy of MAF recognition elements (MARE) (Kataoka, 2007). 
Consequently, the targets of MAF and its role in LEC are unknown. This section 
of work focussed on characterising MAF function in LEC, through the identification 
of LEC-specific MAF target genes; these observations were used to determine the 
role of viral miRNA-dependent MAF regulation during primary KSHV infection.  
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5.2 Hypothesis: MAF plays a role in LEC fate 
determination  
LEC are derived from venous endothelial cells and have a plastic, rather than 
irreversible, differentiation potential (Srinivasan et al., 2007; Johnson et al., 2008). 
Consequently, continual expression of PROX1 is required during embryogenesis 
and throughout adulthood to maintain a LEC phenotype and prevent cells from 
reverting to the default BEC-like state (Wigle et al., 2002; Johnson et al., 2008). 
Previous work from our laboratory and others has shown that KSHV infection of 
LEC induces transcriptional reprogramming, altering the differentiation status of 
the infected cell (Carroll et al., 2004; Hong et al., 2004; Wang et al., 2004). As a 
result of this transcriptional reprogramming, KSHV infected endothelial cells of 
either BEC or LEC lineage are more similar to each other in their transcriptional 
profile than uninfected cells (Wang et al., 2004). KLEC are therefore 
transcriptionally closer to BEC than uninfected LEC, as evidence by the reduced 
inter-sample distance of transcriptional profiles (Fig. 5.1, data taken from (Wang 
et al., 2004)). Despite the up-regulation in corresponding lineage markers, this 
phenotypic convergence is largely due to decreased expression of unique LEC or 
BEC markers in the infected cell (Wang et al., 2004). However, the mechanism 
behind KSHV-induced endothelial reprogramming is unknown. MAF is expressed 
early during embryogenesis and directs cell lineage specification contributing to 
tissue development (Yang and Cvekl, 2007; Eychene et al., 2008). MAF is also 
differentially expressed between LEC and BEC, and has been previously 
characterised as a LEC-specific transcript (Petrova et al., 2002; Hong et al., 
2004).  These findings highlight a potential role for MAF in specifying the LEC 
phenotype. Consequently, miRNA dysregulation of MAF could contribute to the 
mechanism of endothelial reprogramming following KSHV infection. 
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Figure 5.1. KSHV induced transcriptional reprogramming Boxplots of transcriptional profile 
inter-sample distances between uninfected LEC and BEC and following KSHV infection of LEC 
(KLEC). The reduced inter-sample distance between KLEC and BEC compared with LEC and 
BEC, marks convergence in gene expression profile upon KSHV infection of LEC (t-test, p = 
0.0002459).  
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5.3 MAF target identification in LEC 
siRNA-mediated knock-down of MAF in LEC was used to identify potential MAF 
target genes. Cells with reduced MAF levels were subjected to GEM analysis to 
identify significant changes in mRNA abundance. MAF mRNA undergoes RNA 
processing to generate two isoforms: a long species which encodes a short single 
exon encoded protein (MAF-S) or a shorter isoform which is alternatively spliced 
to give a longer, double exon protein (MAF-L) (Fig. 5.2A) (Chesi et al., 1998). The 
splicing reaction removes the majority of the 3’UTR, containing miRNA binding 
sites, from the MAF-L isoform. To ensure neither isoform was preferentially 
knocked down, a pool of four targeting siRNAs was used, which recognised 
regions homologous to both MAF isoforms (Fig. 5.2A). To control for non-
sequence specific effects, LEC were transfected with a non-targeting pool of 
siRNA designed against C. elegans-specific sequences. A time-course 
experiment was performed to determine the time point post-siRNA transfection at 
which to conduct the GEM. MAF mRNA was quantified 48, 72 and 96hrs post 
siRNA transfection (Fig. 5.2B). MAF mRNA was maximally repressed by 
approximately 75% 48hrs post-transfection, relative MAF mRNA levels then 
began to increase (Fig. 5.2B). The GEM experiment was therefore performed 
48hrs post-siRNA transfection. 
 
It was important to quantify the relative expression levels of the two MAF 
isoforms, to determine how they were regulated during KSHV infection. Previously 
MAF mRNA quantification was performed using a commercial TaqMan assay in 
which the primers recognised a sequence common to both MAF mRNA isoforms.  
To determine the relative mRNA abundances of each isoform primers were 
designed against sequences unique to MAF-S or MAF-L. qRT-PCR analysis 
revealed concordant repression of both isoforms when LEC were infected with 
KSHV, in the presence of the miRNA Cluster or MAF siRNA (Fig. 5.3B). The 
miRNA Cluster induced silencing of MAF-L which lacks many of the predicated 
KSHV miRNA binding sites due to splicing of the 3’UTR sequence. This could 
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perhaps be due to miRNA binding sites retained within the second MAF exon. 
Both mRNA isoforms increased in the presence of MAF-expressing lentivirus, 
which encodes the single ORF of MAF-S. It was therefore surprising that MAF-L 
levels also increased slightly and this could be due to MAF auto-activation of the 
endogenous promoter. Concurring with previous findings, MAF-S was more 
abundant than MAF-L as evidence by the lower delta Ct values (Fig. 5.3C) (Chesi 
et al., 1998). These data suggest MAF-S is the predominant MAF isoform in LEC 
(Fig. 5.3C). 
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Figure 5.2. siRNA-mediated MAF knock-down A Schematic depicting alternatively spliced MAF 
isoforms. MAF-S is an intron-less 6.4kb mRNA which generates a 373 amino acid protein. MAF-L 
is alternatively spliced removing a large internal intron and generating a shorter double-exon 
mRNA of 2.2kb. The additional exon encodes 30 amino acids. DNA is represented by white and 
blue rectangles, mRNA is shown in red and protein in blue circles. Arrow represents the promoter. 
Positions of the four targeting siRNAs are indicated, the nucleotide position is shown below the red 
arrows. All four siRNA molecules recognise sequences common to both MAF isoforms. B MAF 
siRNA time course. MAF mRNA was maximally repressed 48 hours post siRNA transfection 
compared to control siRNA (siCON). siMAF mRNA was compared to siCON at the equivalent time 
point,  for comparison only one control bar is shown.  
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Figure 5.3 MAF mRNA isoforms are concordantly regulated. A Schematic depicting 
alternatively spliced MAF mRNA isoforms. B  Relative mRNA levels of both MAF isoforms 
normalised to LEC, pSIN-MCS or siCON. Both isoforms are down-regulated upon KSHV infection, 
expression of the KSHV miRNA Cluster and after transfection of MAF siRNA. Both isoforms 
increase slightly when LEC are transduced with pSIN-MAF lentivirus. C Difference in threshold 
detection cycle (Delta Ct) between MAF and GAPDH for both mRNA isoforms. More abundant 
transcripts have lower delta Ct values, therefore isoform S mRNA is expressed at a higher level 
than isoform L.  
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GEM profiling of LEC in the absence of MAF identified a cohort of genes with 
significantly (q<0.05) altered mRNA abundance compared to LEC transfected with 
the non-targeting control. The heatmap in Figure 5.3A shows the top twenty most 
significantly up- and down-regulated probes, which represent potential MAF target 
genes. In the absence of MAF, mRNA of MAF-repressed targets will increase, 
whereas MAF-activated genes will decrease in abundance (Fig. 5.4A). 
Importantly, MAF was the most significantly down-regulated probe, indicating that 
siRNA knock-down was successful. However, qRT-PCR analysis showed only a 
50% reduction 48hrs post-transfection (Fig. 5.4B). This reduction in MAF 
expression was less pronounced than observed during the time-course 
experiment (Fig. 5.2B), meaning that a larger pool of potential targets may have 
been identified in the context of more robust knock-down. However, those targets 
identified here may represent those genes most sensitive to MAF regulation and 
their expression is affected even in the context of small changes in MAF level, 
similar to those changes observed due to miRNA-mediated regulation. These 
data were subsequently analysed in the context of genes significantly altered 
following KSHV-induced MAF down-regulation to determine whether MAF, and its 
target genes, were involved in the KSHV-mediated LEC transcriptional 
reprogramming. 
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Figure 5.4. MAF knock-down induces changes in gene expression. A Heatmap showing 
probes de-regulated in LEC when MAF is knocked-down by siRNA. The transcriptional profile of 
LEC transfected with siRNA specific for MAF (siMAF) was compared with cells transfected with a 
non-targeting control (siCON) 48hrs post-transfection. Down-regulated genes are in red, up-
regulated in yellow. This set of most significantly different genes has a false discovery rate (q 
value) of <0.05. The Z-score scale shows mean scaled and zero centred log2 GEM expression 
values for each row. Up-regulated probes are in yellow, down-regulated probes in red. B qRT-PCR 
quantification of MAF mRNA in cells transfected with either MAF or control siRNA. MAF mRNA 
was reduced by ~55% compared to cells transfected with a non-targeting control. MAF mRNA is 
normalised to GAPDH and relative to siCON, p: *<0.005. . Error bars correspond to standard 
deviation, n = 3. 
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5.4 MAF knock-down induces up-regulation of BEC 
markers 
KSHV-mediated endothelial reprogramming of LEC results in increased 
expression of BEC marker genes, with a corresponding decrease in LEC-
associated transcripts (Fig. 5.1) (Wang et al., 2004). To determine whether MAF 
knock-down by the KSHV miRNAs played a role in this transcriptional shift, the 
expression of BEC and LEC-specific genes were examined in the context of MAF 
repression. LEC and BEC markers were selected as those with the most 
significant difference in expression between the two cell types (Fig. 5.5, data 
taken from (Lagos et al., 2007). These genes were selected on the basis of 
expression rather than function, and therefore include classic cell surface markers 
and additional BEC- or LEC-specific proteins.   
 
Data from three independent GEM data sets where MAF was down-regulated 
were analysed: KSHV-infected versus non-infected LEC (Lagos et al., 2007); LEC 
transduced with the KSHV miRNA Cluster versus empty lentiviral vector; and LEC 
transfected with siRNA targeting MAF versus non-targeting siRNA control. The 
primary data set was generated previously (Lagos et al., 2007), the remaining two 
data sets were generated as described in Sections 3.5 and 5.3. 
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Figure 5.5. LEC and BEC are distinguished on the basis of their transcriptional profiles. 
Heatmap showing the top 100 differentially expressed probes between LEC and BEC (n=34 LEC, 
n=66 BEC). The gene set has a false discovery rate (FDR q-value) of 0.05. The Z-score scale 
shows mean scaled and zero centred log2 GEM expression values for each row. Up-regulated 
probes are in yellow, down-regulated probes in red. 
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Data were analysed using the pathway orientated method Gene Set Enrichment 
Analysis (GSEA), by the bioinformatician Dr. S. Henderson (CR-UK Viral 
Oncology group, UCL) (Subramanian et al., 2005). This method considers a set of 
related genes, in this instance BEC or LEC markers, and determines whether 
these genes are randomly distributed or localised at the top or bottom of ranked 
expression data. This method enables the identification of changes in gene 
expression in a number of related genes in the context of the whole gene-set, 
which if looked at as changes in individual genes may be missed. Significance is 
placed on concordant changes within a pathway as opposed to large single 
differences in gene expression (Subramanian et al., 2005). An enrichment score 
(ES) was calculated to indicate whether the BEC/LEC markers were significantly 
distributed in any of the three ranked expression data sets; this corresponded to a 
weighted Kolmogorov-Smirnov-like statistic (Subramanian et al., 2005). The 
statistical significance (p value) of the ES score was estimated using a 
permutation test, in which multiple random lists of the same gene number were 
tested to see whether they shared the same distribution as the BEC/LEC markers. 
An ES score was significant if the distribution of more than 95% (p<0.05) of 
control gene sets was considered random. The p value was then adjusted to 
account for multiple hypotheses testing to give a false discovery rate, or q value. 
Lists of 50-250 BEC markers, increasing in 50 gene increments were tested 
across all three GEM data sets. As previously reported, KSHV infection of LEC 
induced an up-regulation in BEC marker genes (Wang et al., 2004) and this 
positive enrichment was identified by GSEA (Fig. 5.5, grey plot), illustrating that 
this is a suitable method of analysis in this context. GSEA also identified a 
significant enrichment in up-regulated BEC marker genes in LEC expressing the 
KSHV miRNA Cluster (Fig. 5.5, green plot) and when MAF was knocked-down by 
siRNA, as evidence by the skewed distribution to the left (Fig. 5.6, red plot). 
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The vertical dotted lines on the distribution plots represent the leading edge gene 
subset for each experiment (Fig. 5.5). This represents the core of a gene set 
which accounts for the enrichment signal (ES score). Leading core edge genes 
(i.e. those genes most highly up-regulated) were compared within each GSEA 
analysis to identify concordantly regulated BEC markers potentially under MAF 
control (Fig. 5.7 and Table 5.1). The proportional Venn diagram shows the 
number of genes present within each leading core edge data set and how many 
of these genes were shared between all three sets (Fig. 5.7). Gene names and 
leading core edge subsets in which they were found are detailed in Table 5.1. 
Three putative MAF targets were highly up-regulated under all three conditions 
(KSHV infection, expression of the miRNA Cluster and siRNA knockdown of 
MAF): TFEC, NRCAM and SLC1A1 (Table 5.1). Two additional genes, HDAC9 
and GULP1, were also included as potential MAF targets, since they were two of 
the most highly up-regulated genes following both KSHV infection and MAF 
siRNA knockdown and were also up-regulated by the miRNA Cluster, although 
not present in the leading edge (Table 5.1). 
 
MAF knock-down in LEC, in three different contexts, led to an increase in BEC 
marker gene expression; therefore this analysis identified a putative role for MAF 
as a transcriptional repressor of BEC identity in LEC. The concordant change 
across all three data sets suggests that the viral miRNAs could contribute to 
KSHV-induced transcriptional reprogramming of LEC through suppression of the 
transcription factor MAF. 
 
 
  
 
 
 
 
 
238 
KLEC, n= 150, q = 0.000
siMAF, n= 250, q = 0.017
Cluster, n= 150, q= 0.012
mRNA Expression levels of BEC specific genes
ES
 
sc
or
e
ES
 
sc
or
e
 
 
 
 
Figure 5.6. BEC markers increase upon MAF knock-down. Gene Set Enrichment Analysis 
(GSEA) demonstrates a significant enrichment of BEC markers in three different GEM 
experiments: LEC infected with KSHV (KLEC, grey line), LEC transfected with siRNA against MAF 
(siMAF, red), and LEC infected with the KSHV miRNA Cluster (green).  Several lists of the 
topmost BEC markers (top 50, 100, 150, 200, 250,) were tested and the most significant list for 
each experiment is plotted. Note that in the case of KSHV-LEC q=0.000 exceeds the precision of 
the test. All curves display a similar skewed distribution to the left indicating increased expression. 
The peak enrichment score (ES) shows the strength of the BEC marker enrichment for each 
experiment and determines the genes that are within the 'leading edge' of the GSEA analysis, this 
is indicated by hatched lines. Vertical lines below the plots represent BEC specific probes. The 
significance calculation shown (q) is a false discovery rate 
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Figure 5.7. BEC markers increased in the context of MAF repression. The intersection of 
genes within the leading edge between the three GEM experiments is represented as an area 
proportional Venn diagram. The numbers indicate how many genes are shared between the 
different leading core edge data sets. The total number of leading core edge genes between all 
three data sets is 88.  
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Gene 
 
siMAF 
 
KLEC 
 
Cluster 
 
Total 
NRCAM 1 1 1 3 
TFEC 1 1 1 3 
SLC1A1 1 1 1 3 
CYYR1 1 1 0 2 
PALMD 1 0 1 2 
HDAC9 1 1 0 2 
OSTM1 1 1 0 2 
IFI27 1 1 0 2 
APBB2 1 0 1 2 
HSPB8 1 0 1 2 
IGF2BP3 1 0 1 2 
CSF2RB 1 1 0 2 
EVI5 1 1 0 2 
PTPRG 1 1 0 2 
LOC40157 0 1 1 2 
TNIK 1 0 1 2 
GULP1 1 1 0 2 
AKAP12 1 1 0 2 
 
 
 
 
Table 5.1 Leading core edge genes. BEC marker genes concordantly up-regulated in multiple 
GEM data sets. 1 indicates genes present within the leading core edge, 0 indicates genes which 
are not present. Only genes present in two or more leading core edge sets are shown. Genes 
highlighted in bold represent candidate MAF target genes selected for experimental validation. 
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5.5 MAF knock-down has no effect on LEC marker 
expression 
KSHV infection of LEC leads to decreased expression of LEC-specific genes 
(Wang et al., 2004) and the GSEA analysis confirmed this negative enrichment as 
evidenced by a skewed distribution to the right (Fig. 5.78). GSEA identified no 
significant change in LEC marker expression in the presence of the KSHV miRNA 
Cluster or when MAF was knocked-down specifically by siRNA (Fig. 5.8B and C). 
These data suggest neither the KSHV miRNA Cluster nor MAF play a role in 
regulating LEC marker expression. 
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Figure 5.8. siRNA MAF knock-down or KSHV miRNA Cluster has no effect on LEC marker 
expression A GSEA demonstrates a significant enrichment in decreased LEC marker expression 
upon KSHV infection.  Several lists of the topmost LEC markers (top 50, 100, 150, 200, 250,) were 
tested and the most significant list is plotted (150). Note that q = 0.000 exceeds the precision of 
the test. Skewed distribution to the right indicates decreased marker expression. Vertical lines 
below the plots represent LEC specific probes. The colour scale represents expression, from red 
(increased expression) to blue (decreased expression). The significance calculation shown (q) is a 
false discovery rate. B KSHV miRNA Cluster expression has no significant effect on LEC marker 
gene expression: q >0.05 C Knock-down MAF by siRNA also has no significant effect on LEC 
markers: q >0.05. 
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5.6 MAF is a repressor of BEC identity  
5.6.1 MAF knock-down induces increased BEC marker 
expression 
The up-regulation of putative MAF target genes identified by GSEA was 
confirmed in independent experiments by qRT-PCR analysis (Fig. 5.9). All five 
putative MAF target genes showed increased expression by this method when 
MAF was knocked-down by siRNA compared to a non-targeting control (Fig. 
5.9A). In the presence of the Cluster, four out of five genes increased compared 
to empty lentiviral vector (Fig. 5.9B). GULP1 did not increase, however this gene 
was not present in the leading core edge of the Cluster GSEA profile (Table 5.1). 
Up-regulation of three out of five genes identified by GSEA was confirmed in 
KSHV infected LEC (Fig. 5.9C). This represents the most complex experimental 
system, whereby additional mechanisms may be influencing gene expression. 
Up-regulation of additional BEC markers was confirmed when MAF was knocked-
down (Fig. 5.10). Four standard BEC markers: MAML2, FLT1, CXCR4 and 
CXCL12, were up-regulated in LEC when MAF was knocked-down by siRNA, 
compared to a non-targeting control (Fig. 5.10). These data further supported a 
role for MAF as a transcriptional repressor of BEC identity in LEC. 
 
  
 
 
 
 
 
244 
0
1
2
3
si-C
ON
MA
F
HD
AC
9
SL
C1
A1
GU
LP
1
NR
CA
M
TF
EC
m
R
N
A 
Fo
ld
 
Ch
a
n
ge
siMAF
0
1
2
3
4
5
6
LE
C
MA
F
HD
AC
9
SL
C1
A1
GU
LP
1
m
R
N
A 
Fo
ld
 
Ch
a
n
ge
KLEC
Cluster
m
R
N
A 
Fo
ld
 
Ch
an
ge
0
1
2
pSI
N
MA
F
HD
AC9
SLC
1A1
NR
CAM TFE
C
3
*
**
**
**
*
*
*
*
**
**
*
*
A
B
C
 
Figure 5.9. GSEA validation. A-C qRT-PCR analysis confirmed the up-regulation of candidate 
MAF target genes identified by GSEA (grey bars). MAF down-regulation by siRNA (A), miRNA 
Cluster (B) and KSHV is shown (C) (white bars). All values were normalised to GAPDH. In each 
condition, expression is relative to the corresponding control siCON, pSIN or LEC (black bar). p 
values: *<0.05; **<0.005. Error bars correspond to standard deviation, n = 3. 
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Figure 5.10. MAF knock-down leads to up-regulation of additional BEC markers. qRT-PCR 
analysis confirmed an up-regulation of additional BEC-specific markers when MAF was knocked-
down by siRNA. LEC were transfected with either a non-targeting control (siCON, black bars) or 
an siRNA pool specific for MAF (siMAF, grey bars). Expression is relative to GAPDH and 
normalised to LEC transfected with siCON. p values: *<0.05 **<0.005. Error bars correspond to 
standard deviation, n = 3. 
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To confirm KSHV miRNA regulation of BEC markers occurs through a mechanism 
dependent on MAF silencing, this phenotype was rescued using a miRNA-
insensitive MAF construct. The MAF ORF (MAF-S, Fig. 5.3A) lacking the 3’UTR 
was cloned into the lentiviral vector pSIN-MCS (Fig. 5.11); in the absence of the 
3’UTR MAF mRNA lacks KSHV miRNA binding sites and is no longer under 
miRNA-regulation. Expression of exogenous MAF ablated the miRNA Cluster-
induced up-regulation of four BEC markers, restoring these mRNA levels to that 
comparable with cells expressing empty lentiviral vector (Fig. 5.11). These data 
suggest that the KSHV miRNA Cluster contributes to endothelial reprogramming 
through silencing of MAF, which normally functions as transcriptional repressor of 
BEC identity in LEC. 
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Figure 5.11. miRNA-insensitive MAF ORF rescues Cluster-mediated up-regulation 
Exogenous MAF lacking the 3’UTR suppressed miRNA Cluster-induced up-regulation of candidate 
MAF target genes. MAF target genes were up-regulated in LEC transduced with the KSHV miRNA 
Cluster as confirmed by qRT-PCR (dark grey bars). Co-infection with Cluster and lentivirus 
expressing the MAF ORF abolished this upregulation (light grey bars). p values comparing KSHV 
Cluster to pSIN-MCS: *<0.05 and **<0.005. Differences between LEC transduced with Cluster 
plus MAF and pSIN-MCS were not significant. Error bars correspond to standard deviation, n = 3. 
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5.6.2 MAF over-expression reduces BEC marker expression  
The data presented here show that knock-down of MAF in LEC induced an up-
regulation of BEC-specific genes. To validate MAF as a transcriptional repressor, 
MAF was over-expressed in BEC, where endogenous levels of MAF are much 
lower than in LEC (Fig. 5.12B) (Petrova et al., 2002; Hong et al., 2004).  LEC and 
BEC are two closely related endothelial cell lineages and, when isolating either 
cell type from tissue such as the skin, their close physical proximity may result in a 
mixed cell population. It was therefore important to confirm the BEC status of cells 
used in the MAF over-expression experiment. Microvascular endothelial cells 
isolated from the dermis (PromoCell, Heidelberg, Germany) and the myometrium 
(provided by Dr. L. Nikitenko, CR-UK Viral Oncology group, UCL) were subjected 
to qRT-PCR quantification of a range of lineage-specific endothelial cell markers 
to determine which cell type faithfully represented BEC (Fig. 5.12A). Levels of 
LEC marker mRNA were similar in both LEC and dermal microvascular 
endothelial cells (DMVEC) (Fig. 5.12A). Specifically, PROX1 was expressed at a 
high level in DMVEC, as evidenced by a low delta Ct, indicating these cells were 
primarily LEC, and not BEC (Fig. 5.12A). Conversely, the lowest levels of PROX1 
mRNA were detected in the myometrium microvascular endothelial cells 
(MMVEC), as evidenced by highest delta Ct value (Fig. 5.12A). Furthermore, 
MMVEC had the lowest delta Ct values for all BEC markers assayed, indicating 
increased mRNA abundance (Fig. 5.12A). MMVEC therefore have increased BEC 
marker expression and express low levels of LEC-associated genes, compared to 
LEC and DMVEC. qRT-PCR of BEC markers identified in the GSEA analysis 
confirmed MMVEC faithfully represented BEC (Fig. 5.12B). Interestingly, MAF 
mRNA levels, similar to PROX1, were negligible in the MMVEC (Fig. 5.12).  Both 
transcription factors were undetectable in MMVEC, at the mRNA level, with 
threshold detection cycles of over 35, generating high delta Ct values (Fig. 5.12). 
These data both confirm MAF as a LEC-specific transcription factor and validate 
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the MMVEC as the appropriate cell type in which to study MAF transcriptional 
repression. Hereafter, MMVEC are referred to as BEC.  
 
  
 
 
 
 
 
250 
MMVEC
LEC
DMVEC
-5
-3
-1
1
3
5
7
9
11
13
15
MAF FLT4 PDPN PROX1 Integrin FLT1 CXCR4
De
lta
 
Ct
LEC markers BEC markers 
De
lta
 
Ct
0
2
4
6
8
10
LE
C
PR
OX
1
MA
F
FL
T4
PD
PN
LY
VE
Int
eg
rin
FL
T1
SL
C1
A1
NR
CA
M
HD
AC
9
TF
EC
CX
CR
4
GU
LP
1
CX
CL
12R
el
a
tiv
e
 
m
RN
A 
le
ve
ls
 
n
o
rm
a
lis
e
d
to
 
LE
C
LEC markers BEC markers
R
el
a
tiv
e
 
m
RN
A 
le
ve
ls
 
n
o
rm
a
lis
e
d
to
 
LE
C
A
B
 
Figure 5.12. qRT-PCR characterisation of BEC. A MMVEC express lower levels of LEC, and 
higher levels of BEC markers compared with DMVEC or LEC. qRT-PCR quantification of a range 
of BEC and LEC markers in three different cell types. Delta Ct corresponds to the difference in 
threshold detection cycle (Ct) between the marker and GAPDH. Unexpressed transcripts have a 
high delta Ct value. MMVEC: myometrium microvascular endothelial cells, DMVEC: dermal 
microvascular endothelial cells B Relative mRNA levels of a range of LEC and BEC markers in 
MMVEC normalised to LEC. MMVEC express lower levels of MAF and other LEC markers, 
including the master regulator PROX1. Conversely, higher levels of BEC markers were detected. 
Hereafter these cells will be referred to as BEC. 
ITGB3 
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BEC were infected with MAF-expressing lentivirus and MAF over-expression 
confirmed by western blotting (Fig. 5.13A). MAF protein levels increased by 
approximately 40 fold in BEC transduced with MAF lentivirus compared to empty 
lentiviral vector (Fig. 5.13A). MAF over-expression in BEC suppressed MAF target 
genes compared to BEC expressing empty lentiviral vector (Fig. 5.13B). MAF 
over-expression reduced HDAC9, CXCR4 and CXCL12 mRNA levels by more 
than 50% (Fig. 5.13B). The remaining BEC marker genes were reduced by 20-
35% at the mRNA level in the presence of exogenous MAF (Fig. 5.13B). These 
data confirm MAF as a transcriptional repressor of BEC markers.  
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Figure 5.13. Exogenous MAF represses BEC marker expression. A Western blot analysis of 
MAF and loading control actin protein in LEC transduced with either empty lentiviral vector (pSIN-
MCS) or MAF expressing lentivirus (pSIN-MAF). Quantification of relative intensity was performed 
by Scion Image software. B In BEC exogenous MAF represses MAF target genes. qRT-PCR 
analysis of BEC marker genes in BEC transduced with pSIN-MCS or MAF lentivirus (pSIN-MAF). 
Values normalised to GAPDH and relative to empty vector, pSIN. p values: *<0.05; **<0.005. Error 
bars correspond to standard deviation, n = 3. 
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5.7 MAF target validation by ChIP  
To continue validating MAF target genes, chromatin immunoprecipitation (ChIP) 
was used to assess the occupation of target gene promoters by MAF. Successful 
target gene PCR amplification from precipitated MAF-bound DNA would confirm 
MAF-regulation of GSEA-identified targets.  
 
5.7.1 MAF immunoprecipitation 
Before proceeding to ChIP, the MAF antibody was assessed by 
immunuprecipitation for the ability to recognise and precipitate native MAF 
protein. As MAF is a nuclear protein, immunoprecipitation experiments were 
performed on fractionated cell lysates, enriched for nuclear proteins.  Western 
blotting for p53 and GAPDH were used to confirmed lysates had been 
fractionated and enriched for either nuclear or cytoplasmic proteins, respectively 
and depleted of proteins from the reciprocal fraction (Fig. 5.14A).   
 
MAF ChIP was previously performed using a rabbit polyclonal antibody (M153) to 
confirm MAF regulation of individual target genes in a range of different cell types 
(Suzuki et al., 2005; Mahoney et al., 2007; Leavenworth et al., 2009). In Figures 
4.1, 4.6 and 5.12, MAF protein was quantified by western blotting using an 
alternative rabbit polyclonal antibody (IMG-6076A), as this antibody gave the 
lowest background and highest sensitivity compared to M153. However, since the 
M153 antibody had been shown to recognise MAF in its native form, and the IMG-
6076A had never been used for ChIP, the M153 antibody was selected for 
immunoprecipitation studies. Equal concentrations of M153 and species matched 
IgG antibodies were used to control for specific enrichment of MAF protein. To 
accurately quantify the relative IgG levels in the control and test antibody, 
increasing volumes of a 1/400 antibody dilution were resolved by SDS-PAGE, 
both antibodies were detected using a goat-anti-rabbit secondary antibody. The 
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IgG heavy chain runs at approximately 50kDa and densitometry analysis was 
performed to quantify this signal for each antibody (Fig. 5.14B). After subtracting 
background signal, the density of M153 band was compared to IgG and corrected 
for dilution factor. M153 antibody was 7.37 times more concentrated than the 
control rabbit IgG. Therefore, for use in the immunoprecipitation, M153 was 
corrected by a factor of 7.4 ensuring an accurate comparison between the test 
MAF antibody and control IgG.  
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Figure 5.14. Antibody optimisation A Nuclear and cytoplasmic fractions were isolated from 293T 
cells. Western blotting for cytoplasmic protein GAPDH showed a significant enrichment in the 
cytoplasmic fraction (top blot). Conversely, TP53 protein was enriched in the nuclear fraction only 
(bottom blot). B Western blot quantifying increasing volume of 1/400 dilution of the indicated 
antibodies. The band running at 50kDa corresponds to the IgG heavy chain. Numbers above the 
blot indicate µl of 1/400 dilution which were resolved. The density of 5µl M153 heavy chain band 
was compared to the 20µl rabbit IgG band. The relative intensities shown below the blot were 
corrected for background and dilution factor. 
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The large amount of protein required for the ChIP assay necessitated the use of 
the 293T cell line rather than primary LEC for these experiments. The ChIP assay 
was optimised using 293T nuclear extracts to reflect this. To enrich for MAF, 
nuclear extracts were produced from 293T cells transduced with the MAF 
lentivirus. Nuclear extracts from pSIN-MCS were also tested to determine whether 
endogenous MAF could be immunoprecipitated. Precipitated protein was resolved 
by SDS-PAGE along with the following control samples: total nuclear extract 
(input); pre-cleared sample (input incubated with protein A/G beads only); 
depleted IgG and depleted MAF (protein not precipitated by antibody-bound 
beads). Previously, the M153 antibody was shown to recognise MAF, as well as 
the large Maf proteins MAFA and MAFB (Kataoka et al., 2004). Therefore, to 
ensure the immunoprecipitation specifically enriched for MAF, and not other large 
Mafs, precipitated protein was detected using the N15 antibody, which recognises 
the unique MAF N-terminus and does not recognise either MAFA or MAFB 
(Kataoka et al., 2004).  
 
A band corresponding to MAF at approximately 40kDa was detected in nuclear 
input from 293T cells transduced with pSIN-MCS and MAF (Fig. 5.15A and B). 
This band was also present in pre-cleared and IgG depleted samples, indicating 
MAF does not bind non-specially to the protein A/G beads or rabbit IgGs (Fig. 
5.15A and B). A differential band running just above 37kDa was enriched in M153 
precipitated samples compared with the rabbit IgG and indicated MAF 
immunoprecipitation (Fig. 5.15A and B). This differential band was present in MAF 
over-expressing (Fig. 5.15A) and empty vector control cells (Fig. 5.15B); therefore 
the MAF antibody was capable of precipitating exogenous and endogenous 
protein. MAF levels were comparable in the depleted IgG and M153 samples (Fig. 
5.15A and B), possibly as a result of high MAF expression whereby MAF was 
successfully pulled down without detectable protein depletion in the M153 
precipitated samples (Fig. 5.15A). To determine whether the correction factor of 
7.4 led to equal concentrations of control IgG and M153 antibodies, blots were 
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stripped and re-probed with secondary goat-anti-rabbit antibody (Fig. 5.15B). 
Although more comparable with the dilution factor correction, IgG heavy chain 
levels were still higher in the M153 samples (Fig. 5.15B). However, this difference 
is unlikely to account for the strong MAF enrichment observed in the M153 
precipitated samples (Fig. 5.15A and B). 
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Figure 5.15. MAF immunoprecipitation A 293T Nuclear extracts from cells transduced with 
pSIN-MAF lentivirus were immunoprecipitated with MAF M153 antibody, or as a control rabbit IgG 
antibody. MAF protein levels in antibody precipitated samples and aliquots from sequential 
experimental stages were quantified by western blotting with the MAF N15 antibody. In both MAF 
expressing cells (left blot) and in cells expressing control empty vector the band running just above 
37kDa corresponding to MAF protein and is enriched in the M153 precipitated samples compared 
with the rabbit IgG  (right blot). Increased MAF protein is detected in MAF over-expressing cells. 
Bands corresponding to antibody light and heavy chains at 25 and 50kDa, respectively, are 
indicated. B As in A, except with 293T nuclear extracts from cells transduced with pSIN-MCS 
lentivirus C Blots were stripped of N15 and re-probed with a goat-anti-rabbit secondary antibody to 
quantify levels of rabbit IgG and M153. IgG heavy chain at 50kDa is more abundant in the M153 
lane compared to the IgG, although this difference has been corrected somewhat by running 7.4 
times less M153 than IgG. M153: MAF antibody. 
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5.7.2 MAF ChIP-PCR 
Immunoprecipitation confirmed antibody recognition and precipitation of 
endogenous MAF protein. The M153 antibody was therefore considered suitable 
for use in ChIP-PCR. To design PCR primers for MAF target genes, the MAF 
DNA binding sequence is required. Since the MAF targets identified in the GSEA 
were all novel, the MAF recognition elements (MARE) in these target genes were 
unknown. HDAC9 was selected as a candidate MAF target for ChIP-PCR 
validation. HDAC9 and MAF are both expressed in 293T cells, therefore although 
HDAC9 was identified as a MAF target in LEC, it may also be under MAF 
regulation in 293T cells. To identify putative MAF binding sites 1kb up and 
downstream of the HDAC9 transcription start site was scanned for putative 
MAREs using TRANSFAC. This sequence spans the transcription start site of all 
HDAC9 mRNA isoforms, and contains several areas of high sequence 
conservation (Fig. 5.16A), which is suggestive of highly conserved regulator 
elements. Promoter analysis identified four potential MAF binding sites, one 
proximal and three distal to the transcription start site (Fig. 5.16B). PCR primers 
were designed against these four putative MAREs, and as a negative control a 
region of upstream DNA which contained no predicted MAF binding sites. Since 
there are no validated MAF target genes in 293T cells for use as a positive 
control, PCR primers were designed against experimentally defined MAREs in 
CD13 (Mahoney et al., 2007) and Cyclin D2 (Hurt et al., 2004). Primers against 
the putative HDAC9 MAREs generated a single amplicon of approximately 100bp 
from genomic DNA, as did primers for the experimentally validated MAREs (Fig. 
5.16.C). These primers were therefore considered suitable for ChIP-PCR 
analysis. 
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Figure 5.16 HDAC9 promoter A One kilobase upstream and downstream of HDAC9 transcription 
start site was selected for MARE analysis (black bar). USCS genome browser showing sequence 
overlap with the five HDAC9 mRNA isoforms and regions of sequence conservation with placental 
mammals and vertebrates. Blocks of sequence conservation, indicated by the red arrows, are 
encompassed in the 2kb HDAC9 sequence, these may represent potential regulatory sequences. 
B Location and sequence of four putative MARE’s identified in the 2kb HDAC9 sequence. The 
transcription start site is indicated by a black arrow. C PCR from genomic DNA testing primers 
designed against the putative HDAC9 MAREs, experimentally validated MAREs (Cyclin D2 and 
CD13) and an upstream HDAC9 region devoid of MAF binding sites (HDAC9 upstream). PCR with 
all primer pairs generated a single band of ~100bp. Validated GAPDH PCR primers were included 
as a positive control   
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In addition to the M153 and control IgG antibodies, a positive control ChIP for 
RNA pol II with subsequent PCR analysis of its actin target was performed on 
293T nuclear extracts. This served as a positive control for the assay protocol. An 
aliquot of sonicated whole cell genomic DNA was used for qPCR input to create a 
standard curve informing on the threshold detection cycle (Ct) of the gene of 
interest at a specific DNA concentration. The concentration of immunoprecipitated 
target DNA was extrapolated using the target Ct and standard curve. Fold-
enrichment was calculated by comparing the amount of target DNA precipitated 
by M153 to that precipitated by control IgG antibody. The RNA Pol II positive 
control ChIP successfully precipitated actin, with a 20-fold DNA enrichment 
compared with rabbit IgG control (Fig. 5.17 and Table 5.2). There was no 
significant enrichment of an upstream region, lacking RNA Pol II binding sites, 
confirming the specificity of the actin promoter enrichment (Fig. 5.17 and Table 
5.2). There was also a significant DNA enrichment of the Cyclin D2 MARE for 
RNA Pol II, giving 90ng DNA per well and a 400-fold DNA enrichment compared 
to control IgG ChIP (Fig. 5.17 and Table 5.2). This strong enrichment in Cyclin D2 
likely reflects the high growth rate of the transformed 293T cells.  However, there 
was no significant enrichment in precipitated DNA for the two MAF positive 
controls CD13 and Cyclin D2. This is reflected by less than 1ng of MARE-
encoding DNA detected by qPCR (Fig. 5.17 and Table 5.2). Similarly, there was 
no significant enrichment in any of the HDAC9 putative MAREs in the M153 ChIP, 
in fact the strongest enrichment was observed for the HDAC9 upstream DNA 
region, lacking a putative MARE (Fig. 5.17 and Table 5.2). Therefore, although 
the ChIP experiment was successful for RNA POL II, it was not possible to 
determine whether the M153 ChIP succeeded in precipitating MAF-bound 
chromatin.  
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Figure 5.17  MAF Chromatin immunoprecipitation The threshold detection cycle (Ct) of 5 fold 
serial dilutions of whole cell sonnicated DNA were amplified with the indicated primers and the 
values plotted as a standard curve (blue diamonds). Target DNA amplification after MAF (pink 
square), RNA pol II (green triangle) and rabbit IgG (red circle) antibody precipitation was 
determined using the threshold detection cycle and equation of the standard curve. The equation 
of each line is shown along with the correlation coefficient, R2.  
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Figure 5.18 MAF Chromatin immunoprecipitation, continued 
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Table 5.2 ChIP Target enrichment. Targets in blue correspond to RNA POL II ChIP, whereas 
targets in black represent MAF ChIP. Fold enrichment is amount of DNA precipitated by either 
RNA POL II or MAF antibodies relative to ng DNA/well precipitated by rabbit IgG antibody. Total 
ng DNA per well is also shown. 
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5.8 MAF auto-regulation 
Previously Sakai et al reported auto-activation of the rat Maf promoter in which 
two Maf binding sites were identified, one resembled a MARE with a cAMP 
responsive element at its core (C-MARE) and the other contained a core MARE 
element (Sakai et al., 2001).  MafB and Jun also activate their own promoters; 
suggesting auto-regulation may be a common feature of Maf and bZIP 
transcription factors (Angel et al., 1988; Huang et al., 2000). To determine 
whether MAF expression in LEC is subject to auto-regulation, MAF mRNA levels 
were assessed in three different endothelial cell types transduced with MAF 
lentivirus (Fig. 5.18A). MAF mRNA levels were elevated in LEC infected with 
0.06ml and 0.3ml of MAF lentivirus compared to empty lentiviral vector (Fig. 
5.18A); but were reduced by approximately 30% in cells infected with 1.5ml of 
MAF-lentivirus, compared to empty vector control (Fig. 5.18A). In BEC and human 
umbilical vein endothelial cells (HUVEC), MAF mRNA levels failed to increase 
when cells were transduced with exogenous MAF, instead mRNA expression 
decreased with increasing concentration of lentivirus (Fig. 5.18A). A time-course 
infection of BEC transduced with MAF lentivirus, showed a modest increase in 
MAF mRNA 8hrs post transduction, after which MAF mRNA began to decrease 
until levels were approximately half that of cells transduced with empty vector 
control (Fig. 5.13B). Despite the reduction in MAF mRNA (Fig. 5.18), MAF protein 
was up-regulated by approximately 40 fold as determined by western blotting of 
lysates from BEC transduced with MAF lentivirus (Fig. 5.13A). Similarly, 
immunofluorescence quantification of LEC transduced with MAF confirmed a 
strong increase in MAF protein compared to cells infected with pSIN-MCS (Fig. 
5.19). These findings suggest a negative feedback loop, which reduces MAF 
mRNA levels once MAF protein accumulates to a threshold level. This repression 
of MAF transcription by exogenous MAF may be context-specific as, conversely, 
auto-activation of rat Maf has been described using luciferase assay data (Sakai 
et al., 2001), 
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MAF localised predominantly to the nucleus of over-expressing cells (Fig. 5.19). 
Nuclear localisation suggests exogenous MAF protein is functional and not 
aberrantly distributed or degraded. In LEC transduced with pSIN-MCS, MAF 
localised to both the nucleus and cytoplasm (Fig. 5.19). Cytoplasmic staining 
could represent newly synthesised MAF protein located in the endoplasmic 
reticulum, or degraded protein located in the ubiquitin-proteosome. This suggests 
endogenous MAF is being actively synthesised and degraded in LEC and may be 
under dynamic regulation.  
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Figure 5.18. MAF auto regulation A MAF mRNA in endothelial cells transduced with MAF-
expressing lentivirus. At low concentrations of MAF lentivirus, mRNA levels increase in LEC, 
relative mRNA levels then decrease to below that of empty vector when cells are infected with 
1.5ml. In BEC and HUVEC (human umbilical vein endothelial cells) MAF mRNA decreases with 
increasing concentration of MAF-expressing lentivirus. MAF mRNA levels are relative to cells 
infected with equal volume of pSIN-MCS for brevity one representative bar is shown. B Time-
course infection assaying MAF mRNA in BEC transduced with 1ml of MAF-lentivirus. MAF mRNA 
increases slightly 8hrs post infection, mRNA levels then decrease with time. MAF mRNA levels 
are normalised to GAPDH and relative to cells infected for the same time period with pSIN-MCS. p 
*: <0.05. 
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Figure 5.19. MAF protein in LEC. MAF protein levels in LEC transduced with pSIN-MCS or pSIN-
MAF as quantified by immunofluorescence. Primary antibody (MAF or IgG) is indicated in the top 
left corner. Cells on the left were stained with FITC-labelled goat-anti-rabbit secondary antibody. 
Right hand panels show DAPI stained cells, nuclear DNA is stained blue.  FITC staining was more 
intense in LEC transduced with MAF compared with pSIN-MCS, indicating increased MAF protein. 
MAF protein was detected in both the nucleus and cytoplasm of pSIN-MCS cells (middle panel, 
red arrowheads). Whereas MAF staining was predominantly nuclear in over-expressing cells 
(bottom panel, purple arrowheads). Low signal in cells incubated with IgG primary reveal low 
background signal, and confirm specificity of MAF staining. 
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5.9 MAF and PROX1 regulate an overlapping set of target 
genes 
PROX1 is the master regulator of the LEC differentiated phenotype; knock-out 
mice are embryonic lethal and lack a lymphatic vasculature (Wigle and Oliver, 
1999; Wigle et al., 2002). Whereas MAF knock-out mice die shortly after birth, 
with the most striking embryonic phenotype a failure of lens fibre elongation and 
microphthalmia (Kim et al., 1999b; Kawauchi et al., 1999; Ring et al., 2000). 
Similar to LEC, high levels of both MAF and PROX1 are expressed in the lens, 
and PROX1 was previously shown to enhance MAF activation of β-crystallin 
transcription in this context (Chen et al., 2002; Cui et al., 2004). However, the 
mechanism behind MAF and PROX1 cooperation is unclear and direct interaction 
has not been demonstrated. Petrova et al observed a set of 63 genes that were 
repressed in BEC following PROX1 over-expression (Petrova et al., 2002). To 
determine whether MAF and PROX1 could act together to repress transcription, 
GSEA was performed to analyse this set of 63 genes, in the context of MAF 
repression following siRNA knockdown in LEC. This analysis identified a 
significant enrichment in this gene set following siRNA knockdown of MAF in LEC 
(Fig. 5.20); genes repressed by PROX1 in BEC, increased when MAF was 
knocked-down in LEC.  In agreement with the data presented here suggesting a 
role for MAF as a repressor of BEC identity, PROX1 also suppressed expression 
of BEC markers in LEC (Fig. 5.20) (Johnson et al., 2008). These data suggest 
PROX1 and MAF may act in concert to repress the default BEC state, through 
regulating an overlapping set of target genes, thereby promoting a LEC 
phenotype.  
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Figure 5.20 Reciprocal regulation of BEC markers by PROX1 and MAF. Gene Set Enrichment 
Analysis (GSEA) shows a significant enrichment in a set of 63 genes which were repressed by 
PROX1 in BEC (Petrova et al., 2002). In LEC, upon siRNA knock-down of MAF, there is a 
significant increase in mRNA abundance of this gene set. The significance calculation shown (q) is 
a false discovery rate. 
 
  
q = <0.01 
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5.10 Discussion 
Although originally classified as a transforming oncogene (Nishizawa et al., 1989; 
Kawai et al., 1992), MAF has subsequently been shown to mediate terminal 
differentiation in a range of cell types (Eychene et al., 2008). Therefore, it was 
hypothesised that MAF may be involved in endothelial differentiation and that de-
regulation of this transcription factor could play a role in KSHV-mediated 
endothelial reprogramming. In concordance with its role in tissue differentiation, 
MAF regulates the expression of distinct target genes according to cell type 
(Hegde et al., 1999; Kim et al., 1999a; Kim et al., 1999b; Ring et al., 2000; Aziz et 
al., 2009). In combination with cell-type specific targets, the degenerate MAF DNA 
recognition element has hindered genome-wide identification of MAF target genes 
(Kataoka, 2007). To gain insight into the genes in LEC which are under MAF 
regulation, GEM analysis was performed using LEC in which MAF had been 
silenced. A cohort of genes was de-regulated in the context of MAF repression 
and these genes were classed as potential MAF targets. Within a set of eighteen 
experimentally validated MAF targets (Table 1.2 and (Eychene et al., 2008)), only 
Cyclin D2 was de-regulated when MAF was silenced in LEC. These data support 
the context-specific regulation of distinct sets of genes by MAF according to cell 
type. 
 
GSEA of siMAF, LEC transduced with the miRNA Cluster and KLEC GEM data 
sets were performed to determine whether MAF de-regulation was responsible for 
the transcriptional convergence of KLEC towards a more BEC-like phenotype. 
Strikingly, a concordant up-regulation in the expression of BEC markers was 
observed in LEC when MAF was silenced; this pattern in gene expression was 
similar to that observed upon KSHV infection of LEC (Wang et al., 2004; Hong et 
al., 2004). Similarly, when the KSHV miRNA Cluster was expressed in LEC, there 
was a significant up-regulation in genes associated BEC differentiation status. 
This analysis suggested the KSHV miRNAs are involved in the transcriptional 
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reprogramming of infected LEC through a mechanism involving MAF silencing.  
Furthermore, the data presented here suggest that MAF functions as a 
transcriptional repressor in LEC. siRNA silencing of MAF led to an increase in 
additional BEC–specific marker genes, supporting a role for MAF as a repressor 
of BEC identity.  
 
MAF contains a transactivation domain and the majority of studies into its function 
show MAF to be a transcriptional activator (Yang and Cvekl, 2007). However, the 
data presented here is consistent with other reports showing that MAF can also 
function as a repressor (Dhakshinamoorthy and Jaiswal, 2002; Aziz et al., 2009).  
The activity of bZIP transcription factors is dependant on both dimerization 
partners and cooperating proteins present within the larger transcription regulation 
complex.  An analysis of bZIP dimerization activity identified MAF as preferentially 
forming heterodimers (Vinson et al., 2002) and multiple proteins are capable of 
dimerizing with MAF in vitro (Newman and Keating, 2003). Therefore, it is 
possible that in LEC, MAF associates with a dimerization partner that confers a 
repressive function to regulate BEC-associated genes, compared to other cell 
types which express higher levels of activating dimerization partners.  
 
A MAF rescue experiment was performed to confirm the up-regulation of BEC 
markers induced by the KSHV miRNA Cluster was by way of MAF targeting. The 
MAF ORF, minus the 3’UTR, was expressed in the context of Cluster-expressing 
LEC. This form of MAF is insensitive to miRNA regulation as it no longer contains 
the miRNA binding sites present in endogenous MAF 3’UTR. Co-expression of 
the MAF ORF ablated the up-regulation of candidate MAF-target genes induced 
by the Cluster. Lentivirus expressing the MAF-S single ORF rescued the miRNA 
induced phenotype, this suggests that there are no miRNA binding sites located in 
the MAF ORF and that MAF-S is predominantly regulated through the 3’UTR. This 
implies that miRNA Cluster-induced silencing of MAF-L (Fig. 5.3) may be a result 
of binding sites in the additional exon. However, the majority of miRNA binding 
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sites are functionally restrained to the 3’UTR, due to ribosomal displacement of 
miRNA containing RISC from target sites situated in ORFs (Gu et al., 2009). 
Further work is needed to clarify the mechanism of Cluster-induced MAF-L down-
regulation and whether this of relevance to KSHV infection.  
 
LEC and BEC were classified by the differential expression of lymphatic and 
blood vessel-specific makers. qRT-PCR analysis presented here showed that, in 
addition to expressing low levels of LEC cell surface markers, negligible PROX1 
and MAF mRNA levels were detected in BEC. This confirmed previous reports 
classifying MAF as a LEC specific protein (Petrova et al., 2002; Hong et al., 
2004). Transducing BEC with MAF lentivirus led to an increase in MAF protein 
and a corresponding decrease in mRNA abundance of BEC-specific genes, 
suggesting the role of MAF in LEC is as a transcriptional repressor. Previously, 
MAF was included in a list of LEC specific genes increased upon KSHV infection 
of BEC (Hong et al., 2004). It could be envisaged that this reciprocal increase in 
MAF, compared to the decrease in KLEC, is responsible for the repression of 
BEC identity, contributing to the move towards a LEC-phenotype in KBEC. Since 
the KSHV miRNAs are also likely to be expressed in KBEC, another mechanism 
could exist which over-rides viral miRNA-mediated MAF silencing in KBEC.  
 
Together these results provide insight into the function of the KSHV miRNAs, 
identify a novel role for viral miRNAs in regulating the cellular differentiation state, 
and identify MAF as a transcription factor involved in the plasticity of LEC (Fig. 
5.21). Sustained PROX1 expression is necessary in the adult mouse to maintain 
the LEC phenotype, otherwise cells revert to the default blood vessel endothelial 
state (Johnson et al., 2008). In suppressing BEC markers, MAF also contributes 
to LEC identity. KSHV miRNA silencing of MAF and the subsequent increase in 
BEC marker expression, explain in part the mechanism behind the 
reprogramming of infected LEC (Fig. 5.21). However, the move towards a BEC-
like phenotype was most pronounced in KSHV-infected LEC, suggesting that 
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there may be factors other than MAF de-regulation contributing to the 
transcriptional reprogramming. Although overall the poorly differentiated KS 
tumour cells are most similar to LEC (Wang et al., 2004), these findings provide 
an explanation for the BEC-like features of KS spindle cells. 
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Figure 5.21 KSHV miRNAs contribute to LEC reprogramming. MAF represses the transcription 
of BEC marker genes in LEC (blue cell). BEC markers, but not MAF, are expressed in BEC 
(orange cell). Upon KSHV infection and expression of the viral miRNAs, MAF is silenced (purple 
cell), leading to increased expression of BEC marker genes. The resulting KSHV infected LEC is 
more similar to BEC than an uninfected cell. BEC marker gene names are shown in black.
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In addition to an increase in BEC-specific genes, KSHV infection represses genes 
associated with LEC differentiation status (Wang et al., 2004; Hong et al., 2004). 
Expression of the KSHV miRNA Cluster or MAF silencing had no effect on LEC 
marker expression. These data show that the viral miRNA contribution to 
endothelial reprogramming is by way of BEC marker regulation only. Instead, the 
reduction in LEC markers is likely by way of PROX1 down-regulation upon KSHV 
infection, although other mechanisms may also contribute (Wang et al., 2004). 
PROX1 was significantly up-regulated in KSHV infected BEC, resulting in an 
increase in LEC specific genes in KBEC (Carroll et al., 2004; Hong et al., 2004). 
These data support the idea that PROX1 has an important role in mediating the 
effects of KSHV on endothelial reprogramming (Carroll et al., 2004; Hong et al., 
2004). 
 
MAF regulates transcription by synergising with an additional transcription factor, 
for example PAX6 in the lens (Kawauchi et al., 1999) and SOX9 in the bone 
(MacLean et al., 2003). Previously, PROX1 and MAF were shown to cooperate in 
the activation of β-crystallin transcription (Chen et al., 2002; Cui et al., 2004). 
Therefore, it was hypothesised that MAF and PROX1 may be acting in concert to 
specify LEC fate. PROX1 expression in BEC repressed a set of BEC-related 
genes (Petrova et al., 2002) and this same set of genes was enriched following 
MAF knockdown in LEC. These data support the hypothesis that these 
transcription factors form a repressor complex, suppressing BEC markers and 
helping to maintain the LEC phenotype. 
 
PROX1 is expressed at mouse E9.5 in a subset of venous endothelial cells (Wigle 
and Oliver, 1999). MAF mRNA is first detected at E9 in the mouse lens placode 
(Kawauchi et al., 1999). However, the timing of MAF expression in the developing 
lymphatic system has not yet been determined. The hierarchy of transcriptional 
regulation by MAF and PROX1 is unknown. However, since MAF knock-out mice 
have no reported lymphatic defect and PROX1 knock-out mice fail to develop a 
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lymphatic system, is seems plausible that MAF is under PROX1 regulation,  rather 
than the opposite. As a LEC-specific transcript, MAF was up-regulated upon 
KSHV infection of BEC, as was PROX1 (Hong et al., 2004). However, when 
PROX1 was silenced in KBEC, there was a corresponding reduction in MAF 
mRNA. These data support the hypothesis that MAF is under PROX1 regulation.  
Further work will clarify the relationship between PROX1 and MAF and delineate 
the members of the transcriptional repressor complex acting to specific LEC fate.  
 
ChIP-PCR was performed in an attempt to directly confirm in situ MAF promoter 
occupation of the BEC genes identified through GSEA. Immunoprecipitation of 
MAF protein in its native form, confirmed the MAF antibody was suitable for use in 
ChIP studies. HDAC9 was selected as a candidate target gene with which to test 
the ChIP-PCR. PCR primers were designed around putative MAF binding sites 
identified in the region surrounding the HDAC9 transcription start site. Although 
the ChIP-PCR was successful for the positive RNA POl II control, there was no 
significant enrichment in any of the putative HDAC9 predicted MAREs. Similarly, 
there was there no enrichment in two experimentally defined MAREs in the MAF 
target genes CD13 or Cyclin D2, included as positive controls. The cell-type 
specific nature of MAF-regulation could explain the failure of the MAF ChIP to 
precipitate the positive controls as these genes may not be under MAF regulation 
in 293T cells. This could hold true for HDAC9 which was identified as a MAF 
target in LEC. Alternatively, HDAC9 may be under MAF regulation but the correct 
MARE was not identified. HDAC9 was selected as a candidate target since it was 
expressed at a high level in 293T cells, however PCR primers could also be 
designed against other putative MAREs identified in additional MAF targets 
genes, such as NRCAM or SLC1A1, to confirm the negative ChIP results 
obtained for HDAC9. 
 
Experimentally validated MAREs often deviate from the canonical sequence, and 
MAF has been shown to regulate genes through a range of different DNA motifs 
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(Kerppola and Curran, 1994; Yoshida et al., 2005; Kataoka, 2007).  Furthermore, 
MAF heterodimers will recognise distinct shorter sequences from the palindromic 
MARE bound by MAF homodimers, making it difficult to identify putative MAREs 
through in silico promoter analysis.   
 
Failure to precipitate MAF binding sequences could also be a consequence of the 
antibody used. M153 not only recognises MAF, but also MAFB and MAFA 
(Kataoka et al., 2004). MAFB is expressed at high levels in the kidney and has a 
major role in renal function (Moriguchi et al., 2006). Therefore, it is possible that in 
the kidney-derived 293T cell line the M153 antibody preferentially precipitated 
MAFB protein over MAF. qPCR for a MAFB target in the M153 precipitated DNA 
would address this issue, however as yet no targets have been characterised.  
Using lysates from MAF over-expressing 293T cells would potentially favour MAF 
precipitation; however exogenous protein does not always regulate targets in the 
same manner as endogenous, potentially skewing the results.  As a positive 
control to confirm the experimental conditions employed were suitable for M153, 
ChIP could be performed using this antibody on a validated target in the 
appropriate cell type, such as IL4 which was precipitated with M153 in T 
lymphocyte cell lines (Tykocinski et al., 2005).  
 
These findings highlight the difficulty of performing ChIP-PCR without a validated 
positive control and a strong consensus DNA binding sequence around which to 
design PCR primers. Therefore, ChIP-Seq or ChIP-chip, two methods which do 
not require prior knowledge of DNA binding regions will be more successful at 
confirming and identifying new MAF target genes. Approximately 100 million cells 
are required per ChIP, making this a challenging experiment to perform with 
primary human LEC. Therefore, 293T cells were selected for ChIP optimisation 
because they are easier to grow and obtain in large numbers. However, for a 
tissue specific transcription factor with a distinct target repertoire in each cell type, 
global target identification studies must be performed in the cell type of interest.   
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Chapter 6. Discussion and future work  
6.1 Summary 
An investigation into KSHV miRNA function in lymphatic endothelial cells 
identified a role for viral miRNAs in reprogramming KSHV infected cells through 
silencing the cellular transcription factor MAF. The main findings of my work are: 
 
Identification of KSHV miRNA targets in LEC (Chapter Three) 
• Characterisation of the viral miRNA profile of Kaposi sarcoma lesions. 
• Development of an experimental system in which to investigate KSHV 
miRNA function in endothelial cells. 
• Identification of putative KSHV miRNA cellular targets in LEC: 
o Experimental identification through GEM analysis of LEC 
expressing the viral miRNA cluster. 
o In silico target prediction analysis. 
 
MAF is a KSHV miRNA target (Chapter Four) 
• MAF is an experimentally validated target of the KSHV miRNA Cluster. 
• Individual KSHV miRNAs, miR-K12-6 and miR-K12-11, regulate MAF 
through specific binding sites located in the 3’UTR. 
• MAF is down-regulated by way of the KSHV miRNAs in KSHV infected 
primary LEC. 
 
KSHV miRNA regulation of MAF induces endothelial reprogramming (Chapter 
Five) 
• MAF is a transcriptional repressor of BEC markers, contributing to the 
maintenance of LEC identity. 
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• The viral miRNA Cluster contributes to KSHV-induced endothelial 
reprogramming through silencing MAF, leading to an up-regulation of 
BEC-associated genes in LEC. 
 
6.2 Conclusions 
Despite encoding many conserved ORFs and large numbers of clustered 
miRNAs in similar genomic locations, gammaherpesvirus miRNAs share little 
sequence conservation. This observation suggests that viral miRNAs have 
evolved to target host and tissue-specific genes to facilitate infection of distinct 
cell lineages. Cellular target identification in a range of KSHV infected cell types 
identified distinct target repertoires according to cellular origin and the method 
adopted (Samols et al., 2007; Ziegelbauer et al., 2009). However, at the onset of 
this work, there had been no investigations into KSHV miRNAs targets in LEC. 
Since LEC are the closest uninfected cell type to the KS spindle cell (Wang et al., 
2004), it was of primary importance to determine the cellular targets of the viral 
miRNAs during KSHV infection of LEC. Furthermore, due to the reduced mode of 
latent gene expression, the viral miRNAs are some of the few gene products 
expressed in KSHV infected spindle cells. Therefore they are likely to play an 
important role in KSHV-mediated oncogenesis.  
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6.2.1 Novel role for viral miRNAs 
Only a small number of viral miRNA targets have been identified, making it 
difficult to gain a full understanding of viral miRNA function. To date, validated 
viral miRNA targets tend to fall into three categories: immune modulators, 
apoptosis inhibitors and regulators of viral reactivation (Umbach and Cullen, 
2009; Cullen, 2010). Since their identification in 2005 (Cai et al., 2005; Pfeffer et 
al., 2005; Samols et al., 2005), there have been six experimentally validated 
KSHV miRNA targets, five of which are cellular (Table 1.4). Silencing of three of 
these targets (IkBα, RBL and KSHV-encoded lytic reactivator RTA) inhibits viral 
replication thereby promoting persistent latent infection (Bellare and Ganem, 
2009; Lei et al., 2010; Lu et al., 2010). Although not the primary regulators of the 
lytic switch, the KSHV miRNAs likely function as a back-up mechanism, 
controlling fluctuations in cellular and viral genes which may trigger lytic 
reactivation. Viral miRNA regulation of the other three cellular genes (BCLAF1, 
BACH1, THSD1), inhibits apoptosis (Ziegelbauer et al., 2009), increases 
permissiveness to KSHV infection and protects cells against oxidative stress (Qin 
et al., 2010), as well as contributing to a pro-angiogenic environment (Samols et 
al., 2007). These studies confirmed that KSHV miRNA-target regulation 
promotes a favourable environment in which to establish persistent infection. 
Currently there is little evidence for a role in pathogenesis for viral miRNAs. 
Indeed, the main reported phenotype of KSHV genomes lacking the viral miRNA 
Cluster was enhanced lytic replication (Lei et al., 2010; Lu et al., 2010).  
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miRNAs were first identified through their control of C. elegans larval 
development, and subsequently have been shown to mediate differentiation and 
development in a range of tissues from drosophila to mammals (Chen et al., 
2004; Thum et al., 2007; Davidson-Moncada et al., 2010).  The work presented 
in this thesis provides the first example of viral miRNAs modulating the 
differentiation status of an infected cell (Hansen et al., 2010). Although this is the 
first example of viral miRNAs modulating differentiation, certain oncogenic 
viruses have long been known to regulate the cellular differentiation status to 
promote infection. EBV hijacks the normal development of B cells to establish life 
long infection in the B cell compartment (Kuppers, 2003). EBV infection of naïve 
B cells induces proliferation and germinal center reaction; these EBV positive 
germinal centers then differentiate into memory B cells which are the long term 
reservoir of EBV (Babcock et al., 1998). Similarly, it has been proposed that 
KSHV may directly interfere with the B cell development pathway, through vIL6 
promoting naïve infected B cells to differentiate directly into plasmablasts (Jenner 
et al., 2003; Barozzi et al., 2007). This could explain the plasmablastic features of 
KSHV-related PEL and multicentric Castleman’s disease (MCD) (Dupin et al., 
1995). Furthermore, HPV makes use of epithelial differentiation during the 
productive lifecycle phase (Fehrmann and Laimins, 2003). Following cell division, 
HPV infected daughter cells leave the basal layer and migrate towards the 
suprabasal region where they begin to differentiate, uninfected cells exit the cell 
cycle here whereas infected cells continue to enter S-phase (Doorbar et al., 
1997). The data presented within this thesis showing KSHV miRNA regulation of 
MAF altering the differentiation status of infected LEC, highlights the importance 
of differentiation status during viral infection.  
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6.2.2 Mechanism underlying KSHV-induced reprogramming 
In 2004 three groups independently reported KSHV-induced endothelial cell 
reprogramming (Carroll et al., 2004; Hong et al., 2004; Wang et al., 2004). All 
groups described induction of a lymphatic signature upon KSHV infection of 
BEC; Wang et al also showed the reverse phenotype in KSHV infected LEC 
(Carroll et al., 2004; Hong et al., 2004; Wang et al., 2004). These studies clearly 
highlight the capacity of KSHV to reprogram the endothelial transcriptome; 
however the mechanism underlying these changes was poorly defined.  
Silencing PROX1 in KSHV-infected BEC, decreased expression of multiple 
lymphatic genes (Hong et al., 2004), suggesting that in KBEC, lymphatic-specific 
genes may be switched on as a consequence of PROX1 induction. Notably, 
ectopic expression of PROX1 in BEC failed to recapitulate the full phenotype of 
KBEC, suggesting there are other KSHV-induced mechanisms contributing to 
this reprogramming (Hong et al., 2002; Petrova et al., 2002; Carroll et al., 2004). 
Wang et al reported a significant reduction in PROX1 mRNA in KLEC, which 
could be responsible, in part, for inducing a BEC signature in LEC (Wang et al., 
2004). However, the mechanism responsible for PROX1 induction in KBEC and 
repression in KLEC has yet to be determined.  
 
Expression of the KSHV miRNA Cluster was sufficient to induce BEC-specific 
genes in LEC. This induction was shown to be by way of MAF silencing. 
Therefore, the work presented in this thesis identifies a novel mechanism 
contributing to the KSHV-induced reprogramming of LEC (Hansen et al., 2010) 
and expands on previous studies documenting this reprogramming (Wang et al., 
2004). The induction of a BEC-like signature in LEC was most prominent after 
infection with the whole virus, suggesting that multiple factors work in concert to 
reprogram LEC. Down-regulation of the lymphatic specific transcription factors 
PROX1 and MAF could be two of the main mechanisms driving the transition 
towards a BEC phenotype. The KSHV-encoded miRNAs are responsible for MAF 
down-regulation, however no significant change in PROX1 mRNA was observed 
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in LEC expressing the miRNA Cluster.  A number of cellular miRNAs are also 
induced upon KSHV infection (Lagos et al., 2010); therefore it is possible that 
cellular miRNAs may also contribute to KSHV-induced reprogramming, 
potentially through silencing PROX1. Further work is needed to elucidate the 
additional mechanisms contributing to the reprogramming, such as the factors 
responsible for suppression of LEC markers in KLEC.  
 
The in vitro experimental system employed within this thesis models primary 
KSHV infection of LEC; under these conditions MAF silencing induces a BEC-like 
signature. Differentiated LEC are slow dividing primary cells, therefore in vivo the 
global effect of KSHV-induced reprogramming could be to drive LEC towards a 
less differentiated phenotype, promoting cell division and hence viral 
propagation. Although KLEC in culture display no growth advantage compared 
with LEC, infected cells may need the stimulus of the tumour inflammatory 
microenvironment to initiate proliferation. Alternatively, the observed 
reprogramming could reflect KSHV infection of circulating endothelial progenitor 
cells in vivo. Here KSHV infection may drive the progenitors towards poorly 
differentiated spindle precursor cells, expressing both LEC and BEC markers. 
However, the down-regulation of key LEC transcription factors, which are only 
switched on after LEC specification, suggests that KSHV has evolved 
mechanisms to alter the status of fully differentiated cells, rather than 
progenitors. Clearly, there are many questions still to be answered regarding the 
in vivo cellular reservoirs of KSHV and the functional significance of the 
reprogramming. For example, it is not known whether the poorly differentiated 
status of spindle cells and endothelial progenitors is more conducive to latency. 
The inability to maintain long-term culture of KSHV infected LEC and the lack a 
suitable mouse model has hindered investigations into the role of reprogrammed 
cells during primary infection and throughout disease progression.   
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6.2.3 MAF: a novel LEC-specifying protein  
The LEC phenotype is initiated upon expression of PROX1 in a subset of venous 
endothelial cells in the anterior cardinal vein during embryogenesis (Wigle and 
Oliver, 1999). PROX1 triggers a cascade of gene expression driving cells 
towards a lymphatic fate (Wigle et al., 2002). Despite the established role of 
PROX1 as the lymphatic master regulator, there still remains much to be 
discovered regarding lymphangiogenesis. The initiating lymphatic signal is still 
unknown, as are many PROX1-responsive genes responsible for the lymphatic 
phenotype (Oliver and Alitalo, 2005). Identification of MAF as a KSHV miRNA 
target prompted investigations into its function in LEC.  This work identified a 
novel role for MAF in suppressing BEC-specific genes, helping to maintain the 
LEC phenotype. A report describing the plasticity of LEC (Johnson et al., 2008), 
showed PROX1 expression was required both for the initiation and maintenance 
of the lymphatic phenotype. Loss of PROX1 in adult murine lymphatic vessels 
induced a morphological shift towards blood vessels (Johnson et al., 2008). 
Similarly, MAF expression is required in differentiated LEC to suppress the BEC 
phenotype; consequently loss of MAF through KSHV infection induces a shift 
towards a BEC phenotype. These data support the reported plasticity of LEC and 
highlight the sensitivity of these cells to the dosage of lineage-specifying 
transcription factors. The findings of this thesis add the lymphatic vasculature to 
the list of tissues in which MAF plays a lineage specifying role (Yang and Cvekl, 
2007).  
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6.3 Future Work 
6.3.1 KSHV miRNA target identification 
The GEM experiment in Chapter Three identified a cohort of genes de-regulated 
at the mRNA level in the presence of the KSHV miRNA Cluster; subsequently a 
single miRNA target was experimentally validated. Further experiments will be 
performed to gain insight into additional KSHV miRNA targets and the 
significance of target regulation during primary infection and in KS. This 
approach identified only the viral miRNA targets that were affected at the mRNA 
level. As an alternative to GEM analysis, stable isotope labeling by amino acids 
in cell culture (SILAC) has been employed to investigate the effects of miRNAs 
on the proteome (Vinther et al., 2006). This approach has the benefit of 
monitoring changes in abundance of protein, and therefore can identify viral 
miRNA targets silenced solely by translation inhibition which may have been 
missed in the GEM experiment. In addition, SILAC data can be used to 
substantiate some of the small fold changes in mRNA abundance identified in the 
GEM experiment, as many genes silenced via translation inhibition were also 
shown to be marginally down-regulated at the RNA level (Baek et al., 2008; 
Selbach et al., 2008).  SILAC could be performed on LEC expressing the Cluster 
and KSHV infected LEC. The overlap of genes would inform on viral miRNA 
targets compared to genes regulated by cellular miRNAs induced upon infection. 
Performing SILAC on samples throughout a time course of KSHV infection could 
provide insight into how viral and cellular miRNA activity changes during 
infection.   
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Another method of identifying functional miRNA interaction sites is by 
immunoprecipitation of Argonaute bound to target RNAs which are subsequently 
identified by high-throughput sequencing (Chi et al., 2009). This technique known 
as HITS-CLIP (high-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation) could be employed on KLEC and Cluster expressing LEC 
to generate a genome-wide interaction map, informing on which miRNAs are 
actively associated with Argonaute during infection. This method could also be 
employed on KS biopsies, which will inform on how miRNA targets change from 
primary infection towards late stage disease. 
 
Two groups have independently created a KSHV bacmid (Bacterial artificial 
chromosome, BAC36) lacking the viral miRNA Cluster (Lei et al., 2010; Lu et al., 
2010). Infection of cells with this mutated BAC increased viral lytic gene 
expression and lytic replication, confirming a role for the KSHV miRNAs in 
stabilising latency (Lei et al., 2010; Lu et al., 2010). Infection of LEC with KSHV 
lacking the miRNA Cluster would compliment target identification by GEM and 
SILAC, as well as facilitating investigations into viral miRNA function. For 
example, KLEC infected with wild-type virus or virus lacking the miRNA Cluster 
could be assayed for differences in lymphangiogenic assays, such as tube 
formation in three dimensional culture (Bruyere and Noel, 2010). This system 
could also be employed to confirm the role of KSHV miRNAs in endothelial 
reprogramming by comparing markers of endothelial differentiation in LEC 
infected with wild type KSHV and those infected with the miRNA deletion mutant.   
In addition to target identification, functional assays will be employed in the future 
to identify pathways and processes manipulated by the KSHV miRNAs.   
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6.3.2 MAF and PROX1 
A set of PROX1 responsive genes in BEC (Petrova et al., 2002), were also de-
regulated upon MAF siRNA-mediated silencing in LEC. In the lens, MAF and 
PROX1 have been shown to cooperate in the activation of β-crystallin 
transcription (Chen et al., 2002; Cui et al., 2004). Given the tendency for MAF to 
synergise with additional transcription factors (Kataoka, 2007), it is plausible that 
MAF and PROX1 form a transcriptional repressor complex acting to maintain the 
LEC phenotype. Future work will characterise the relationship between these two 
transcription factors in LEC and determine whether PROX1 augments MAF 
repression of BEC genes. In addition, COUPTFII will be also investigated, as this 
transcription factor augments PROX1 activation of certain LEC genes, helping to 
establish LEC fate (Lee et al., 2009; Yamazaki et al., 2009). Therefore, it is 
possible that all three LEC-specifying transcription factors are working in concert. 
Co-immunoprecipitation for all three proteins will determine whether they interact 
within a transcription complex.  Alternatively, MAF immunoprecipitation in LEC, 
followed by mass spectrometry analysis would fully characterise all proteins 
cooperating in the repressor complex. Furthermore, this analysis could potentially 
identify the MAF bZIP dimerization partners. Since MAF is primarily a 
transcriptional activator, identification of its dimer partner in LEC where it acts as 
a repressor, would shed light on which proteins are responsible for conferring 
repressor activity.   
 
Future work will also delineate whether there is reciprocal regulation between 
PROX1 and MAF. The phenotype of PROX1 and MAF homozygous mice 
partially overlapped (Ring et al., 2000). However, in Maf  homozygous null mice 
there was no change in Prox1 mRNA in the mutant lens, suggesting that at least 
in this tissue, Prox1 expression is not under Maf control (Ring et al., 2000). 
Conversely, MAF up-regulation in KSHV infected BEC could be reduced through 
silencing PROX1 (Hong et al., 2004), implying that PROX1 may control MAF 
expression. The effect of both proteins on levels of the corresponding 
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transcription factor should be assessed to confirm whether MAF is a genuine 
PROX1 target. Luciferase promoter studies and competitive DNA binding assays 
such as electric mobility shift assay (EMSA) could be employed to identify the 
site of PROX1 binding in the MAF promoter.  
 
6.3.3 The role of MAF role during lymphangiogenesis  
The work in this thesis identified MAF as a LEC-specifying transcription factor. 
Experiments were performed solely on differentiated LEC, whereas there has 
been no investigation into MAF function in the development of the lymphatic 
system. Previously, three groups independently created Maf homozygous null 
mice, the most striking embryonic phenotype was microphthalmia and defective 
lens formation (Kim et al., 1999; Kawauchi et al., 1999; Ring et al., 2000). 
Homozygous null mice were born at the expected Mendelian frequency, but died 
shortly after birth of undetermined causes (Kim et al., 1999; Kawauchi et al., 
1999; Ring et al., 2000). Heterozygous mice were born at the expected 
frequency, survived past weaning and displayed no eye defects (Kim et al., 1999; 
Kawauchi et al., 1999; Ring et al., 2000).  None of the studies reported any gross 
defects in the lymphatic system (Kim et al., 1999; Kawauchi et al., 1999; Ring et 
al., 2000). This may be due to functional redundancy between LEC-specifying 
transcription factors, including COUPTFII and PROX1. Alternatively, MAF may 
play a role after development of the lymphatic system, helping to maintain the 
adult LEC phenotype.  
 
Future work will employ the use of Maf knock out mice and pups to determine 
whether Maf plays an important role in lymphangiogenesis. First the expression 
profile of Maf will be characterised throughout the stages of lymphatic 
development to determine when in the LEC-specifying transcription cascade Maf 
is expressed.  The timing and location of MAF expression during 
lymphangiogenesis will be compared with that of PROX1 and COUPTFII. The 
lymphatic system of MAF homozygous null mice will be closely inspected at the 
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four main steps of development: LEC competence, LEC bias, LEC specification 
and lymphatic vessel differentiation and maturation (Oliver, 2004). 
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Affymetrix probe ID Gene LFC  Cluster:Empty vector Average Expresssion p Value q Value
224997_x_at H19 -1.12 0.46 6.2 0.00001 0.09
219764_at FZD10 -1.09 0.47 6.25 0.00007 0.13
224646_x_at H19 -0.99 0.50 9.17 0.00000 0.07
203394_s_at HES1 -0.94 0.52 9.67 0.00002 0.11
1566324_a_at MAF -0.88 0.54 6.5 0.00000 0.07
202409_at IGF2 -0.86 0.55 9.92 0.00003 0.11
213416_at CERKL -0.85 0.55 4.58 0.00002 0.11
228793_at JMJD1C -0.85 0.55 8.32 0.00007 0.13
202350_s_at MATN2 -0.84 0.56 8.28 0.00002 0.11
235944_at HMCN1 -0.82 0.57 5.14 0.00000 0.07
203395_s_at HES1 -0.81 0.57 8.43 0.00008 0.13
219452_at DPEP2 -0.71 0.61 7.14 0.00008 0.13
203868_s_at VCAM1 -0.68 0.62 5.08 0.00012 0.14
231181_at <NA> -0.66 0.63 8.94 0.00008 0.13
229004_at <NA> -0.61 0.66 6.77 0.00003 0.11
230673_at PKHD1L1 -0.61 0.66 8.85 0.00006 0.13
205756_s_at F8 -0.61 0.66 8.35 0.00008 0.13
201427_s_at SEPP1 -0.60 0.66 11.71 0.00002 0.11
205392_s_at CCL14 -0.60 0.66 10.05 0.00009 0.13
213106_at ATP8A1 -0.58 0.67 8.75 0.00002 0.11
209348_s_at MAF -0.57 0.67 11.53 0.00007 0.13
204301_at KBTBD11 -0.56 0.68 9.22 0.00012 0.14
200766_at CTSD -0.52 0.70 9.77 0.00003 0.11
1562273_at CNGA4 -0.51 0.70 3.75 0.00003 0.11
226822_at STOX2 -0.50 0.71 7.25 0.00014 0.14
229638_at IRX3 -0.47 0.72 7.27 0.00006 0.13
238764_at CSAD -0.47 0.72 4.99 0.00009 0.13
210980_s_at ASAH1 -0.45 0.73 10.52 0.00005 0.13
234638_at LARGE -0.45 0.73 3.91 0.00009 0.13
214660_at ITGA1 -0.44 0.74 6.94 0.00007 0.13
229327_s_at MAF -0.44 0.74 8.89 0.00014 0.14
219262_at SUV39H2 0.40 1.32 4.11 0.00013 0.14
212806_at <NA> 0.42 1.34 7.45 0.00013 0.14
231930_at ELMOD1 0.43 1.35 7.78 0.00012 0.14
208930_s_at ILF3 0.44 1.36 7.65 0.00013 0.14
205552_s_at OAS1 0.46 1.38 7.52 0.00005 0.13
219463_at C20orf103 0.46 1.38 7.12 0.00014 0.14
242629_at <NA> 0.47 1.39 5.02 0.00013 0.14
218857_s_at ASRGL1 0.48 1.39 9.14 0.00003 0.11
229886_at C5orf34 0.48 1.39 7 0.00011 0.14
203819_s_at C7orf30 0.49 1.40 8.68 0.00014 0.14
230058_at SDCCAG3 0.50 1.41 5.31 0.00005 0.13
200841_s_at EPRS 0.50 1.41 8 0.00013 0.14
1559840_s_at TBX18 0.51 1.42 7.01 0.00002 0.11
213979_s_at CTBP1 0.52 1.43 9.71 0.00006 0.13
207601_at SULT1B1 0.55 1.46 8.49 0.00003 0.11
237062_at RNF10 0.56 1.47 6.87 0.00006 0.13
230256_at C1orf104 0.61 1.53 5.83 0.00005 0.13
215509_s_at BUB1 0.62 1.54 7.35 0.00009 0.14
206715_at TFEC 0.85 1.80 4.74 0.00003 0.11
 
 
Appendix Table A1 Top 50 probes de-regulated in the presence of the KSHV miRNA 
cluster. The top 50 de-regulated probes are identified by the affymetrix probe id and gene 
symbol. Probes down-regulated in LEC expressing the Cluster compared to empty lentiviral 
vector are shown in black, those up-regulated are in blue.  
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Appendix Table A2 PITA prediction results Top 205 KSHV miRNA targets as predicted by 
PITA. The target and targeting miRNA are listed as is the location of the target site in the 3’UTR 
The degree of seed complementation is indicated under the Seed heading, 8 refers to the size of 
the seed, a 1 in the second column indicates a G:U wobble in the seed whereas a 1 in the third 
column indicates a single mismatch. The PITA score is explained in Figure 3.12 and Section 
3.6.1.  
 
Ensemble ID Gene microRNA Start End Seed PITA score 
ENSG00000196715 VKORC1L1 kshv-miR-K12-2 3232 3224 08:00:00 -16.41
ENSG00000065060 C6orf107 kshv-miR-K12-6-5p 2290 2282 08:00:00 -16.42
ENSG00000198417 MT1F kshv-miR-K12-1 105 97 08:00:01 -16.42
ENSG00000161960 SNORA67 kshv-miR-K12-10b 2070 2062 08:01:00 -16.42
ENSG00000132128 LRRC41 kshv-miR-K12-4-3p 68 60 08:01:00 -16.43
ENSG00000088888 MAVS_HUMAN kshv-miR-K12-10b 1703 1695 08:00:01 -16.45
ENSG00000087263 OGFOD1 kshv-miR-K12-4-3p 1041 1033 08:01:00 -16.45
ENSG00000185432 METTL7A kshv-miR-K12-4-3p 1852 1844 08:01:00 -16.47
ENSG00000169504 CLIC4 kshv-miR-K12-11 1903 1895 08:00:01 -16.48
ENSG00000163808 KIF15 kshv-miR-K12-6-5p 130 122 08:00:00 -16.48
ENSG00000183853 KIRREL kshv-miR-K12-10b 3429 3421 08:01:00 -16.48
ENSG00000047188 YTHDC2 kshv-miR-K12-10b 480 472 08:01:00 -16.48
ENSG00000140464 PML kshv-miR-K12-1 286 278 08:01:00 -16.49
ENSG00000182319 SG223_HUMAN kshv-miR-K12-8 62 54 08:01:00 -16.5
ENSG00000174903 RAB1C kshv-miR-K12-10b 84 76 08:00:01 -16.51
ENSG00000170442 KRT86 kshv-miR-K12-8 64 56 08:01:00 -16.52
ENSG00000066322 ELOVL1 kshv-miR-K12-11 702 694 08:00:01 -16.53
ENSG00000108946 PRKAR1A kshv-miR-K12-6-5p 1006 998 08:01:00 -16.54
ENSG00000135999 EPC2 kshv-miR-K12-2 121 113 08:00:01 -16.55
ENSG00000069509 FUNDC1 kshv-miR-K12-10a 127 119 08:00:01 -16.56
ENSG00000184863 RBM33 kshv-miR-K12-6-3p 2376 2368 08:01:00 -16.57
ENSG00000120314 WDR55 kshv-miR-K12-2 1023 1015 08:01:00 -16.57
ENSG00000116148 CCNL2 kshv-miR-K12-2 2947 2939 08:01:00 -16.58
ENSG00000174371 EXO1 kshv-miR-K12-10b 217 209 08:00:01 -16.59
ENSG00000025800 KPNA6 kshv-miR-K12-6-3p 3378 3370 08:00:01 -16.6
ENSG00000183155 RABIF kshv-miR-K12-11 1562 1554 08:01:00 -16.62
ENSG00000072364 AFF4 kshv-miR-K12-6-5p 2326 2318 08:01:00 -16.64
ENSG00000183856 IQGAP3 kshv-miR-K12-1 1041 1033 08:01:00 -16.65
ENSG00000038382 TRIO kshv-miR-K12-6-3p 1656 1648 08:00:01 -16.65
ENSG00000088832 FKBP1A kshv-miR-K12-11 334 326 08:00:01 -16.66
ENSG00000048740 CUGBP2 kshv-miR-K12-4-3p 245 237 08:01:00 -16.67
ENSG00000166224 SGPL1 kshv-miR-K12-4-3p 149 141 08:01:00 -16.69
ENSG00000165219 GAPVD1 kshv-miR-K12-6-3p 1369 1361 08:00:00 -16.71
ENSG00000165219 GAPVD1 kshv-miR-K12-6-3p 2136 2128 08:00:00 -16.71
ENSG00000163171 CDC42EP3 kshv-miR-K12-11 613 605 08:00:01 -16.72
ENSG00000112773 FAM46A kshv-miR-K12-6-3p 1861 1853 08:01:00 -16.74
ENSG00000138685 FGF2 kshv-miR-K12-2 5290 5282 08:00:01 -16.75
ENSG00000069493 CLEC2D kshv-miR-K12-10b 796 788 08:00:01 -16.77
ENSG00000069493 CLEC2D kshv-miR-K12-10b 869 861 08:00:01 -16.77
ENSG00000141720 PIP4K2B kshv-miR-K12-10a 3381 3373 08:00:00 -16.77
ENSG00000141720 PIP4K2B kshv-miR-K12-10b 3381 3373 08:00:01 -16.77
ENSG00000162300 ZFPL1 kshv-miR-K12-8 442 434 08:01:00 -16.77
ENSG00000187720 THSD4 kshv-miR-K12-6-5p 799 791 08:01:00 -16.79
ENSG00000129194 SOX15 kshv-miR-K12-2 105 97 08:00:00 -16.82
ENSG00000167658 EEF2 kshv-miR-K12-10a 276 268 08:01:00 -16.84
ENSG00000124164 VAPB kshv-miR-K12-6-5p 814 806 08:00:00 -16.85
ENSG00000124164 VAPB kshv-miR-K12-6-5p 884 876 08:00:00 -16.85
ENSG00000124422 USP22 kshv-miR-K12-6-3p 1752 1744 08:00:01 -16.86
ENSG00000173418 NAT5 kshv-miR-K12-4-3p 269 261 08:01:00 -16.87
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ENSG00000173418 NAT5 kshv-miR-K12-4-3p 324 316 08:01:00 -16.87
ENSG00000108175 ZMIZ1 kshv-miR-K12-6-3p 3473 3465 08:00:00 -16.87
ENSG00000197622 CDC42SE1 kshv-miR-K12-6-3p 272 264 08:01:00 -16.89
ENSG00000075420 FNDC3B kshv-miR-K12-6-5p 2337 2329 08:01:00 -16.91
ENSG00000170915 PAQR8 kshv-miR-K12-2 844 836 08:01:00 -16.92
ENSG00000189306 ZG14_HUMAN kshv-miR-K12-10b 1249 1241 08:00:01 -16.94
ENSG00000150712 MTMR12 kshv-miR-K12-1 543 535 08:01:00 -16.95
ENSG00000170348 TMED10 kshv-miR-K12-6-3p 3057 3049 08:00:01 -16.95
ENSG00000182180 MRPS16 kshv-miR-K12-4-3p 1548 1540 08:01:00 -16.97
ENSG00000125266 EFNB2 kshv-miR-K12-10b 1688 1680 08:00:01 -16.98
ENSG00000054523 KIF1B kshv-miR-K12-6-3p 1092 1084 08:00:01 -16.98
ENSG00000054523 KIF1B kshv-miR-K12-6-3p 2907 2899 08:00:01 -16.98
ENSG00000198205 ZXDA kshv-miR-K12-4-3p 676 668 08:01:00 -16.99
ENSG00000185896 LAMP1 kshv-miR-K12-10a 632 624 08:01:00 -17
ENSG00000185896 LAMP1 kshv-miR-K12-10a 2162 2154 08:01:00 -17
ENSG00000043143 PHF15 kshv-miR-K12-6-3p 1749 1741 08:00:01 -17.03
ENSG00000158352 SHROOM4 kshv-miR-K12-6-5p 1421 1413 08:00:00 -17.05
ENSG00000112159 MDN1 kshv-miR-K12-10b 3084 3076 08:00:01 -17.06
ENSG00000178075 GRAMD1C kshv-miR-K12-6-3p 704 696 08:00:01 -17.08
ENSG00000108406 DHX40 kshv-miR-K12-10a 912 904 08:00:00 -17.11
ENSG00000108406 DHX40 kshv-miR-K12-10b 912 904 08:00:01 -17.11
ENSG00000088766 CRLS1 kshv-miR-K12-2 2559 2551 08:00:01 -17.13
ENSG00000088766 CRLS1 kshv-miR-K12-2 2761 2753 08:00:01 -17.13
ENSG00000152767 FARP1 kshv-miR-K12-10b 613 605 08:01:00 -17.13
ENSG00000159140 SON kshv-miR-K12-6-5p 462 454 08:01:00 -17.13
ENSG00000125834 STK35 kshv-miR-K12-10b 2979 2971 08:01:00 -17.14
ENSG00000204420 G6B_HUMAN kshv-miR-K12-1 1348 1340 08:01:00 -17.15
ENSG00000175866 BAIAP2 kshv-miR-K12-4-5p 1176 1168 08:00:01 -17.17
ENSG00000132740 IGHMBP2 kshv-miR-K12-8 644 636 08:00:01 -17.19
ENSG00000135677 GNS kshv-miR-K12-10a 2919 2911 08:00:00 -17.24
ENSG00000135677 GNS kshv-miR-K12-10b 2919 2911 08:00:01 -17.24
ENSG00000143157 POGK kshv-miR-K12-6-3p 386 378 08:00:01 -17.24
ENSG00000103423 DNAJA3 kshv-miR-K12-10a 132 124 08:01:00 -17.25
ENSG00000103423 DNAJA3 kshv-miR-K12-10a 168 160 08:01:00 -17.25
ENSG00000114383 TUSC2 kshv-miR-K12-10b 871 863 08:00:00 -17.26
ENSG00000186638 Q5T7B8-2 kshv-miR-K12-6-3p 969 961 08:01:00 -17.31
ENSG00000076356 PLXNA2 kshv-miR-K12-8 1253 1245 08:00:01 -17.32
ENSG00000130147 SH3BP4 kshv-miR-K12-6-3p 1678 1670 08:00:01 -17.32
ENSG00000105993 DNAJB6 kshv-miR-K12-10b 770 762 08:01:00 -17.35
ENSG00000174371 EXO1 kshv-miR-K12-2 400 392 08:01:00 -17.36
ENSG00000120549 KIAA1217 kshv-miR-K12-6-3p 876 868 08:00:00 -17.4
ENSG00000084090 STARD7 kshv-miR-K12-1 722 714 08:00:01 -17.43
ENSG00000182667 NTRI_HUMAN kshv-miR-K12-10b 62 54 08:01:00 -17.44
ENSG00000168734 PKIG kshv-miR-K12-10b 371 363 08:01:00 -17.45
ENSG00000112339 HBS1L kshv-miR-K12-2 3810 3802 08:00:01 -17.46
ENSG00000132256 TRIM5 kshv-miR-K12-6-3p 734 726 08:01:00 -17.46
ENSG00000132256 TRIM5 kshv-miR-K12-6-3p 91 83 08:01:00 -17.49
ENSG00000123933 MXD4 kshv-miR-K12-1 1170 1162 08:01:00 -17.51
ENSG00000173269 MMRN2 kshv-miR-K12-4-3p 305 297 08:01:00 -17.52
ENSG00000165757 KIAA1462 kshv-miR-K12-6-3p 212 204 08:00:00 -17.56
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ENSG00000170906 NDUFA3 kshv-miR-K12-6-3p 61 53 08:01:00 -17.57
ENSG00000132716 WDR42A kshv-miR-K12-6-3p 556 548 08:01:00 -17.58
ENSG00000092140 KIAA1333 kshv-miR-K12-10b 1232 1224 08:00:01 -17.6
ENSG00000100288 CHKB kshv-miR-K12-10b 1150 1142 08:00:01 -17.61
ENSG00000085832 EPS15 kshv-miR-K12-10b 2405 2397 08:00:01 -17.62
ENSG00000099219 ERMP1 kshv-miR-K12-6-3p 393 385 08:00:01 -17.65
ENSG00000099219 ERMP1 kshv-miR-K12-6-3p 631 623 08:00:01 -17.65
ENSG00000102471 NDFIP2 kshv-miR-K12-4-3p 2889 2881 08:00:01 -17.66
ENSG00000118689 FOXO3 kshv-miR-K12-10b 280 272 08:00:01 -17.69
ENSG00000101849 TBL1X kshv-miR-K12-10b 2694 2686 08:00:00 -17.72
ENSG00000132912 DCTN4 kshv-miR-K12-10b 774 766 08:00:01 -17.73
ENSG00000125968 ID1 kshv-miR-K12-8 86 78 08:01:00 -17.73
ENSG00000178202 KDELC2 kshv-miR-K12-6-3p 1393 1385 08:01:00 -17.74
ENSG00000169184 MN1 kshv-miR-K12-6-5p 1401 1393 08:00:00 -17.76
ENSG00000198960 ARMCX6 kshv-miR-K12-8 469 461 08:01:00 -17.77
ENSG00000148335 C9orf32 kshv-miR-K12-6-5p 192 184 08:00:00 -17.77
ENSG00000066583 ISOC1 kshv-miR-K12-8 132 124 08:00:01 -17.77
ENSG00000139211 AMIGO2 kshv-miR-K12-4-5p 1516 1508 08:00:00 -17.78
ENSG00000132912 DCTN4 kshv-miR-K12-1 1272 1264 08:00:01 -17.78
ENSG00000165879 FRAT1 kshv-miR-K12-6-3p 508 500 08:00:00 -17.82
ENSG00000134882 UBAC2 kshv-miR-K12-10b 694 686 08:01:00 -17.87
ENSG00000134882 UBAC2 kshv-miR-K12-10b 1073 1065 08:01:00 -17.87
ENSG00000111530 CAND1 kshv-miR-K12-6-3p 149 141 08:00:01 -17.89
ENSG00000066117 SMARCD1 kshv-miR-K12-10a 130 122 08:01:00 -17.9
ENSG00000146757 ZNF92 kshv-miR-K12-6-3p 567 559 08:01:00 -17.94
ENSG00000125534 C20orf149 kshv-miR-K12-1 123 115 08:01:00 -17.97
ENSG00000185070 FLRT2 kshv-miR-K12-10b 3457 3449 08:00:01 -17.99
ENSG00000075790 BCAP29 kshv-miR-K12-10b 1070 1062 08:00:00 -18.01
ENSG00000075790 BCAP29 kshv-miR-K12-10b 1312 1304 08:00:00 -18.01
ENSG00000102309 PIN4 kshv-miR-K12-6-3p 322 314 08:00:00 -18.01
ENSG00000102309 PIN4 kshv-miR-K12-6-3p 920 912 08:00:00 -18.01
ENSG00000127603 MACF1 kshv-miR-K12-6-5p 5856 5848 08:00:00 -18.02
ENSG00000182356 POM121L1 kshv-miR-K12-10a 103 95 08:01:00 -18.03
ENSG00000123130 ACOT9 kshv-miR-K12-10a 1089 1081 08:01:00 -18.04
ENSG00000129667 RHBDF2 kshv-miR-K12-10a 587 579 08:00:01 -18.05
ENSG00000129667 RHBDF2 kshv-miR-K12-10a 1478 1470 08:00:01 -18.05
ENSG00000134531 EMP1 kshv-miR-K12-6-3p 442 434 08:00:01 -18.17
ENSG00000160209 PDXK kshv-miR-K12-10b 4534 4526 08:00:01 -18.25
ENSG00000123146 CD97 kshv-miR-K12-6-3p 67 59 08:00:01 -18.33
ENSG00000145833 DDX46 kshv-miR-K12-10b 1184 1176 08:00:01 -18.38
ENSG00000197969 VPS13A kshv-miR-K12-4-3p 89 81 08:00:01 -18.47
ENSG00000173531 MST1 kshv-miR-K12-10a 401 393 08:01:00 -18.48
ENSG00000166025 AMOTL1 kshv-miR-K12-10a 1067 1059 08:00:01 -18.49
ENSG00000166025 AMOTL1 kshv-miR-K12-10a 2118 2110 08:00:01 -18.49
ENSG00000007168 PAFAH1B1 kshv-miR-K12-10b 373 365 08:01:00 -18.51
ENSG00000063587 ZNF275 kshv-miR-K12-1 3404 3396 08:01:00 -18.51
ENSG00000119986 AVPI1 kshv-miR-K12-6-3p 392 384 08:01:00 -18.52
ENSG00000168522 FNTA kshv-miR-K12-6-5p 158 150 08:00:00 -18.52
ENSG00000158062 UBXD5 kshv-miR-K12-10b 360 352 08:01:00 -18.53
ENSG00000172534 HCFC1 kshv-miR-K12-8 1666 1658 08:01:00 -18.55
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ENSG00000143324 XPR1 kshv-miR-K12-6-3p 1457 1449 08:01:00 -18.62
ENSG00000165219 GAPVD1 kshv-miR-K12-2 623 615 08:01:00 -18.7
ENSG00000165219 GAPVD1 kshv-miR-K12-2 1390 1382 08:01:00 -18.7
ENSG00000163960 UBXD7 kshv-miR-K12-1 52 44 08:00:01 -18.71
ENSG00000114554 PLXNA1 kshv-miR-K12-8 2841 2833 08:01:00 -18.73
ENSG00000182197 EXT1 kshv-miR-K12-10a 722 714 08:01:00 -18.78
ENSG00000115649 C2orf24 kshv-miR-K12-6-5p 445 437 08:01:00 -18.79
ENSG00000105281 SLC1A5 kshv-miR-K12-10b 371 363 08:00:00 -18.82
ENSG00000153558 FBXL2 kshv-miR-K12-6-3p 342 334 08:00:01 -18.83
ENSG00000159256 MORC3 kshv-miR-K12-6-3p 112 104 08:01:00 -18.84
ENSG00000095951 HIVEP1 kshv-miR-K12-6-3p 610 602 08:00:01 -18.91
ENSG00000163820 FYCO1 kshv-miR-K12-6-3p 103 95 08:00:01 -18.92
ENSG00000188529 FUSIP1 kshv-miR-K12-1 148 140 08:01:00 -19.01
ENSG00000163960 UBXD7 kshv-miR-K12-10a 1196 1188 08:00:01 -19.04
ENSG00000125430 HS3ST3B1 kshv-miR-K12-6-3p 2084 2076 08:00:00 -19.15
ENSG00000197119 SLC25A29 kshv-miR-K12-4-3p 184 176 08:00:01 -19.19
ENSG00000116641 DOCK7 kshv-miR-K12-10b 661 653 08:00:00 -19.2
ENSG00000116016 EPAS1 kshv-miR-K12-10b 1536 1528 08:00:01 -19.28
ENSG00000128989 ARP19_HUMAN kshv-miR-K12-4-3p 4376 4368 08:00:01 -19.37
ENSG00000198198 KIAA0467 kshv-miR-K12-10a 428 420 08:01:00 -19.41
ENSG00000105245 NUMBL kshv-miR-K12-10b 118 110 08:01:00 -19.43
ENSG00000197373 NP_001091084.1 kshv-miR-K12-6-3p 192 184 08:01:00 -19.53
ENSG00000205236 NP_116581.3 kshv-miR-K12-6-3p 192 184 08:01:00 -19.53
ENSG00000157106 SMG1_HUMAN kshv-miR-K12-4-3p 1952 1944 08:01:00 -19.7
ENSG00000136758 YME1L1 kshv-miR-K12-10a 855 847 08:01:00 -19.93
ENSG00000136758 YME1L1 kshv-miR-K12-10a 945 937 08:01:00 -19.93
ENSG00000168264 IRF2BP2 kshv-miR-K12-6-5p 627 619 08:00:00 -20.03
ENSG00000213699 C2orf18 kshv-miR-K12-11 732 724 08:00:00 -20.09
ENSG00000212870 MT-ND5 kshv-miR-K12-6-3p 338 330 08:01:00 -20.09
ENSG00000114861 FOXP1 kshv-miR-K12-1 1641 1633 08:01:00 -20.2
ENSG00000114861 FOXP1 kshv-miR-K12-1 2296 2288 08:01:00 -20.2
ENSG00000136933 RABEPK kshv-miR-K12-6-3p 61 53 08:01:00 -20.26
ENSG00000162971 C2orf60 kshv-miR-K12-6-5p 3562 3554 08:00:00 -20.44
ENSG00000103423 DNAJA3 kshv-miR-K12-10b 132 124 08:00:00 -20.75
ENSG00000160094 ZNF362 kshv-miR-K12-10a 1590 1582 08:01:00 -20.84
ENSG00000182356 POM121L1 kshv-miR-K12-10b 103 95 08:00:00 -21.13
ENSG00000181634 TNFSF15 kshv-miR-K12-10b 331 323 08:01:00 -21.17
ENSG00000173436 C1orf151 kshv-miR-K12-1 961 953 08:00:00 -21.2
ENSG00000164754 RAD21 kshv-miR-K12-1 1041 1033 08:00:00 -21.31
ENSG00000104643 MTMR9 kshv-miR-K12-4-3p 3847 3839 08:00:00 -21.4
ENSG00000177469 PTRF kshv-miR-K12-10b 344 336 08:01:00 -21.59
ENSG00000112031 MTRF1L kshv-miR-K12-1 2029 2021 08:01:00 -21.68
ENSG00000164151 NP_056140.1 kshv-miR-K12-10a 52 44 08:00:01 -21.82
ENSG00000168461 RAB31 kshv-miR-K12-4-3p 3129 3121 08:01:00 -21.86
ENSG00000066117 SMARCD1 kshv-miR-K12-10b 130 122 08:00:00 -21.9
ENSG00000149257 SERPINH1 kshv-miR-K12-10b 387 379 08:01:00 -21.93
ENSG00000155016 CYP2U1 kshv-miR-K12-6-5p 2576 2568 08:01:00 -22.07
ENSG00000204218 RGL2 kshv-miR-K12-10a 416 408 08:00:00 -22.37
ENSG00000204218 RGL2 kshv-miR-K12-10b 416 408 08:00:01 -22.37
ENSG00000138468 SENP7 kshv-miR-K12-4-3p 1330 1322 08:00:00 -22.62
ENSG00000172757 CFL1 kshv-miR-K12-10b 304 296 08:00:01 -22.69
 
 
 
 
 
 
